

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number  
**WO 2004/027042 A3**

(51) International Patent Classification<sup>7</sup>: **C07K 1/00**,  
14/00, 17/00, C07H 21/02, 21/04, C12Q 1/00, G01N  
33/53, C12N 15/00, 15/09, 15/63, 15/70

(74) Agents: **CHRISTENBURY, Lynne, M. et al.**; E. I. Du  
Pont De Nemours and Company, Legal Patent Records  
Center, 4417 Lancaster Pike, Wilmington, DE 19805 (US).

(21) International Application Number:  
PCT/US2003/029834

(22) International Filing Date:  
23 September 2003 (23.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/412,795 23 September 2002 (23.09.2002) US  
60/427,324 18 November 2002 (18.11.2002) US

(71) Applicant (for all designated States except US): **E. I. DU  
PONT DE NEMOURS AND COMPANY** [US/US]; 1007  
Market Street, Wilmington, DE 19898 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CASPAR, Timothy**  
[US/US]; 2927 Barley Mill Road, Yorklyn, DE 19736  
(US). **CORDOVA, Daniel** [US/US]; 5 Cold Spring  
Circle, Hockessin, DE 19707 (US). **GUTTERIDGE,**  
**Steven** [US/US]; 4 Austin Road, Wilmington, DE 19810  
(US). **RAUH, James, J.** [US/US]; 55 Martha's Drive,  
Conowingo, MD 21918 (US). **SMITH, Rejane, M.**  
[US/US]; 176 Middlecroft Road, Elkton, MD 21921 (US).  
**WU, Lihong** [CN/US]; 301 Winterview Way, Newark, DE  
19711 (US). **TAO, Yong** [CN/US]; 9 Hummingbird Lane,  
Newark, DE 19711 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
18 November 2004

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: ISOLATION AND USE OF RYANODINE RECEPTORS

(57) Abstract: The genes encoding ryanodine receptor homologs have been characterized from multiple insect families including lepidopteran tobacco budworm (*Heliothis virescens*), homopteran green peach aphid (*Myzus persicae*), corn plant hopper (*Peregrinus maidis*), cotton melon aphid (*Aphis gossypii*) and fruitfly (*Drosophila melanogaster*). The full-length genes have been isolated, cloned and amplified in bacterial cells. Expression in insect cells shows that the recombinant protein folds into a functional calcium release channel. The genes and their corresponding polypeptides have a number of uses including, but not limited to, the isolation of other pest ryanodine receptors, the development of screens to identify insecticidally active compounds, use of fragments of genes as pesticides, fragments of protein for antibody production, fragments of protein for determination of the structure of insecticide binding sites, and identification of insecticides that disrupt the calcium balance in cells through other messengers that interact with the receptor calcium release mechanism. Methods are outlined for overcoming toxic effects of expressing recombinant proteins in host cells.

WO 2004/027042 A3

**THIS PAGE BLANK (USPTO)**

for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region, 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

5 Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the entire protein or a suitable subfragment or subdomain. This cDNA fragment may then be purified on a 1% NuSieve GTG™ low melting agarose gel (FMC, Philadelphia, PA). Buffer and agarose contain 10 µg/mL ethidium bromide for visualization of the DNA fragment. The fragment can then be  
10 purified from the agarose gel by digestion with GELase™ (Epicentre Technologies) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 µL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase (New England Biolabs, Beverly, MA). The fragment containing the ligated adapters can be purified from the excess  
15 adapters using low melting agarose as described above. The vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5 electrocompetent cells (Invitrogen Life Technologies™, Carlsbad, CA).  
20 Transformants can be selected on agar plates containing LB media and 100 µg/mL ampicillin. Transformants containing the gene encoding the instant polypeptides are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.

For high level expression, a plasmid clone with the cDNA insert in the correct  
25 orientation relative to the T7 promoter can be transformed into *E. coli* strain BL21(DE3) (Studier et al. (1986) *J. Mol. Biol.* 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25°C. At an optical density at 600 nm of approximately 1, IPTG (isopropylthio-β-galactoside, the inducer) can be added to a final concentration of 0.4 mM and incubation can be continued for 3 h at  
30 25°C. Cells are then harvested by centrifugation and re-suspended in 50 µL of 50 mM Tris-HCl at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe sonicator. The mixture is centrifuged and the protein concentration of the  
35 supernatant determined. One µg of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight. Clearly those skilled in the art might choose other bacterial expression vectors, particularly

those that offer a variety of choices of sequences that when fused in-frame with the cDNA insert provide a polypeptide extension that can aid purification like a His tag, MBP or GST extension at either the N- or C-termini of the recombinant protein.

The cDNA inserts can also be expressed in yeast cells. The ryanodine receptor polypeptides can be evaluated by expression of the encoded polypeptides in a yeast (*Saccharomyces cerevisiae*) strain YPH (Stratagene) and assaying the membrane components for ryanodine-sensitive calcium transport. Plasmid DNA (200 ng) from any of the cDNA clones can be used as a template for PCR using primers set forth in the present invention. Amplification is performed using the GC melt kit (Clontech) with a 1 M final concentration of GC melt reagent. Amplification took place in a Perkin Elmer 9700 thermocycler for 30 cycles as follows: 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 2 minutes. The amplified insert is then incubated with a modified pRS315 plasmid (NCBI General Identifier No. 984798; Sikorski, R. S. and Hieter, P. (1989) *Genetics* 122:19-27) that had been digested with appropriate restriction enzymes. Plasmid pRS315 had been previously modified by the insertion of a bidirectional gal1/10 promoter between the Xho I and Hind III sites. The plasmid is then transformed into the YPH yeast strain using standard procedures where the insert recombines through gap repair to form the desired transformed yeast strain (Hua, S. B. et al. (1997) *Plasmid* 38:91-96.).

Yeast cells are prepared according to a modification of the methods of Pompon et al. (Pompon, D. et al. (1996) *Meth. Enz.* 272:51-64). Briefly, a yeast colony is grown overnight (to saturation) in SG (-Leucine) medium at 30°C with good aeration. A 1:50 dilution of this culture is made into 500 mL of YPGE medium with adenine supplementation and allowed to grow at 30°C with good aeration to an OD<sub>600</sub> of 1.6 (24-30 h). Fifty mL of 20% galactose is added, and the culture is allowed to grow overnight at 30°C. The cells are recovered by centrifugation at 5,500 rpm for five minutes in a Sorvall GS-3 rotor. The cell pellet is resuspended in 500 mL of 0.1 M potassium phosphate buffer (pH 7.0) and then allowed to grow at 30°C for another 24 hours.

The cells are recovered by centrifugation as described above and the presence of ryanodine receptor activity is determined using any of the assays outlined in Examples 9, 10, or 11.

#### EXAMPLE 7

##### Expression of *Heliothis virescens* Ryr cDNA in Insect Cells

The *Heliothis virescens*, and other, Ryr cDNAs appears to be quite toxic to *Escherichia coli* when placed into a vector under the control of an insect expression vector (e.g. pIB/V5-His, Invitrogen Life Technologies™, Carlsbad CA). Under these conditions, the cells grow very slowly and frameshift mutations are spontaneously



introduced. Two cloning strategies that completely eliminate any expression of the Ryr gene in *E. coli* would circumvent the growth problems.

In the first strategy, the Ryr gene is cloned into a modified pXINSECT-DEST39 vector (Invitrogen), placing the Ryr gene under the control of an insect actin promoter. In order to completely eliminate leaky expression of the Ryr gene during growth in *E. coli*, a "stop" fragment was placed just downstream of the His tag in the vector, but upstream of the Ryr gene. This stop fragment contains the strong transcriptional terminator T1T2 from the *E. coli* *rmB* gene (Orosz et al (1991) *Eur J Biochem* 201:653-659). Also present within this stop fragment is a stop codon in frame with the initiator ATG of the vector. Flanking the stop fragment are Lox sites in direct orientation, such that in the presence of the Cre enzyme, the entire stop fragment will be excised from the vector (Odell and Russell (1994) *Homologous Recomb Gene Silencing Plants*; ed, J. Paszkowski; pp 219-270), leaving behind a "footprint" of a single Lox site. The stop vector was designed such that following Cre-mediated excision of the stop fragment, the Ryr gene is in frame with the initiator ATG and there are no stop codons present between the ATG and the Ryr gene. The combination of the ATG, His tag, and *attB1* from the vector and the residual Lox footprint and associated linker sequences, adds 53 foreign amino acids to the mature Ryr gene product. Construction of the pHE7 vector is outlined in Figure 7.

The Invitrogen Gateway Entry™ vector pEntr2B (Invitrogen Life Technologies™, Carlsbad, CA) was modified to add a PvuI site in the polylinker. pEntr2B was digested with EcoRI and KpnI. Two oligonucleotides, SEQ ID NO:131 (5'-gatccgcgcccgatcggtacc-3') and SEQ ID: 132 (5'-cgatcgcgcccgcg -3') were annealed and ligated into the digested vector to produce pEntr2B/PvuI. The HV Ryr gene from pXLHv7 was digested with PacI and PmeI. pENTR2B/PvuI was partially digested with PvuI (there is a second site in pEntr2B/PvuI) and completely digested with EcoRV and the correct fragment was gel-purified. The PacI sticky end of the Ryr fragment is compatible with the PvuI sticky end and the PmeI and EcoRV ends are both blunt. The 15.4 kb Ryr gene fragment from pXLHv7 was then ligated into the pENTR2B/PvuI to create pENTR2B/PvuI/HV7.

The stop fragment was created by annealing 6 oligonucleotides, SEQ ID NO: 133 - SEQ ID NO:138 and then PCR amplified using primers SEQ ID NO:139 (5'-ccttttttcagcgcta-3') and SEQ ID NO:140 (5'-gagagagagtttaaataa-3'). The resulting product was digested with AfeI and DraI to produce blunt ends, and ligated into the unique AfeI site of pXINSECT-DEST39 to produce pDEST39/LOX.

As an alternative to using pDEST39/LOX, the stop fragment from pDEST39/LOX was excised with XbaI and HindIII and cloned into the pIB/V5-His-

DEST (Invitrogen Life Technologies™, Carlsbad, CA) vector cut with XbaI and HindIII to produce pIBDEST/LOX. pIBDEST/LOX and pDEST39/LOX are functionally similar, both having a stop fragment that can be removed by Cre. One difference is the promoter which controls the transcription of the Ryr gene in insect cells is the actin promoter in pDEST39/LOX but the OpIE2 promoter in pIBDEST/LOX. Also, pIBDEST/LOX contains a blasticidin gene to allow stably transfected cells to be selected.

The *Heliothis* ryanodine receptor cDNA was transferred from pENTR2B/PvuII/HV7 to pDEST39/LOX using Invitrogen's Clonase LR reaction according to the manufacturer's recommendation to produce pHE7. In vitro reaction of pHE7 with Cre (Invitrogen) according to the manufacturer's recommendation correctly excised the stop fragment and left behind the predicted Lox footprint.

Excision of the stop fragment from pHE7, in the target insect cells was accomplished by cotransfecting them with pMLS104 (Siegal and Hartl (1996) *Genetics* 144:715-726), as a source of Cre, into SF9 cells. As an alternate approach, the Cre-mediated excision of the stop fragment was done by incubating pHE7 with Cre enzyme in vitro. In these cases, the pMLS104 plasmid was not cotransfected with the pHE7 plasmid. The conditions for the Cre reaction were taken from the Creator DNA cloning kit (BD Biosciences™, San Diego, CA, Clontech Protocol PT3460-1). For each 250 ng of pHE7 plasmid, 100 ng of Cre recombinase (Clontech Laboratories Inc.™, Palo Alto, CA, catalog no.8480-1) was used in a 15 minute, room temperature reaction. The reaction was performed in a reaction solution that included 1X Cre reaction buffer and 1X BSA supplied with the Cre recombinase as purchased from Clontech™. Following the 15 minute reaction, the enzyme was heat-killed at 70 degrees C for 5 minutes. With minor variations to account for non-unique restriction sites, four other Hv clones were constructed (pHI2, pHI3, pHI6, pHI7) with the organization of Cre recognition elements described for pHE7, but fused to the OpIE2 promoter in pIBDEST/LOX.

In a second approach, the toxicity of expression of *Heliothis virescens* Ryr in *E coli*, was overcome using a modified insect expression vector such as pIB/V5-His (Invitrogen). An intron fragment was amplified with primers (forward primer: SEQ ID NO:147, 5'-cagtaaagcttgagtcattggaatttagac-3'; reverse primer: SEQ ID NO:148, 5'-tctggatcctgtgttggaattgggga-3') from *Heliothis virescens* genomic DNA. The purified PCR product was inserted into a pIB vector into the HindIII and BamHI sites. The DNA sequence of the modified vector was confirmed by DNA sequencing and the Ryr gene from pXLHv7 excised and inserted behind the intron (SEQ ID NO:149), to produce vector pIBiHv7.

### Transfection Protocol

All reagents, lab ware and techniques were sterile throughout the transfection. Plasmids were isolated using Qiagen™ plasmid midi prep kit (Qiagen™, Valencia, CA, catalog no. 12143).

5 SF9 cells were grown at 27 degrees C in a Corning 125 ml polycarbonate Erlenmeyer flask to a density of 3.1 million cells per ml in SF900-II serum free media (Gibco catalog no. 10902-088, Invitrogen™, Carlsbad, CA). One million cells were transferred to one well of a Corning 6-well, flat bottom cell culture dish (Corning Inc., Acton, MA, catalog no. 3516). SF900-II media was used to bring the final volume in  
10 the dish to 2 ml and the cells were incubated at 27 degrees C for 21 h. Following the incubation the media was aspirated from the dish and replaced with 1 ml of SF900-II media pre-warmed to 27 degrees C.

In the case of the vectors containing the Cre recognition elements, the transfection solution was mixed in a 1.5 ml microfuge tube by combining 5ug of  
15 pHE7 plasmid, 5ug of pMLS104 Cre plasmid and 0.5ug of lacZ reporter plasmid, 15 ug of cellfectin reagent (Invitrogen cat. # 10362-010) and SF900-II serum free media (Gibco catalog # 10902-088, Invitrogen™, Carlsbad, CA) in a total volume of 500 ul. The solution was incubated for 1 hour at room temperature just prior to the transfection.

20 The transfection was accomplished by adding the transfection solution drop-wise to the dish and incubating 4 h at room temperature with gentle rocking. After the 4 h incubation the media was replaced with 2 ml of SF900-II media pre-warmed to 27 degrees C and the cells were incubated 3 days at 27 degrees C.

25 Functional expression of the Ryr cDNAs was observed for all clones (pHE7, pH12, pH13, pH16, or pH17) as described in Example 9. There was no discernable difference between the functional expression observed from pH17 and pHE7.

As one skilled in the art would appreciate, several excision systems can be used that would be comparable to that described herein. Examples of excision systems would include, but are not limited to, Cre/Lox, Flp/Frt, Clonase™/Att,  
30 Gin/Gix, and R/RS (Odell et al. (1990) *Mol Gen Genet* 223:369-378; Lyznik et al. (1993) *Nuc Acids Res* 21:969-975; Invitrogen Life Technologies™; Maeser and Kahmann (1991) *Mol Gen Genet* 230:170-176; and Onouchi et al. (1991) *Nuc Acids Res* 19: 6373-6378; respectively). These would include homologous excision systems based on the introduction of intron sequences from genomic DNA other  
35 than the sequence (SEQ ID:....) described in the second strategy.

As one skilled in the art would appreciate, several fragments bounded by excision sites can be used to eliminate or down-regulate expression in *E. coli* equivalent to that described herein. Examples of such fragments would include, but

are not limited to, transcriptional terminators, stop codons that are in frame with the Ryr coding sequence, operators that are recognized by transcriptional repressors, translational attenuators, and sequences which interact with antisense or co-suppression constructs.

As one skilled in the art would appreciate, the stop fragment can be inserted at many different locations in the Ryr cDNA equivalent to that described herein. Examples of suitable locations would include, but are not limited to, in the promoter upstream of the gene, in the 5' untranslated leader, within the coding sequence, and in the 3' untranslated region.

#### EXAMPLE 8

##### Expression of Ryr cDNA in Insect Cells

The Ryr cDNA's from *Drosophila melanogaster* (pIB43D, SEQ ID NO: 9), green peach aphid (*Myzus persicae*) (pIB-GPA7-1, SEQ ID NO: 3), cotton melon aphid (*Aphis gossypii*) (pIB-CMA4-3, SEQ ID NO: 5), and corn plant hopper (*Peregrinus maidis*) (pXL-CPH9, SEQ ID NO: 7) are introduced into the Cre-Lox expression system in the same way as for the cDNA's from *Heliothis virescens* described in Example 7. The cDNA's are released from the vector by digestion with PacI and PmeI. In some cases, there is an internal PmeI site in the cDNA and in these cases, a partial PmeI and complete PacI digestion is performed and the fragment corresponding to the full length cDNA is gel-purified. pENTR2B/PvuI is partially digested with PvuI (there is a second site in pEnt2B/PvuI) and completely digested with EcoRV and the correct fragment is gel-purified. The PacI sticky end of the Ryr fragment is compatible with the PvuI sticky end and the PmeI and EcoRV ends are both blunt. The Ryr gene is then ligated into the pENTR2B/PvuI to insert each cDNA into pENTR2B/PvuI.

The cDNA's are transferred from pENTR2B/PvuI into pDEST39/LOX or pIBDEST/LOX with Invitrogen's Clonase LR reaction according to the manufacturer's recommendation. These expression vectors are transfected into SF9 cells either in combination with pMLS104 or following reaction with Cre in vitro using the protocol described in Example 7 and activity of the Ryr is assayed as described in Examples 9-11.

Similarly, any person skilled in the art would be able to excise the Ryr genes from any source, insect or otherwise and ligate into vectors that satisfy the concept of the second approach in that an intron is used to terminate any expression of the toxic gene in the bacterial host, yet be recognized in an insect cell and be excised by the normal RNA processing machinery of the cell. Transfection of cells would be achieved as described in Example 5.

38/8845  
TITLE

JC05 Rec'd PCT/PTO 21 MAR 2005

## ISOLATION AND USE OF RYANODINE RECEPTORS

This application claims the benefit of U.S. Provisional Application No. 60/412,795, filed September 23, 2002, and of U.S. Provisional Application No. 60/427,324, filed November 18, 2002, the disclosures of which are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

The present invention is in the field of ryanodine receptors and, in particular, relates to recombinant constructs useful for modulating ryanodine receptor activity and to methods for evaluating compounds that modulate such activity.

BACKGROUND OF THE INVENTION

Calcium homeostasis in the cytosol of vertebrate and invertebrate muscle cells is essential for normal cellular activity. It is a complex process involving balancing calcium from extracellular sources that moves through calcium selective channels on the plasma membrane of the cell, and calcium in internal stores controlled by a calcium activated calcium release channel located in the membrane of the sarcoplasmic reticulum. Release of calcium from the sarcoplasmic reticulum plays a crucial role in excitation-contraction coupling in muscle tissue (Pessah et al., (1986) *J Biol Chem* 261:8643-8648) and the initiation and propagation of calcium signaling events.

The calcium activated calcium release channel internal to the cell is called the ryanodine receptor (Ryr) because of the interaction of the receptor with a natural insecticide ryanodine, an alkaloid from the *Ryania speciosa*. Ryanodine binding sites have been studied in an effort to understand the properties of the  $Ca^{2+}$  release channel in insects as a possible target for insecticide action (Lehmberg et al., (1994) *Pesticide Biochem and Physiol* 48: 145-152). However, no synthetic insecticides acting on the ryanodine receptor as a primary mode of action have been discovered until recently. Chemistry based on derivatives of anthranilamides with very potent activity on pest species activate this receptor in a manner leading to calcium release, thereby disrupting the calcium balance of the insect cell. The response of the organism as a result of this disruption is unrelieved muscle contraction, including cardiac, skeletal and pharyngeal muscles, leading to lethargy and cessation of feeding.

It is reported in insects that there is only one form of the receptor-ion channel. Studies in insect tissues indicate that the receptor has similar properties and size to its mammalian homologue (Denser et al., (1998) *Pestic. Sci.* 54:345-352). The ryanodine receptor has been most studied in mammals where there are three

currently recognized isoforms (types 1, 2, and 3) which are subject to differential regulation and have different tissue distributions.

Full-length genomic DNA sequence (Takeshima et al. (1994) *FEBS Lett.*, 337: 81-87) and cDNA sequence (Xu et al. (2000) *Biophys J.* 78: 1270-1281) of the *Drosophila* gene encoding a ryanodine receptor is known and available from public databases (NCBI Accession No. D17389), from other invertebrates, e.g. *Caenorhabditis elegans* (NCBI Accession No. D45899) and a small segment of the C-terminus of the ryanodine receptor from the tobacco budworm, a lepidopteran pest (*Heliothis virescens*; Puente et al., (2000) *Insect Biochem. Mol Biol.* 30: 335-347). The sequence from *Drosophila* has been cloned and expressed in Chinese Hamster Ovary (CHO) cells and the receptor-ion channel shown to be functional using electro-conductance techniques (Xu et al. (2000) *Biophys J.* 78: 1270-1281).

Crop destruction by pests such as insects results in a considerable economic loss and serious reduction in productivity. For example, lepidopteran pest species cause \$500MM of damage to various crop species annually. Homopteran pests account for a further \$2000MM. Recently, two areas of chemistry have shown good control of lepidopteran pests. From an analysis of intracellular calcium changes and the physiological response of the pest to the compounds the mode of action is by disruption of normal muscle function through the release and eventual depletion of internal calcium stores in the muscle and central nervous system. Thus, based on the response of cells expressing the ryanodine receptor either in natural or recombinant systems to various types of low molecular weight chemical structures, it is clear the receptor and potentially other attendant components that interact with it are important targets for pest control.

#### SUMMARY OF THE INVENTION

This invention concerns an isolated nucleotide fragment comprising a nucleic acid sequence consisting of a nucleic acid sequence encoding a ryanodine receptor having an amino acid sequence identity of at least 75%, 80%, 85%, 90%, 95%, or 100% when compared to a polypeptide selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, 128, 130, 144, or 146. Also of interest is the complement of such isolated nucleic acid fragments.

In a second embodiment, this invention concerns an isolated nucleic acid fragment wherein the nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO:1, 3, 5, 7, 9, 127, 129, 143, or 145.

In a third embodiment, this invention concerns such previously mentioned nucleic acid fragments, and complements thereof, wherein the fragment or parts thereof are useful in a recombinant construct for the purpose of over-expression, antisense inhibition, or co-suppression of ryanodine receptor activity in a host cell.

In a fourth embodiment, this invention concerns recombinant DNA constructs comprising any of the foregoing nucleic acid fragment or complement thereof or part of either operably linked to at least one regulatory sequence. Also, of interest are eukaryotic or prokaryotic host cells comprising such recombinant DNA constructs in their genome. Useful host cells include, but are not limited to, E.coli, yeast, Sf9, S2, Xenopus oocytes, HEK-293 and CHO cells.

In a fifth embodiment, this invention concerns a method to isolate nucleic acid fragments encoding ryanodine receptors and related polypeptides, comprising:

(a) comparing SEQ ID NO:2, 4, 6, 8, 10, 128, 130, 144, and 146 and other ion channel and receptor polypeptide sequences;

(b) identifying the conserved sequences of 4 or more amino acids obtained in step a;

(c) designing degenerate oligomers based on the conserved sequences identified in step b; and

(d) using the degenerate oligomers of step c to isolate sequences encoding polypeptides having ryanodine receptor activity by sequence dependent protocols.

In a sixth embodiment, this invention concerns an isolated polypeptide having ryanodine receptor activity, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10, 128, 130, 144, or 146 have at least 75%, 80%, 85%, 90%, 95%, or 100% identity. One skilled in the art would realize that any integer percent identity from 75% to 100% would be useful in isolating ryanodine receptor-like polypeptide sequences.

In a seventh embodiment, this invention concerns a method for evaluating at least one compound for its ability to modulate calcium homeostasis, the method comprising the steps of:

(a) transforming a host cell with any one of the aforementioned recombinant constructs;

(b) growing the transformed host cell under conditions that are suitable for expression of the recombinant construct wherein expression of the recombinant construct results in altered calcium homeostasis;

(c) treating the transformed host cell of step (a) with a compound to be tested; and

(d) determining changes in intracellular homeostasis by the test compound in order to select compounds with potential for altering calcium release.

This method wherein the method can be, but is not limited to, a ligand binding assay. Furthermore, this method can be based on assessing functional

activity by detecting the effect of a compound on the functional activity of the transformed host cell or ion channels obtained from such cells.

In an eighth embodiment, this invention concerns a method for evaluating at least one compound which modulates ryanodine receptor activity, the method comprising the steps of:

(a) contacting at least one compound with a polypeptide encoded by any one of the aforementioned isolated nucleic acid fragments; and

(b) evaluating the ryanodine receptor activity of the polypeptide of (a) after said polypeptide has been contacted with the compound or compounds.

This method wherein the method can be, but is not limited to, a ligand binding assay. Furthermore, this method can be useful wherein the polypeptide is contacted with more than one compound.

A further embodiment of the present invention would be an isolated nucleic acid fragment encoding an insect ion channel comprising at least two polypeptide sequences set forth in any of SEQ ID NOs:63-119 provided that said polypeptide sequences do not comprise any of SEQ ID NOs:56, 120-126.

Yet another embodiment would be a method for identifying a nucleic acid sequence encoding an insect ion channel comprising:

a) obtaining an isolated nucleic acid sequence encoding a first polypeptide having at least 100 amino acids;

b) comparing the first polypeptide sequence with a comparative polypeptide sequence selected from the group consisting of SEQ ID NOs:63-119 to identify a region between the first polypeptide and the comparative polypeptide having 100% sequence identity wherein said region is as long as the comparative polypeptide; and

c) repeating step (b) with a different comparative polypeptide sequence, wherein said different comparative polypeptide sequence is selected from the group consisting of SEQ ID NOs:63-119 until a second region having 100% sequence identity is found, wherein said second region is as long as the different comparative polypeptide. The method could be further characterized by the length of the first polypeptide having a length of from 100 to 6,000 amino acids.

Yet a further embodiment of the present invention would be a method for expressing an isolated nucleic acid fragment encoding a toxic insect ion channel comprising:

a) transforming a host with a recombinant construct comprising in the 5' to 3' direction a promoter operably linked to the toxic insect ion channel nucleic acid, wherein the promoter comprises a transcription termination nucleic acid fragment, and/or an in-frame translation stop codon, situated between said promoter



and the isolated nucleic acid fragment encoding the toxic insect ion channel, and further wherein the transcription termination nucleic acid fragment, and/or an in-frame translation stop codon, is flanked on each end by at least one nucleic acid sequence consisting essentially of excisable sequences; and

5           b) growing the transformed host under conditions that are suitable for the expression of the recombinant construct. The excisable sequences may be any sequences recognized by recombinase enzymes, such as but not limited to, lox sites.

10           A related embodiment of the present would encompass the recombinant constructs themselves comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding a toxic insect ion channel, wherein the promoter comprises a transcription termination nucleic acid fragment, and/or at least one in-frame translational termination codon, situated between said promoter and the isolated nucleic acid fragment encoding the toxic insect ion channel, and further  
15           wherein the transcription termination nucleic acid fragment, and/or at least one in-frame translational termination codon, is flanked on each end by at least one nucleic acid sequence consisting essentially of excisable sequences. The excisable sequences may be any sequences recognized by recombinase enzymes, such as but not limited to, lox sites.

20           Another embodiment of the present invention would be a method for expressing an isolated nucleic acid fragment encoding a toxic insect ion channel comprising:

25           a) transforming a host with a recombinant expression construct comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding the toxic insect ion channel, wherein said fragment also comprises an intron which interferes with expression of said fragment, and

            b) growing the transformed host under conditions that are suitable for the expression of the recombinant construct.

30           In still another embodiment, the present invention would encompass a recombinant expression construct comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding a toxic insect ion channel wherein said isolated nucleic acid fragment also comprises an intron which interferes with expression of the toxic insect ion channel.

#### BRIEF DESCRIPTION OF THE FIGURES AND SEQUENCE LISTINGS

35           The invention can be more fully understood from the following detailed description and the accompanying drawings and Sequence Listing which form a part of this application.

Figure 1 shows an alignment of the deduced amino acid sequences for five ryanodine receptors from a lepidopteran species, tobacco budworm (*Heliothis virescens*, SEQ ID NOs:2, 128, 130, 144 and 146), green peach aphid (*Myzus persicae*, SEQ ID NO:4), cotton melon aphid (*Aphis gossypii*, SEQ ID NO:6), and corn plant hopper (*Peregrinus maidis*, SEQ ID NO:8), compared to a fruitfly (*Drosophila melanogaster*) sequence generated by the methods disclosed herein (SEQ ID NO:10), the *Drosophila* art sequence (NCBI General Identifier No. gi 17352471, SEQ ID NO:56), an unannotated sequence from the mosquito (*Anopheles gambiae*) genome sequencing project (gi 21301556, SEQ ID NO:57), the ryanodine receptor from nematodes (*Caenorhabditis elegans*, gi 1871447, SEQ ID NO:58), sea urchin (*Hemicentrotus pulcherrimus*, gi 18656155, SEQ ID NO:59), mouse (*Mus musculus*, gi 13569850, SEQ ID NO:60), rabbit (*Oryctolagus cuniculus*, gi 1245376, SEQ ID NO:61), and human (*Homo sapiens*, gi 4506757, SEQ ID NO:62). Insect specific sequences can be identified by finding homologous subsequences that are conserved between all of the insect sequences but not among the non-insect sequences. A number of these sequences can be found in SEQ ID NOs:63-119.

Figure 2 shows chemical structures of three classes of anthranilamides that were used in the calcium release assays presented in Example 9, or in the radio-labeled binding studies presented in Example 11.

Figure 3 shows an example of calcium responses elicited by either caffeine or Compound 16 (Table 7), from a recombinant *Spodoptera frugiperda* cell line (Sf9) transiently expressing a *Drosophila melanogaster* ryanodine receptor. Cells were challenged 96 hr post-transfection with the ryanodine receptor agonist, caffeine (10 mM) and Compound 16 (10 and 100 nM). No significant calcium responses were observed with caffeine (10 mM) or Compound 16 (10 and 100 nM) in control cells without DNA.

Figure 4 shows an example of calcium responses elicited by either caffeine or Compound 5 (Table 7), from a recombinant *Spodoptera frugiperda* cell line (Sf9) transiently expressing a recombinant *Heliothis virescens* ryanodine receptor. Cells were challenged 72 hr post-transfection with the ryanodine receptor agonist, caffeine (10 mM) and Compound 5 (3  $\mu$ M). No significant calcium responses were observed with caffeine (10 mM) or Compound 5 (3  $\mu$ M) in control cells without DNA.

Figure 5 shows an example of calcium responses elicited by either caffeine or Compound 14 (Table 7), from a recombinant *Spodoptera frugiperda* cell line (Sf9) stably expressing a recombinant *Heliothis virescens* ryanodine receptor. Cells were challenged with the ryanodine receptor agonist, caffeine (10 mM) and Compound 14 (1  $\mu$ M). Sf9 cells were allowed to attach to a glass coverslip then loaded with the

calcium probe Fura-2 AM and assayed using a calcium imaging system to monitor calcium mobilization.

Figure 6 shows the caffeine dose response curve for wild type *Spodoptera frugiperda* (Sf9-WT), and recombinant Sf9 cells stably expressing *Drosophila melanogaster* ryanodine receptors (Sf9-DryR). Sf9 cells were loaded with the calcium probe Fura-2 then plated into a 96-well microtiter plate and assayed using a Molecular Devices' FlexStation™ plate reader with integrated fluidics to measure calcium mobilization.

Figure 7 shows a schematic overview of construction of pHE7. For clarity, DNA fragments are not drawn to scale, circular plasmids are depicted in a linear fashion, and only the relevant portions of the plasmids are shown.

Table 1 lists the polypeptides that are described herein, the designation of the genomic or cDNA clones that comprise the nucleic acid fragments encoding polypeptides representing all or a substantial portion of these polypeptides, and the corresponding identifier (SEQ ID NO:) as used in the attached Sequence Listing. The sequence descriptions and Sequence Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825.

TABLE 1

## Nucleic Acid Fragments Encoding Ryanodine Receptors

Ryanodine Receptor	Clone Designation	SEQ ID NO:	
		(Nucleotide)	(Amino Acid)
tobacco budworm ( <i>Heliothis virescens</i> )	pXL-Hv3-5	1	2
tobacco budworm ( <i>Heliothis virescens</i> )	pXLHv7	127	128
tobacco budworm ( <i>Heliothis virescens</i> )	pXLHv2	129	130
tobacco budworm ( <i>Heliothis virescens</i> )	pXLHv3	143	144
tobacco budworm ( <i>Heliothis virescens</i> )	pXLHv6	145	146
green peach aphid ( <i>Myzus persicae</i> )	pIB-GPA7-1	3	4
cotton melon aphid ( <i>Aphis gossypii</i> )	pIB-CMA4-3	5	6
corn plant hopper ( <i>Peregrinus maidis</i> )	pXL-CPH9	7	8
fruit fly ( <i>Drosophila melanogaster</i> )	pIB43D	9	10

The odd-numbered SEQ ID NOs:1, 3, 5, 7, 9, 127, 129, 143, and 145 represent the polynucleotide sequences for the sequences encoding a ryanodine receptor from the species indicated. The even-numbered SEQ ID NOs:2, 4, 6, 8, 10, 128, 130, 144, and 146 represent the translated amino acid sequence derived from the corresponding odd-numbered polynucleotide sequence. SEQ ID NOs:11-55 are nucleotide primers used in PCR amplification, and sequencing, experiments during the isolation and characterization of the ryanodine receptors from various insect sources. An unannotated mosquito genomic sequence (SEQ ID NO:57) is believed to encode a partial ryanodine receptor (from analysis done by the authors of the present invention). SEQ ID NOs:56, 58-62 and 120-126 are ryanodine receptor sequences existing in the Genbank database. SEQ ID NOs:63-119 are amino acid sequence motifs believed to be conserved in insect ryanodine receptors. SEQ ID NOs:131-142 represent PCR primer sequences and oligonucleotides used in the amplification of ryanodine receptor coding regions for cloning into expression vectors (see Example 7).

The Sequence Listing contains the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUBMB standards described in *Nucleic Acids Res.* 13:3021-3030 (1985) and in the *Biochemical J.* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

#### DETAILED DESCRIPTION OF THE INVENTION

As used herein, an "isolated nucleic acid fragment" is a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. An isolated nucleic acid fragment in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA. Nucleotides (usually found in their 5'-monophosphate form) are referred to by their single letter designation as follows: "A" for adenylate or deoxyadenylate (for RNA or DNA, respectively), "C" for cytidylate or deoxycytidylate, "G" for guanylate or deoxyguanylate, "U" for uridylate, "T" for deoxythymidylate, "R" for purines (A or G), "Y" for pyrimidines (C or T), "K" for G or T, "H" for A or C or T, "I" for inosine, "W" for A or T, "S" for C or G, and "N" for any nucleotide.

The terms "subfragment that is functionally equivalent" and "functionally equivalent subfragment" are used interchangeably herein. These terms refer to a portion or subsequence of an isolated nucleic acid fragment in which the ability to alter gene expression or produce a certain phenotype is retained whether or not the fragment or subfragment encodes an active enzyme. For example, the fragment or subfragment can be used in the design of chimeric constructs to produce the desired phenotype in a transformed plant. Chimeric constructs can be designed for use in co-suppression or antisense by linking a nucleic acid fragment or subfragment thereof, whether or not it encodes an active enzyme, in the appropriate orientation relative to a plant promoter sequence.

The terms "homology", "homologous", "substantially similar", "consisting essentially of", and "corresponding substantially" are used interchangeably herein. They refer to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid fragment to mediate gene expression or produce a certain phenotype. These terms also refer to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially alter the functional properties of the resulting nucleic acid fragment relative to the initial, unmodified fragment. It is therefore understood, as those skilled in the art will appreciate, that the invention encompasses more than the specific exemplary sequences.

Moreover, the skilled artisan recognizes that substantially similar nucleic acid sequences encompassed by this invention are also defined by their ability to hybridize, under moderately stringent conditions (for example, 1 X SSC, 0.1% SDS, 60°C) with the sequences exemplified herein, or to any portion of the nucleotide sequences reported herein and which are functionally equivalent to the gene or the promoter of the invention. Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar fragments, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes determine stringency conditions. One set of preferred conditions involves a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 45°C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions involves the use of higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60°C. Another preferred set of highly stringent conditions involves the use of two final washes in 0.1X SSC, 0.1% SDS at 65°C.

With respect to the degree of substantial similarity between the target (endogenous) mRNA and the RNA region in the construct having homology to the target mRNA, such sequences should be at least 25 nucleotides in length, preferably at least 50 nucleotides in length, more preferably at least 100 nucleotides in length, again more preferably at least 200 nucleotides in length, and most preferably at least 300 nucleotides in length; and should be at least 80% identical, preferably at least 85% identical, more preferably at least 90% identical, and most preferably at least 95% identical.

It is well understood by one skilled in the art that many levels of sequence identity are useful in identifying related polypeptide sequences. Useful examples of percent identities are 75%, 80%, 85%, 90%, or 95%, or any integer percentage from 75% to 100%. Sequence alignments and percent similarity calculations may be determined using a variety of comparison methods designed to detect homologous sequences including, but not limited to, the Megalign program of the LASARGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences are performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments and calculation of percent identity of protein sequences using the Clustal method are KTUPLE=1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. For nucleic acids these parameters are KTUPLE=2, GAP PENALTY=5, WINDOW=4

and DIAGONALS SAVED=4. For large protein sequences the Clustal W program (Thompson et al. (1994) Nuc Acids Res 22:4673-4680) was used. Default parameters were used (GAP PENALTY=10, GAP LENGTH PENALTY=0.2, DELAY DIVERGENT SEQ (%)=30, DNA TRANSITION WEIGHT=0.50, PROTEIN WEIGHT MATRIX: Gonnet 250, DNA WEIGHT MATRIX:IUB). Pairwise alignment also used default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=0.10, PROTEIN WEIGHT MATRIX: Gonnet Series, DNA WEIGHT MATRIX:IUB).

"Gene" refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. "Native gene" refers to a gene as found in nature with its own regulatory sequences. "Chimeric construct", "recombinant construct", or recombinant expression construct" refers to a combination of nucleic acid fragments that are not normally found together in nature. Accordingly, a recombinant construct may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that normally found in nature. A "foreign" gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric constructs. A "transgene" is a gene that has been introduced into the genome by a transformation procedure.

"Coding sequence" refers to a DNA sequence that codes for a specific amino acid sequence. "Regulatory sequences" refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include, but are not limited to, promoters, translation leader sequences, introns, and polyadenylation recognition sequences. The term "in-frame translational termination codon" refers to a UAA, UAG, or UGA stop codon present within the preferred reading frame of an RNA transcript.

"Promoter" refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an "enhancer" is a DNA sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoter sequences can also be located within the transcribed portions of genes, and/or downstream of the transcribed sequences. Promoters may be derived in their

entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a gene to be expressed in most cell types at most times are commonly referred to as "constitutive promoters". New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and Goldberg, (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of some variation may have identical promoter activity. The term "inducible promoter" refers to a promoter that is normally quiescent that can be activated by trans-acting factors. Examples of such factors include, but are not limited to, proteins, chemicals, and factors that alter the local structure of the DNA.

An "intron" is an intervening sequence in a gene that does not encode a portion of the protein sequence. Thus, such sequences are transcribed into RNA but are then excised and are not translated. The term is also used for the excised RNA sequences. An "exon" is a portion of the sequence of a gene that is transcribed and is found in the mature messenger RNA derived from the gene, but is not necessarily a part of the sequence that encodes the final gene product.

The "translation leader sequence" refers to a DNA sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner, R. and Foster, G. D. (1995) *Molecular Biotechnology* 3:225).

The "3' non-coding sequences" refer to DNA sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al., (1989) *Plant Cell* 1:671-680.

"RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript



or it may be a RNA sequence derived from post-transcriptional processing of the primary transcript and is referred to as the mature RNA. "Messenger RNA (mRNA)" refers to the RNA that is without introns and that can be translated into protein by the cell. "cDNA" refers to a DNA that is complementary to and synthesized from a mRNA template using the enzyme reverse transcriptase. The cDNA can be single-stranded or converted into the double-stranded form using the Klenow fragment of DNA polymerase I. "Sense" RNA refers to RNA transcript that includes the mRNA and can be translated into protein within a cell or *in vitro*. "Antisense RNA" refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (U.S. Patent No. 5,107,065). The complementarity of an antisense RNA may be with any part of the specific gene transcript, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. "Functional RNA" refers to antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes. The terms "complement" and "reverse complement" are used interchangeably herein with respect to mRNA transcripts, and are meant to define the antisense RNA of the message.

The term "endogenous RNA" refers to any RNA which is encoded by any nucleic acid sequence present in the genome of the host prior to transformation with the recombinant construct of the present invention, whether naturally-occurring or non-naturally occurring, i.e., introduced by recombinant means, mutagenesis, etc.

The term "non-naturally occurring" means artificial, not consistent with what is normally found in nature.

The term "operably linked" refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is regulated by the other. For example, a promoter is operably linked with a coding sequence when it is capable of regulating the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in a sense or antisense orientation. In another example, the complementary RNA regions of the invention can be operably linked, either directly or indirectly, 5' to the target mRNA, or 3' to the target mRNA, or within the target mRNA, or a first complementary region is 5' and its complement is 3' to the target mRNA.

The term "transcriptional termination nucleic acid fragment" refers to a nucleic acid fragment containing sequences recognized by nucleic acid binding proteins, or causing secondary structure(s), that cause RNA polymerase to stop transcription.

The term "expression", as used herein, refers to the production of a functional end-product. Expression of a gene involves transcription of the gene and translation of the mRNA into a precursor or mature protein. "Antisense inhibition" refers to the production of antisense RNA transcripts capable of suppressing the expression of the target protein. "Co-suppression" refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Patent No. 5,231,020).

The term "excisable sequence", "excision site", or "excision sequence" are used interchangeably, and refer to any sequence, such as the Lox sequence, that is recognized by a recombinase enzyme, such as Cre. The activity of the Cre removes two Lox sequences, and any other nucleic acid between the Lox sequences, from a longer DNA fragment by recombination. As one skilled in the art would appreciate, several excision systems can be used that would be comparable to Cre/Lox described in Example 7. Examples of excision systems would include, but are not limited to, Cre/Lox (Odell et al. (1990) *Mol Gen Genet* 223:369-378); Flp/Frt (Lyznik et al. (1993) *Nuc Acids Res* 21:969-975); Clonase™/Att (Invitrogen Life Technologies™); Gin/Gix (Maeser and Kahmann (1991) *Mol Gen Genet* 230:170-176); and R/RS (Onouchi et al. (1991) *Nuc Acids Res* 19: 6373-6378).

As one skilled in the art would appreciate, several fragments flanked by excision sites can be used to eliminate or down-regulate expression in host cells equivalent to that described herein. Examples of such fragments include, but are not limited to, transcriptional terminators, stop codons that are in frame with the Ryr coding sequence, operators that are recognized by transcriptional repressors, translational attenuators, and sequences which interact with antisense or co-suppression constructs.

As one skilled in the art would appreciate, a stop fragment can be inserted at many different locations in the Ryr cDNA equivalent to that described herein. Examples of suitable locations would include, but are not limited to, in the promoter upstream of the gene, in the 5' untranslated leader, within the coding sequence, and in the 3' untranslated region.

As one skilled in the art would realize, placement of an intron within the coding region of a ryanodine receptor gene would impair the expression of active ryanodine receptor in host cells that are incapable of processing the intron removal from the RNA transcript.

"Mature" protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. "Precursor" protein refers to the primary product of translation

of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

"Motifs", "subsequences" or "segment" refer to short regions of conserved sequences of nucleic acids or amino acids that comprise part of a longer sequence. For example, it is expected that such conserved subsequences would be important for function, and could be used to identify new homologues of ryanodine receptors. It is expected that some or all of the elements may be found in a putative ryanodine receptor. Also, it is expected that one or two of the conserved amino acids in any given motif may differ in a true ryanodine receptor.

The term "homologous subsequence" used herein is meant to indicated two sequences that have 100% identity and co-linearity without gaps when aligned.

"Stable transformation" refers to the transfer of a nucleic acid fragment into a genome of a host organism, including both nuclear and organellar genomes, resulting in genetically stable inheritance. In contrast, "transient transformation" refers to the transfer of a nucleic acid fragment into the nucleus, or DNA-containing organelle, of a host organism resulting in gene expression without integration or stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" organisms. The preferred method of cell transformation of rice, corn and other monocots is the use of particle-accelerated or "gene gun" transformation technology (Klein et al., (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050), or an *Agrobacterium*-mediated method using an appropriate Ti plasmid containing the transgene (Ishida Y. et al., 1996, *Nature Biotech.* 14:745-750). The term "transformation" as used herein refers to both stable transformation and transient transformation.

The term "host cell" refers to any cell or organism into which an isolated nucleic acid fragment has been stably or transiently introduced. The host cell may be part of a larger organism, an individual in tissue culture, or a free-living organism. Examples of host cells include, but are not limited to, bacteria, fungi, insect, plant, and animal.

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook, J., Fritsch, E.F. and Maniatis, T. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter "Sambrook").

The term "recombinant" refers to an artificial combination of two otherwise separated segments of sequence, e.g., by chemical synthesis or by the manipulation of isolated segments of nucleic acids by genetic engineering techniques.

of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

"Motifs", "subsequences" or "segment" refer to short regions of conserved sequences of nucleic acids or amino acids that comprise part of a longer sequence.

For example, it is expected that such conserved subsequences would be important for function, and could be used to identify new homologues of ryanodine receptors. It is expected that some or all of the elements may be found in a putative ryanodine receptor. Also, it is expected that one or two of the conserved amino acids in any given motif may differ in a true ryanodine receptor.

The term "homologous subsequence" used herein is meant to indicated two sequences that have 100% identity and co-linearity without gaps when aligned.

"Stable transformation" refers to the transfer of a nucleic acid fragment into a genome of a host organism, including both nuclear and organellar genomes, resulting in genetically stable inheritance. In contrast, "transient transformation" refers to the transfer of a nucleic acid fragment into the nucleus, or DNA-containing organelle, of a host organism resulting in gene expression without integration or stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" organisms. The preferred method of cell transformation of rice, corn and other monocots is the use of particle-accelerated or "gene gun" transformation technology (Klein et al., (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050), or an *Agrobacterium*-mediated method using an appropriate Ti plasmid containing the transgene (Ishida Y. et al., 1996, *Nature Biotech.* 14:745-750). The term "transformation" as used herein refers to both stable transformation and transient transformation.

The term "host cell" refers to any cell or organism into which an isolated nucleic acid fragment has been stably or transiently introduced. The host cell may be part of a larger organism, an individual in tissue culture, or a free-living organism. Examples of host cells include, but are not limited to, bacteria, fungi, insect, plant, and animal.

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook, J., Fritsch, E.F. and Maniatis, T. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter "Sambrook").

The term "recombinant" refers to an artificial combination of two otherwise separated segments of sequence, e.g., by chemical synthesis or by the manipulation of isolated segments of nucleic acids by genetic engineering techniques.

"PCR" or "Polymerase Chain Reaction" is a technique for the synthesis of large quantities of specific DNA segments, consists of a series of repetitive cycles (Perkin Elmer Cetus Instruments, Norwalk, CT). Typically, the double stranded DNA is heat denatured, the two primers complementary to the 3' boundaries of the target segment are annealed at low temperature and then extended at an intermediate temperature. One set of these three consecutive steps is referred to as a cycle.

Polymerase chain reaction ("PCR") is a powerful technique used to amplify DNA millions of fold, by repeated replication of a template, in a short period of time. (Mullis et al, *Cold Spring Harbor Symp. Quant. Biol.* 51:263-273 (1986); Erlich et al, European Patent Application 50,424; European Patent Application 84,796; European Patent Application 258,017, European Patent Application 237,362; Mullis, European Patent Application 201,184, Mullis et al U.S. Patent No. 4,683,202; Erlich, U.S. Patent No. 4,582,788; and Saiki et al, U.S. Patent No. 4,683,194). The process utilizes sets of specific in vitro synthesized oligonucleotides to prime DNA synthesis. The design of the primers is dependent upon the sequences of DNA that are desired to be analyzed. The technique is carried out through many cycles (usually 20-50) of melting the template at high temperature, allowing the primers to anneal to complementary sequences within the template and then replicating the template with DNA polymerase.

The products of PCR reactions are analyzed by separation in agarose gels followed by ethidium bromide staining and visualization with UV transillumination. Alternatively, radioactive dNTPs can be added to the PCR in order to incorporate label into the products. In this case the products of PCR are visualized by exposure of the gel to x-ray film. The added advantage of radiolabeling PCR products is that the levels of individual amplification products can be quantitated.

The terms "recombinant construct", "expression construct" and "recombinant expression construct" are used interchangeably herein. These terms refer to a functional unit of genetic material that can be inserted into the genome of a cell using standard methodology well known to one skilled in the art. Such construct may be itself or may be used in conjunction with a vector. If a vector is used then the choice of vector is dependent upon the method that will be used to transform host plants as is well known to those skilled in the art. For example, a plasmid vector can be used. The skilled artisan is well aware of the genetic elements that must be present on the vector in order to successfully transform, select and propagate host cells comprising any of the isolated nucleic acid fragments of the invention. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al., (1985) *EMBO J.* 4:2411-2418; De Almeida et al., (1989) *Mol. Gen. Genetics*

218:78-86), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

5       The term "ryanodine receptor" as used herein refers to an internal calcium (Ca or Ca<sup>++</sup>) release channel-receptor associated with the endoplasmic/sarcoplasmic reticulum. While these channels are known to exhibit selectivity for calcium ions, other cations such as, but not limited to, potassium can permeate through these channels. The terms "ryanodine receptor", "ion channel  
10 receptor", "ion channel", and "ryanodine-like receptor" are meant to encompass the family of ion-channel membrane proteins of the present invention. The terms are used interchangeably herein. The ryanodine receptor does not necessarily require ryanodine binding activity to serve as an ion channel. Functional ion channels with the characteristics described in the present invention are claimed even when the  
15 binding of ryanodine or other compounds may be altered due to amino acid changes in the protein sequence. The binding of other non-ryanodine compounds by the ryanodine receptor may occur at the same, or different, regions of the ryanodine receptor.

20       The term "toxic nucleic acid fragment", "toxic ryanodine receptor nucleic acid fragment", or "toxic insect ion channel" refers to an isolated nucleic acid fragment or subfragment thereof which when present in an organism causes the growth and/or survival of the organism to be compromised. Toxicity may be due to the isolated nucleic acid fragment itself, an RNA that is transcribed from the isolated nucleic acid  
25 fragment or a protein which is translated from an RNA derived from the isolated nucleic acid fragment. The growth defect caused by the gene may be alleviated by a mutation within the isolated nucleic acid fragment or subfragment thereof that modifies that part of the gene that causes the toxicity. In this case, growth impairment may be entirely relieved, but the original gene is still considered toxic because growth impairment was only relieved by the modification of the isolated  
30 nucleic acid fragment.

35       The present invention relates to an isolated nucleotide fragment comprising: a nucleic acid sequence encoding a ryanodine receptor having an amino acid sequence identity of at least 75% when compared to a polypeptide selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, 128, 130, 144, and 146; or the complement thereof.

In a preferred embodiment, the amino acid sequence identity can be at least 80%, 85%, 90%, 95% or 100% or any integer percentage from 80% to 100%.

The isolated nucleic acid fragment encoding a ryanodine receptor which is modulated by ryanodine alkaloids and anthranilamide insecticides has been isolated from the lepidopteran, tobacco budworm (*Heliothis virescens*, five isoforms) and three homopteran insects, cotton melon aphid (*Aphis gossypii*) corn plant hopper  
5 (*Peregrinus maidis*) green peach aphid (*Myzus persicae*), and fruit fly (*Drosophila melanogaster*). Heretofore, the full-length nucleic acid sequence or amino acid sequence of the ryanodine receptor from tobacco budworm, a lepidopteran pest species, was not known, nor that there are at least two variants of these nucleic acid sequences. Examples of homopteran sequences from cotton melon aphid, corn  
10 plant hopper, and green peach aphid were also unknown previous to the disclosure in the present invention. The fruit fly sequence is a new variant that differs from all previously disclosed nucleic acid sequences encoding a *Drosophila* ryanodine receptor.

Nucleic acid fragments were isolated from these pest species using PCR and  
15 their DNA and amino acid sequence as described below in the Examples. The use of these genes for the development of assays to screen for other insecticides with similar modes of action is described. Use of the isolated nucleic acid fragments, subfragments thereof or the polypeptide encoded by these fragments for insecticidal applications is also disclosed.

The isolated nucleic acid fragments can be expressed in cells to provide a  
20 functioning ryanodine receptor that responds to the presence or absence of modulators of calcium homeostasis. This would provide a basis to screen for compounds that activate the release of internal calcium stores, block their release or like ryanodine, hold the ion channel in an open configuration at particular  
25 concentrations, yet block the channel at elevated concentrations.

Thus, in another embodiment the present invention concerns a method for evaluating at least one compound for its ability to modulate calcium homeostasis, the method comprising the steps of:

(a) transforming a host cell with a recombinant construct as described  
30 herein;

(b) growing the transformed host cell under conditions that are suitable for expression of the recombinant construct wherein expression of the recombinant construct results in altered calcium homeostasis;

(c) treating the transformed host cell of step (a) with a compound to be  
35 tested; and

(d) determining changes in intracellular calcium homeostasis by the test compound in order to select compounds with potential for altering calcium release.

"Modulation" as used herein refers to the alteration of the function of activity of the protein, in this case, alteration of calcium homeostasis or as mentioned below, alteration of ryanodine receptor activity.

In still a further embodiment, this invention concerns a method for evaluating at least one compound which modulates ryanodine receptor activity, the method comprising the steps of:

(a) contacting at least one compound with a polypeptide encoded by an isolated nucleic acid fragment of the invention; and

(b) evaluating the ryanodine receptor activity of the polypeptide of (a) after said polypeptide has been contacted with the compound or compounds.

The ryanodine receptor from a variety of species is functional as a homotetramer of subunits each one being about 0.5MDa in size. The C-terminal 20% of the protein forms the membrane spanning region that constitutes the channel through which calcium ions flow into the cytosolic milieu from internal calcium stores (Bhat et al. (1997), *Biophys J* 73:1329-36). The remaining 80% of the protein on the cytosolic side of the membrane interacts with a number of other proteins and cellular low molecular weight components. The effects of these components is to modulate calcium flow by favoring the 'open' or 'closed' state of the channel thus the release of calcium and the balance of the ion in the cytosol relative to internal stores.

The effect of interfering with the calcium balance particularly in muscle tissue is to disrupt the normal processes involved in contraction and relaxation, i.e. excitation-contraction coupling (ECC). For example, mutations in the human cardiac ryanodine type 2 receptor have been implicated in sudden cardiac arrest syndrome (Marks et al (2000) *Cell* 101:365-76) and malignant hypothermia (Tong et al (1997) *J Biol Chem* 272:26322-26326).

While ryanodine has been used as a natural insect control agent, the structural complexity of the compound has prevented significant commercialization. It would be desirable to identify easily synthesized small compounds, possessing insecticidal activity, that stimulate the release of internal calcium stores via interaction with the ryanodine receptor complex.

Other small molecules that have been found to interact with the ryanodine receptor are those based on an anthranilamide structure. Examples of these molecules termed "GN analog" compounds are shown in Figure 2 and their use is outlined in Examples 9 and 11. It is envisioned that many types of chemistry and derivatives may be useful in altering the function of the ryanodine receptor complex. While the overall effect on the organism is comparable to that of ryanodine, namely lethargy and paralysis, these other molecules differ in their mode of action from



### Transfection Protocol

All reagents, lab ware and techniques were sterile throughout the transfection. Plasmids were isolated using Qiagen™ plasmid midi prep kit (Qiagen™, Valencia, CA, catalog no. 12143).

5 SF9 cells were grown at 27 degrees C in a Corning 125 ml polycarbonate Erlenmeyer flask to a density of 3.1 million cells per ml in SF900-II serum free media (Gibco catalog no. 10902-088, Invitrogen™, Carlsbad, CA). One million cells were transferred to one well of a Corning 6-well, flat bottom cell culture dish (Corning Inc., Acton, MA, catalog no. 3516). SF900-II media was used to bring the final volume in  
10 the dish to 2 ml and the cells were incubated at 27 degrees C for 21 h. Following the incubation the media was aspirated from the dish and replaced with 1 ml of SF900-II media pre-warmed to 27 degrees C.

In the case of the vectors containing the Cre recognition elements, the transfection solution was mixed in a 1.5 ml microfuge tube by combining 5ug of  
15 pHE7 plasmid, 5ug of pMLS104 Cre plasmid and 0.5ug of lacZ reporter plasmid, 15 ug of cellfectin reagent (Invitrogen cat. # 10362-010) and SF900-II serum free media (Gibco catalog # 10902-088, Invitrogen™, Carlsbad, CA) in a total volume of 500 ul. The solution was incubated for 1 hour at room temperature just prior to the transfection.

20 The transfection was accomplished by adding the transfection solution drop-wise to the dish and incubating 4 h at room temperature with gentle rocking. After the 4 h incubation the media was replaced with 2 ml of SF900-II media pre-warmed to 27 degrees C and the cells were incubated 3 days at 27 degrees C.

25 Functional expression of the Ryr cDNAs was observed for all clones (pHE7, pH12, pH13, pH16, or pH17) as described in Example 9. There was no discernable difference between the functional expression observed from pH17 and pHE7.

As one skilled in the art would appreciate, several excision systems can be used that would be comparable to that described herein. Examples of excision systems would include, but are not limited to, Cre/Lox, Flp/Frt, Clonase™/Att,  
30 Gin/Gix, and R/RS (Odell et al. (1990) *Mol Gen Genet* 223:369-378; Lyznik et al. (1993) *Nuc Acids Res* 21:969-975; Invitrogen Life Technologies™; Maeser and Kahmann (1991) *Mol Gen Genet* 230:170-176; and Onouchi et al. (1991) *Nuc Acids Res* 19: 6373-6378; respectively). These would include homologous excision systems based on the introduction of intron sequences from genomic DNA other  
35 than the sequence (SEQ ID:....) described in the second strategy.

As one skilled in the art would appreciate, several fragments bounded by excision sites can be used to eliminate or down-regulate expression in *E. coli* equivalent to that described herein. Examples of such fragments would include, but

are not limited to, transcriptional terminators, stop codons that are in frame with the Ryr coding sequence, operators that are recognized by transcriptional repressors, translational attenuators, and sequences which interact with antisense or co-suppression constructs.

As one skilled in the art would appreciate, the stop fragment can be inserted at many different locations in the Ryr cDNA equivalent to that described herein. Examples of suitable locations would include, but are not limited to, in the promoter upstream of the gene, in the 5' untranslated leader, within the coding sequence, and in the 3' untranslated region.

#### EXAMPLE 8

##### Expression of Ryr cDNA in Insect Cells

The Ryr cDNA's from *Drosophila melanogaster* (pIB43D, SEQ ID NO: 9), green peach aphid (*Myzus persicae*) (pIB-GPA7-1, SEQ ID NO: 3), cotton melon aphid (*Aphis gossypii*) (pIB-CMA4-3, SEQ ID NO: 5), and corn plant hopper (*Peregrinus maidis*) (pXL-CPH9, SEQ ID NO: 7) are introduced into the Cre-Lox expression system in the same way as for the cDNA's from *Heliothis virescens* described in Example 7. The cDNA's are released from the vector by digestion with *PacI* and *PmeI*. In some cases, there is an internal *PmeI* site in the cDNA and in these cases, a partial *PmeI* and complete *PacI* digestion is performed and the fragment corresponding to the full length cDNA is gel-purified. *pENTR2B/PvuI* is partially digested with *PvuI* (there is a second site in *pENTR2B/PvuI*) and completely digested with *EcoRV* and the correct fragment is gel-purified. The *PacI* sticky end of the Ryr fragment is compatible with the *PvuI* sticky end and the *PmeI* and *EcoRV* ends are both blunt. The Ryr gene is then ligated into the *pENTR2B/PvuI* to insert each cDNA into *pENTR2B/PvuI*.

The cDNA's are transferred from *pENTR2B/PvuI* into *pDEST39/LOX* or *pIBDEST/LOX* with Invitrogen's Clonase LR reaction according to the manufacturer's recommendation. These expression vectors are transfected into SF9 cells either in combination with *pMLS104* or following reaction with Cre in vitro using the protocol described in Example 7 and activity of the Ryr is assayed as described in Examples 9-11.

Similarly, any person skilled in the art would be able to excise the Ryr genes from any source, insect or otherwise and ligate into vectors that satisfy the concept of the second approach in that an intron is used to terminate any expression of the toxic gene in the bacterial host, yet be recognized in an insect cell and be excised by the normal RNA processing machinery of the cell. Transfection of cells would be achieved as described in Example 5.

## EXAMPLE 9

### Calcium Release Assays

#### Calcium imaging and acquisition protocols using primary insect cells:

Embryonic neuronal cultures of the American cockroach *Periplaneta*

5 *americana* were established, with minor modifications, following the method of Beadle and Lees (1988) (in Cell Culture Approaches to Invertebrate Neuroscience, Academic Press, New York, pp 123-127). Briefly, 26-27-day old oothecae were collected, surface-sterilized and cut open along a line one-third of the distance below the dorsal midline. The heads were removed and placed in Schneider's  
10 *Drosophila* medium (Invitrogen Life Technologies™, Carlsbad, CA). Using fine forceps 40 brains were individually removed and placed in a small glass vial containing 700 µl of '5 + 4' medium ('5 + 4' medium contained 5 parts Schneider's *Drosophila* medium plus 4 parts roach Basal Medium Eagle, with Earle's salts (BME, Sigma™, St. Louis, MO). Roach BME (with Earle's salts) contained 5 parts  
15 Hepes (1 M), 1 part penicillin/streptomycin and 44 parts BME (with Earle's salts). '5 + 4' medium was made fresh and sterile filtered (0.2 µm filter) just prior to use). The brains were dissociated by sequential trituration as follows: 1) brains were passed through a standard Pasteur pipette 10 times; 2) the resulting tissue suspension was passed an additional 5 times through a Pasteur pipet with tip flamed to about half of  
20 its original diameter; 3) a final 5 passes were performed using a Pasteur pipet with tip flamed to slightly less than half of its original diameter. A repeat pipettor was used to dispense a 5 µl volume of the resulting suspension into the center of each well of a 96-well, glass-bottom plate previously coated with poly-L-lysine (0.2 mg/ml solution). Cells attached to the bottom of the wells during a 50 min incubation at 27-  
25 29 °C. 150 µl of a 1:1 mixture of Leibovitz's L-15 medium and Yunker's modified Grace's medium was added, and plates were maintained in a humid incubator at 27-29 °C until use. After cells were allowed to attach wells were filled with a 1:1 mixture of Leibovitz's L-15 medium and Yunker's modified Grace's medium (Leibovitz's L-15 and Grace's medium were obtained from Invitrogen Life  
30 Technologies™, Carlsbad, CA and Yunker's modified Grace's medium was made with Grace's medium modified by addition of 5 mg L-methionine, 10 mg L-alanine, 182 mg MgCl<sub>2</sub>·6H<sub>2</sub>O, 1 g Albumin Fraction V, 7 ml Fetal bovine serum, 10 ml Chick embryo extract, 2 ml Penicillin/Streptomycin, and 2 mg 20-hydroxyecdysone (prepared in ethanol prior to addition) to a final volume of 100 ml and sterile filtered (0.2 µm filter)). Cells were maintained in a high humidity incubator at 29 °C until  
35 testing.

The calcium imaging and acquisition protocols using roach neuronal cells is as follows:

Cells were rinsed in standard physiological saline having the following composition (mM): NaCl 190; CaCl<sub>2</sub> 9; KCl 3.1; probenidol 1; Tris buffer 10; pH 7.2. Cells were then bathed in standard physiological saline containing the calcium sensitive fluoroprobe Fluo-4 AM (2  $\mu$ M) and Pluronic F127 (0.002%) for 45 min.

5 Cells were then rinsed in standard physiological saline for at least 15 min prior to testing. Within the hour prior to testing, standard physiological saline was replaced with standard physiological saline containing the organic cation channel blocker pimozone (10  $\mu$ M), to inhibit influx of external calcium through voltage-gated calcium channels. The 96-well plate was placed on a Prior™ motorized stage mounted onto  
10 a Nikon Diaphot microscope and imaged using a 20X Fluor objective (NA 0.75). Individual wells from the 96-well plate were sequentially excited with light at 495 nm, and the emitted fluorescence at 530 nm was detected using a Hamamatsu ORCA ER digital camera with 2 pixel binning (image size 672 x 512 pixels).

Acquisition control, image processing and image analysis were conducted  
15 using Universal Imaging Corporation's MetaMorph™ imaging software (Universal Imaging, West Chester, PA). A series of 3 "control" images were acquired for each well. Experimental compounds were added followed by acquisition of 4  
"experimental" images for each well. Finally, a positive control compound (a GN analog from Group 2 in Table 7) was added and 2 "standard" images acquired for  
20 each well. Experimental and positive control compounds were added via a multi-channel pipettor, although an automated fluidic system could also be used.

After completion of image acquisition for single or multiple test plates, post-acquisition image processing was performed on the stack of 9 images from each individual well consisting of the following operations: (1) A "classification" image  
25 was generated which consisted of a composite of the maximum gray value for each pixel in the image stack. This "classification" image was then used for cell identification. (2) In order to differentiate cell fluorescence from that of background or cellular debris a threshold was set inclusive of pixels having values between 1100–4090 (12-bit image, maximum value of 4095). (3) Individual cells were  
30 identified based on meeting the following morphometric criteria: (a) Cell perimeter having a total area between 98–750 pixels, (b) Cell shape being elliptical or round in nature, measured as the ratio of length to breadth (1.0–2.5), and (c) Cells being devoid of "holes" in the region of interest (pixels with gray values excluded by the threshold in the second operation described above). Such parameters had been  
35 experimentally optimized for this cell type.

From the above "classification" image regions of interest (ROIs) were generated along the periphery of each identified cell and the mean pixel value for each ROI measured. This measurement was repeated for each image in the stack.

Similar calculations were conducted across each well on the 96-well plate and all data recorded in a spreadsheet program such as Microsoft Excel™. Compound-stimulated release of internal calcium stores resulted in a rise in free intracellular  $[Ca^{2+}]$  which thereby caused the fluorescence emission of Fluo-4 to increase.

- 5 Alternatively, Fluo-3 AM, Fura-2 AM or other calcium-sensitive fluoroprobes could also be used.

Calcium imaging and acquisition protocols using recombinant insect cell lines:

- Several drops of a suspension of recombinant *Spodoptera frugiperda* cell line, Sf9, transiently expressing insect ryanodine receptors were placed on a poly-L-lysine-coated coverslip and allowed to attach. Cells were then rinsed in physiological saline having the following composition (mM): NaCl 130; KCl 5.4; MgCl<sub>2</sub> 1.2; CaCl<sub>2</sub> 1.0; NaHCO<sub>3</sub> 4.2; NaH<sub>2</sub>PO<sub>4</sub> 7.3; Glucose 10; Sucrose 63; MES 20; pH 6.3. Cells were then bathed in physiological saline containing the calcium sensitive fluoroprobe, Fura-2 AM (2  $\mu$ M), and Pluronic F127 (0.002%) for 30 min.
- 15 Cells were rinsed in standard physiological saline for at least 15 min prior to testing. Testing was conducted in standard physiological saline, as the cell lines are devoid of functional voltage-gated calcium channels.

- Imaging studies were conducted using a Nikon Diaphot microscope with a 40X oil immersion objective (NA 1.3). Image acquisition and processing was performed using the MetaFluor™ imaging system from Universal Imaging Corporation (West Chester, Pennsylvania). Calcium calibration was carried out using the Grynkiewicz equation with a dissociation constant ( $K_d$ ) of 145 nM for Fura-2 (Grynkiewicz et al., 1985). Cell-attached coverslips were placed in a sealed chamber with physiological saline continuously perfused across the cells using a peristaltic pump. Test compounds solubilized in physiological saline were applied by switching the perfusate source.
- 25

- For studies involving the stable recombinant *Spodoptera frugiperda* cell line, Sf9, (other cell lines could also be used such as Sf21, S2, etc) expressing an insect ryanodine receptor from *Drosophila melanogaster*, or *Heliothis virescens* (alternatively receptors from other species such as *Myzus persicae*, *Peregrinus maidis*, *Aphis gossypii*, etc) were grown in T75 (or other appropriate sized) flasks in supplemented Grace's insect medium. Cells were maintained in an incubator at 22 °C until testing. Cells were suspension-loaded with the calcium sensitive fluoroprobe, Fura-2 AM (1-2  $\mu$ M) and Pluronic F127 (0.002%) in culture medium for 30 minutes under agitation. Cells were then centrifuged and the pellet resuspended in physiological saline having the following composition (mM): NaCl 130; KCl 5.4; MgCl<sub>2</sub> 1.2; CaCl<sub>2</sub> 1.0; NaHCO<sub>3</sub> 4.2; NaH<sub>2</sub>PO<sub>4</sub> 7.3; Glucose 10; Sucrose 63; MES 20; pH 6.3 at approximately 150,000-200,000 cells per well (96-well plate). After a 30
- 35

minute equilibration period the cell plate was tested using a Molecular Devices' FlexStation™ system with dual wavelength excitation (340 and 380 nm) and fluorescence emission measured at 510 nm. Test and control samples were added using integrated fluidics and the intracellular calcium monitored over a 2 minute period.

Using the above protocols Figure 3 demonstrates the responses to the ryanodine receptor agonist, caffeine (10 mM) and Cpd 16 (10 and 100 nM) on a recombinant Sf9 cell transiently expressing *Drosophila melanogaster* ryanodine receptors (Figure 3). Similarly, recombinant *Heliothis virescens* ryanodine receptors transiently expressed in Sf9 cells exhibited an increase in cytosolic  $[Ca^{2+}]$  following challenges with caffeine (10 mM) and Cpd 5 (3  $\mu$ M) as shown in Figure 4. Cells transfected with lipid only (- DNA) or non-transfected cells do not exhibit significant response to caffeine (10 mM) or anthranilamide chemistry. As observed with transiently expressing cells, caffeine and anthranilamide chemistry induce calcium mobilization in stably transfected Sf9 cells expressing recombinant *Heliothis virescens* ryanodine receptor, as shown in Figure 5. Furthermore, in Figure 6 it is shown that while wild-type Sf9 cells are insensitive to caffeine, stably transfected Sf9 cells expressing recombinant *Drosophila melanogaster* ryanodine receptor exhibit a dose dependent calcium mobilization.

Alternatively, excitation and fluorescence emission acquisition and liquid handling can be obtained using a whole plate-based imaging reader such as Molecular Device's FLIPR™ system.

Using the above protocols a number of known ryanodine receptor agents from the published literature have been evaluated against native cockroach ryanodine receptors (in embryonic neuronal cells) and transiently or stably expressed recombinant *Drosophila melanogaster* receptors (expressed in Sf9 cells) with results shown in Table 6.

Table 6

Known Ryanodine Receptor Agent Activity On  
Endogenous and Expressed Insect Ryanodine Receptors

Chemical Family	Example molecule	Chemical structure	Assay Results		
			Radioligand Displacement ( <i>P. americana</i> )	Calcium Release ( <i>P. americana</i> )	Calcium Release ( <i>D. melanogaster</i> )






Ryanoids	Ryanodine		Inactive	Antagonist	Antagonist
Xanthines	Caffeine		Inactive	Agonist	Agonist
Eudostomins	Bromoeudistomin D		Not tested	Agonist	Not tested
Antraquinones	Doxorubicin		Not tested	Inactive	Inactive
Polycationic reagents	Ruthenium Red		Displacer	Inactive	Antagonist

Table 7

5

Data For Selected Anthranilamide Analogs (as shown in Figure 2)  
Tested in Radioligand Displacement and Calcium Release Assays

Molecule	R1	R2	R3	R4	R5	Assay Type		
						Displacement IC <sub>50</sub> (nM)	Calcium Release Threshold (nM)	
							<i>P. americana</i>	<i>P. americana</i>
Group 1								
Cpd 1	isopropyl	H	CH3	CF3	F	< 300	< 1000	< 300
Cpd 2	isopropyl	H	CH3	CF3	Cl	< 300	< 300	< 300
Cpd 3	isobutyl	Br	CH3	CF3	Cl	< 300	Not tested	Not tested
Cpd 4	isopropyl	Br	CH3	CF3	F	Not tested	Not tested	
Group 2								
Cpd 5	isopropyl	H	CH3	CF3	Cl	< 300	< 300	< 300

Cpd 6	CH3	H	CH3	CF3	Cl	< 300	< 300	Not teste
Cpd 7	isopropyl	H	CH3	Br	Cl	< 300	< 300	Not teste
Cpd 8	isopropyl	H	CH3	Cl	Cl	< 300	< 300	Not teste
Cpd 9	isopropyl	Br	CH3	CF3	Cl	< 300	< 300	Not teste
Cpd 10	isopropyl	Cl	CH3	CF3	Cl	< 300	< 300	Not teste
Cpd 11	CH3	Cl	CH3	CF3	Cl	< 300	< 300	< 300
Cpd 12	isopropyl	Br	CH3	Br	Cl	< 300	< 300	Not teste
Cpd 13	isopropyl	Cl	CH3	Br	Cl	< 300	Not tested	Not teste
Cpd 14	CH3	Cl	CH3	Br	Cl	< 300	< 300	< 300
Cpd 15	CH3	Br	CH3	CF3	Cl	< 300	< 300	Not teste
Cpd 16	isopropyl	Cl	CH3	Cl	Cl	< 300	< 300	< 300
Cpd 17	CH3	Cl	CH3	Cl	Cl	< 300	< 300	Not teste
Cpd 18	CH2CH3	Br	Br	CF3	Cl	< 300	Not tested	Not teste
<b>Group 3</b>								
Cpd 19	isopropyl	H	Cl	CF3	CH3	< 3000	< 10000	< 10000
Cpd 20	isobutyl	H	Cl	CF3	CH3	Not tested	Not tested	< 3000
Cpd 21	isopropyl	H	CH3	CF3	CH3	Not tested	Not tested	< 3000

### EXAMPLE 10

#### Roach Muscle Membrane Preparation

5 The procedure for preparation of membranes from cockroach femoral muscle for radioligand binding studies was essentially as described by Schmitt, et.al. (1996) *Pesticide Science* 48:375-385. A brief description of the steps involved is as follows:

10 Mid and hind legs from 6-9 week old cockroaches were excised and immediately placed in liquid nitrogen. Excised legs could be stored at -80 °C for several months, if necessary, prior to further fractionation. Typically, membrane preparations started with approximately 55 g (wet weight) of excised legs. All subsequent steps were carried out at 4°C.

15 50 mM Tris-HCL, pH 7.4 was added at a ratio of 9 ml buffer to 1 g (wet weight) of legs. The legs were homogenized on ice using a Polytron (Brinkmann Instruments, Westbury, NY) for 2 min at Setting #3. In order to remove all fragments of cuticle, the homogenate was first passed through two layers of cheesecloth and then through one layer of glass wool overlaid on two layers of cheesecloth. On occasion, the cheesecloth clogged with particulates prior to passing all material through. In such cases, fresh cheesecloth (and glass wool) was  
20 used for the remainder of the suspension. The filtrate was collected in 50 ml centrifuge tubes and centrifuged in a Sorvall SS-34 rotor at 1,950 x g<sub>max</sub> for 20 min. The supernatant was collected and centrifuged for 30 min at 30,000 x g<sub>max</sub>. The



resulting pellet was resuspended in buffer A (1.5 M KCl, 0.3 M sucrose, 0.5 mM CaCl<sub>2</sub>, 20 mM Tris-HCl, pH 8.0). The membrane suspension was homogenized by hand (about 25 strokes) using a glass-teflon homogenizer. Protein concentration of the suspension was determined by the method of Lowry, et. al. (1951) *J. Biol.*

5 *Chem.* 193:265-275. Subsequently, the membrane suspension was adjusted to 4 µg protein/µl by addition of buffer A and then stored in 1 ml aliquots at -80 °C.

#### EXAMPLE 11

##### Radio-ligand Binding Assays

Ryanodine used were obtained from Sigma (St. Louis, MO).

10 The structures for the following compounds are shown in Figure 2 and Table 7.

1-(3-Chloro-2-pyridinyl)-N-[2-methyl-6-[(1-methylethyl) amino]carbonyl]phenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (**Cpd 5**) was prepared at DuPont (Wilmington, DE).

15 N-[4-Bromo-2-methyl-6-[(1-methylethyl)amino]carbonyl]phenyl]-1-(2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (**Cpd 4**) was prepared at DuPont (Wilmington, DE).

[<sup>3</sup>H]-Ryanodine (Ryanodine [9,21-<sup>3</sup>H(N)]) was obtained from PerkinElmer™ Life Sciences (Boston, MA). 1-(2-Fluorophenyl)-N-[2-methyl-4-tritio-6-[(1-methylethyl)amino]carbonyl]phenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (**Cpd 1**) was prepared at 21 Ci/mmol from N-[4-Bromo-2-methyl-6-[(1-methylethyl)amino]carbonyl]phenyl]-1-(2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (**Cpd 4**) by PerkinElmer™ Life Sciences (Boston, MA).

##### [<sup>3</sup>H]-GN analog [**Cpd 1**] binding to roach femoral muscle membranes:

25 For saturation binding assays, the assay mixture (200 µl total volume/well; 96-well, U-bottom, polypropylene plates) contained 163 µl of buffer B (0.375 M KCL, 0.3 M Sucrose, 0.0005 M CaCl<sub>2</sub>, 0.020 M Tris-HCl, pH 8.0), 10 µl of various concentrations of **Cpd 1** in DMSO, and 2 µl of DMSO. For determination of 'Non-Specific' binding, the DMSO was replaced by 2 µl of a combined solution (in DMSO) of 0.001 M ryanodine plus **Cpd 5** at a concentration 1,000-fold excess that of **Cpd 1** in the corresponding 'Total' binding tube. The assay was begun by addition of 25 µl of roach muscle membranes at 2 µg/µl (prepared by thawing and addition of an equal volume of buffer B), and incubation was carried out for 60 min at 32 °C. Assays were carried out in triplicate.

35 Displacement of **Cpd 1** by selected compounds was as follows: to each well containing 163 µl of buffer B, 2 µl of 0.001 M ryanodine (in DMSO) and 25 µl of roach muscle membranes (at 2 µg/µl prepared as described above), was added 2 µl of various concentrations of the selected compound in DMSO. The compound was

allowed to pre-incubate with the membranes for 10 min at 32 °C. Following pre-incubation, 8 µl of 625 nM **Cpd 1** in DMSO was added and incubation was allowed to proceed for 60 min at 32 °C. Assays were carried out in triplicate.

Following incubation, assays were quenched with ice-cold buffer B and immediately filtered on pre-wetted Unifilter 96 GF/B filter microplates using a Unifilter 96 Harvester (PerkinElmer™, Boston, MA). Each assay well was then washed 10 times with buffer B, and collected on the same filter microplate. The filter microplates were then placed in a vacuum oven at 32 °C for 3 h, following which 50 µl of Microscint 0 (PerkinElmer™, Boston, MA) was added to each well. Plates were then heat sealed and counted using a Topcount microplate scintillation counter (PerkinElmer™, Boston, MA).

[<sup>3</sup>H]-Ryanodine binding to roach femoral muscle membranes:

For saturation binding assays, the assay mixture (200 µl total volume/well; 96-well, U-bottom, polypropylene plates) contained 155 µl of buffer A (1.5 M KCL, 0.3 M Sucrose, 0.0005 M CaCl<sub>2</sub>, 0.020 M Tris-HCl, pH 8.0), 10 µl of various concentrations of [<sup>3</sup>H]-ryanodine in ethanol, and 10 µl of DMSO. For determination of non-specific binding, the DMSO was replaced by 10 µl of ryanodine (in DMSO) at a concentration 1,000-fold excess that of [<sup>3</sup>H]-ryanodine in the corresponding Total binding tube. The assay was begun by addition of 25 µl of roach muscle membranes at 2 µg/µl (prepared by thawing and addition of an equal volume of buffer A), and incubation was carried out for 60 min at 32 °C. Assays were carried out in triplicate.

Displacement of [<sup>3</sup>H]-ryanodine by selected compounds was as follows. To each well containing 155 µl of buffer A and 25 µl of roach muscle membranes (at 2 µg/µl prepared as described above), was added 10 µl of various concentrations of the selected compound in DMSO. The compound was allowed to pre-incubate with the membranes for 10 min at 32 °C. Following pre-incubation, 10 µl of 200 nM [<sup>3</sup>H]-ryanodine in ethanol was added and incubation was allowed to proceed for 60 min at 32 °C. Assays were carried out in triplicate.

Following incubation, assays were quenched with ice-cold buffer A and immediately filtered on pre-wetted Unifilter 96 GF/B filter microplates using a Unifilter 96 Harvester (PerkinElmer™, Boston, MA). Each assay well was then washed 10 times with buffer A, and collected on the same filter microplate. The filter microplates were then placed in a vacuum oven at 32 °C for 3 h, following which 50 µl of Microscint 0 (PerkinElmer™, Boston, MA) was added to each well. Plates were then heat sealed and counted using a Topcount microplate scintillation counter (PerkinElmer™, Boston, MA)

EXAMPLE 12Expression Vector for *Drosophila melanogaster* Ryanodine Receptor Gene

Based on the published ryanodine receptor gene sequence of *Drosophila melanogaster* (NCBI accession number D17389), two primers were designed (SEQ ID NO:141, 5'-accacctaattaattccgatttgaggcgctgcg-3'; and SEQ ID NO:142, 5'-gcctccgtttaaacgaccgtccagtgccagtggaag-3'). These primers were used for long PCR reactions following the condition in Example 1 using a cDNA library from adult *Drosophila melanogaster* (Clontech) as template. The full-length ryanodine receptor genes were cloned into a pCR-XL-TOPO® vector (Invitrogen Life Technologies™, Carlsbad, CA) and the full-length genes subsequently sub-cloned into modified pIBV5His or pFASTBac vectors as described in Example 2.

CLAIMS

What is claimed is:

1. An isolated nucleotide fragment comprising:
  - 5 (a) a nucleic acid sequence encoding a ryanodine receptor having an amino acid sequence identity of at least 80% when compared to a polypeptide selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 128, 130, 144, and 146; or
  - (b) the complement of (a).
- 10 2. The isolated nucleic acid fragment of claim 1 wherein the sequence identity is at least 85%.
3. The isolated nucleic acid fragment of claim 1 wherein the sequence identity is at least 90%.
- 15 4. The isolated nucleic acid fragment of claim 1 wherein the sequence identity is at least 95%.
5. The isolated nucleic acid fragment of Claim 1 wherein the amino acid sequence of the polypeptide comprises the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10, 128, 130, 144, or 146.
- 20 6. An isolated nucleic acid fragment comprises a nucleotide sequence of SEQ ID NO:1, 3, 5, 7, 9, 127, 129, 143, or 145.
7. A recombinant construct comprising the isolated nucleic acid fragment of claim 1 or 5 operably linked to at least one regulatory sequence.
8. A transformed host cell comprising the recombinant construct of Claim 7.
- 25 9. The host cell of claim 8 wherein said cell is selected from the group consisting of E.coli, yeast, Sf9, Sf21, S2, Xenopus oocytes, HEK-293 and CHO.
10. A method to isolate nucleic acid fragments encoding ryanodine receptors and related polypeptides, comprising:
  - (a) comparing SEQ ID NO:2, 4, 6, 8, 10, 128, 130, 144 and 146, and other ion channel and receptor polypeptide sequences;
  - 30 (b) identifying the conserved sequences of 4 or more amino acids obtained in step a;
  - (c) designing degenerate oligomers based on the conserved sequences identified in step b; and
  - (d) using the degenerate oligomers of step c to isolate sequences
  - 35 encoding polypeptides having ryanodine receptor activity by sequence dependent protocols.

11. An isolated polypeptide having ryanodine receptor activity, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 128, 130, 144, or 146, have at least 80% identity.

12. The polypeptide of Claim 11, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 128, 130, 144, or 146, have at least 85% identity.

13. The polypeptide of Claim 11, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 128, 130, 144, or 146, have at least 90% identity.

14. The polypeptide of Claim 11, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 128, 130, 144, or 146, have at least 95% identity.

15. The polypeptide of Claim 11, wherein the amino acid sequence of the polypeptide comprises the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10, 128, 130, 144, or 146.

16. A method for evaluating at least one compound for its ability to modulate calcium homeostasis, the method comprising the steps of:

- (a) transforming a host cell with the recombinant construct of Claim 7;
- (b) growing the transformed host cell under conditions that are suitable for expression of the recombinant construct wherein expression of the recombinant construct results in altered calcium homeostasis;
- (c) treating the transformed host cell of step (a) with a compound to be tested; and
- (d) determining changes in intracellular calcium homeostasis by the test compound in order to select compounds with potential for altering calcium release.

17. A method for evaluating at least one compound which modulates ryanodine receptor activity, the method comprising the steps of:

- (a) contacting at least one compound with a polypeptide encoded by an isolated nucleic acid fragment of claim 1; and
- (b) evaluating the ryanodine receptor activity of the polypeptide of (a) after said polypeptide has been contacted with the compound or compounds.

18. The method of claim 16 or 17 wherein the method is a ligand binding assay.

19. The method of claim 16 wherein the method is based on assessing functional activity by detecting the effect of a compound on the functional activity of the transformed host cell.

20. The method of claim 19 wherein the polypeptide is contacted with more than one compound.

21. An isolated nucleic acid fragment encoding an insect ion channel comprising at least two polypeptide sequences set forth in any of SEQ ID NOs:63-119 provided that said polypeptide sequences do not comprise any of SEQ ID NOs: 56, 120-126.

5 22. A method for identifying a nucleic acid sequence encoding an insect ion channel comprising:

a) obtaining an isolated nucleic acid sequence encoding a first polypeptide having at least 100 amino acids;

10 b) comparing the first polypeptide sequence with a comparative polypeptide sequence selected from the group consisting of SEQ ID NOs:63-119 to identify a region between the first polypeptide and the comparative polypeptide having 100% sequence identity wherein said region is as long as the comparative polypeptide; and

15 c) repeating step (b) with a different comparative polypeptide sequence, wherein said different comparative polypeptide sequence is selected from the group consisting of SEQ ID NOs:63-119 until a second region having 100% sequence identity is found, wherein said second region is as long as the different comparative polypeptide.

20 23. The method of claim 22 wherein the first polypeptide has a length from 100 to 6,000 amino acids.

24. A method for expressing an isolated nucleic acid fragment encoding a toxic insect ion channel which comprises:

25 a) transforming a host with a recombinant construct comprising in the 5' to 3' direction a promoter operably linked to the toxic insect ion channel nucleic acid wherein the promoter comprises a transcription termination nucleic acid fragment situated between said promoter and the isolated nucleic acid fragment encoding the toxic insect ion channel, and

30 further wherein the transcription termination nucleic acid fragment is flanked on each end by at least one nucleic acid sequence consisting essentially of excisable sequences; and

b) growing the transformed host under conditions that are suitable for the expression of the recombinant construct.

25. A method for expressing an isolated nucleic acid fragment encoding a toxic insect ion channel which comprises:

35 a) transforming a host with a recombinant construct comprising in the 5' to 3' direction a promoter operably linked to the toxic insect ion channel nucleic acid

wherein the promoter comprises a nucleic acid fragment comprising at least one in-frame translational termination codon situated between said promoter and the isolated nucleic acid fragment encoding the toxic insect ion channel, and

5 further wherein the nucleic acid fragment comprising the translation termination codon is flanked on each end by at least one nucleic acid sequence consisting essentially of excisable sequences; and

b) growing the transformed host under conditions that are suitable for the expression of the recombinant construct.

26. A method for expressing an isolated nucleic acid fragment encoding a toxic insect ion channel which comprises:

10 a) transforming a host with a recombinant construct comprising in the 5' to 3' direction a promoter operably linked to the toxic insect ion channel nucleic acid

wherein the promoter comprises a nucleic acid fragment consisting essentially of at least one transcription termination nucleic acid fragment and at least one in-frame translational termination codon situated between said promoter and the isolated nucleic acid fragment encoding the toxic insect ion channel, and

15 further wherein the transcription termination nucleic acid fragment and the translational termination codon are flanked on each end by at least one nucleic acid sequence consisting essentially of excisable sequences; and

20 b) growing the transformed host under conditions that are suitable for the expression of the recombinant construct.

27. A method for expressing an isolated nucleic acid fragment encoding a toxic insect ion channel which comprises:

25 a) transforming a host with a recombinant construct comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding the toxic insect ion channel,

wherein said fragment also comprises an intron which interferes with expression of said fragment, and

30 b) growing the transformed host under conditions that are suitable for the expression of the recombinant construct.

28. The method of any of claims 24, 25 or 26 wherein the excisable sequences are lox sequences.

29. A recombinant construct comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding a toxic insect ion channel

35 wherein the promoter comprises a transcription termination nucleic acid fragment situated between said promoter and the isolated nucleic acid fragment encoding the toxic insect ion channel, and

further wherein the transcription termination nucleic acid fragment is flanked on each end by at least one nucleic acid sequence consisting essentially of excisable sequences.

5 30. A recombinant construct comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding a toxic insect ion channel

wherein the promoter comprises a nucleic acid fragment comprising at least one in-frame translational termination codon situated between said promoter and the isolated nucleic acid fragment encoding the toxic insect ion channel, and

10 further wherein the nucleic acid fragment comprising the translation termination codon is flanked on each end by at least one nucleic acid sequence consisting essentially of excisable sequences.

15 31. A recombinant construct comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding a toxic insect ion channel

wherein the promoter comprises a nucleic acid fragment consisting essentially of at least one transcription termination nucleic acid fragment and at least one in-frame translational termination codon situated between said promoter and the isolated nucleic acid fragment encoding the toxic insect ion channel, and

20 further wherein the transcription termination nucleic acid fragment and the translational termination codon are flanked on each end by at least one nucleic acid sequence consisting essentially of excisable sequences.

32. The recombinant construct of any of claim 29, 30 or 31 wherein the excisable sequences are lox sequences.

25 33. A recombinant construct comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding a toxic insect ion channel

wherein said isolated nucleic acid fragment also comprises an intron which interferes with expression of the toxic insect ion channel.

30



FIGURE 1A

SEQ ID NO: 2	MAEAGGAS-EQDDVSILRTEDMVMCSCTATG-----ERVCLAABEGFGRNHRHCFFLENIAD-KNIPPDLSQCQFVIEQALSVRALQELV
SEQ ID NO: 128	MAEAGGAS-EQDDVSFLRTEDMVCLSCCTATG-----ERVCLAABEGFGRNHRHCFFLENIAD-KNIPPDLSQCQFVIEQALSVRALQELV
SEQ ID NO: 130	MAEAGGAS-EQDDVSFLRTEDMVCLSCCTATG-----ERVCLAABEGFGRNHRHCFFLENIAD-KNIPPDLSQCQFVIEQALSVRALQELV
SEQ ID NO: 144	MAEAGGAS-EQDDVSFLRTEDMVCLSCCTATG-----ERVCLAABEGFGRNHRHCFFLENIAD-KNIPPDLSQCQFVIEQALSVRALQELV
SEQ ID NO: 146	MAEAGGAS-EQDDVSFLRTEDMVCLSCCTATG-----ERVCLAABEGFGRNHRHCFFLENIAD-KNIPPDLSQCQFVIEQALSVRALQELV
SEQ ID NO: 4	MADSEGSS--EQDDVSFLRTEDMVCLSCCTATG-----ERVCLAABEGFGRNHRHCFFLENIAD-KNIPPDLSQCQFVIEQALSVRALQELV
SEQ ID NO: 6	MADSEGSS--EQDDVSFLRTEDMVCLSCCTATG-----ERVCLAABEGFGRNHRHCFFLENIAD-KNIPPDLSQCQFVIEQALSVRALQELV
SEQ ID NO: 8	MADSEGGS--EQDDVSFLRTEDMVCLSCCTATG-----ERVCLAABEGFGRNHRHCFFLENIAD-KNIPPDLSQCQFVIEQALSVRALQELV
SEQ ID NO: 10	MAEAGGGS--EQDDVSFLRTEDMVCLSCCTATG-----ERVCLAABEGFGRNHRHCFFLENIAD-KNIPPDLSQCQFVIEQALSVRALQELV
SEQ ID NO: 56	MAEAGGGS--EQDDVSFLRTEDMVCLSCCTATG-----ERVCLAABEGFGRNHRHCFFLENIAD-KNIPPDLSQCQFVIEQALSVRALQELV
SEQ ID NO: 57	-----DMVCLSCCTATG-----ERVCLAABEGFGRNHRHCFFLENIAD-KNIPPDLSQCQFVIEQALSVRALQELV
SEQ ID NO: 58	MADKEEQGGGEQDDVSFLRTGDIVCLSCVASHNRDGVLSERVCLCTEGFGRNRMCTLENVSD-KDIPPDIAIMCMXYIDNALSMRALQEMM
SEQ ID NO: 59	-MASQDAE-----DEVSLRTGDQNLVCS--QS-----LGHVLLGABEGFGRNRCVLEEASN-QNVPPDLSICVFLNQALSVRALQEMV
SEQ ID NO: 60	MADAGEGE-----DEIQFLRTDDEVVLQCTATIHKE-----QQKCLAAABEGFGRNLCFLESTNSKNVPPDLSICTFVLEQSLSVRALQEML
SEQ ID NO: 61	MADGGEGE-----DEIQFLRTDDEVVLQCTATIHKE-----QQKCLAAABEGFGRNLCFLESTNSKNVPPDLSICTFVLEQSLSVRALQEML
SEQ ID NO: 62	MADGGEGE-----DEIQFLRTDDEVVLQCTATIHKE-----QQKCLAAABEGFGRNLCFLESTNSKNVPPDLSICTFVLEQSLSVRALQEML
SEQ ID NO: 2	TAAGSETGKE-----NLGKGTSGYRLLYGNAILLRHLNSDMYLACLSTS--SSQDKLAFDVLQQLQHSQGEACWWTIHPASKQRSEG
SEQ ID NO: 128	TAAGSETG-----KGTSGGHRLLYGNAILLRHLNSDMYLACLSTS--SSQDKLAFDVLQQLQHSQGEACWWTIHPASKQRSEG
SEQ ID NO: 130	TAAGSETG-----KGTSGGHRLLYGNAILLRHLNSDMYLACLSTS--SSQDKLAFDVLQQLQHSQGEACWWTIHPASKQRSEG
SEQ ID NO: 144	TAAGSETGKE-----NLGKGTSGGHRLLYGNAILLRHLNSDMYLACLSTS--SSQDKLAFDVLQQLQHSQGEACWWTIHPASKQRSEG
SEQ ID NO: 146	TAAGSETGKE-----NLGKGTSGGHRLLYGNAILLRHLNSDMYLACLSTS--SSQDKLAFDVLQQLQHSQGEACWWTIHPASKQRSEG
SEQ ID NO: 4	TAASSQEG-----KGTSGGHRLLYGNAILLRHQNDSMYLACLSTS--SSNDKLSFDVLQQLQHSQGEACWWTIHPASKQRSEG
SEQ ID NO: 6	TATSSQEG-----KGTSGGHRLLYGNAILLRHQNDSMYLACLSTS--SSNDKLSFDVLQQLQHSQGEACWWTIHPASKQRSEG
SEQ ID NO: 8	TAAGSEEG-----KG-TGSGGHRLLYGNAILLRHQNDSMYLACLSTS--SSNDKLSFDVLQQLQHSQGEACWWTIHPASKQRSEG
SEQ ID NO: 10	TAAGSETG-----KGTSGGHRLLYGNAILLRHQNDSMYLACLSTS--SSNDKLSFDVLQQLQHSQGEACWWTIHPASKQRSEG
SEQ ID NO: 56	TAAGSETG-----KGTSGGHRLLYGNAILLRHQNDSMYLACLSTS--SSNDKLSFDVLQQLQHSQGEACWWTIHPASKQRSEG
SEQ ID NO: 57	TAAGSETG-----KGTSGGHRLLYGNAILLRHQNDSMYLACLSTS--SSNDKLSFDVLQQLQHSQGEACWWTIHPASKQRSEG
SEQ ID NO: 58	SADSDHKS-----ASGAGGCHKLLYGHAVQLKHVQSEMVLACLSSC--SSNDKLSFDVLQQLQHSQGEACWWTIHPASKQRSEG
SEQ ID NO: 59	ITDQIDQGGQ-----AGHRTLLYGHAMLLQHSLSMHLACLPTS--SSKDKLAFDVLQQLQHSQGEACWWTIHPASKQRSEG
SEQ ID NO: 60	ANTVEKSEGQVDVEKWKFMFKTAQGGGHRLLYGHAILLRHSYSGMYLCCLSLTSRSSTDKLAFDVLQQLQHSQGEACWWTIHPASKQRSEG
SEQ ID NO: 61	ANTVEKSEGQVDVEKWKFMFKTAQGGGHRLLYGHAILLRHSYSGMYLCCLSLTSRSSTDKLAFDVLQQLQHSQGEACWWTIHPASKQRSEG
SEQ ID NO: 62	ANTVEKSEGQVDVEKWKFMFKTAQGGGHRLLYGHAILLRHSYSGMYLCCLSLTSRSSTDKLAFDVLQQLQHSQGEACWWTIHPASKQRSEG

JC05 Rec'd PCT/PTO 21 MAR 2005

THIS PAGE BLANK (USPTO)

**FIGURE 1B**

SEQ ID NO: 2	EKVRVGDDLLILSVVAIERYLHTTKE--NEVSIVNASFHVTHWSVQPYGTG-----ISRMKYGVGVGGDVLRFHHG-GDECLTI
SEQ ID NO: 128	EKVRVGDDLLILSVVATERYLHTTKE--NEVSIVNASFHVTHWSVQPYGTG-----ISRMKYGVGVGGDVLRFHHG-GDECLTI
SEQ ID NO: 130	EKVRVGDDLLILSVVATERYLHTTKE--NEVSIVNASFHVTHWSVQPYGTG-----ISRMKYGVGVGGDVLRFHHG-GDECLTI
SEQ ID NO: 144	EKVRVGDDLLILSVVATERYLHTTKE--NEVSIVNASFHVTHWSVQPYGTG-----ISRMKYGVGVGGDVLRFHHG-GDECLTI
SEQ ID NO: 146	EKVRVGDDLLILSVVATERYLHTTKE--NEVSIVNASFHVTHWSVQPYGTG-----ISRMKYGVGVGGDVLRFHHG-GDECLTI
SEQ ID NO: 4	EKVPVGDDLLILSVVATERYLHTAKE--NELSVNASFHVTHWSVQPYGTG-----ISRMKYGVGVGGDVLRFHHG-GDECLTI
SEQ ID NO: 6	EKVRVGDDLLILSVVATERYLHTAKE--NELSVNASFHVTHWSVQPYGTG-----ISRMKYGVGVGGDVLRFHHG-GDECLTI
SEQ ID NO: 8	EKVRVGDDLLILSVVATERYLHTTKE--NDLSIVNASFHVTHWSVQPYGTG-----ISRMKYGVGVGGDVLRFHHG-GDECLTI
SEQ ID NO: 10	EKVRVGDDLLIPSVVATERYLHTTKE--NEQSIIVNASFHVTHWSVQPYGTG-----ISRMKYGVGVGGDVLRFHHG-GDECLTI
SEQ ID NO: 56	EKVRVGDDLLILSVVATERYLHTTKE--NEQSIIVNASFHVTHWSVQPYGTG-----ISRMKYGVGVGGDVLRFHHG-GDECLTI
SEQ ID NO: 57	EKVRVGDDLLILSVVATERYLHTTKE--NDLSIVNASFHVTHWSVQPYGTG-----ISRMKYGVGVGGDVLRFHHG-GDECLTI
SEQ ID NO: 58	EKVRVGDDVILSVVATERYLHMAYS--KGYMVIASFHTLWNIQSVSSG-----SMRTRNMGFLFGNDVLRFLFHG-NDECLTI
SEQ ID NO: 59	EKVRVGDDLLILVNATERYLHLSVERDDQPMIVVASFQOTLWTVAPVSSGIVIKAMAKKYGDTKVLGFLNGLDLTLRFSRGHMDECLTV
SEQ ID NO: 60	EKVRVGDDLLILSVSSERYLHLSYG--NSSWHVDAAFQOTLWSVAPISS-----GSEAAQGYLIGGDVLRLLHGHMDECLTV
SEQ ID NO: 61	EKVRVGDDLLILSVSSERYLHLSYG--NGSLHVDAAFQOTLWSVAPISS-----GSEAAQGYLIGGDVLRLLHGHMDECLTV
SEQ ID NO: 62	EKVRVGDDLLILSVSSERYLHLSYG--NGSLHVDAAFQOTLWSVAPISS-----GSEAAQGYLIGGDVLRLLHGHMDECLTV
SEQ ID NO: 2	P-STWTKDGGQNIIVYKGGSVMSQARSLRLELARTKWAGGFINWYHPMRIRHITTTGRYLGVNDQNELYLVSREEPTTASCAFCRLRQEKD
SEQ ID NO: 128	P-STWTKDGGQNIIVYEGGSVMSQARSLRLELARTKWAGGFINWYHPMRIRHITTTGRYLGVNDQNELYLVSREEATTASCAFCRLRQEKD
SEQ ID NO: 130	P-STWTKDGGQNIIVYEGGSVMSQARSLRLELARTKWAGGFINWYHPMRIRHITTTGRYLGVNDQNELYLVSREEATTASCAFCRLRQEKD
SEQ ID NO: 144	P-STWTKDGGQNIIVYEGGSVMSQARSLRLELARTKWAGGFINWYHPMRIRHITTTGRYLGVNDQNELYLVSREEATTASCAFCRLRQEKD
SEQ ID NO: 146	P-STWTKDGGQNIIVYEGGSVMSQARSLRLELARTKWAGGFINWYHPMRIRHITTTGRYLGVNDQNELYLVSREEATTASCAFCRLRQEKD
SEQ ID NO: 4	P-SSWSNVSGQNIIVYEGGSVMSQARSLRLELARTKWAGGFINWYHPMRIRHITTTGRYLGVNNENNELHLVCREEATTASSTFFLRQEKD
SEQ ID NO: 6	P-STWSNVSGQNIIVYEGGSVMSQARSLRLELARTKWAGGFINWYHPMRIRHITTTGRYLGVNNENNELHLVCREEATTASSTFFLRQEKD
SEQ ID NO: 8	P-STWSEAPGQNIIVYEGGSVMSQARSLRLELARTKWAGGFINWYHPMRIRHITTTGRYLGVNNENNELHLVDEATTALSACFLRQEKD
SEQ ID NO: 10	P-STWGREGQNIIVYEGGVMAQARSLRLELARTKWAGGFINWYHPMRIRHITTTGRYLGVNDSNELILVKKKEASIAITTTFCRLRQEKD
SEQ ID NO: 56	P-STWGREGQNIIVYEGGVMAQARSLRLELARTKWAGGFINWYHPMRIRHITTTGRYLGVNDSNELILVKKKEASIAITTTFCRLRQEKD
SEQ ID NO: 57	P-STWSLDGQNIIVYEGGSVMSQARSLRLELARTKWAGGFINWYHPMRIRHITTTGRYLGVNNENNELILMSRDQATTSTQTAFLVRLQEKD
SEQ ID NO: 58	P-ENWSEHPQHNMVIEYEGAAVTQARSLRVELIRMKWHGALVGEQVFRIKHITTSGRYLGVLN-SVQLYHKEKADFDTLTAFLVMQCNKD
SEQ ID NO: 59	PPVCGKDDNISEVSDTGAQYARSLWRAELILKKWNGSVSVWGPFCRIRHLTSGKYLAVLENGTVICIVPRKSCNLDDTIFCFQOSRE
SEQ ID NO: 60	P-SGEHGEERRTVHYEGGAVSVHARSRLRLETLIRVAWSGSHIRWGQPFRLRHVTTGKYLKSLMEDKNLLMDKEKADVKSTAFPRSSKE
SEQ ID NO: 61	P-SGEHGEERRTVHYEGGAVSVHARSRLRLETLIRVAWSGSHIRWGQPFRLRHVTTGKYLKSLMEDKNLLMDKEKADVKSTAFPRSSKE
SEQ ID NO: 62	P-SGEHGEERRTVHYEGGAVSVHARSRLRLETLIRVAWSGSHIRWGQPFRLRHVTTGKYLKSLMEDKNLLMDKEKADVKSTAFPRSSKE

JC05 Rec'd PO [redacted] 21 MAR 2005

THIS PAGE BLANK (USPTO)

**FIGURE 1C**

SEQ ID NO: 2	DQKQVLEDKDLEVI	GAPIIKYGDSTVIVQ	HSETGLWLSYKSYET	TKKGVGKVEEKQAIL	HEEGKMDGLDLSRSQ	EEEEMTARVIRKCS
SEQ ID NO: 128	DQKQVLEDKDLEVI	GAPIIKYGDSTVIVQ	HSETGLWLSYKSYET	TKKGVGKVEEKQAIL	HEEGKMDGLDLSRSQ	EEEEMTARVIRKCS
SEQ ID NO: 130	DQKQVLEDKDLEVI	GAPIIKYGDSTVIVQ	HSETGLWLSYKSYET	TKKGVGKVEEKQAIL	HEEGKMDGLDLSRSQ	EEEEMTARVIRKCS
SEQ ID NO: 144	DQKQVLEDKDLEVI	GAPIIKYGDSTVIVQ	HSETGLWLSYKSYET	TKKGVGKVEEKQAIL	HEEGKMDGLDLSRSQ	EEEEMTARVIRKCS
SEQ ID NO: 146	DQKQVLEDKDLEVI	GAPIIKYGDSTVIVQ	HSETGLWLSYKSYET	TKKGVGKVEEKQAIL	HEEGKMDGLDLSRSQ	EEEEMTARVIRKCS
SEQ ID NO: 4	DQKIILEDKDLEVI	GAPIIKYGDSTVIVQ	HSDTGLWLFYKSYET	TKKGVGKVEEKQAVL	HEEGKMDGLDLSRSQ	EEEEMTARVIRKCS
SEQ ID NO: 6	DQKIILEDKDLEVI	GAPIIKYGDSTVIVQ	HSDTGLWLFYKSYET	TKKGVGKVEEKQAVL	HEEGKMDGLDLSRSQ	EEEEMTARVIRKCS
SEQ ID NO: 8	DQKVLEDKDLEVI	GAPIIKYGDSTVIVQ	HSETGLWLFYKSYET	TKKGVGKVEEKQAVL	HEEGKMDGLDLSRSQ	EEEEMTARVIRKCS
SEQ ID NO: 10	DEKKVLEDKDLEVI	GAPIIKYGDSTVIVQ	HSETGLWLFYKSYET	TKKGVGKVEEKQAIL	HEEGKMDGLDLSRSQ	EEEEMTARVIRKCS
SEQ ID NO: 56	DEKKVLEDKDLEVI	GAPIIKYGDSTVIVQ	HSETGLWLFYKSYET	TKKGVGKVEEKQAIL	HEEGKMDGLDLSRSQ	EEEEMTARVIRKCS
SEQ ID NO: 57	DQKVLEDKDLEVI	GAPIIKYGDSTVIVQ	HSETGLWLFYKSYET	TKKGVGKVEEKQAIL	HEEGKMDGLDLSRSQ	EEEEMTARVIRKCS
SEQ ID NO: 58	PKKQMLDEKEEGM	GATIRYGETNAFI	QHVKTQLWLSYQTT	TEVTKKGLKVEEKKA	VALKDGHMDDCYTFF	MALEESKSARVIRKCS
SEQ ID NO: 59	D-LANYDSKQDHGM	GSADIKYGDSTVLI	QHMKTGHLWLSYLV	VES-VVGGRAAERK-V	VVNLPEGHMDDGFS	VVRARAEESSAGIIRKSTL
SEQ ID NO: 60	K-LDVGVKKEVDGM	GTSEIKYGDSTVLI	QHVDTGLWLYQAVD	VKSARMGSIQK-AIM	HHEGHMDDGLNLSR	SQHEESRTARVIRSTVF
SEQ ID NO: 61	K-LDGGVRKEVDGM	GTSEIKYGDSTVLI	QHVDTGLWLYQAVD	VKSARMGSIQK-AIM	HHEGHMDDGLNLSR	SQHEESRTARVIRSTVF
SEQ ID NO: 62	K-LDVGVKKEVDGM	GTSEIKYGDSTVLI	QHVDTGLWLYQAVD	VKSARMGSIQK-AIM	HHEGHMDDGLNLSR	SQHEESRTARVIRSTVF
SEQ ID NO: 2	LFTKFINGLETLQ	-ENRRHSNFFASV	NLGEVMVCMLEDLT	NYFAQPEDMEHEEKQ	NKFRALNRQDLFQ	EGLNLILEAIDKINVITSQ
SEQ ID NO: 128	LFTKFINGLETLQ	-ENRRHSNFFASV	NLGEVMVCMLEDLT	NYFAQPEDMEHEEKQ	NKFRALNRQDLFQ	EGLNLILEAIDKINVITSQ
SEQ ID NO: 130	LFTKFINGLETLQ	-ENRRHSNFFASV	NLGEVMVCMLEDLT	NYFAQPEDMEHEEKQ	NKFRALNRQDLFQ	EGLNLILEAIDKINVITSQ
SEQ ID NO: 144	LFTKFINGLETLQ	-ENRRHSNFFASV	NLGEVMVCMLEDLT	NYFAQPEDMEHEEKQ	NKFRALNRQDLFQ	EGLNLILEAIDKINVITSQ
SEQ ID NO: 146	LFTKFINGLETLQ	-ENRRHSNFFASV	NLGEVMVCMLEDLT	NYFAQPEDMEHEEKQ	NKFRALNRQDLFQ	EGLNLILEAIDKINVITSQ
SEQ ID NO: 4	LFTQFISGLENLQ	-SNRRSLFCFVNL	NEMVCMLEDLTNY	FAQPEEDMEHEEKQ	NKFRALNRQDLFQ	EGLNLILEAIDKINVITSQ
SEQ ID NO: 6	LFTQFISGLENLQ	-SNRRSLFCFVNL	NEMVCMLEDLTNY	FAQPEEDMEHEEKQ	NKFRALNRQDLFQ	EGLNLILEAIDKINVITSQ
SEQ ID NO: 8	LFTQFIRGLETLQ	-VNRHSLFCATV	NLNMVCMLEDLTNY	FAQPADMEHEEKQ	NKFRALNRQDLFQ	EGLNLILEAIDKINVITSQ
SEQ ID NO: 10	LFTQFITALETQ	-SNRRHSIFFQK	VNLNMVCMLEDLTNY	FSQPEDMEHEEKQ	NKFRALNRQDLFQ	EGLNLILEAIDKINVITSQ
SEQ ID NO: 56	LFTQFITALETQ	-SNRRHSIFFQK	VNLNMVCMLEDLTNY	FSQPEDMEHEEKQ	NKFRALNRQDLFQ	EGLNLILEAIDKINVITSQ
SEQ ID NO: 57	LFTKFINGLETLQ	-ENRRHSIFFQK	VNLNMVCMLEDLTNY	FAQPNDEQDFEEKQ	NHLRALNRQDLFQ	EGLNLILEAIDKINVITSQ
SEQ ID NO: 58	VLNKFLKGIDALQ	LE-GNQSTDWTRV	DINEVLKLMEDLTNY	FAQPNDEQDFEEKQ	NHLRALNRQDLFQ	EGLNLILEAIDKINVITSQ
SEQ ID NO: 59	LFNQFFDALDSL	RGEKEDQLAWNS	FNLSVVDILEDLTNY	FAQPNDEQDFEEKQ	NHLRALNRQDLFQ	EGLNLILEAIDKINVITSQ
SEQ ID NO: 60	LFNRFIRGLDALS	---KKVKLPTID	LPFIESVSLSLQD	LIGYFHPPEHLEHED	KQNRALNRQDLFQ	EGLNLILEAIDKINVITSQ
SEQ ID NO: 61	LFNRFIRGLDALS	---KKAKASSVD	LPFIESVSLSLQD	LIGYFHPPEHLEHED	KQNRALNRQDLFQ	EGLNLILEAIDKINVITSQ
SEQ ID NO: 62	LFNRFIRGLDALS	---KKAKASTVD	LPFIESVSLSLQD	LIGYFHPPEHLEHED	KQNRALNRQDLFQ	EGLNLILEAIDKINVITSQ

JC05 Rec'd PCT/PTO 21 MAR 2005

**THIS PAGE BLANK (USPTO)**

GFLAGFLAGDESGQSWEMISGYLYQLLAAIIKGNHNTNCAQFANSNRNLNWLFSRLGSQASGEGTGMLDVHLHCILDSPEALNMMRDEHIKV	ID NO: 2
GFLAGFLAGDESGQSWEMISGYLYQLLAAIIKGNHNTNCAQFANSNRNLNWLFSRLGSQASGEGTGMLDVHLHCILDSPEALNMMRDEHIKV	ID NO: 128
GFLAGFLAGDESGQSWEMISGYLYQLLAAIIKGNHNTNCAQFANSNRNLNWLFSRLGSQASGEGTGMLDVHLHCILDSPEALNMMRDEHIKV	ID NO: 130
GFLAGFLAGDESGQSWEMISGYLYQLLAAIIKGNHNTNCAQFANSNRNLNWLFSRLGSQASGEGTGMLDVHLHCILDSPEALNMMRDEHIKV	ID NO: 144
GFLAGFLAGDESGQSWEMISGYLYQLLAAIIKGNHNTNCAQFANSNRNLNWLFSRLGSQASGEGTGMLDVHLHCILDSPEALNMMRDEHIKV	ID NO: 146
GFMVS - LAGDESGQSWDVISGYLYQLLAAIIKGNHNTNCAQFANTNRNLNWLFSRLGSQASSETGMLDVHLHCILDSPEALNMMKDEHIKV	ID NO: 4
GFMVS - LAGDESGQSWDVISGYLYQLLAAIIKGNHNTNCAQFANTNRNLNWLFSRLGSQASSETGMLDVHLHCILDSPEALNMMKDEHIKV	ID NO: 6
GFLVS - LAGDESGQSWDISGYLYQLLAAIIKGNHNTNCAQFANSNRNLNWLFSRLGSQASSETGMLDVHLHCILDSPEALNMMRDEHIKV	ID NO: 8
GFLASFLAGDETGQSWDLISTYLYQLLAAIIKGNHNTNCAQFANSNRNLNWLFSRLGSQASSEGSGMLDVHLHCILDSPEALNMMRDEHIKV	ID NO: 10
GFLASFLAGDETGQSWDLISTYLYQLLAAIIKGNHNTNCAQFANSNRNLNWLFSRLGSQASSEGSGMLDVHLHCILDSPEALNMMRDEHIKV	ID NO: 56
GFLASFLADESGQSWDLISTYLYQLLAAIIKGNHNTNCAQFANSNRNLNWLFSRLGSQASSEGSGMLDVHLHCILDSPEALNMMRDEHIKV	ID NO: 57
PDFAG - LIGEETHVKWEQISTYLYLYVAAIMIKGNHYNCAQFASAQRLDWLFGRLSNPQSAEG - ILDVLYCVLTSPESPEALNMININEGHIRS	ID NO: 58
RDFAA - IVGEDAGDLWQDITVLYLYKLLAAMIRHNHNCAQFASQVRLDWLINRLESQQASKG - VLEVLHCVLVSPESPEALNIIKENHIKS	ID NO: 59
AHFAD - VAGREAGESWKSTILNSLYELLAALIRGNRKNCQAQFSG -- SLDWLIISRLELEASSG - ILEVHLHCVLVSPESPEALNIIKEGHIKS	ID NO: 60
AHFAD - VAGREAGESWKSTILNSLYELLAALIRGNRKNCQAQFSG -- SLDWLIISRLELEASSG - ILEVHLHCVLVSPESPEALNIIKEGHIKS	ID NO: 61
AHFAD - VAGREAGESWKSTILNSLYELLAALIRGNRKNCQAQFSG -- SLDWLIISRLELEASSG - ILEVHLHCVLVSPESPEALNIIKEGHIKS	ID NO: 62
IISLLEKHGRDPKVLVDLCSLCVGVNGVAVRSSQNNICDYLLPGKNLLLOQTALVDHVSVSRPNIFVGRVEGSVYVRKWKYFEVTMDHIE - KT	ID NO: 2
IISLLEKHGRDPKVLVDLCSLCVGVNGVAVRSSQNNICDYLLPGKNLLLOQTALVDHVSVSRPNIFVGRVEGSVYVRKWKYFEVTMDHIE - KT	ID NO: 128
IISLLEKHGRDPKVLVDLCSLCVGVNGVAVRSSQNNICDYLLPGKNLLLOQTALVDHVSVSRPNIFVGRVEGSVYVRKWKYFEVTMDHIE - KT	ID NO: 130
IISLLEKHGRDPKVLVDLCSLCVGVNGVAVRSSQNNICDYLLPGKNLLLOQTALVDHVSVSRPNIFVGRVEGSVYVRKWKYFEVTMDHIE - KT	ID NO: 144
IISLLEKHGRDPKVLVDLCSLCVGVNGVAVRSSQNNICDYLLPGKNLLLOQTALVDHVSVSRPNIFVGRVEGSVYVRKWKYFEVTMDHIE - KT	ID NO: 146
IISLLEKHGRDPKVLVDLCSLCVGVNGVAVRSSQNNICDFLLQGNKLLLOQTLLVDHVASVRPNIFVGHVSGSVYVRKWKYFEVAIDHVE - QT	ID NO: 4
IISLLEKHGRDPKVLVDLCSLCVGVNGVAVRSSQNNICDFLLQGNKLLLOQTLLVDHVASVRPNIFVGHVSGSVYVRKWKYFEVAIDHVE - QT	ID NO: 6
IISLLEKHGRDPKVLVDLCSLCVGVNGVAVRSSQNNICDFLLPGKNLLLOQTLLVDHVASVRPNIFVGHVSGSVYVRKWKYFEVAIDHVE - QT	ID NO: 8
IISLLEKHGRDPKVLVDLCSLCVGVNGVAVRSSQNNICDFLLPGKNLLLOQTLLVDHVASVRPNIFVGRVDSGSMVQKWKYFEVTMDHIE - QT	ID NO: 10
IISLLEKHGRDPKVLVDLCSLCVGVNGVAVRSSQNNICDFLLPGKNLLLOQTLLVDHVASIRPNIFVGRVDSGSMVQKWKYFEVTMDHIE - QT	ID NO: 56
IISLLEKHGRDPKVLVDLCSLCVGVNGVAVRSSQNNICDFLLPGKNLLLOQTGLVDHVASIRPNIFVGRVDSGSMVQKWKYFEVTMDHIE - QM	ID NO: 57
VISLLEKVGDRPKVLVDLSSICEGNGMAVRSSQNLITQYLLPGKOLLLOQTSMRDHVSSMMPNVMLGVVEGSALFRKWKYFEAEVEHIE - TM	ID NO: 58
MISQLEKHGRDPKVLVDLCSLCVGVNGVAVRSNQNLICDNLPSRDILLLOQTAVDVEVVCVRPNVSIISVDKNSITVYKWKYFEVAIDKQE - AG	ID NO: 59
IISLLDKHGRNHHKVLVDLCSLCVCHGVAVRSNQHLICDNLPPGRDILLLOQTRLNVHVSRRPNIFLGVSEGSQAQYKKWKYELMVDHTEPFV	ID NO: 60
IISLLDKHGRNHHKVLVDLCSLCVCHGVAVRSNQHLICDNLPPGRDILLLOQTRLNVHVSRRPNIFLGVSEGSQAQYKKWKYELMVDHTEPFV	ID NO: 61
IISLLDKHGRNHHKVLVDLCSLCVCHGVAVRSNQHLICDNLPPGRDILLLOQTRLNVHVSRRPNIFLGVSEGSQAQYKKWKYELMVDHTEPFV	ID NO: 62

JC05 Rec'd PCT/PTO 21 MAR 2005

THIS PAGE BLANK (USPTO)



**FIGURE 1E**

SEQ ID NO:2	THMPHLRIGWANTTGYVYPGGGKKGNGVGGDDLYSYGFDGAYLWSGGRKTPVNRTHAEEPYRKGDVIGCALDLTVPIINFMFNGVR
SEQ ID NO:128	THMPHLRIGWANTTGYVYPGGGKKGNGVGGDDLYSYGFDGAYLWSGGRKTPVNRTHAEEPYRKGDVIGCALDLTVPIINFMFNGVR
SEQ ID NO:130	THMPHLRIGWANTTGYVYPGGGKKGNGVGGDDLYSYGFDGAYLWSGGRKTPVNRTHAEEPYRKGDVIGCALDLTVPIINFMFNGVR
SEQ ID NO:144	THMPHLRIGWANTTGYVYPGGGKKGNGVGGDDLYSYGFDGAYLWSGGRKTPVNRTHAEEPYRKGDVIGCALDLTVPIINFMFNGVR
SEQ ID NO:146	THMPHLRIGWANTTGYVYPGGGKKGNGVGGDDLYSYGFDGAYLWSGGRKTPVNRTHAEEPYRKGDVIGCALDLTVPIINFMFNGVR
SEQ ID NO:4	THLNPHIRIGWANTAGVYPPGGGKKGNGVGGDDLYSYGFDGAYLWSGGRKTPVNRTHAEEPYRKGDVIGCALDLTVPIINFMFNGVR
SEQ ID NO:6	THLNPHIRIGWANTAGVYPPGGGKKGNGVGGDDLYSYGFDGAYLWSGGRKTPVNRTHAEEPYRKGDVIGCALDLTVPIINFMFNGVR
SEQ ID NO:8	THMPHLRIGWANTSGVYPPGGGKKGNGVGGDDLYSYGFDGAYLWSGGRKTPVNRTHAEEPYRKGDVIGCALDLTVPIINFMFNGVR
SEQ ID NO:10	THMPHLRIGWANTSGVYPPGGGKKGNGVGGDDLYSYGFDGAYLWSGGRKTPVNRTHAEEPYRKGDVIGCALDLTVPIINFMFNGVR
SEQ ID NO:56	THMPHLRIGWANTSGVYPPGGGKKGNGVGGDDLYSYGFDGAYLWSGGRKTPVNRTHAEEPYRKGDVIGCALDLTVPIINFMFNGVR
SEQ ID NO:57	THMPHLRIGWANTSGVYPPGGGKKGNGVGGDDLYSYGFDGAYLWSGGRKTPVNRTHAEEPYRKGDVIGCALDLTVPIINFMFNGVR
SEQ ID NO:58	TKQTPYLRIGWANSVGFPPGGGKKGNGVGGDDLYSYGFDGAYLWSGGRKTPVNRTHAEEPYRKGDVIGCALDLTVPIINFMFNGVR
SEQ ID NO:59	TSRPVHFRVWATTTQGFRTYLRGGEGWNGSVVDDLYSYGFDGAYLWSGGRKTPVNRTHAEEPYRKGDVIGCALDLTVPIINFMFNGVR
SEQ ID NO:60	TAEATHLRVWASTEGYSPPYPPGGGKKGNGVGGDDLYSYGFDGAYLWSGGRKTPVNRTHAEEPYRKGDVIGCALDLTVPIINFMFNGVR
SEQ ID NO:61	TAEATHLRVWASTEGYSPPYPPGGGKKGNGVGGDDLYSYGFDGAYLWSGGRKTPVNRTHAEEPYRKGDVIGCALDLTVPIINFMFNGVR
SEQ ID NO:62	TAEATHLRVWASTEGYSPPYPPGGGKKGNGVGGDDLYSYGFDGAYLWSGGRKTPVNRTHAEEPYRKGDVIGCALDLTVPIINFMFNGVR
SEQ ID NO:2	VTGSFTNFNLEGMFFPVISCSKLSRFLLGGEHGRRLRYAAPEGYSPLVESILLPQQILSLEP--CFYFGNLSKRALAGP-PLVQDDDTAFV
SEQ ID NO:128	VTGSFTNFNLEGMFFPVISCSKLSRFLLGGEHGRRLRYAAPEGYSPLVESILLPQQILSLEP--CFYFGNLSKRALAGP-PLVQDDDTAFV
SEQ ID NO:130	VTGSFTNFNLEGMFFPVISCSKLSRFLLGGEHGRRLRYAAPEGYSPLVESILLPQQILSLEP--CFYFGNLSKRALAGP-PLVQDDDTAFV
SEQ ID NO:144	VTGSFTNFNLEGMFFPVISCSKLSRFLLGGEHGRRLRYAAPEGYSPLVESILLPQQILSLEP--CFYFGNLSKRALAGP-PLVQDDDTAFV
SEQ ID NO:146	VTGSFTNFNLEGMFFPVISCSKLSRFLLGGEHGRRLRYAAPEGYSPLVESILLPQQILSLEP--CFYFGNLSKRALAGP-PLVQDDDTAFV
SEQ ID NO:4	VQGAFRDNLDMFFPVISCSKSVSCRFLLGGEHGRRLRYAAPEGYSPLVESILLPQQILSLEP--CFYFGNLSKRALAGP-PLVQDDDTAFV
SEQ ID NO:6	VQGAFRDNLDMFFPVISCSKSVSCRFLLGGEHGRRLRYAAPEGYSPLVESILLPQQILSLEP--CFYFGNLSKRALAGP-PLVQDDDTAFV
SEQ ID NO:8	IRGCFRDNLDGMFFPVISCSKSVSCRFLLGGEHGRRLRYAAPEGYSPLVESILLPQQILSLEP--CFYFGNLSKRALAGP-PLVQDDDTAFV
SEQ ID NO:10	IRGCFRDNLDGMFFPVISCSKSVSCRFLLGGEHGRRLRYAAPEGYSPLVESILLPQQILSLEP--CFYFGNLSKRALAGP-PLVQDDDTAFV
SEQ ID NO:56	IRGCFRDNLDGMFFPVISCSKSVSCRFLLGGEHGRRLRYAAPEGYSPLVESILLPQQILSLEP--CFYFGNLSKRALAGP-PLVQDDDTAFV
SEQ ID NO:57	IRGCFRDNLDGMFFPVISCSKSVSCRFLLGGEHGRRLRYAAPEGYSPLVESILLPQQILSLEP--CFYFGNLSKRALAGP-PLVQDDDTAFV
SEQ ID NO:58	IRGCFRDNLDGMFFPVISCSKSVSCRFLLGGEHGRRLRYAAPEGYSPLVESILLPQQILSLEP--CFYFGNLSKRALAGP-PLVQDDDTAFV
SEQ ID NO:59	IRGCFRDNLDGMFFPVISCSKSVSCRFLLGGEHGRRLRYAAPEGYSPLVESILLPQQILSLEP--CFYFGNLSKRALAGP-PLVQDDDTAFV
SEQ ID NO:60	IRGCFRDNLDGMFFPVISCSKSVSCRFLLGGEHGRRLRYAAPEGYSPLVESILLPQQILSLEP--CFYFGNLSKRALAGP-PLVQDDDTAFV
SEQ ID NO:61	IRGCFRDNLDGMFFPVISCSKSVSCRFLLGGEHGRRLRYAAPEGYSPLVESILLPQQILSLEP--CFYFGNLSKRALAGP-PLVQDDDTAFV
SEQ ID NO:62	IRGCFRDNLDGMFFPVISCSKSVSCRFLLGGEHGRRLRYAAPEGYSPLVESILLPQQILSLEP--CFYFGNLSKRALAGP-PLVQDDDTAFV

JC05 Rec'd PTO 21 MAR 2005

THIS PAGE BLANK (USPTO)

**FIGURE 1F**

SEQ ID NO:2	PTPVDTLQITLPTYVEQIRDKLAENIHEMWAMNKEIAGWMYGDQREDLHKIHPCLVPFERLPPAEKRYDIQLAVQTLKTILALGYIISLD
SEQ ID NO:128	PTPVDTLQITLPTYVEQIRDKLAENIHEMWAMNKEIAGWMYGDQREDLHKIHPCLVPFERLPPAEKRYDIQLAVQTLKTILALGYIISLD
SEQ ID NO:130	PTPVDTLQITLPTYVEQIRDKLAENIHEMWAMNKEIAGWMYGDQREDLHKIHPCLVPFERLPPAEKRYDIQLAVQTLKTILALGYIISLD
SEQ ID NO:144	PTPVDTLQITLPTYVEQIRDKLAENIHEMWAMNKEIAGWMYGDQREDLHKIHPCLVPFERLPPAEKRYDIQLAVQTLKTILALGYIISLD
SEQ ID NO:146	PTPVDTLQITLPTYVEQIRDKLAENIHEMWAMNKEIAGWMYGDQREDLHKIHPCLVPFERLPPAEKRYDIQLAVQTLKTILALGYIISLD
SEQ ID NO:4	PNPVDTSMTLPSYIENIKDKLAENIHEMWAMNKEIAGWYGDQRNDTRKYHPCLIQFDKLPAAEKRYDSQLAVQTLKTIVIALGVHISID
SEQ ID NO:6	PNPVDTSMTLPSYIENIKDKLAENIHEMWAMNKEIAGWYGDQRNDTRKYHPCLIQFDKLPAAEKRYDSQLAVQTLKTIVIALGVHISID
SEQ ID NO:8	PTPVDTTKVSPLPNYIESIRDKLAENIHEMWAMNKEIAGWYGEKRDYHRIHPCLTHFEKLPAAEKRYDNQLAVQTLKTIISLGYITMD
SEQ ID NO:10	PKPVDTTGVTLPSSVDQIKEKLAENIHEMWALNKIEAGWSWGEHRDDYHRIHPCLTHFEKLPAAEKRYDNQLAVQTLKTIISLGYITMD
SEQ ID NO:56	PKPVDTTGVTLPSSVDQIKEKLAENIHEMWALNKIEAGWSWGEHRDDYHRIHPCLTHFEKLPAAEKRYDNQLAVQTLKTIISLGYITMD
SEQ ID NO:57	PKPVDTSIVTLPSVETIKDKLAENIHEMWALNKIEAGWTGERRDDYHRIHPCLTSFEKLPAAEKRYDNQLAVQTLKTILALGYIISMD
SEQ ID NO:58	PTPIDVSATQLNHHATEMHQVAENLHELMWAMNKEIAGWYGETRSETSRKHPCLTKEFLPETEKKNILLALTMTKTIEALGVHLITE
SEQ ID NO:59	PAPVDTANVNLPGYIEMLRDKLAENIHELWCMNKEIAGWTGVPVDDSKKHVHDSLMFFSSLSSEKQKNFDTMAYETLRTLMALGVHISID
SEQ ID NO:60	PVPVDTSIQIVLPPHLERIPERLAENIHELWVMNKEIAGWYGPVDDNKRQHPCLVEFCKLPQEQERNYNLQMSLETLKTLLALGCHVGIA
SEQ ID NO:61	PIPVDTSIQIVLPPHLERIPERLAENIHELWVMNKEIAGWYGPVDDNKRQHPCLVEFCKLPQEQERNYNLQMSLETLKTLLALGCHVGIS
SEQ ID NO:62	PIPVDTSIQIVLPPHLERIPERLAENIHELWVMNKEIAGWYGPVDDNKRQHPCLVEFCKLPQEQERNYNLQMSLETLKTLLALGCHVGIS
SEQ ID NO:2	KPPAR--IRNVRLPNEPFMQSNGYKPAPLDL SAVLTPKMDLQVQLAENTHNLWARERIQQGWTYGLNE--DSDMHRSPHLVPYPKVDD
SEQ ID NO:128	KPPAR--IRNVRLPNEPFMQSNGYKPAPLDL SAVLTPKMDLQVQLAENTHNLWARERIQQGWTYGLNE--DSDMHRSPHLVPYPKVDD
SEQ ID NO:130	KPPAR--IRNVRLPNEPFMQSNGYKPAPLDL SAVLTPKMDLQVQLAENTHNLWARERIQQGWTYGLNE--DSDMHRSPHLVPYPKVDD
SEQ ID NO:144	KPPAR--IRNVRLPNEPFMQSNGYKPAPLDL SAVLTPKMDLQVQLAENTHNLWARERIQQGWTYGLNE--DSDMHRSPHLVPYPKVDD
SEQ ID NO:146	KPPAR--IRNVRLPNEPFMQSNGYKPAPLDL SAVLTPKMDLQVQLAENTHNLWARERIQQGWTYGLNE--DSDMHRSPHLVPYPKVDD
SEQ ID NO:4	NPPSR--IKTVRLPNEPFMQSNGYKPAPLDL SAILSGKWEELIDQLAENTHNLWAKERIQQGWTYGLNE--ELQMLRSPHLVPYSKVDD
SEQ ID NO:6	NPPSR--IKTVRLPNEPFMQSNGYKPAPLDL SAINLSGKWEELIDQLAENTHNLWAKERIQQGWTYGLNE--ELQMLRSPHLVPYSKVDD
SEQ ID NO:8	KPPSR--IKTVRLPNEPFMQSNGYKPAPLDL SAVLTPKMDLQVQLAENTHNLWAKERIQQGWTYGLNE--DSDMLRSPHLVPYCKVDE
SEQ ID NO:10	KPPAR--IRPVRLPNEIFMQSNGYKPAPLDL SAVLTPKMDLQVQLAENTHNLWAKERIQQGWTYGLNE--DSENHRSPHLVPYAKVDE
SEQ ID NO:56	KPPAR--IRPVRLPNEIFMQSNGYKPAPLDL SAVLTPKMDLQVQLAENTHNLWAKERIQQGWTYGLNE--DSENHRSPHLVPYAKVDE
SEQ ID NO:57	KPPAR--IRPVRLPNEIFMQSNGYKPAPLDL SAVLTPKMDLQVQLAENTHNLWAKERIQQGWTYGLNE--DSENHRSPHLVPYAKVDE
SEQ ID NO:58	KPPAR--IRPVRLPNEIFMQSNGYKPAPLDL SAVLTPKMDLQVQLAENTHNLWAKERIQQGWTYGLNE--DSENHRSPHLVPYAKVDE
SEQ ID NO:59	DETSKSTLRLRLPMN--YLMNSGYKPAPLYNLSTHLNVKWEKVELLAENAHNVWAKORIAQGWTYGLSE--ETS YKRNQPLVPYNQLND
SEQ ID NO:60	DEHAEKVKMKLPKN--YQLTSGYKPAPMDL SFIKLTSPSEAMVDKLAENAHNVWARDRIRQGWTYGIQQ--DVKNRRNRLVPYTLDD
SEQ ID NO:61	DEHAEKVKMKLPKN--YQLTSGYKPAPMDL SFIKLTSPSEAMVDKLAENAHNVWARDRIRQGWTYGIQQ--DVKNRRNRLVPYTLDD
SEQ ID NO:62	DEHAEDKVKMKLPKN--YQLTSGYKPAPMDL SFIKLTSPSEAMVDKLAENAHNVWARDRIRQGWTYGIQQ--DVKNRRNRLVPYTPPLDD

JC05 Rec'd PCT/PA 21 MAR 2005

THIS PAGE BLANK (11SP70)

FIGURE 1G

SEQ ID NO:2 AIKKANRDTASETVRTLLVGYMLDPPPTGEQHEA-----LLLEASKQKQADFRTRYAEKNYAVSSGKWYFEFEILLTAGPMRVGWAHADMAP  
SEQ ID NO:128 AIKKANRDTASETVRTLLVGYMLDPPPTGEQHEA-----LLLEASKQKQADFRTRYAEKNYAVSSGKWYFEFEILLTAGPMRVGWAHADMAP  
SEQ ID NO:130 AIKKANRDTASETVRTLLVGYMLDPPPTGEQHEA-----LLLEASKQKQADFRTRYAEKNYAVSSGKWYFEFEILLTAGPMRVGWAHADMAP  
SEQ ID NO:144 AIKKANRDTASETVRTLLVGYMLDPPPTGEQHEA-----LLLEASKQKQADFRTRYAEKNYAVSSGKWYFEFEILLTAGPMRVGWAHADMAP  
SEQ ID NO:146 AIKKANRDTASETVRTLLVGYMLDPPPTGEQHEA-----LLLEASKQKQADFRTRYAEKNYAVSSGKWYFEFEILLTAGPMRVGWAHADMAP  
SEQ ID NO:4 AIKKANRDTASETVRTLLVGYMLDPPPTGEQHEA-----LLTDDNSNRLLTFRTRYAEKNYAVSSGKWYFEFEILLTAGPMRVGWAHADMAP  
SEQ ID NO:6 AIKKANRDTASETVRTLLVGYMLDPPPTGEQHEA-----LLTDDNSNRLLTFRTRYAEKNYAVSSGKWYFEFEILLTAGPMRVGWAHADMAP  
SEQ ID NO:8 AIKKANRDTASETVRTLLVGYMLDPPPTGEQHEA-----LLAEASRLRQTHFRTRYAEKNYAVSSGKWYFEFEILLTAGPMRVGWAHADMAP  
SEQ ID NO:10 AIKKANRDTASETVRTLLVGYMLDPPPTGEQHEA-----LLAEASRLRQTHFRTRYAEKNYAVSSGKWYFEFEILLTAGPMRVGWAHADMAP  
SEQ ID NO:56 AIKKANRDTASETVRTLLVGYMLDPPPTGEQHEA-----LLAEASRLRQTHFRTRYAEKNYAVSSGKWYFEFEILLTAGPMRVGWAHADMAP  
SEQ ID NO:57 AIKKANRDTASETVRTLLVGYMLDPPPTGEQHEA-----LLAEASRLRQTHFRTRYAEKNYAVSSGKWYFEFEILLTAGPMRVGWAHADMAP  
SEQ ID NO:58 AIKKANRDTASETVRTLLVGYMLDPPPTGEQHEA-----LLAEASRLRQTHFRTRYAEKNYAVSSGKWYFEFEILLTAGPMRVGWAHADMAP  
SEQ ID NO:59 AIKKANRDTASETVRTLLVGYMLDPPPTGEQHEA-----LLAEASRLRQTHFRTRYAEKNYAVSSGKWYFEFEILLTAGPMRVGWAHADMAP  
SEQ ID NO:60 AIKKANRDTASETVRTLLVGYMLDPPPTGEQHEA-----LLAEASRLRQTHFRTRYAEKNYAVSSGKWYFEFEILLTAGPMRVGWAHADMAP  
SEQ ID NO:61 AIKKANRDTASETVRTLLVGYMLDPPPTGEQHEA-----LLAEASRLRQTHFRTRYAEKNYAVSSGKWYFEFEILLTAGPMRVGWAHADMAP  
SEQ ID NO:62 AIKKANRDTASETVRTLLVGYMLDPPPTGEQHEA-----LLAEASRLRQTHFRTRYAEKNYAVSSGKWYFEFEILLTAGPMRVGWAHADMAP

SEQ ID NO:2 GMMLGQDENSWA FDGYNNEEKVYSGNTESFGKQWAGDVGVFLDLIDKTTISFSLNGELLMDALGGETTFADVQGDN--FVPACTILGVGQK  
SEQ ID NO:128 GMMLGQDENSWA FDGYNNEEKVYSGNTESFGKQWAGDVGVFLDLIDKTTISFSLNGELLMDALGGETTFADVQGDN--FVPACTILGVGQK  
SEQ ID NO:130 GMMLGQDENSWA FDGYNNEEKVYSGNTESFGKQWAGDVGVFLDLIDKTTISFSLNGELLMDALGGETTFADVQGDN--FVPACTILGVGQK  
SEQ ID NO:144 GMMLGQDENSWA FDGYNNEEKVYSGNTESFGKQWAGDVGVFLDLIDKTTISFSLNGELLMDALGGETTFADVQGDN--FVPACTILGVGQK  
SEQ ID NO:146 GMMLGQDENSWA FDGYNNEEKVYSGNTESFGKQWAGDVGVFLDLIDKTTISFSLNGELLMDALGGETTFADVQGDN--FVPACTILGVGQK  
SEQ ID NO:4 GYQIGSDENSWA FDGYNNEEKIYMGTAESFGRQWQVGVFLDLMDHTTISFSLNGELLMDALGGETTFADVQGDN--FVPACTILGVGQK  
SEQ ID NO:6 GYQIGSDENSWA FDGYNNEEKIYMGTAESFGRQWQVGVFLDLMDHTTISFSLNGELLMDALGGETTFADVQGDN--FVPACTILGVGQK  
SEQ ID NO:8 GSQIGNDEYSWA FDGYNNEEKIYMGTAESFGRQWQVGVFLDLMDHTTISFSLNGELLMDALGGETTFADVQGDN--FVPACTILGVGQK  
SEQ ID NO:10 GAMLGSEDTSWA FDGYNNEEKIYMGTAESFGRQWQVGVFLDLMDHTTISFSLNGELLMDALGGETTFADVQGDN--FVPACTILGVGQK  
SEQ ID NO:56 GAMLGSEDTSWA FDGYNNEEKIYMGTAESFGRQWQVGVFLDLMDHTTISFSLNGELLMDALGGETTFADVQGDN--FVPACTILGVGQK  
SEQ ID NO:57 GTMLGSDDASWA FDGYN--GQK  
SEQ ID NO:58 ETQLGADDRSYA FDGYNNEEKIYMGTAESFGRQWQVGVFLDLMDHTTISFSLNGELLMDALGGETTFADVQGDN--FVPACTILGVGQK  
SEQ ID NO:59 RSEVGTGCSFA FDGYNNEEKIYMGTAESFGRQWQVGVFLDLMDHTTISFSLNGELLMDALGGETTFADVQGDN--FVPACTILGVGQK  
SEQ ID NO:60 DLELGSDDERAFA FDGYNNEEKIYMGTAESFGRQWQVGVFLDLMDHTTISFSLNGELLMDALGGETTFADVQGDN--FVPACTILGVGQK  
SEQ ID NO:61 DQELGSDDERAFA FDGYNNEEKIYMGTAESFGRQWQVGVFLDLMDHTTISFSLNGELLMDALGGETTFADVQGDN--FVPACTILGVGQK  
SEQ ID NO:62 DQELGSDDERAFA FDGYNNEEKIYMGTAESFGRQWQVGVFLDLMDHTTISFSLNGELLMDALGGETTFADVQGDN--FVPACTILGVGQK

JC05 Rec'd [REDACTED] PTO 21 MAR 2005

THIS PAGE BLANK (UNCLASSIFIED)

**FIGURE 1H**

SEQ ID NO:2	ARLTGQDVNTLKYFTTCGLQEGYEPFCVNMKRDVTHWYTKDQPIFENTDEMID-TRIDVTRIPAGSDTPPCLKISHNTFE-----TMEKA
SEQ ID NO:128	ARLTGQDVNTLKYFTTCGLQEGYEPFCVNMKRDVTHWYTKDQPIFENTDEMID-TRIDVTRIPAGSDTPPCLKISHNTFE-----TMEKA
SEQ ID NO:130	ARLTGQDVNTLKYFTTCGLQEGYEPFCVNMKRDVTHWYTKDQPIFENTDEMID-TRIDVTRIPAGSDTPPCLKISHNTFE-----TMEKA
SEQ ID NO:144	ARLTGQDVNTLKYFTTCGLQEGYEPFCVNMKRDVTHWYTKDQPIFENTDEMID-TRIDVTRIPAGSDTPPCLKISHNTFE-----TMEKA
SEQ ID NO:146	ARLTGQDVNTLKYFTTCGLQEGYEPFCVNMKRDVTHWYTKDQPIFENTDEMID-TRIDVTRIPAGSDTPPCLKISHNTFE-----TMEKA
SEQ ID NO:4	AKLTGQDVNSLKYFTTCGLQEGYEPFCVNMKRPVAYWYTKDQPIFENTDDFS--SVIDVTRIPAGSDTPPCLKISHNTFE-----TMEKA
SEQ ID NO:6	AKLTGQDVNSLKYFTTCGLQEGYEPFCVNMKRPVYTWYTKDQPIFENTDDFS--SVIDVTRIPAGSDTPPCLKISHNTFE-----TMEKA
SEQ ID NO:8	AKLTGQDVNTLKYFTTCGLQEGYEPFCVNMKRDVTHWYTKDQPIFENTDEMID-TRIDVTRIPAGSDTPPCLKISHNTFE-----TMEKA
SEQ ID NO:10	ARLTGQDVNTLKYFTTCGLQEGYEPFCVNMKRDVTHWYTKDQPIFENTDEMID-TRIDVTRIPAGSDTPPCLKISHNTFE-----TMEKA
SEQ ID NO:56	ARLTGQDVNTLKYFTTCGLQEGYEPFCVNMKRDVTHWYTKDQPIFENTDEMID-TRIDVTRIPAGSDTPPCLKISHNTFE-----TMEKA
SEQ ID NO:57	ARVYVQDVNTLKYFTTCGLQEGYEPFCVNMKRDVTHWYTKDQPIFENTDEMID-TRIDVTRIPAGSDTPPCLKISHNTFE-----TMEKA
SEQ ID NO:58	GRNFGQDVNTLKYFTTCGLQEGYEPFCVNMKRDVTHWYTKDQPIFENTDEMID-TRIDVTRIPAGSDTPPCLKISHNTFE-----TMEKA
SEQ ID NO:59	GRNFGQDVNTLKYFTTCGLQEGYEPFCVNMKRDVTHWYTKDQPIFENTDEMID-TRIDVTRIPAGSDTPPCLKISHNTFE-----TMEKA
SEQ ID NO:60	GRNFGQDVNTLKYFTTCGLQEGYEPFCVNMKRDVTHWYTKDQPIFENTDEMID-TRIDVTRIPAGSDTPPCLKISHNTFE-----TMEKA
SEQ ID NO:61	GRNFGQDVNTLKYFTTCGLQEGYEPFCVNMKRDVTHWYTKDQPIFENTDEMID-TRIDVTRIPAGSDTPPCLKISHNTFE-----TMEKA
SEQ ID NO:62	GRNFGQDVNTLKYFTTCGLQEGYEPFCVNMKRDVTHWYTKDQPIFENTDEMID-TRIDVTRIPAGSDTPPCLKISHNTFE-----TMEKA
SEQ ID NO:2	NWEFLRLSLPVI CHNEFIDEAEKARRWVEIKDRQILMK-----EAVEAQMS-----AHIDQIMRSGFTMNDIKGLHVE-DNQEE
SEQ ID NO:128	NWEFLRLSLPVI CHNEFIDEAEKARRWVEIKDRQILMK-----EAVEAQMS-----AHIDQIMRSGFTMNDIKGLHVE-DNQEE
SEQ ID NO:130	NWEFLRLSLPVI CHNEFIDEAEKARRWVEIKDRQILMK-----EAVEAQMS-----AHIDQIMRSGFTMNDIKGLHVE-DNQEE
SEQ ID NO:144	NWEFLRLSLPVI CHNEFIDEAEKARRWVEIKDRQILMK-----EAVEAQMS-----AHIDQIMRSGFTMNDIKGLHVE-DNQEE
SEQ ID NO:146	NWEFLRLSLPVI CHNEFIDEAEKARRWVEIKDRQILMK-----EAVEAQMS-----AHIDQIMRSGFTMNDIKGLHVE-DNQEE
SEQ ID NO:4	NWEFLRLSLPVI CHNEFIDEAEKARRWVEIKDRQILMK-----EAVEAQMS-----AHIDQIMRSGFTMNDIKGLHVE-DNQEE
SEQ ID NO:6	NWEFLRLSLPVI CHNEFIDEAEKARRWVEIKDRQILMK-----EAVEAQMS-----AHIDQIMRSGFTMNDIKGLHVE-DNQEE
SEQ ID NO:8	NWEFLRLSLPVI CHNEFIDEAEKARRWVEIKDRQILMK-----EAVEAQMS-----AHIDQIMRSGFTMNDIKGLHVE-DNQEE
SEQ ID NO:10	NWEFLRLSLPVI CHNEFIDEAEKARRWVEIKDRQILMK-----EAVEAQMS-----AHIDQIMRSGFTMNDIKGLHVE-DNQEE
SEQ ID NO:56	NWEFLRLSLPVI CHNEFIDEAEKARRWVEIKDRQILMK-----EAVEAQMS-----AHIDQIMRSGFTMNDIKGLHVE-DNQEE
SEQ ID NO:57	NWEFLRLSLPVI CHNEFIDEAEKARRWVEIKDRQILMK-----EAVEAQMS-----AHIDQIMRSGFTMNDIKGLHVE-DNQEE
SEQ ID NO:58	NWEFLRLSLPVI CHNEFIDEAEKARRWVEIKDRQILMK-----EAVEAQMS-----AHIDQIMRSGFTMNDIKGLHVE-DNQEE
SEQ ID NO:59	NWEFLRLSLPVI CHNEFIDEAEKARRWVEIKDRQILMK-----EAVEAQMS-----AHIDQIMRSGFTMNDIKGLHVE-DNQEE
SEQ ID NO:60	NWEFLRLSLPVI CHNEFIDEAEKARRWVEIKDRQILMK-----EAVEAQMS-----AHIDQIMRSGFTMNDIKGLHVE-DNQEE
SEQ ID NO:61	NWEFLRLSLPVI CHNEFIDEAEKARRWVEIKDRQILMK-----EAVEAQMS-----AHIDQIMRSGFTMNDIKGLHVE-DNQEE
SEQ ID NO:62	NWEFLRLSLPVI CHNEFIDEAEKARRWVEIKDRQILMK-----EAVEAQMS-----AHIDQIMRSGFTMNDIKGLHVE-DNQEE

JC05 Rec'd PTO 21 MAR 2005

THIS PAGE BLANK (USPTO)



FIGURE 11

SEQ ID NO:2	LPSSKMK-----RLP--SRPPRK-----GSMTRGVTIQYNNNLPQGVNGMHRSTSEAEAKYDLGAQGLTP-D-DKDKKRGSRSPFK
SEQ ID NO:128	LPSSKMK-----RLP--SRPPRK-----GSMTRGVTIQYNNNLPQGVNGMHRSTSEAEAKYDLGAQGLTP-D-DKDKKRGSRSPFK
SEQ ID NO:130	LPSSKMK-----RLP--SRPPRK-----GSMTRGVTIQYNNNLPQGVNGMHRSTSEAEAKYDLGAQGLTP-D-DKDKKRGSRSPFK
SEQ ID NO:144	LPSSKMK-----RLP--SRPPRK-----GSMTRGVTIQYNNNLPQGVNGMHRSTSEAEAKYDLGAQGLTP-D-DKDKKRGSRSPFK
SEQ ID NO:146	LPSSKMK-----RLP--SRPPRK-----GSMTRGVTIQYNNNLPQGVNGMHRSTSEAEAKYDLGAQGLTP-D-DKDKKRGSRSPFK
SEQ ID NO:4	ENDEIMPNTAPLPGRKNQPPPPRPKR-----GSLSRHDDLTIE-----DGKLNRSSELNFNIYNHONGDQDINKDDKKKRGSRSPFR
SEQ ID NO:6	ENDEIMPNTAPLPGRKNQPPPPRPKR-----GSLSRHDDLTIE-----DGKLNRSSELNFNIYNHONGDQDINKDDKKKRGSRSPFR
SEQ ID NO:8	EADMMMQSTPTTKSKMRQP--SRPPRK-----GSLSRNEDMPMIG--SLEQSKMNRSTSELDNRYNADLQN-----DKDDKKKRGSRSPFR
SEQ ID NO:10	AEADHMM-----RGP--NRPPRK-----ITFETDMSAALDEMQRSTSVLDMNGLGE--EMDDKKKRGSRSPFK
SEQ ID NO:56	AEADHMM-----RGP--NRPPRK-----ITFETDMSAALDEMQRSTSVLDMNGLGE--EMDDKKKRGSRSPFK
SEQ ID NO:57	EADMMR-----NGP--RRPSRHQGRGLSP-----PGIEINGEATSDGELNAYSDENELEGG-----DDKDKKRGSRSPFR
SEQ ID NO:58	RTNSKQPSVDG-----DEP--PAVRRS-----LLELP-----HD-ERQIAEDSMRDLNDRHSEKPKKGLLSRLRDSNTRKNFR
SEQ ID NO:59	RVNGYNGDTK-----ELT--KKEKKK-----LASLP-----LGRKIPMSRAASSETSTVQSPDSSF--ERSGSPSPAKSKRSKFT
SEQ ID NO:60	EFNNHKOYAO-----EKP--SRLKQR-----FLLR-----RTKPDYSTGHSARLT
SEQ ID NO:61	EFNNHKOYAO-----EKP--SRLKQR-----FLLR-----RTKPDYSTGHSARLT
SEQ ID NO:62	EFNNHKOYAO-----EKP--SRLKQR-----FLLR-----RTKPDYSTGHSARLT
SEQ ID NO:2	FFRSK---RGESSDRAKSRKSKTPDPDPFSDTEVSPERGA---RRPNPQIKVSQANQR-YNGMNAAPSRRTNLYGSQVGLNSNAQMATPTQD
SEQ ID NO:128	FFRSK---RGESSDRAKSRKSKTPDPDPFSDTEVSPERGA---RRPNPQIKVSQANQR-YNGMNAAPSRRTNLYGSQVGLN---MATPTQD
SEQ ID NO:130	FFRSK---RGESSDRAKSRKSKTPDPDPFSDTEVSPERGA---RRPNPQIKVSQANQR-YNGMNAAPSRRTNLYGSQVGLN---MATPTQD
SEQ ID NO:144	FFRSK---RGESSDRAKSRKSKTPDPDPFSDTEVSPERGA---RRPNPQIKVSQANQR-YNGMNAAPSRRTNLYGSQVGLNSNAQMATPTQD
SEQ ID NO:146	FFRSK---RGESSDRAKSRKSKTPDPDPFSDTEVSPERGA---RRPNPQIKVSQANQR-YNGMNAAPSRRTNLYGSQVGLNSNAQMATPTQD
SEQ ID NO:4	FFRSK---KEGSDNPCKRAKTPDPARNVDPRNAHRPNTLNERNVTPOIRVSQMDLK-LVPPAIPDR-----PGG
SEQ ID NO:6	FFRSK---KEGSDNPCKRAKTPDPARNVDPRNAHRPNTLNERNVTPOIRVSQMDLK-LVPPAIPDR-----PGG
SEQ ID NO:8	FFRSK---REASNERSKKAKSPENSMMEADRGQMGRS-QHHMMRTPTVKVTAPDMK-VIPPTIPER-----SNM
SEQ ID NO:10	FFSKKS---RDQSRKMGARTLDTSLERRNTVA---HGR---NVVNOQMTTRAPTILR-LNNAEIPPS-----PVPQG
SEQ ID NO:56	FFSKKS---RDQSRKMGARTLDTSLERRNTVA---HGR---NVVNOQMTTRAPTILR-LNNAEIPPS-----PVPQG
SEQ ID NO:57	LFGKK---RDQSKDKLDRRTPEPEPKS-----NLKVTQRGQATR-MSNSDLR-----AQA
SEQ ID NO:58	DSDRRKEEKAQLFQMKANSRFDAGSLDTSTLPTGOK---DVLASEMPLSGPGRQLTIKSSIKKNKK-----GKKAIEIA
SEQ ID NO:59	KSSMSDGAHPEDTLAKPTGYEVDGQRSPCAARRGKK--HDLRTPEASPPGTLTREYIPLKSDNEGSV-----GSDNHGR
SEQ ID NO:60	-----EDVLAD-----
SEQ ID NO:61	-----EDVLAD-----
SEQ ID NO:62	-----EDVLAD-----

JC05 Rec'd PCTO 21 MAR 2005

**THIS PAGE BLANK (USPTO)**

SEQ	ID	NO:2	VVENVNVRQSCYVMVRADELINVEVMAEATAKAGSQGMFICGSVDTSITSGVSFTCEGKDTSFKFQWMEPDKLFPAPISVEATSKELQIELGR-
SEQ	ID	NO:128	VVENVNVRQSCYVMVRADELINVEVMAEATAKAGSQGMFICGSVDTSITSGVSFTCEGKDTSFKFQWMEPDKLFPAPIFVEATSKELQIELGR-
SEQ	ID	NO:130	VVENVNVRQSCYVMVRADELINVEVMAEATAKAGSQGMFICGSVDTSITSGVSFTCEGKDTSFKFQWMEPDKLFPAPIFVEATSKELQIELGR-
SEQ	ID	NO:144	VVENVNVRQSCYVMVRADELINVEVMAEATAKAGSQGMFICGSVDTSITSGVSFTCEGKDTSFKFQWMEPDKLFPAPIFVEATSKELQIELGR-
SEQ	ID	NO:146	VVENVNVRQSCYVMVRADELINVEVMAEATAKAGSQGMFICGSVDTSITSGVSFTCEGKDTSFKFQWMEPDKLFPAPIFVEATSKELQIELGR-
SEQ	ID	NO:4	ILESIDRQSCYMVRSDELINVEVNDSSGKAASQGMFTIGCFIDIAATGLMSTCEGKETSFKFQWEPDIDKLPAPIFVEASSKEILQIELGR-
SEQ	ID	NO:6	ILESIDRQSCYMVRSDELINVEVNDSSGKGASQGMFAIGCFIDIAATGMVSTCEGKETSFKFQWEPDIDKLPAPIFVEASSKEILQIELGR-
SEQ	ID	NO:8	VNESVDRQSCYMVRSDELINVEVNDSSGKGASQGMFICGFVDAATGYISFTCEGKETSHKFQWEPDKLFPAPIFVEATSKELQIELGR-
SEQ	ID	NO:10	AIERIDRQSCYVVRADELNFNEVTQDASGKGASQGMFVGCVFVDATATGIIRFTCEGKDTSHRMWMEPDTKLFPAPIFVEATSKELQIELGR-
SEQ	ID	NO:156	AIERIDRQSCYVVRADELNFNEVTQDASGKGASQGMFVGCVFVDATATGIIRFTCEGKDTSHRMWMEPDTKLFPAPIFVEATSKELQIELGR-
SEQ	ID	NO:157	TIEIVNRQSCYMVRADELNFNEVTQDSSGKGASQGMFVGCVFVDATATGTRIPTCEGKETSHVFLWMEPDTKLFPAPIFVEATSKELQIELGR-
SEQ	ID	NO:158	TVDSVQSNQCYMVNVSELLATT--PDVANTKVSGTHIGCIIDTSIGEEISFQVGSVDTGKIKFLBPGAMLFPAAFTPTATEILQFELGR-
SEQ	ID	NO:159	VQESSKRRDCFTVCVGDHMDLLI-TPEGRRISSGLVVGCVVDACNGELYFTINGRDISTKYQVEPKTKLPAPAVFKPTSKEMLQFELGRS
SEQ	ID	NO:160	VHESIKRSNCYMVVCAGESMS-----PGQGRNNNSGLEIGCVVDAASGLLTFIANGKELSTYYYQVEPSTKLFPAPVFAQATSPNVFQFELGR-
SEQ	ID	NO:161	VHESIKRSNCYMVVCAGESMS-----PGQGRNN-NGLEIGCVVDAASGLLTFIANGKELSTYYYQVEPSTKLFPAPVFAQATSPNVFQFELGR-
SEQ	ID	NO:162	VHESIKRSNCYMVVCAGESMS-----PGQGRNN-NGLEIGCVVDAASGLLTFIANGKELSTYYYQVEPSTKLFPAPVFAQATSPNVFQFELGR-

JC05 Rec'd PCT/PTO 21 MAR 2005

**THIS PAGE BLANK (USPTO)**

**FIGURE 1K**

SEQ ID NO:2	-----SATSPLSAAVLPTSDKHV	IPQPPRLKVQCLKPHQWARVP	NQSLQVHALKLSGIRGWSML	CEDAVSMLAL	
SEQ ID NO:128	-----SATSPLSAAVLPTSDKHV	IPQPPRLKVQCLKPHQWARVP	NQSLQVHALKLSDIRGWSML	CEDAVSMLAL	
SEQ ID NO:130	-----SATSPLSAAVLPTSDKHV	IPQPPRLKVQCLKPHQWARVP	NQSLQVHALKLSDIRGWSML	CEDAVSMLAL	
SEQ ID NO:144	-----SATSPLSAAVLPTSDKHV	IPQPPRLKVQCLKPHQWARVP	NQSLQVHALKLSDIRGWSML	CEDAVSMLAL	
SEQ ID NO:146	-----SATSPLSAAVLPTSDKHV	IPQPPRLKVQCLKPHQWARVP	NQSLQVHALKLSDIRGWSML	CEDAVSMLAL	
SEQ ID NO:4	-----TSTTLPLSAAVLQNSERHVL	POFPRLKVQCLRPHQWARVP	NDLSHTLKLSDIRGWSIL	CEDPVSMIAL	
SEQ ID NO:6	-----TSTTLPLSAAVLQNSERHVL	POFPRLKVQCLRPHQWARVP	NDLSHTLKLSDIRGWSIL	CEDPVSMIAL	
SEQ ID NO:8	-----TSTTLPLSAAVLQNSERHVL	POFPRLKVQCLRPHQWARVP	NDLSHTLKLSDIRGWSIL	CEDPVSMIAL	
SEQ ID NO:10	-----TPTTLPLSAAVLPTSDKHIN	POSPRLKVQCLRPHQWARVP	NQSLQVHALKLSDIRGWSML	CEDPVSMIAL	
SEQ ID NO:56	-----TPTTLPLSAAVLPTSDKHIN	POSPRLKVQCLRPHQWARVP	NQSLQVHALKLSDIRGWSML	CEDPVSMIAL	
SEQ ID NO:57	-----TPTTLPLSAAVLPTSDKHIN	POSPRLKVQCLRPHQWARVP	NQSLQVHALKLSDIRGWSML	CEDPVSMIAL	
SEQ ID NO:58	-----IKYTFPLSAAMFKCEKSL	VPFCPPRLTVEQIESVYWARVP	NETLRTTALKLSEVRGWSV	CNDPVRIMSV	
SEQ ID NO:59	-----KILERRSSVQSEIAQMSVN	QNCPLPSAAWFRGDTHNPT	QPCPSRVEVQVMYTNWTWAR	APLQTMNIEFKMSDNGWLV	SCPEPVSWLGV
SEQ ID NO:60	-----IKNVMPLSAGLFKSEHKNP	VPVQCPCPRLHVQFLSHVLS	MRMPNQFLKVDVSRISERQ	GWLVCCLDPLQFMSL	
SEQ ID NO:61	-----IKNVMPLSAGLFKSEHKNP	VPVQCPCPRLHVQFLSHVLS	MRMPNQFLKVDVSRISERQ	GWLVCCLDPLQFMSL	
SEQ ID NO:62	-----IKNVMPLSAGLFKSEHKNP	VPVQCPCPRLHVQFLSHVLS	MRMPNQFLKVDVSRISERQ	GWLVCCLDPLQFMSL	
SEQ ID NO:2	HIPEEDRCIDILELEIMDKLLS	FHSHTLTLYAALCVQSNYRAA	HALCSHADQKQLLYAIOQYMS	GPLRQGFYDLLTALHLESHATTMEA	
SEQ ID NO:128	HIPEEDRCIDILEPIEMDKLLS	FHSHTLTLYAALCVQSNYRAA	HALCTHVDQKQLLYAIOQYMS	GPLRQGFYDLLIALHLESHATTMEA	
SEQ ID NO:130	HIPEEDRCIDILELEIMDKLLS	FHSHTLTLYAALCVQSNYRAA	HALCTHVDQKQLLYAIOQYMS	GPLRQGFYDLLIALHLESHATTMEA	
SEQ ID NO:144	HIPEEDRCMDILELEIMDKLLS	FHSHTLTLYAALCVQSNYRAA	HALCTHVDQKQLLYAIOQYMS	GPLRQGFYDLLIALHLESHATTMEA	
SEQ ID NO:146	HIPEEDRCIDILELEIMDKLLS	FHSHTLTLYAALCVQSNYRAA	HALCTHVDQKQLLYAIOQYMS	GPLRQGFYDLLIALHLESHATTMEA	
SEQ ID NO:4	HIPEEDRCIDILELEIMDKLLS	FHAHTLTLYAAVCYQANYRAA	HIILCTHVNQKQLLYAICSEYMS	GPLRQGFYDLLIALHLESHATTMEV	
SEQ ID NO:6	HIPEEDRCIDILELEIMDKLLS	FHAHTLTLYAAVCYQANYRAA	HIILCTHVNQKQLLYAICSEYMS	GPLRQGFYDLLIALHLESHATTMEV	
SEQ ID NO:8	HIPEEDRSIDILELEIMDKLLS	FHAHTLTLYAALCFQSNYRAA	HTLCSHVDEKQLLYAIRSDYMS	GPLRQGFYDLLIALHLESHATTMEV	
SEQ ID NO:10	RIPEEDRCIDILELEIMDKLLS	FHAHSLTLYAALCVQSNYRAA	HALCQHVQKQLLYAIRSEYMS	GPLRQGFYDLLIALHLESHATTMEV	
SEQ ID NO:56	HIPEEDRCIDILELEIMDKLLS	FHAHSLTLYAALCVQSNYRAA	HALCQHVQKQLLYAIRSEYMS	GPLRQGFYDLLIALHLESHATTMEV	
SEQ ID NO:57	HIPEEDRCIDILELEIDRLLQ	FHAHTLTLYALCVQSNYRAA	HALCSHVQKQLLYAIOSEYMS	GPLRGLGFYDLLISLHLESHATTMEV	
SEQ ID NO:58	YIPEKQSLDILEMIEMPDMLE	FHRQTLNLYCKLASHGNH	KVAHTLCQHIDEDQIMVAIKSHYLS	SGPMRQGFHDLILGLHLSMHTAARN	
SEQ ID NO:59	HIPEENRCMDILELVEHEDL	KFAHTLTLYCSVSGHGNH	VHAHALINHVNEQIMVCLQCPYIS	GPLRIGYNNLLHALHLQTHVSARLK	
SEQ ID NO:60	HIPEENRSVDILELTEQEELL	QFHYHTLTLYSAVCA	LGNNHVAHALCSHVDEPQLLYA	IAENKMPGLLRAGYYDLLIDIHLSSYATARLM	
SEQ ID NO:61	HIPEENRSVDILELTEQEELL	KFHYHTLTLYSAVCA	LGNNHVAHALCSHVDEPQLLYA	IAENKMPGLLRAGYYDLLIDIHLSSYATARLM	
SEQ ID NO:62	HIPEENRSVDILELTEQEELL	KFHYHTLTLYSAVCA	LGNNHVAHALCSHVDEPQLLYA	IAENKMPGLLRAGYYDLLIDIHLSSYATARLM	

JC05 Rec'd PCT 01 MAR 2005

**THIS PAGE BLANK (USPTO)**

FIGURE 1L

SEQ ID NO:2	CKNEFVPLGPELKALYEEDMG--HSLR-----SLQTESVRPQMKMTDIA-----ESITEISNLYSPYFPFLEVVREF
SEQ ID NO:128	CKNEFVPLGPELKALYEEDMG--HSLR-----SLQTESVRPQMKMTDIA-----ESITEISNLYSPYFPFLEVAREF
SEQ ID NO:130	CKNEFVPLGPELKALYEEDMG--HSLR-----SLQTESVRPQMKMTDIA-----ESITEISNLYSPYFPFLEVVREF
SEQ ID NO:144	CKNEFVPLGPELKALYEEDMG--HSLR-----SLQTESVRPQMKMTDIA-----ESITEISNLYSPYFPFLEVVREF
SEQ ID NO:146	CKNEFVPLGPELKALYEEDMG--HSLR-----SLQTESVRPQMKMTDIA-----ESITEISNLYSPYFPFLEVVREF
SEQ ID NO:4	CKXEYIIPLGHELTLYDDPQMG--HSLR-----SLQTESVRPQMKMTDIA-----VIDNVRNLYSPYFPFLEVVREF
SEQ ID NO:6	CKXEYIIPLGHELTLYDDPQMG--HSLR-----SLQTESVRPQMKMTDIA-----VIDNVRNLYSPYFPFLEVVREF
SEQ ID NO:8	CKNEFIIPIGQELKDVEDPEMC--HSLR-----SLKTESVLPQMKMTDIA-----PSEVVDNIRSLYSPQFPLDVVRDF
SEQ ID NO:10	CKNEYITPLGAELKELYSDEEMQ--HSLR-----SLVTESVRPQMKMTDIA-----EPIPDIDQLYSPKFPFLEVVREF
SEQ ID NO:56	CKNEYITPLGAELKELYSDEEMQ--HSLR-----SLVTESVRPQMKMTDIA-----EPIPDIDQLYSPKFPFLEVVREF
SEQ ID NO:57	CKNEYIIPLGSELRELYIDPEMC--HSLR-----SLQTESVRPQMKMTDIA-----EPIPDIDQLYSPKFPFLEVVREF
SEQ ID NO:58	MAKEYIIPLVQQLKQVLDPS--ESRYPIQIGESVMSLSQMASEPVK-----KHVSREDEMKLLPPSVDFEALKKH
SEQ ID NO:59	TQDEFIIPLMAGPKPVDEELDIDSSMSIKRALSTTKSVIRPQINIGPSAD--S-----SHQSFSQSMKASEQAPPGFNHMLVKQH
SEQ ID NO:60	MNNEFIVPMTTEETKSIPLFPDENKKHGLP--GIGLSTSLRPRMRF-----SSPSFVSINDCYQSPFPLDILKAK
SEQ ID NO:61	MNNEFIVPMTTEETKSIPLFPDENKKHGLP--GIGLSTSLRPRMRF-----SSPSFVSINDCYQSPFPLDILKAK
SEQ ID NO:62	MNNEYIVPMTTEETKSIPLFPDENKKHGLP--GIGLSTSLRPRMRF-----SSPSFVSINDCYQSPFPLDILKSK
SEQ ID NO:2	VMQALAEAVETNQVHNWDPVGGSNENFLPLIKLVDRLLLVGMWRDEDEVEKLLIMTNPETWDP-----S
SEQ ID NO:128	VMQALAEAVETNQVHNWDPVGGSNENFLPLIKLVDRLLLVGMWRDEDEVEKLLIMTNPETWDP-----S
SEQ ID NO:130	VMQALAEAVETNQVHNWDPVGGSNENFLPLIKLVDRLLLVGMWRDEDEVEKLLIMTNPETWDP-----S
SEQ ID NO:144	VMQALAEAVETNQVHNWDPVGGSNENFLPLIKLVDRLLLVGMWRDEDEVEKLLIMTNPETWDP-----S
SEQ ID NO:146	VMQALAEAVETNQVHNWDPVGGSNENFLPLIKLVDRLLLVGMWRDEDEVEKLLIMTNPETWDP-----S
SEQ ID NO:4	VMAALEEAVLVNQVHNWDPVGGSNENFLPLIKLVDRLLLVGMWRDEDEVEKLLIMTNPETWDP-----E
SEQ ID NO:6	VMAALEEAVLVNQVHNWDPVGGSNENFLPLIKLVDRLLLVGMWRDEDEVEKLLIMTNPETWDP-----E
SEQ ID NO:8	VMAALDEAVQINQVHNWDPVGGSNENFLPLIKLVDRLLLVGMWRDEDEVEKLLIMTNPETWDP-----A
SEQ ID NO:10	VMEALKDAVEINQVHNWDPVGGSNENFLPLIKLVDRLLLVGMWRDEDEVEKLLIMTNPETWDP-----A
SEQ ID NO:56	VMEALKDAVEINQVHNWDPVGGSNENFLPLIKLVDRLLLVGMWRDEDEVEKLLIMTNPETWDP-----A
SEQ ID NO:57	VMSALQEAQVQINQVHNWDPVGGSNENFLPLIKLVDRLLLVGMWRDEDEVEKLLIMTNPETWDP-----S
SEQ ID NO:58	VMSLQSAATHAVMNCRDILGGDNTNHFEPFLKFDQLLVIGLINDEEELCLRLIHPQAFD-----
SEQ ID NO:59	VISSLGEAVAHGVSHCRDPVGGSNENFLPLIKLVDRLLLVGMWRDEDEVEKLLIMTNPETWDP-----D
SEQ ID NO:60	TIQMLTEAVKEGSLHARDPVGGTTEFLFVPLIKLVDRLLLVGMWRDEDEVEKLLIMTNPETWDP-----GE
SEQ ID NO:61	TIQMLTEAVKEGSLHARDPVGGTTEFLFVPLIKLVDRLLLVGMWRDEDEVEKLLIMTNPETWDP-----GE
SEQ ID NO:62	TIQMLTEAVKEGSLHARDPVGGTTEFLFVPLIKLVDRLLLVGMWRDEDEVEKLLIMTNPETWDP-----GE

JC05 Rec'd PTO 21 MAR 2005

THIS PAGE BLANK (USPTO)



FIGURE 1M

SEQ ID NO:2	FDKEGKOEHRKGLLHMKWAEGAKLQMCYLLQHLNDIQLRHRVEATIAFAHDFVGDLTQDLRRYTEIKQ-SDLPSAVAAKKTREFRCPPR
SEQ ID NO:128	FDKEGKOEHRKGLLHMKWAEGAKLQMCYLLQHLNDIQLRHRVEATIAFAHDFVGDLTQDLRRYTEIKQ-SDLPSAVAAKKTREFRCPPR
SEQ ID NO:130	FDKEGKOEHRKGLLHMKWAEGAKLQMCYLLQHLNDIQLRHRVEATIAFAHDFVGDLTQDLRRYTEIKQ-SDLPSAVAAKKTREFRCPPR
SEQ ID NO:144	FDKGGKOEHRKGLLHMKWAEGAKLQMCYLLQHLNDIQLRHRVEATIAFAHDFVGDLTQDLRRYTEIKQ-SDLPSAVAAKKTREFRCPPR
SEQ ID NO:146	FDKEGKOEHRKGLLHMKWAEGAKLQMCYLLQHLNDIQLRHRVEATIAFAHDFVGDLTQDLRRYTEIKQ-SDLPSAVAAKKTREFRCPPR
SEQ ID NO:4	FQKGPDEHRKGLLHMKWAEGAKLQMCYLLHHLCDIQLRHRVESIISFSYQFVNDIQIDQLRRYNEIKQ-SDLPSAVAAKKTREFRCPPR
SEQ ID NO:6	FQKGPDEHRKGLLHMKWAEGAKLQMCYLLHHLCDIQLRHRVESIISFSYQFVNDIQIDQLRRYNEIKQ-SDLPSAVAAKKTREFRCPPR
SEQ ID NO:8	FEKDGKOEHRKGLLHMKWAEGAKLQMCYLLHHLCDIQLRHRVESIISFSYQFVNDIQIDQLRRYNEIKQ-SDLPSAVAAKKTREFRCPPR
SEQ ID NO:10	FEREGKOEHRKGLLHMKWAEGAKLQMCYLLHHLCDIQLRHRVESIISFSYQFVNDIQIDQLRRYNEIKQ-SDLPSAVAAKKTREFRCPPR
SEQ ID NO:56	FEREGKOEHRKGLLHMKWAEGAKLQMCYLLHHLCDIQLRHRVESIISFSYQFVNDIQIDQLRRYNEIKQ-SDLPSAVAAKKTREFRCPPR
SEQ ID NO:57	FEKEGRDEHRKGLLHMKWAEGAKLQMCYLLHHLCDIQLRHRVESIISFSYQFVNDIQIDQLRRYNEIKQ-SDLPSAVAAKKTREFRCPPR
SEQ ID NO:58	-ENYETGTTQKGLTQLELAEPVKIQLVSIIDHLCDIQLRHRVESIISFSYQFVNDIQIDQLRRYNEIKQ-SDLPSAVAAKKTREFRCPPR
SEQ ID NO:59	ETKKGVSSETVGMQLQMHLDPEVKLQMCYLLHHLCDIQLRHRVESIISFSYQFVNDIQIDQLRRYNEIKQ-SDLPSAVAAKKTREFRCPPR
SEQ ID NO:60	EEAKGKRPKEGILLQMKLPEPVKLQMCYLLHHLCDIQLRHRVESIISFSYQFVNDIQIDQLRRYNEIKQ-SDLPSAVAAKKTREFRCPPR
SEQ ID NO:61	EEAKGKRPKEGILLQMKLPEPVKLQMCYLLHHLCDIQLRHRVESIISFSYQFVNDIQIDQLRRYNEIKQ-SDLPSAVAAKKTREFRCPPR
SEQ ID NO:62	EEAKGKRPKEGILLQMKLPEPVKLQMCYLLHHLCDIQLRHRVESIISFSYQFVNDIQIDQLRRYNEIKQ-SDLPSAVAAKKTREFRCPPR

SEQ ID NO:2	EQMNVILSFKHLEE-----EDKENCPCGEELIARMNEFHDITLMAHVSLHALQEPDAAENQEP- AKPGAFGKLYNIINTVKELEEE
SEQ ID NO:128	EQMNVILSFKHLEE-----EDKENCPCGEELIARMNEFHDITLMAHVSLHALQEPDAAENQEP- AKPGAFGKLYNIINTVKELEEE
SEQ ID NO:130	EQMNVILSFKHLEE-----EDKENCPCGEELIARMNEFHDITLMAHVSLHALQEPDAAENQEP- AKPGAFGKLYNIINTVKELEEE
SEQ ID NO:144	EQMNVILSFKHLEE-----EDKENCPCGEELIARMNEFHDITLMAHVSLHALQEPDAAENQEP- AKPGAFGKLYNIINTVKELEEE
SEQ ID NO:146	EQMNVILSFKHLEE-----EDKENCPCGEELIARMNEFHDITLMAHVSLHALQEPDAAENQEP- AKPGAFGKLYNIINTVKELEEE
SEQ ID NO:4	EQMNVILGFKNLDI-----DDKENCILGDELRLRERLNSFHEKLMHKVSLIALQEPSEEDDKLDLNNINREGKIKQFYNF INAVKDEANE
SEQ ID NO:6	EQMNVILGFKNLDI-----DDKENCILGDELRLRERLNSFHEKLMHKVSLIALQEPSEEDDKLDLNNINREGKIKQFYNF INAVKDEANE
SEQ ID NO:8	EQMNVILGFKNLEE-----GDIENCPCGDELRLRERLNSFHEKLMHKVSLIALQEPSEEDDKLDLNNINREGKIKQFYNF INAVKDEANE
SEQ ID NO:10	EQMNVILGFKNLEE-----GDIENCPCGDELRLRERLNSFHEKLMHKVSLIALQEPSEEDDKLDLNNINREGKIKQFYNF INAVKDEANE
SEQ ID NO:56	EQMNVILGFKNLEE-----GDIENCPCGDELRLRERLNSFHEKLMHKVSLIALQEPSEEDDKLDLNNINREGKIKQFYNF INAVKDEANE
SEQ ID NO:57	EQMNVILGFKNLEE-----GDIENCPCGDELRLRERLNSFHEKLMHKVSLIALQEPSEEDDKLDLNNINREGKIKQFYNF INAVKDEANE
SEQ ID NO:58	EQMNVILGFKNLEE-----GDIENCPCGDELRLRERLNSFHEKLMHKVSLIALQEPSEEDDKLDLNNINREGKIKQFYNF INAVKDEANE
SEQ ID NO:59	EQMNVILGFKNLEE-----GDIENCPCGDELRLRERLNSFHEKLMHKVSLIALQEPSEEDDKLDLNNINREGKIKQFYNF INAVKDEANE
SEQ ID NO:60	EQMNVILGFKNLEE-----GDIENCPCGDELRLRERLNSFHEKLMHKVSLIALQEPSEEDDKLDLNNINREGKIKQFYNF INAVKDEANE
SEQ ID NO:61	EQMNVILGFKNLEE-----GDIENCPCGDELRLRERLNSFHEKLMHKVSLIALQEPSEEDDKLDLNNINREGKIKQFYNF INAVKDEANE
SEQ ID NO:62	EQMNVILGFKNLEE-----GDIENCPCGDELRLRERLNSFHEKLMHKVSLIALQEPSEEDDKLDLNNINREGKIKQFYNF INAVKDEANE

JC05 Rec'd PCT/STO 21 MAR 2005

THIS PAGE BLANK (USPTO)

**FIGURE 1N**

SEQ ID NO:2 AKAIEPPPKTPEEKFRKVLQITIVNWAEEESQIETPKLVREMFSLVRQYDAVGELIRALEKTYVINAKTKLDVAEMWVGLSQIRALLPV  
SEQ ID NO:128 AKAIEPPPKTPEEKFRKVLQITIVNWAEEESQIETPKLVREMFSLVRQYDAVGELIRALEKTYVINAKTKLDVAEMWVGLSQIRALLPV  
SEQ ID NO:130 AKAIEPPPKTPEEKFRKVLQITIVNWAEEESQIETPKLVREMFSLVRQYDAVGELIRALEKTYVINAKTKLDVAGMWVGLSQIRALLPV  
SEQ ID NO:144 AKAIEPPPKTPEEKFRKVLQITIVNWAEEESQIETPKLVREMFSLVRQYDAVGELIRALEKTYVINAKTKLDVAEMWVGLSQIRALLPV  
SEQ ID NO:146 AKAIEPPPKTPEEKFRKVLQITIVNWAEEESQIETPKLVREMFSLVRQYDAVGELIRALEKTYVINAKTKLDVAEMWVGLSQIRALLPV  
SEQ ID NO:4 DGLN-EHEKKIPEEIEFRKVLISTIVSWAEEETQIETPKLVREMFSLVRQYDSVGELIRALEKTYVINFKTKEDVAQMWVGLSQIRSLLPV  
SEQ ID NO:6 NGLN-EHEKKIPEEIEFRKVLITIVSWAEEETQIETPKLVREMFSLVRQYDSVGELIRALEKTYVINFKTKEDVAQMWVGLSQIRSLLPV  
SEQ ID NO:8 PQIEEPEKKTPEEIEFRKVLITIVSWAEEETQIESPKLVREMFSLVRQYDTVGELIRALEKTYVINSKTKODDAALMWVGLSQIRALLPV  
SEQ ID NO:10 PKEVEPEKKTPEEIEFRKVLITIVSWAEEESQIENPKLVREMFSLVRQYDTVGELIRALEKTYVINTRARDDVAEMWVGLSQIRALLPV  
SEQ ID NO:56 PKEVEPEKKTPEEIEFRKVLITIVSWAEEESQIENPKLVREMFSLVRQYDTVGELIRALEKTYVINTRARDDVAEMWVGLSQIRALLPV  
SEQ ID NO:57 PKEPVEEKKKTPEEIEFRKVLITIVSWAEEESQIENPKLVREMFSLVRQYDTVGELIRALEKTYVINTRARDDVAEMWVGLSQIRALLPV  
SEQ ID NO:58 VLEEGMEMQKGTQNFREIIVTMLREWAQADFIESKSLIRNMFRLLRQYSGIREIRDAMSQTYVHERNEKQVDFVLLTSLGQIRSLTIV  
SEQ ID NO:59 SPAGAILQEFSSDSLHLISNTMIKWAEEKHIEDPTLVREMFNLLHRQYDVGELCSALQKSYVSSNQRDDIVHLLTSLGQIRSLTIV  
SEQ ID NO:60 QAEKPVASDSRKCSSTLQQLISETWVRWAQESVIEDPELVAMFVLLHRQYDVGIGGLVRALPKTYTINGVSVEDTINLLASLGQIRSLLSV  
SEQ ID NO:61 QTEKPVESDSRKCSSTLQQLISETWVRWAQESVIEDPELVAMFVLLHRQYDVGIGGLVRALPKTYTINGVSVEDTINLLASLGQIRSLLSV  
SEQ ID NO:62 QAEKPVESDSRKCSSTLQQLISETWVRWAQESVIEDPELVAMFVLLHRQYDVGIGGLVRALPKTYTINGVSVEDTINLLASLGQIRSLLSV

SEQ ID NO:2 QMSQEEELMRKRLWKL VNNHTFFQHPDLIRVLRVHENVMVMMNTLGRRAQAQS---DAQSSQPVAE-----  
SEQ ID NO:128 QMSQEEELMRKRLWKL VNNHTFFQHPDLIRVLRVHENVMVMMNTLGRRAQAQS---DAQSSQPVAE-----  
SEQ ID NO:130 QMSQEEELMRKRLWKL VNNHTFFQHPDLIRVLRVHENVMVMMNTLGRRAQAQS---DAQSSQPVAE-----  
SEQ ID NO:144 QMSQEEELMRKRLWKL VNNHTFFQHPDLIRVLRVHENVMVMMNTLGRRAQAQS---DAQSSQPVAE-----  
SEQ ID NO:146 QMSQEEELMRKRLWKL VNNHTFFQHPDLIRVLRVHENVMVMMNTLGRRAQAQS---DAQSSQPVAE-----  
SEQ ID NO:4 QMSQEEELMRERLWKL VNNHTFFQHPDLIRVLRMHNVMVMMNTLGRRAQAQS---PGGTPVTGQDGEIV-----  
SEQ ID NO:6 QMSQEEELMRERLWKL VNNHTFFQHPDLIRVLRMHNVMVMMNTLGRRAQAQS---PGGTPVTGQDGEIV-----  
SEQ ID NO:8 QMSQEEELMRERLWKL VNNHTFFQHPDLIRVLRVHENVMVMMNTLGRRAQAQS---DAPQAGEGEPV-----  
SEQ ID NO:10 QMSQEEELMRKRLWKL VNNATFFQHPDLIRILRVHENVMVMMNTLGRRAQAQS---DAPQSEVAEGAP-----  
SEQ ID NO:56 QMSQEEELMRKRLWKL VNNATFFQHPDLIRILRVHENVMVMMNTLGRRAQAQS---DAPQSEVAEGAP-----  
SEQ ID NO:57 QMSQEEELMRKRLWKL VNNHTFFQHPDLIRILRVHENVMVMMNTLGRRAQAQS---DAPQATADGEESA-----  
SEQ ID NO:58 QFEHTTEAILKRGWLKLMNRIFFFQHPDLMRLLSVHENVMSIMMNLITAQGG-----TVEHEGDELKEK-----  
SEQ ID NO:59 QMGSVVEEALIKHLWEVTDNKVYFQHPDLMRALCVHETVMNVMMNVNLEKHQTSIQLTSEEEAESAQGGVGTGASTAAAPKTQVCVYRF  
SEQ ID NO:60 RMGKHEEKLMIIRGLGDIMNNKVYFQHPNLMRALGMHETVMEVMNVNVLGGGE-----  
SEQ ID NO:61 RMGKHEEKLMIIRGLGDIMNNKVYFQHPNLMRALGMHETVMEVMNVNVLGGGE-----  
SEQ ID NO:62 RMGKHEEKLMIIRGLGDIMNNKVYFQHPNLMRALGMHETVMEVMNVNVLGGGE-----

JC05 Rec'd T/PTO 21 MAR 2005

**THIS PAGE BLANK (USPTO)**

**FIGURE 10**

SEQ ID NO:2	-----NKEKDTSHMVAACCRFLCYFCRTGRQKQKAMFDHDFDFFLENSNILLSPSLRGSTPLDVAYSSLMNTTELALALREHYLEK
SEQ ID NO:128	-----SKEKDTSHMVAACCRFLCYFCRTGRQKQKAMFDHDFDFFLENSNILLSPSLRGSTPLDVAYSSLMNTTELALALREHYLEK
SEQ ID NO:130	-----NKEKDTSHMVAACCRFLCYFCRTGRQKQKAMFDHDFDFFLENSNILLSPSLRGSTPLDVAYSSLMNTTELALALREHYLEK
SEQ ID NO:144	-----NKEKDTSHMVAACCRFLCYFCRTGRQKQKAMFDHDFDFFLENSNILLSPSLRGSTPLDVAYSSLMNTTELALALREHYLEK
SEQ ID NO:146	-----NKEKDTSHMVAACCRFLCYFCRTGRQKQKAMFDHDFDFFLENSNILLSPSLRGSTPLDVAYSSLMNTTELALALREHYLEK
SEQ ID NO:4	-----PKEKDTSHMVAACCRFLCYFCRTSRQKQKAMFDHDFDFFLENSNILLSPSLRGSTPLDVAYSSLMNTTELALALREHYLEK
SEQ ID NO:6	-----PKEKDTSHMVAACCRFLCYFCRTSRQKQKAMFDHDFDFFLENSNILLSPSLRGSTPLDVAYSSLMNTTELALALREHYLEK
SEQ ID NO:8	-----AKEKDTSHMVAACCRFLCYFCRTSRQKQKAMFDHDFDFFLENSNILLSPSLRGSTPLDVAYSSLMNTTELALALREHYLEK
SEQ ID NO:10	-----SKEKDTSHMVAACCRFLCYFCRTGRQKQKAMFDHDFDFFLENSNILLSPSLRGSTPLDVAYSSLMNTTELALALREHYLEK
SEQ ID NO:56	-----SKEKDTSHMVAACCRFLCYFCRTGRQKQKAMFDHDFDFFLENSNILLSPSLRGSTPLDVAYSSLMNTTELALALREHYLEK
SEQ ID NO:57	-----PKEKDTSHMVAACCRFLCYFCRTGRQKQKAMFDHDFDFFLENSNILLSPSLRGSTPLDVAYSSLMNTTELALALREHYLEK
SEQ ID NO:58	-----APIKDTSEMVVACSRFLCYFCRTSRQKQKAMFEHLSFLLDNATMLLARPSLRGSPPLDVAYSSFMNDNNELALKEEELDK
SEQ ID NO:59	LARRARMCHSKORFARALTAGCCRFLLCYFCRTSRQKQKAMFDHDFDFFLENSNILLSPSLRGSTPLDVAYSSFMNDNNELALKEEELDK
SEQ ID NO:60	-----SKEITFPKVMVACCRFLCYFCRTSRQKQKAMFDHLSYLLNSSVGLASPMRGSTPLDVAAASVMDNNELALALREPDLEK
SEQ ID NO:61	-----SKEITFPKVMVACCRFLCYFCRTSRQKQKAMFDHLSYLLNSSVGLASPMRGSTPLDVAAASVMDNNELALALREPDLEK
SEQ ID NO:62	-----SKEITFPKVMVACCRFLCYFCRTSRQKQKAMFDHLSYLLNSSVGLASPMRGSTPLDVAAASVMDNNELALALREPDLEK
SEQ ID NO:2	IAV-YLSRCGLQSNSELVEKGYPDGLGWDPEGGERYLDLFLRFCVWNGESVEENANLVIRLLIRRPECIGPALRGEG-EGLLKAIVDANKM
SEQ ID NO:128	IAV-YLSRCGLQSNSELVEKGYPDGLGWDPEGGERYLDLFLRFCVWNGESVEENANLVIRLLIRRPECIGPALRGEG-EGLLKAIVDANKM
SEQ ID NO:130	IAV-YLSRCGLQSNSELVEKGYPDGLGWDPEGGERYLDLFLRFCVWNGESVEENANLVIRLLIRRPECIGPALRGEG-EGLLKAIVDANKM
SEQ ID NO:144	IAV-YLSRCGLQSNSELVEKGYPDGLGWDPEGGERYLDLFLRFCVWNGESVEENANLVIRLLIRRPECIGPALRGEG-EGLLKAIVDANKM
SEQ ID NO:146	IAV-YLSRCGLQSNSELVEKGYPDGLGWDPEGGERYLDLFLRFCVWNGESVEENANLVIRLLIRRPECIGPALRGEG-EGLLKAIVDANKM
SEQ ID NO:4	IAI-YLSRCGLQSNSELVEKGYPDGLGWDPEGGERYLDLFLRFCVWNGESVEENANLVIRLLIRRPECIGPALRGEG-EGLLRAITDANKM
SEQ ID NO:6	IAI-YLSRCGLQSNSELVEKGYPDGLGWDPEGGERYLDLFLRFCVWNGESVEENANLVIRLLIRRPECIGPALRGEG-EGLLRAITDANKM
SEQ ID NO:8	IAI-YLSRCGLQSNSELVEKGYPDGLGWDPEGGERYLDLFLRFCVWNGESVEENANLVIRLLIRRPECIGPALRGEG-EGLLRAITDANKM
SEQ ID NO:10	IAV-YLSRCGLQSNSELVEKGYPDGLGWDPEGGERYLDLFLRYCVWNGESVEENANLVIRLLIRRPECIGPALRGEG-EGLLRAIVEANRM
SEQ ID NO:56	IAV-YLSRCGLQSNSELVEKGYPDGLGWDPEGGERYLDLFLRYCVWNGESVEENANLVIRLLIRRPECIGPALRGEG-EGLLRAIVEANRM
SEQ ID NO:57	IAI-YLSRCGLQSNSELVEKGYPDGLGWDPEGGERYLDLFLRYCVWNGESVEENANLVIRLLIRRPECIGPALRGEG-EGLLKAIVDANKM
SEQ ID NO:58	VAV-YLSRCGLQSNSELITKGYDDIGWDPEGGERYIDFLRFVWINGENVEENANLVIRLLIRRPECIGVALKKEG-QGLFSAFKEAIAL
SEQ ID NO:59	VIT-FLSRCGVQDNARLRAMGNPYLDGTPLDGERYIDFLRFVWINGENVEENANLVIRMLIRHPECIGPALRGEG-KGLLAAMEEAIIDL
SEQ ID NO:60	VVARYLAGCGLQSCQMLVSKGYDDIGWNPVEGERYIDFLRFVAVFCNGESVEENANVVVRLIRRPECIGPALRGEGGNGLLAAMEEAIKI
SEQ ID NO:61	VVR-YLAGCGLQSCQMLVSKGYDDIGWNPVEGERYIDFLRFVAVFCNGESVEENANVVVRLIRRPECIGPALRGEGGNGLLAAMEEAIKI
SEQ ID NO:62	VVR-YLAGCGLQSCQMLVSKGYDDIGWNPVEGERYIDFLRFVAVFCNGESVEENANVVVRLIRRPECIGPALRGEGGNGLLAAMEEAIKI

JC05 Rec'd [REDACTED] /PTO 21 MAR 2005

**THIS PAGE BLANK (USPTO)**

**FIGURE 1P**

SEQ ID NO:2	SERADRRKRLRE-----MEQ--EGDVNFSHPLPESDED-EDYIDTGAAIILNFYCTLVLDLLGRCAPDAGVIALGKNESLRARAILRSLVP
SEQ ID NO:128	SERADRRKRLRE-----MEQ--EGDVNFSHPLPESDED-EDYIDTGAAIILNFYCTLVLDLLGRCAPDAGVIALGKNESLRARAILRSLVP
SEQ ID NO:130	SERADRRKRLRE-----MEQ--EGDVNFSHPLPESDED-EDYIDTGAAIILNFYCTLVLDLLGRCAPDAGVIALGKNESLRARAILRSLVP
SEQ ID NO:144	SERADRRKRLRE-----MEQ--EGDVNFSHPLPESDED-EDYIDTGAAIILNFYCTLVLDLLGRCAPDAGVIALGKNESLRARAILRSLVP
SEQ ID NO:146	SERADRRKRLRE-----MEQ--EGDVNFSHPLPESDED-EDYIDTGAAIILNFYCTLVLDLLGRCAPDAGVIALGKNESLRARAILRSLVP
SEQ ID NO:4	SERITERRKKFLE-----ES-GNQENIQLDHPLPESDDD-EDYIDTGAAIILNFYCTLVLDLLGRCAPDSSVIALGKNESLRARAILRSLVP
SEQ ID NO:6	SERIAERRKKFLE-----ES-GNQENIQLDHPLPESDED-EDYIDTGAAIILNFYCTLVLDLLGRCAPDSSVIALGKNESLRARAILRSLVP
SEQ ID NO:8	SERADRRKVMQD-----EPEGTTVMVHFEHPLPESDDD-EDYIDTGAAIILNFYCTLVLDLLGRCAPDSSVIALGKNESLRARAILRSLVP
SEQ ID NO:10	SERISDRCKMQD-----EAEGTIAGLNFTTHPLPEGEED-EDYIDTGAAIILNFYCTLVLDLLGRCAPDSSVIALGKNESLRARAILRSLVP
SEQ ID NO:56	SERISDRCKMQD-----EAEGTIAGLNFTTHPLPEGEED-EDYIDTGAAIILNFYCTLVLDLLGRCAPDSSVIALGKNESLRARAILRSLVP
SEQ ID NO:57	SERISERRKMQD-----EAEGTITGLNFHSHPLPEGDDD-EDYIDTGAAIILNFYCTLVLDLLGRCAPDAAVIEQGNESLRARAILRSLVP
SEQ ID NO:58	SEDIRLLENDSHPL-----SLLSSGLLGENPTYPKDAEGEDYIDLGAATLDFYSSLVLDLLAKCAPDPMALQAGKGDLSLRARAILRSLIS
SEQ ID NO:59	SETAEEGYLISAPTMATSEEDGEVRPIDASQDEEGDED-EDDVTGTGAAILTFATLIDLLGRCAPDENLRSQGRTEPQIRAILRSLVP
SEQ ID NO:60	AEDPSR-----DGPSPGSSKTLTDEEEE-DDTIHMGNAIMTFFAALIDLLGRCAPDPMHLLHAGKGEAIRIRSLRSLIP
SEQ ID NO:61	AEDPSR-----DGPSPGSSKTLTDEEEE-DDTIHMGNAIMTFFAALIDLLGRCAPDPMHLLHAGKGEAIRIRSLRSLIP
SEQ ID NO:62	AEDPSR-----DGPSPGSSKTLTDEEEE-DDTIHMGNAIMTFFAALIDLLGRCAPDPMHLLHAGKGEAIRIRSLRSLIP
SEQ ID NO:2	LEDLQGVLSLRFLLNPPAA-----GEERP KSDMPSGLI PGHKQSVGLFLGRVYGIETQELFYKLLLEAFPLDLRAATMLDRNDGCE
SEQ ID NO:128	LEDLQGVLSLRFLLNPPAA-----GEERP KSDMPSGLI PGHKQSVGLFLGRVYGIETQELFYKLLLEAFPLDLRAATMLDRNDGCE
SEQ ID NO:130	LEDLQGVLSLRFLLNPPAA-----GEERP KSDMPSGLI PGHKQSVGLFLGRVYGIETQELFYKLLLEAFPLDLRAATMLDRNDGCE
SEQ ID NO:144	LEDLQGVLSLRFLLNPPAA-----GEERP KSDMPSGLI PGHKQSVGLFLGRVYGIETQELFYKLLLEAFPLDLRAATMLDRNDGCE
SEQ ID NO:146	LEDLQGVLSLRFLLNPPAA-----GEERP KSDMPSGLI PGHKQSVGLFLGRVYGIETQELFYKLLLEAFPLDLRAATMLDRNDGCE
SEQ ID NO:4	LEDLHGVL SLRFLLQNPPAA-----GQDRPKSDMPSGLI PGHKQSVGLFLGRVYGIEMQELFFTLLEAFPLDLRTATMLDRNDGLES
SEQ ID NO:6	LEDLHGVL SLRFLLQNPPAA-----GQDRPKSDMPSGLI PGHKQSVGLFLGRVYGIEMQELFFTLLEAFPLDLRTATMLDRNDGLES
SEQ ID NO:8	LEDLQGVLSLKFLLQNPPAA-----GEERP KSDMPSGLI PGHKQSVGLFLGRVYGIETQELFFRLLLEAFPLDLRAATMLDRNDGSES
SEQ ID NO:10	LEDLQGVLSLKFLLSQTPA-----GEEKPKSDMPSGLI PNNKQSVGLFLGRVYGIEMQELFYRLLEDAFLPDLRTATILDKSDGSES
SEQ ID NO:56	LEDLQGVLSLKFLLSQTPA-----GEEKPKSDMPSGLI PNNKQSVGLFLGRVYGIEMQELFYRLLEDAFLPDLRTATILDKSDGSES
SEQ ID NO:57	LEDLQGVLSLKFLLTNPAL-----GEDRPKSDMPSGLI PGHKQSVGLFLGRVYGIETQELFYRLLEDAFLPDLRAATMLDRSDGSES
SEQ ID NO:58	LDDLQGVLSLKFLLTNPAL-----SIEDTGPIPLGILLPNNKQSVGLFLGRVYGIEMQELFYRLLEDAFLPDLRAATMLDRSDGSES
SEQ ID NO:59	LDDLQGVLSLKFLLTNLAAP-----SIEDTGPIPLGILLPNNKQSVGLFLGRVYGIEMQELFYRLLEDAFLPDLRAATMLDRSDGSES
SEQ ID NO:60	LGLDLGVLSIAFQMPTIAK-----DGKVEPDMAGFCPDHKAAMVFLDRVYGIEMQELFYRLLEDAFLPDLRAAAASLDTAALSAT
SEQ ID NO:61	LGLDLGVLSIAFQMPTIAK-----DGNVVEPDMAGFCPDHKAAMVFLDRVYGIEMQELFYRLLEDAFLPDLRAAAASLDTAALSAT
SEQ ID NO:62	LGLDLGVLSIAFQMPTIAK-----DGNVVEPDMAGFCPDHKAAMVFLDRVYGIEMQELFYRLLEDAFLPDLRAAAASLDTAALSAT

THIS PAGE BLANK (USPTO)



FIGURE 1Q

SEQ ID NO: 2	DMALSMNRYIGNSILPLLIKHAYFYNEAENYASLLDATHLHTVYRLSKNRMMLTKGQREAVSDFLVALTSAMQPSMMLLKLLRKLTVDVSKLS
SEQ ID NO: 128	DMALSMNRYIGNSILPLLIKHAYFYNEAENYASLLDATHLHTVYRLSKNRMMLTKGQREAVSDFLVALTSAMQPSMMLLKLLRKLTVDVSKLS
SEQ ID NO: 130	DMALSMNRYIGNSILPLLIKHAYFYNEAENYASLLDATHLHTVYRLSKNRMMLTKGQREAVSDFLVALTSAMQPSMMLLKLLRKLTVDVSKLS
SEQ ID NO: 144	DMALSMNRYIGNSILPLLIKHAYFYNEAENYASLLDATHLHTVYRLSKNRMMLTKGQREAVSDFLVALTSAMQPSMMLLKLLRKLTVDVSKLS
SEQ ID NO: 146	DMALSMNRYIGNSILPLLIKHAYFYNEAENYASLLDATHLHTVYRLSKNRMMLTKGQREAVSDFLVALTSAMQPSMMLLKLLRKLTVDVSKLS
SEQ ID NO: 4	DMALAMNRYIGNSVLPPLLIHSHSKFYSESGNYANLLDATHLHTVYRLSKNRMMLTKGQREAVSDFLVALTSQMQPSMMLLKLLRKLTVDVSNLS
SEQ ID NO: 6	DMALAMNRYIGNSVLPPLLIHSHSKFYSESGNYANLLDATHLHTVYRLSKNRMMLTKGQREAVSDFLVALTSQMQPSMMLLKLLRKLTVDVSNLS
SEQ ID NO: 8	DMALAMNRYIGNSILPLLIHSHSKFYNEADNYASLLDATHLHTVYRLSKNRMMLTKGQREAVSDFLVALTSQMQPSMMLLKLLRKLTVDVSKLT
SEQ ID NO: 10	DMALAMNRYIGNSILPLLIHSHSKFYNEAENYASLLDATHLHTVYRLSKNRMMLTKGQREAVSDFLVALTSQMQPSMMLLKLLRKLTVDVSKLS
SEQ ID NO: 56	DMALAMNRYIGNSILPLLIHSHSKFYNEAENYASLLDATHLHTVYRLSKNRMMLTKGQREAVSDFLVALTSQMQPSMMLLKLLRKLTVDVSKLS
SEQ ID NO: 57	DMALSMNRYIGNSILPLLIHSHSKFYNEAENYASLLDATHLHTVYRLSKNRMMLTKGQREAVSDFLVALTSQMQPSMMLLKLLRKLTVDVSKLS
SEQ ID NO: 58	DTALALNRYLCNSVLPPLLTNNHSHFFADAEHHSALLDATHLHTVYRMNRLKSLTKNQORDAVSDFLVAITRELPAMMIKLLKKVITDILTMN
SEQ ID NO: 59	DMALALNRYICNSVLPPLLTNNHSEMFESADQFASLLDSTLHTVYRLASCRLTRGQRTVADFLVALTRSLKPSMMQORLLRKLINDVPLA
SEQ ID NO: 60	DMALALNRYLCTAVLPPLLTRCARLPAGTEHHSALLDSTLHTVYRLSKGCSLTKAQSDSIEVCLLSICGQURPPSMQHLRRLVDFVPLLN
SEQ ID NO: 61	DMALALNRYLCTAVLPPLLTRCAPLPAGTEHHSALLDSTLHTVYRLSKGCSLTKAQSDSIEVCLLSICGQURPPSMQHLRRLVDFVPLLN
SEQ ID NO: 62	DMALALNRYLCTAVLPPLLTRCAPLPAGTEHHSALLDSTLHTVYRLSKGCSLTKAQSDSIEVCLLSICGQURPPSMQHLRRLVDFVPLLN
SEQ ID NO: 2	EY-TTVALRLTLHYERCAKYVGSTGAG-QGAFGASSDEEKRLTMMLFSSIFDSLSKMDYEPPELFGKALPCLIAIGCALPPDYTLTSKNYD
SEQ ID NO: 128	EY-TTVALRLTLHYERCAKYVGSTGAG-QGAFGASSDEEKRLTMMLFSSIFDSLSKMDYEPPELFGKALPCLIAIGCALPPDYTLTSKNYD
SEQ ID NO: 130	EY-TTVALRLTLHYERCAKYVGSTGAG-QGAFGASSDEEKRLTMMLFSSIFDSLSKMDYEPPELFGKALPCLIAIGCALPPDYTLTSKNYD
SEQ ID NO: 144	EY-TTVALRLTLHYERCAKYVGSTGAG-QGAFGASSDEEKRLTMMLFSSIFDSLSKMDYEPPELFGKALPCLIAIGCALPPDYTLTSKNYD
SEQ ID NO: 146	EY-TTVALRLTLHYERCAKYVGSTGAG-QGAFGASSDEEKRLTMMLFSSIFDSLSKMDYEPPELFGKALPCLIAIGCALPPDYTLTSKNYD
SEQ ID NO: 4	EY-TTVALRLTLHYDRCAKYVGSTGG--QGIYGASSDEEKRLTMMLFSSIFDSLSKMDYDPELFGKALPCLISAIGCALPPDYSLSKNHD
SEQ ID NO: 6	EY-TTVALRLTLHYDRCAKYVGSTGG--QGIYGASSDEEKRLTMMLFSSIFDSLSKMDYDPELFGKALPCLISAIGCALPPDYSLSKNHD
SEQ ID NO: 8	EY-TTVALRLTLHYDRCAKYVGSTGG--QGLYGSSDEEKRLTMMLFSSIFDSLSKMDYDPELFGKALPCLISAIGCALPPDYSLSKNHD
SEQ ID NO: 10	EY-TTVALRLTLHFDRCAKYVGSTQG--QGSYGASSDEEKRLTMMLFSSIFDSLSKMDYDPELFGKALPCLISAIGCALPPDYSLSKNHD
SEQ ID NO: 56	EY-TTVALRLTLHFDRCAKYVGSTQG--QGSYGASSDEEKRLTMMLFSSIFDSLSKMDYDPELFGKALPCLISAIGCALPPDYSLSKNHD
SEQ ID NO: 57	EY-TTVALRLTLHYERCAKYVTTGGQASQFSSDEEKRLTMMLFSSIFDSLSKMDYDPELFGKALPCLISAIGCALPPDYSLSKNHD
SEQ ID NO: 58	DMNLVPLRLITLHYERCCKYVGSNGH----YGVASEQEKRLSMMLFDALFTGLFDALAEKEYDEELFDRALPCLISAIGCALPPDYSLSKNHD
SEQ ID NO: 59	EY-SYVALKILQHYERCCKYVGSNGG--WGSYGAANDEEKRLTMMLFTGLFDALAEKEYDEELFDRALPCLISAIGCALPPDYSLSKNHD
SEQ ID NO: 60	EH-AKMPKLKLTNHYERCCKYVCLPGG--WGNFGAASEEELHLSRKLFWGIFDALSQKYEQELFKLALPCLISAVAGALPPDYMESNY--
SEQ ID NO: 61	EH-AKMPKLKLTNHYERCCKYVCLPGG--WGNFGAASEEELHLSRKLFWGIFDALSQKYEQELFKLALPCLISAVAGALPPDYMESNY--
SEQ ID NO: 62	EH-AKMPKLKLTNHYERCCKYVCLPGG--WGNFGAASEEELHLSRKLFWGIFDALSQKYEQELFKLALPCLISAVAGALPPDYMESNY--

JC05 Rec'd T/PTO 21 MAR 2005

THIS PAGE BLANK (USPTO)

**FIGURE 1R**

SEQ ID NO:2	DEFYGEQAAGDLNPNQYDPPINTSSVALNNDLNTIVQKFSHYHDAWASRKIENGWVYGEWSDSQKTHPRLKPYNMLNDY-----EK
SEQ ID NO:128	DEFYGEQAAGDLNPNQYDPPINTSSVALNNDLNTIVQKFSHYHDAWASRKIENGWVYGEWSDSQKTHPRLKPYNMLNDY-----EK
SEQ ID NO:130	DEFYGEQAAGDLNPNQYDPPINTSSVALNNDLNTIVQKFSHYHDAWASRKIENGWVYGEWSDSQKTHPRLKPYNMLNDY-----EK
SEQ ID NO:144	GEFYGEQAAGDLNPNQYDPPINTSSVALNNDLNTIVQKFSHYHDAWASRKIENGWVYGEWSDSQKTHPRLKPYNMLNDY-----EK
SEQ ID NO:146	DEFYGEQAAGDLNPNQYDPPINTSSVALNNDLNTIVQKFSHYHDAWASRKIENGWVYGEWSDSQKTHPRLKPYNMLNDY-----EK
SEQ ID NO:4	DEWYGSKONIQQPSDGPYNPQPINITSIVLDNDLNSIVHKEFSHYHDAWASRKIENGWVYGEQFNDVNSKSHPRKPYNMLSEY-----EK
SEQ ID NO:6	DEWYGSKONIQQPSDGPYNPQPINITSIVLDNDLNSIVHKEFSHYHDAWASRKIENGWVYGEQFNDVNSKSHPRKPYNMLSEY-----EK
SEQ ID NO:8	DELYGARDSQAGPSDGPYNPQPINTHSVVLNNDLNTIVQKFSHYHDAWASRKIENGWVYGEQFNDVNSKSHPRKPYNMLNDIVEPSIER
SEQ ID NO:10	EDYIGRQMG--APDQPOQYMPNPIDTNNVHLDNDLNSIVQKFSHYHDAWASRRLEGGWVYGD IRSNDNRKHPRLKPYNMLSEY-----ER
SEQ ID NO:56	EDYIGRQMG--APDQPOQYMPNPIDTNNVHLDNDLNSIVQKFSHYHDAWASRRLEGGWVYGD IRSNDNRKHPRLKPYNMLSEY-----ER
SEQ ID NO:57	DDLKGKPTGG--GPDQPHYNPQPIDTTAVQLTNDLNQIVQKFSHYHDAWASRKIENGWVYGDQWSDANKTHPRLKPYNMLTSEY-----ER
SEQ ID NO:58	DVRNKRREE-----EGAWIPRTVDVSRCEINRDLKMTLFAEHFHDWSARSKLEKGVHGDLYSRANFTHPRLKPYFALLKDF-----EK
SEQ ID NO:59	DESYVRESC--FDADGIYQPKPVDNSKVLNLSLSFSDRFAEHLHDSWALAMFDNGWTHGEAENSAMKESCMRLRPYKTLTTK-----EK
SEQ ID NO:60	VSMMEKQSS--MDSEGPNPQPVDTSTNITPEKLEYFINKYAEHSHDKWSMDKLANGWIYGEIYSDSSKIQLPMKPYKLLSEK-----EK
SEQ ID NO:61	VSMMEKQSS--MDSEGPNPQPVDTSTNITPEKLEYFINKYAEHSHDKWSMDKLANGWIYGEIYSDSSKIQLPMKPYKLLSEK-----EK
SEQ ID NO:62	VSMMEKQSS--MDSEGPNPQPVDTSTNITPEKLEYFINKYAEHSHDKWSMDKLANGWIYGEIYSDSSKIQLPMKPYKLLSEK-----EK
SEQ ID NO:2	ERYKEPVRESLKALLAIGWSVEHSEVDIPSNRRSSMGRQSKSGRRPPEIVT--DSATPFNYPNHPVDMTNLTLSREMQNMAERLADNAHD
SEQ ID NO:128	ERYKEPVRESLKALLAIGWSVEHSEVDIPSNRRSSMGRQSKSGRRPPEIVT--DSATPFNYPNHPVDMTNLTLSREMQNMAERLADNAHD
SEQ ID NO:130	ERYKEPVRESLKALLAIGWSVEHSEVDIPSNRRSSMGRQSKSGRRPPEIVT--DSATPFNYPNHPVDMTNLTLSREMQNMAERLADNAHD
SEQ ID NO:144	ERYKEPVRESLKALLAIGWSVEHSEVDIPSNRRSSMGRQSKSGRRPPEIVT--DSATPFNYPNHPVDMTNLTLSREMQNMAERLADNAHD
SEQ ID NO:146	ERYKEPVRESLKALLAIGWSVEHSEVDIPSNRRSSMGRQSKSGRRPPEIVT--DSATPFNYPNHPVDMTNLTLSREMQNMAERLADNAHD
SEQ ID NO:4	ELYKEPVRESLKALLAIGWSIEHSENDAPLNNRGSVRRQSK-----SN-----ENVTPFDYHPNPIDMTNLTLTREMQNMAERLAENSHD
SEQ ID NO:6	ELYKEPVRESLKALLAIGWSIEHSENDAPLNNRGSVRRQSK-----SN-----ENVTPFDYHPNPIDMTNLTLTREMQNMAERLAENSHD
SEQ ID NO:8	ERYKEPVRESLKALLAIGWTVSEHSEADVPLTSRGSTRQSK-----PNAMV--DSSTPFNYPNHPIDMTNLTLTREMQNMAERLAENSHD
SEQ ID NO:10	ERYRDPVRECKGLLAIGWTVSEHSEVEVPLNHRGSTRQSK-----PQINE-----GSPFNYPNHPVDMNSNLTLSREMQNMAERLAENSHD
SEQ ID NO:56	ERYRDPVRECKGLLAIGWTVSEHSEVEVALNHRGSTRQSK-----PQINEFQNEGSPFNYPNHPVDMNSNLTLSREMQNMAERLAENSHD
SEQ ID NO:57	ERYREPVRRESLKALLALHWRIEHSEGDVPLSNRGSMRRQSK-----PNLELQDGTGSPFNYPNHPVDMTNLTLSREMQNMAERLAENSHD
SEQ ID NO:58	SFYKERCSECLKALMWNYSFEMMDRDAN--DRASAARTLSG-----TSISNFAKPIDLSSMTLEKDMVNAEKNVAEHSHL
SEQ ID NO:59	DSYREPVRRESLKALLAIGWSVERSKASEQQOAHRRRLSK-----ASLGA-----MESPHGYNPRPIDVSNITLTREMOTMAERLAENSHD
SEQ ID NO:60	EIYRWPIKESLKTMLANGWRIERTREGDSMALYNRTRISQ-----TSQVS-----IDAAHGYSPPRAIDMSNVTLSRDLHAMAEMMAENYHN
SEQ ID NO:61	EIYRWPIKESLKTMLANGWRIERTREGDSMALYNRTRISQ-----TSQVS-----VDAAHGYSPPRAIDMSNVTLSRDLHAMAEMMAENYHN
SEQ ID NO:62	EIYRWPIKESLKTMLARTMRTERTREGDSMALYNRTRISQ-----TSQVS-----VDAAHGYSPPRAIDMSNVTLSRDLHAMAEMMAENYHN

JC05 Rec'd [REDACTED]/PTO 21 MAR 2005

THIS PAGE BLANK (USPTO)

**FIGURE 1S**

SEQ ID NO:2 IWAKKKKEELVTNGGGIHPQLVPYDILLTDKEKKKDRERSQEFLLKYLQYQGYKHLRPSKAPQ-SDTEQT-TTGVAIELRFAYSLSLEKLIQY  
SEQ ID NO:128 IWAKKKKEELVTNGGGIHPQLVPYDILLTDKEKKKDRERSQEFLLKYLQYQGYKHLRPSKAPQ-SDTEQT-TTGVAIELRFAYSLSLEKLIQY  
SEQ ID NO:130 IWAKKKKEELVTNGGGIHPQLVPYDILLTDKEKKKDRERSQEFLLKYLQYQGYKHLRPSKAPQ-SDTEQT-TTGVAIELRFAYSLSLEKLIQY  
SEQ ID NO:144 IWAKKKKEELVTNGGGIHPQLVPYDILLTDKEKKKDRERSQEFLLKYLQYQGYKHLRPSKAPQ-SDTEQT-TTGVAIELRFAYSLSLEKLIQY  
SEQ ID NO:146 IWAKKKKEELVTNGGGIHPQLVPYDILLTDKEKKKDRERSQEFLLKYLQYQGYKHLRPSKAPQ-SDTEQT-TTGVAIELRFAYSLSLEKLIQY  
SEQ ID NO:4 IWAKKKKEEVLMLCGGGIHNQLVPYDILLTDKEKKKDRERSQEFLLKYLQYQGYKHLRPNRNGGPPSEAEQL-AAASTGELRFSYSLSLEKLIHY  
SEQ ID NO:6 IWAKKKKEEVLMLCGGGIHNQLVPYDILLTDKEKKKDRERSQEFLLKYLQYQGYKHLRPNRNGGPPSEAEQL-AAASTGELRFSYSLSLEKLIHY  
SEQ ID NO:8 IWAKKKKEELITCGGGIHPQLVPYDILLTDKEKKKDRERSQEFLLKYLQYQGYKHLRPSRTGGPSESEQL-AAQATGELRFAYSLSLEKLIQY  
SEQ ID NO:10 IWAKKKKEELNCGGGIHPQLVPYDILLTDKEKKKDRERSQEFLLKYLQYQGYKHLRPSRTGGPSESEQL-AAQATGELRFAYSLSLEKLIQY  
SEQ ID NO:56 IWAKKKKEELNCGGGIHPQLVPYDILLTDKEKKKDRERSQEFLLKYLQYQGYKHLRPSRTGGPSESEQL-AAQATGELRFAYSLSLEKLIQY  
SEQ ID NO:57 IWAKKKKEELNCGGGIHPQLVPYDILLTDKEKKKDRERSQEFLLKYLQYQGYKHLRPSRTGGPSESEQL-AAQATGELRFAYSLSLEKLIQY  
SEQ ID NO:58 IWAKKKKEELNCGGGIHPQLVPYDILLTDKEKKKDRERSQEFLLKYLQYQGYKHLRPSRTGGPSESEQL-AAQATGELRFAYSLSLEKLIQY  
SEQ ID NO:59 IWAKKKKEELNCGGGIHPQLVPYDILLTDKEKKKDRERSQEFLLKYLQYQGYKHLRPSRTGGPSESEQL-AAQATGELRFAYSLSLEKLIQY  
SEQ ID NO:60 IWAKKKKEELNCGGGIHPQLVPYDILLTDKEKKKDRERSQEFLLKYLQYQGYKHLRPSRTGGPSESEQL-AAQATGELRFAYSLSLEKLIQY  
SEQ ID NO:61 IWAKKKKEELNCGGGIHPQLVPYDILLTDKEKKKDRERSQEFLLKYLQYQGYKHLRPSRTGGPSESEQL-AAQATGELRFAYSLSLEKLIQY  
SEQ ID NO:62 IWAKKKKEELNCGGGIHPQLVPYDILLTDKEKKKDRERSQEFLLKYLQYQGYKHLRPSRTGGPSESEQL-AAQATGELRFAYSLSLEKLIQY

SEQ ID NO:2 IDRATINMKLLKPST-TFSRRSSFKTSTRDIKFFSKVVLPLMEKYFSTHRNYFIATATATNSVG--AASLKEKEMVAALFCKLASLLRSR  
SEQ ID NO:128 IDRATINMKLLKPST-TFSRRSSFKTSTRDIKFFSKVVLPLMEKYFSTHRNYFIATATATNSVG--AASLKEKEMVAALFCKLASLLRSR  
SEQ ID NO:130 IDRATINMKLLKPST-TFSRRSSFKTSTRDIKFFSKVVLPLMEKYFSTHRNYFIATATATNSVG--AASLKEKEMVAALFCKLASLLRSR  
SEQ ID NO:144 IDRATINMKLLKPST-TFSRRSSFKTSTRDIKFFSKVVLPLMEKYFSTHRNYFIATATATNSVG--AASLKEKEMVAALFCKLASLLRSR  
SEQ ID NO:146 IDRATINMKLLKPST-TFSRRSSFKTSTRDIKFFSKVVLPLMEKYFSTHRNYFIATATATNSVG--AASLKEKEMVAALFCKLASLLRSR  
SEQ ID NO:4 IDRASINMKLLKPSG-TFSRRSSFKICTRDIKFFSKVVLPLVEKYFSTHRNYFITVATASSVLG--AASLKEKEMVASLFCCKLANLLRSK  
SEQ ID NO:6 IDRASINMKLLKPSG-TFSRRSSFKICTRDIKFFSKVVLPLVEKYFSTHRNYFITVATASSVLG--AASLKEKEMVASLFCCKLANLLRSK  
SEQ ID NO:8 IDRASINMKLLKPSG-TFSRRSSFKICTRDIKFFSKVVLPLVEKYFSTHRNYFITVATASSVLG--AASLKEKEMVASLFCCKLANLLRSK  
SEQ ID NO:10 LDRATINMKLLKPST-TFSRRSSFKTATRD IKFFSKVVLPLMEKYFSTHRNYFIATATATNSVG--AASLKEKEMVASIFCKLAALLRNR  
SEQ ID NO:56 LDRATINMKLLKPST-TFSRRSSFKTATRD IKFFSKVVLPLMEKYFSTHRNYFIATATATNSVG--AASLKEKEMVASIFCKLAALLRNR  
SEQ ID NO:57 SDRATINMKLLKPSG-TFSRRSSFKICTRDIKFFSKVVLPLVEKYFSTHRNYFIATATATNSVG--AASLKEKEMVASLFCCKLASLLRHR  
SEQ ID NO:58 LEQASLKMKSVPKPSQ-ELTRRNSFKKEGQDVFFKFKVVLPLMHAYFNAHKNYFLEGSSIVQGTGT---ASNKEKEMVANLFCRLAALLRITK  
SEQ ID NO:59 VDKSQANLKPQRQDQDSFRSSKKESSGDRGYKFFAKVVLPLIEKYFQAHSSYFVADPNAPQNGRSGGASTREKELVSSSLFCCKLAQLIRQK  
SEQ ID NO:60 VDEAHQVILEFDGGS---RSKGEHPPPYEQEIKFFAKVVLPLIDQYFKNHRLYFLSAASRPLCTG-GHASNKEKEMVTSLSFCKLGVLVVRHR  
SEQ ID NO:61 VDEAHQVILEFDGGS---RSKGEHPPPYEQEIKFFAKVVLPLIDQYFKNHRLYFLSAASRPLCTG-GHASNKEKEMVTSLSFCKLGVLVVRHR  
SEQ ID NO:62 VDEAHQVILEFDGGS---RGKGEHPPPYEQEIKFFAKVVLPLIDQYFKNHRLYFLSAASRPLCTG-GHASNKEKEMVTSLSFCKLGVLVVRHR

JC05 Rec~~CT~~/PTO 21 MAR 2005

**THIS PAGE BLANK (USPTO)**

**FIGURE 1T**

SEQ ID NO:2 LAAFGPDVRIITVRCLQVLVRGIDAKSLVKNCPDEFIRTSMLTFFNNVADDVGHITIMNLQDG-KYAHLR-GTHLKTSTSLGYIHGVLLPILT  
SEQ ID NO:128 LAAFGPDVRIITVRCLQVLVRGIDAKSLVKNCPDEFIRTSMLTFFNNVADDVGHITIMNLQDG-KYAHLR-GTHLKTSTSLGYINGVLLPILT  
SEQ ID NO:130 LAAFGPDVRIITVRCLQVLVRGIDAKSLVKNCPDEFIRTSMLTFFNNVADDVGHITIMNLQDG-KYAHLR-GTHLKTSTSLGYINGVLLPILT  
SEQ ID NO:144 LAAFGPDVRIITVRCLQVLVRGIDAKSLVKNCPDEFIRTSMLTFFNNVADDVGHITIMNLQDG-KYAHLR-GTHLKTSTSLGYINGVLLPILT  
SEQ ID NO:146 LAAFGPDVRIITVRCLQVLVRGIDAKSLVKNCPDEFIRTSMLTFFNNVADDVGHITIMNLQDG-KYAHLR-GTHLKTSTSLGYINGVLLPILT  
SEQ ID NO:4 LMAFGADVRIITVRCLQVLVRGIDAKSLVKNCPDEFIRTSMLTFFNNVADDVGHITIMNLQDG-KYAHLR-GTHLKTSTSLFYVNDVILPVLS  
SEQ ID NO:6 LMAFGADVRIITVRCLQVLVRGIDAKSLVKNCPDEFIRTSMLTFFNNVADDVGHITIMNLQDG-KYAHLR-GTHLKTSTSLFYVNDVILPVLS  
SEQ ID NO:8 LAAFGADVRIITVRCLQVLVRGIDAKSLVKNCPDEFIRTSMLTFFNNVADDVGHITIMNLQDG-KYAHLR-GTHLKTSTSLFYVNDVILPVLT  
SEQ ID NO:10 LSAFGPDVRIITVRCLQVLVRGIDARTLTKNCPDEFIRTSMLTFFNQTSDDLGNITILNLQDG-KYSHLR-GTHLKTSTSLGYVNVQVILPVLT  
SEQ ID NO:56 LSAFGPDVRIITVRCLQVLVRGIDARTLTKNCPDEFIRTSMLTFFNQTSDDLGNITILNLQDG-KYSHLR-GTHLKTSTSLGYVNVQVILPVLT  
SEQ ID NO:57 LAAFGADVRIITVRCLQVLVRGIDAKSLVKNCPDEFIRTSMLTFFNNVADDVGHITIMNLQDG-KYDRLR-GTHLKTSTSLAYVNVQVILPVLT  
SEQ ID NO:58 NRAFSGVAKITVRCLQVLVRGIDARTLTKNCPDEFIRTSMLTFFNNVADDVGHITIMNLQDG-KYDRLR-GTHLKTSTSLAYVNVQVILPVLT  
SEQ ID NO:59 INLFGRDLVPFIRIRVVAQSIDASSVVKHSDAIAKNGLLVFFRHSDDLVAIVDSVTSGGRFTHIKSNQVHKHSLAVNYVPGVILPVLI  
SEQ ID NO:60 ISLFGNDATSIIVNCHILGQTLDAITVMKTGLDSVKSAALRAFLDNAEDELKTMENLKQG-QFTHTR-SQPKGVTOIINYYTTVALLPMLS  
SEQ ID NO:61 ISLFGNDATSIIVNCHILGQTLDAITVMKTGLDSVKSAALRAFLDNAEDELKTMENLKQG-QFTHTR-NQPRGVTOIINYYTTVALLPMLS  
SEQ ID NO:62 ISLFGNDATSIIVNCHILGQTLDAITVMKTGLDSVKSAALRAFLDNAEDELKTMENLKQG-QFTHTR-NQPKGVTOIINYYTTVALLPMLS

SEQ ID NO:2 AKFDHLANCEYGADLLLDLDEIQVASYKMLGSLYALGTDASLTHDRKYLKTEIERHKPALGSCIGAFSSTFPVAFQEPHLNKHNOFSLNRI  
SEQ ID NO:128 AKFDHLANCEYGADLLLDLDEIQVASYKMLGSLYALGTDASLTHDRKYLKTEIERHKPALGSCIGAFSSTFPVAFLEPHLNKHNOFSLNRI  
SEQ ID NO:130 AKFDHLANCEYGADLLLDLDEIQVASYKMLGSLYALGTDASLTHDRKYLKTEIERHKPALGSCIGAFSSTFPVAFLEPHLNKHNOFSLNRI  
SEQ ID NO:144 AKFDHLANCEYGADLLLDLDEIQVASYKMLGSLYALGTDASLTHDRKYLKTEIERHKPALGSCIGAFSSTFPVAFLEPHLNKHNOFSLNRI  
SEQ ID NO:146 AKFDHLANCEYGADLLLDLDEIQVASYKMLGSLYALGTDASLTHDRKYLKTEIERHKPALGSCIGAFSSTFPVAFLEPHLNKHNOFSLNRI  
SEQ ID NO:4 SLFDHLAAAYEYGNELLLNEIQVAAAYKMLSSLYTLGTDTSLSLTHDRKYLKTEIERHHPALGSCIGAFSSTFPVAFLEPHLNKHNOFSLNRI  
SEQ ID NO:6 SLFDHLAAAYEYGNELLLNEIQVAAAYKMLSSLYTLGTDTSLSLTHDRKYLKTEIERHHPALGSCIGAFSSTFPVAFLEPHLNKHNOFSLNRI  
SEQ ID NO:8 AMFDHLAAACEYGSDDLVLDEIQVASYKMLGSLYTLGIDVTLTHDRKYLKTEIERHHPALGSCIGAFSSTFPVAFLEPHLNKHNOFSLNRI  
SEQ ID NO:10 AMFDHLAAACEYGSDDLVLDEIQVASYKMLGSLYTLGIDVTLTHDRKYLKTEIERHHPALGSCIGAFSSTFPVAFLEPHLNKHNOFSLNRI  
SEQ ID NO:56 AMFDHLAAACEYGSDDLVLDEIQVASYKMLGSLYTLGIDVTLTHDRKYLKTEIERHHPALGSCIGAFSSTFPVAFLEPHLNKHNOFSLNRI  
SEQ ID NO:57 SLFDHLAAACEYGSDDLVLDEIQVASYKMLGSLYTLGIDVTLTHDRKYLKTEIERHHPALGSCIGAFSSTFPVAFLEPHLNKHNOFSLNRI  
SEQ ID NO:58 TWFAHLARNHFGTDLDDLIQVAAAYKMLSSLYTLGIDVTLTHDRKYLKTEIERHHPALGSCIGAFSSTFPVAFLEPHLNKHNOFSLNRI  
SEQ ID NO:59 SLFQHLARNHNYGADLLLDLDEIQVASYKMLGSLYTLGIDVTLTHDRKYLKTEIERHHPALGSCIGAFSSTFPVAFLEPHLNKHNOFSLNRI  
SEQ ID NO:60 SLFEHIGQHQFGEDLILEDVQVSCYRILTSYALGTSKSI-----Y--VERQSRALGECIAAFAGAFPIAFLETHLDKHNYSIYNTR  
SEQ ID NO:61 SLFEHIGQHQFGEDLILEDVQVSCYRILTSYALGTSKSI-----Y--VERQSRALGECIAAFAGAFPIAFLETHLDKHNYSIYNTR  
SEQ ID NO:62 SLFEHIGQHQFGEDLILEDVQVSCYRILTSYALGTSKSI-----Y--VERQSRALGECIAAFAGAFPIAFLETHLDKHNYSIYNTR

JC05 Rec'd T/PTO 21 MAR 2005

**THIS PAGE BLANK (USPTO)**



FIGURE 1U

SEQ ID NO: 2	ADHS---LEAQDIMQKMEQCMP	TTLE	TI	LG	VD	QF	VE	SD	KTY	NE	A	P	H	I	D	V	V	L	P	L	L	C	S	Y	L	P	F	F	W	A	Q	G	P	D	N	V	T	P	T	G	G	N	----	H	V	T	M	V	T	A	E	H																																				
SEQ ID NO: 128	ADHS---LEAQDIMQKMEQCMP	TTLE	TI	LG	VD	QF	VE	SD	KTY	NE	A	P	H	I	D	V	V	L	P	L	L	C	S	Y	L	P	F	F	W	A	Q	G	P	D	N	V	T	P	T	G	G	N	----	H	V	T	M	V	T	A	E	H																																				
SEQ ID NO: 130	ADHS---LEAQDIMQKMEQCMP	TTLE	AI	LG	VD	QF	VE	SD	KTY	NE	A	P	H	I	D	V	V	L	P	L	L	C	S	Y	L	P	F	F	W	A	Q	G	P	D	N	V	T	P	T	G	G	N	----	H	V	T	M	V	T	A	E	H																																				
SEQ ID NO: 144	ADHS---LEAQDIMQKMEQCMP	TTLE	TI	LG	VD	QF	VE	SD	KTY	NE	A	P	H	I	D	V	V	L	P	L	L	C	S	Y	L	P	F	F	W	A	Q	G	P	D	N	V	T	P	T	G	G	N	----	H	V	T	M	V	T	A	E	H																																				
SEQ ID NO: 146	ADHS---LEAQDIMQKMEQCMP	TTLE	TI	LG	VD	QF	VE	SD	KTY	NE	A	P	H	I	D	V	V	L	P	L	L	C	S	Y	L	P	F	F	W	A	Q	G	P	D	N	V	T	P	T	G	G	N	----	H	V	T	M	V	T	A	E	H																																				
SEQ ID NO: 4	ADSS---LEAQDIMSRTG	TMPT	LE	TV	NE	VD	QF	VE	SE	KTY	D	A	P	H	I	D	V	L	P	L	L	C	S	Y	L	P	F	F	W	A	Q	G	P	D	N	V	A	L	T	T	G	N	----	H	V	T	M	V	T	S	E	H																																				
SEQ ID NO: 6	ADSS---LEAQDIMSRTG	TMPT	LE	TV	NE	VD	QF	VE	SE	KTY	D	A	P	H	I	D	V	L	P	L	L	C	S	Y	L	P	F	F	W	A	Q	G	P	D	N	V	A	L	T	T	G	N	----	H	V	T	M	V	T	S	E	H																																				
SEQ ID NO: 8	ADHS---LEAQDIMSRTG	TMPT	LE	TV	NE	VD	QF	VE	SE	KTY	D	A	P	H	I	D	V	L	P	L	L	C	S	Y	L	P	F	F	W	A	Q	G	P	D	N	V	A	L	T	T	G	N	----	H	V	T	M	V	T	S	E	H																																				
SEQ ID NO: 10	ADHS---LEAQDIMSRTG	TMPT	LE	TV	NE	VD	QF	VE	SE	KTY	D	A	P	H	I	D	V	L	P	L	L	C	S	Y	L	P	F	F	W	A	Q	G	P	D	N	V	A	L	T	T	G	N	----	H	V	T	M	V	T	S	E	H																																				
SEQ ID NO: 56	ADHS---LEAQDIMSRTG	TMPT	LE	TV	NE	VD	QF	VE	SE	KTY	D	A	P	H	I	D	V	L	P	L	L	C	S	Y	L	P	F	F	W	A	Q	G	P	D	N	V	A	L	T	T	G	N	----	H	V	T	M	V	T	S	E	H																																				
SEQ ID NO: 57	ADTS---LEAQDIMSRTG	TMPT	LE	TV	NE	VD	QF	VE	SE	KTY	D	A	P	H	I	D	V	L	P	L	L	C	S	Y	L	P	F	F	W	A	Q	G	P	D	N	V	A	L	T	T	G	N	----	H	V	T	M	V	T	S	E	H																																				
SEQ ID NO: 58	QDQS---VQVQ	EM	L	Q	N	L	S	T	H	I	P	H	E	K	L	L	T	D	L	E	T	V	A	N	N	T	M	S	D	V	P	N	V	D	L	P	M	C	S	Y	M	A	H	W	F	S	V	G	P	D	K	D	E	Q	R	A	S	V	Q	T	S	V	S	C	D	H																						
SEQ ID NO: 59	ELRG-AT	VE	G	E	E	L	I	K	A	G	I	P	T	L	P	A	V	V	T	E	D	K	A	M	S	G	A	K	Y	D	O	A	P	H	I	E	V	I	L	P	M	L	C	S	Y	L	N	Y	W	W	Q	G	P	D	N	I	C	R	R	Q	N	----	Y	W	T	M	V	N	S	G	N																	
SEQ ID NO: 60	SSRRTA	L	S	L	P	A	N	V	E	D	V	C	P	N	I	P	S	L	E	K	L	M	T	E	I	I	E	L	A	E	S	G	I	R	T	O	M	P	Y	M	M	E	V	I	L	P	M	L	C	S	Y	M	S	R	W	W	E	H	G	P	E	N	H	P	E	R	A	E	M	----	C	C	T	A	L	N	S	E	H									
SEQ ID NO: 61	SSRRAA	L	S	L	P	A	N	V	E	D	V	C	P	N	I	P	S	L	E	K	L	M	E	E	I	V	E	L	A	E	S	G	I	R	T	O	M	P	H	V	M	E	V	I	L	P	M	L	C	S	Y	M	S	R	W	W	E	H	G	P	E	N	H	P	E	R	A	E	M	----	C	C	T	A	L	N	S	E	H									
SEQ ID NO: 62	SSRRAA	L	S	L	P	T	N	V	E	D	V	C	P	N	I	P	S	L	E	K	L	M	E	E	I	V	E	L	A	E	S	G	I	R	T	O	M	P	H	V	M	E	V	I	L	P	M	L	C	S	Y	M	S	R	W	W	E	H	G	P	E	N	H	P	E	R	A	E	M	----	C	C	T	A	L	N	S	E	H									
SEQ ID NO: 2	MNQLLKN	V	L	K	L	I	K	K	N	I	G	N	E	N	A	P	M	W	T	R	I	A	T	Y	T	Q	Q	I	I	I	N	S	E	E	L	L	R	D	S	F	L	P	A	E	R	V	R	K	R	T	D	N	M	F	H	K	E	S	L	R	G	F	I	K	S	T	D	D	T	S	Q	V	E	S	I	Q	E	D	W									
SEQ ID NO: 128	MNQLLKN	V	L	K	L	I	K	K	N	I	G	N	E	N	A	P	M	W	T	R	I	A	T	Y	T	Q	Q	I	I	I	N	S	E	E	L	L	R	D	S	F	L	P	A	E	R	V	R	K	R	T	D	N	M	F	H	K	E	S	L	R	G	F	I	K	S	T	D	D	T	S	Q	V	E	S	I	Q	E	D	W									
SEQ ID NO: 130	MNQLLKN	V	L	K	L	I	K	K	N	I	G	N	E	N	A	P	M	W	T	R	I	A	T	Y	T	Q	Q	I	I	I	N	S	E	E	L	L	R	D	S	F	L	P	A	E	R	V	R	K	R	T	D	N	M	F	H	K	E	S	L	R	G	F	I	K	S	T	D	D	T	S	Q	V	E	S	I	Q	E	D	W									
SEQ ID NO: 144	MNQLLKN	V	L	K	L	I	K	K	N	I	G	N	E	N	A	P	M	W	T	R	I	A	T	Y	T	Q	Q	I	I	I	N	S	E	E	L	L	R	D	S	F	L	P	A	E	R	V	R	K	R	T	D	N	M	F	H	K	E	S	L	R	G	F	I	K	S	T	D	D	T	S	Q	V	E	S	I	Q	E	D	W									
SEQ ID NO: 146	MNQLLKN	V	L	K	L	I	K	K	N	I	G	N	E	N	A	P	M	W	T	R	I	A	T	Y	T	Q	Q	I	I	I	N	S	E	E	L	L	R	D	S	F	L	P	A	E	R	V	R	K	R	T	D	N	M	F	H	K	E	S	L	R	G	F	I	K	S	T	D	D	T	S	Q	V	E	S	I	Q	E	D	W									
SEQ ID NO: 4	MNCLLKN	V	L	K	L	I	K	K	N	I	G	N	D	N	A	P	M	W	T	O	I	A	A	Y	T	Q	Q	I	I	I	N	S	E	E	L	L	K	O	P	F	L	P	A	E	R	V	K	R	T	E	T	L	Y	H	K	E	S	L	R	G	F	I	K	S	T	D	D	T	S	Q	I	E	A	Q	I	E	D	W										
SEQ ID NO: 6	MNCLLKN	V	L	K	L	I	K	K	N	I	G	N	D	N	A	P	M	W	T	O	I	A	A	Y	T	Q	Q	I	I	I	N	S	E	E	L	L	K	O	P	F	L	P	A	E	R	V	K	R	T	E	T	L	Y	H	K	E	S	L	R	G	F	I	K	S	T	D	D	T	S	Q	I	E	A	Q	I	E	D	W										
SEQ ID NO: 8	MNQLLKN	V	L	K	M	I	K	K	N	I	G	N	S	A	P	M	W	T	R	I	A	A	Y	T	Q	Q	I	I	I	N	S	E	E	L	L	K	O	P	F	L	P	A	E	R	V	K	R	T	D	A	M	F	H	K	E	S	L	R	G	F	I	K	S	A	S	D	D	T	S	Q	I	E	A	Q	I	E	D	W										
SEQ ID NO: 10	MNPLLRN	V	L	K	M	I	K	K	N	I	G	N	D	N	A	P	M	W	T	R	I	A	A	Y	T	Q	Q	I	I	I	N	S	E	E	L	L	K	O	P	F	L	P	A	E	R	V	K	R	T	E	N	M	L	H	K	E	S	L	R	G	F	I	K	S	A	T	D	D	T	S	Q	V	E	T	Q	I	E	D	W									
SEQ ID NO: 56	MNPLLRN	V	L	K	M	I	K	K	N	I	G	N	D	N	A	P	M	W	T	R	I	A	A	Y	T	Q	Q	I	I	I	N	S	E	E	L	L	K	O	P	F	L	P	A	E	R	V	K	R	T	E	N	M	L	H	K	E	S	L	R	G	F	I	K	S	A	T	D	D	T	S	Q	V	E	T	Q	I	E	D	W									
SEQ ID NO: 57	MNHLKQ	V	L	K	M	I	R	K	N	I	A	N	E	N	A	P	M	W	T	R	I	A	T	Y	T	Q	Q	I	I	I	N	S	E	E	L	L	K	O	V	F	L	P	A	E	R	V	K	R	T	E	N	M	L	H	K	E	S	L	R	G	F	I	K	S	A	T	D	D	T	S	Q	I	E	A	Q	I	E	D	W									
SEQ ID NO: 58	INRIF	N	A	L	L	K	M	I	R	N	H	V	G	I	E	N	A	P	W	L	C	R	V	N	F	F	A	V	O	I	I	I	N	S	E	E	L	L	K	O	P	E	L	L	K	T	H	F	V	P	I	E	K	L	E	R	T	S	K	V	F	K	A	E	E	D	L	K	E	Y	P	M	G	G	Q	E	M	E	E	T	E	F	A	I	L	E	D	Y
SEQ ID NO: 59	LNNV	L	G	N	V	L	T	L	V	K	N	L	G	S	E	N	A	P	M	S	R	I	A	A	T	A	K	P	I	L	N	D	A	Q	P	E	L	L	K	T	H	F	L	P	M	E	K	L	K	K	A	A	M	V	S	E	E	D	H	L	K	A	E	A	R	G	----	D	M	S	E	A	E	L	L	I	D	E	F									
SEQ ID NO: 60	MNTLLG	N	I	L	K	I	I	Y	N	N	L	G	I	D	E	G	A	M	K	R	L	A	V	S	Q	P	I	I	N	K	V	K	P	Q	L	L	K	T	H	F	L	P	M	E	K	L	K	K	A	A	M	V	S	E	E	D	H	L	K	A	E	A	R	G	----	D	M	S	E	A	E	L	L	I	D	E	F											
SEQ ID NO: 61	MNTLLG	N	I	L	K	I	I	Y	N	N	L	G	I	D	E	G	A	M	K	R	L	A	V	S	Q	P	I	I	N	K	V	K	P	Q	L	L	K	T	H	F	L	P	M	E	K	L	K	K	A	A	M	V	S	E	E	D	H	L	K	A	E	A	R	G	----	D	M	S	E	A	E	L	L	I	D	E	F											
SEQ ID NO: 62	MNTLLG	N	I	L	K	I	I	Y	N	N	L	G	I	D	E	G	A	M	K	R	L	A	V	S	Q	P	I	I	N	K	V	K	P	Q	L	L	K	T	H	F	L	P	M	E	K	L	K	K	A	A	T	V	S	E	E	D	H	L	K	A	E	A	R	G	----	D	M	S	E	A	E	L	L	I	D	E	F											

JC05 Rec'd USPTO 21 MAR 2005

**THIS PAGE BLANK (USPTO)**

**FIGURE 1V**

SEQ ID NO:2	QLVRDIYSFYPLLIKYYVDLQRNHWLRNNVPEAEELYNHVAEIFNIWSKSYFLKEEQNFISANEIDNMVLIIMPTATRRV---TAVTDGT
SEQ ID NO:128	QLVRDIYSFYPLLIKYYVDLQRNHWLRNNVPEAEELYNHVAEIFNIWSKSYFLKEEQNFISANEIDNMVLIIMPTATRRV---TAVTDGT
SEQ ID NO:130	QLVRDIYSFYPLLIKYYVDLQRNHWLRNNVPEAEELYNHVAEIFNIWSKSYFLKEEQNFISANEIDNMVLIIMPTATRRV---TAVTDGT
SEQ ID NO:144	QLVRDIYSFYPLLIKYYVDLQRNHWLRNNVPEAEELYNHVAEIFNIWSKSYFLKEEQNFISANEIDNMVLIIMPTATRRV---TAVTDGT
SEQ ID NO:146	QLVRDIYSFYPLLIKYYVDLQRNHWLRNNVPEAEELYNHVAEIFNIWSKSYFLKEEQNFISANEIDNMVLIIMPTATRRV---TAVTDGT
SEQ ID NO:4	QLVVRDIYAFYPLLIKYYVDLQRNHWLRNNVPEAEELYNHVAEIFNIWSKSYFLKEEQNFISANEIDNMVLIIMPTATRRS---AVISETS
SEQ ID NO:6	QLVVRDIYAFYPLLIKYYVDLQRNHWLRNNVPEAEELYNHVAEIFNIWSKSYFLKEEQNFISANEIDNMVLIIMPTATRRS---AVISETS
SEQ ID NO:8	QLVVRDIYAFYPLLIKYYVDLQRNHWLRNNVPEAEELYNHVAEIFNIWSKSYFLKEEQNFISANEIDNMVLIIMPTATRRS---AVSDSA
SEQ ID NO:10	NLLVRDIYSFYPLLIKYYVDLQRNHWLRNNVPEAEELYNHVAEIFNIWSKSYFLKEEQNFISANEIDNMVLIIMPTATRR---SAISEGA
SEQ ID NO:56	NLLVRDIYSFYPLLIKYYVDLQRNHWLRNNVPEAEELYNHVAEIFNIWSKSYFLKEEQNFISANEIDNMVLIIMPTATRR---SAISEGA
SEQ ID NO:57	QLVVRDIYSFYPLLIKYYVDLQRNHWLRNNVPEAEELYNHVAEIFNIWSKSYFLKEEQNFISANEIDNMVLIIMPTATRRS---AAVSGDM
SEQ ID NO:58	ARLVRTYAFYPLLIKYYVDLQRNHWLRNNVPEAEELYNHVAEIFNIWSKSYFLKEEQNFISANEIDNMVLIIMPTATRRS---KAA
SEQ ID NO:59	HLIIRDLIYAFYPLLIKYYVDLQRNHWLRNNVPEAEELYNHVAEIFNIWSKSYFLKEEQNFISANEIDNMVLIIMPTATRRS---KAA
SEQ ID NO:60	TTIARDLIYAFYPLLIKYYVDLQRNHWLRNNVPEAEELYNHVAEIFNIWSKSYFLKEEQNFISANEIDNMVLIIMPTATRRS---KMSKAA
SEQ ID NO:61	TTIARDLIYAFYPLLIKYYVDLQRNHWLRNNVPEAEELYNHVAEIFNIWSKSYFLKEEQNFISANEIDNMVLIIMPTATRRS---KMSKAA
SEQ ID NO:62	TTIARDLIYAFYPLLIKYYVDLQRNHWLRNNVPEAEELYNHVAEIFNIWSKSYFLKEEQNFISANEIDNMVLIIMPTATRRS---KMSKAA
SEQ ID NO:2	PQGGG--KKKKKHRDKKRDKEVQASLMVACLKRLLPVGLNLFAGREQELVQHCKDRFLKVGTLKKMSEQDVAEFAKTQTLTLPDKIDPA
SEQ ID NO:128	PQGGG--KKKKKHRDKKRDKEVQASLMVACLKRLLPVGLNLFAGREQELVQHCKDRFLKVGTLKKMSEQDVAEFAKTQTLTLPDKIDPA
SEQ ID NO:130	PQGGG--KKKKKHRDKKRDKEVQASLMVACLKRLLPVGLNLFAGREQELVQHCKDRFLKVGTLKKMSEQDVAEFAKTQTLTLPDKIDPA
SEQ ID NO:144	PQGGG--KKKKKHRDKKRDKEVQASLMVACLKRLLPVGLNLFAGREQELVQHCKDRFLKVGTLKKMSEQDVAEFAKTQTLTLPDKIDPA
SEQ ID NO:146	PQGGG--KKKKKHRDKKRDKEVQASLMVACLKRLLPVGLNLFAGREQELVQHCKDRFLKVGTLKKMSEQDVAEFAKTQTLTLPDKIDPA
SEQ ID NO:4	LG-GSTGKKKKKHRDKKRDKEVQASLMVACLKRLLPVGLNLFAGREQELVQHCKDRFLKVGTLKKMSEQDVAEFAKTQTLTLPDKIDPA
SEQ ID NO:6	LG-GSSGKKKKKHRDKKRDKEVQASLMVACLKRLLPVGLNLFAGREQELVQHCKDRFLKVGTLKKMSEQDVAEFAKTQTLTLPDKIDPA
SEQ ID NO:8	APPGSGKKKKKHRDKKRDKEVQASLMVACLKRLLPVGLNLFAGREQELVQHCKDRFLKVGTLKKMSEQDVAEFAKTQTLTLPDKIDPA
SEQ ID NO:10	PAVGKVKKKKKHRDKKRDKEVQASLMVACLKRLLPVGLNLFAGREQELVQHCKDRFLKVGTLKKMSEQDVAEFAKTQTLTLPDKIDPA
SEQ ID NO:56	PAVGKVKKKKKHRDKKRDKEVQASLMVACLKRLLPVGLNLFAGREQELVQHCKDRFLKVGTLKKMSEQDVAEFAKTQTLTLPDKIDPA
SEQ ID NO:57	PASGGKVKKKKKHRDKKRDKEVQASLMVACLKRLLPVGLNLFAGREQELVQHCKDRFLKVGTLKKMSEQDVAEFAKTQTLTLPDKIDPA
SEQ ID NO:58	IAERK---E-GQIKDKHAASIVIAALKRLLPIGLNIFAGREQELVQHCKDRFLKVGTLKKMSEQDVAEFAKTQTLTLPDKIDPA
SEQ ID NO:59	SLPGEP-PKLOSTAPKRPDQGHGSPPSLIIAALKRLLPIGLNIFAGREQELVQHCKDRFLKVGTLKKMSEQDVAEFAKTQTLTLPDKIDPA
SEQ ID NO:60	ISDQER-KKWK-----RKGDYSMTQSLIIAALKRLLPIGLNIFAGREQELVQHCKDRFLKVGTLKKMSEQDVAEFAKTQTLTLPDKIDPA
SEQ ID NO:61	VSDQER-KKWK-----RKGDYSMTQSLIIAALKRLLPIGLNIFAGREQELVQHCKDRFLKVGTLKKMSEQDVAEFAKTQTLTLPDKIDPA
SEQ ID NO:62	VSDQER-KKWK-----RKGDYSMTQSLIIAALKRLLPIGLNIFAGREQELVQHCKDRFLKVGTLKKMSEQDVAEFAKTQTLTLPDKIDPA

JC05 Rec'd P&H PTO 21 MAR 2005

**THIS PAGE BLANK** (USPTO)



JC05 Rec'd  PTO 21 MAR 2005

**THIS PAGE BLANK (USPTO)**

**FIGURE 1X**

SEQ ID NO: 2 ACFRQTSLSLPRHRACNIFARTYYELWLEENI - RQEVMIEDLTQSFEDAE ----- LKSDVVVEEGEKPDPLTQLVTTTS  
SEQ ID NO: 128 ACFRQTSLSLPRHRACNIFARTYYELWLEENI - GQEVMIEDLTQSFEDAE ----- LKSDVVVEEGEKPDPLTQLVTTTF  
SEQ ID NO: 130 ACFRQTSLSLPRHRACNIFARTYYELWLEENI - GQEVMIEDLTQSFEDAE ----- LKSDVVVEEGEKPDPLTQLVTTTF  
SEQ ID NO: 144 ACFRQTSLSLPRHRACNIFARTYYELWLEENI - GQEVMIEDLTQSFEDAE ----- LKSDVVVEEGEKPDPLTQLVTTTF  
SEQ ID NO: 146 ACFRQTSLSLPRHRACNIFARTYYELWLEENI - GQEVMIEDLTQSFEDAE ----- LKSDVVVEEGEKPDPLTQLVTTTF  
SEQ ID NO: 4 ACFRQTSLSLPRHRACNIFARTYYELWLEENI - GQEVMIEDLTQSFEDAE ----- LKSDVVVEEGEKPDPLTQLVTTTF  
SEQ ID NO: 6 ACFRQTSLSLPRHRACNIFARTYYELWLEENI - GQEVMIEDLTQSFEDAE ----- LKSDVVVEEGEKPDPLTQLVTTTF  
SEQ ID NO: 8 ACFRQTSLSLPRHRACNIFARTYYELWLEENI - GQEVMIEDLTQSFEDAE ----- LKSDVVVEEGEKPDPLTQLVTTTF  
SEQ ID NO: 10 ACFRQTSLSLPRHRACNIFARTYYELWLEENI - GQEVMIEDLTQSFEDAE ----- LKSDVVVEEGEKPDPLTQLVTTTF  
SEQ ID NO: 56 ACFRQTSLSLPRHRACNIFARTYYELWLEENI - GQEVMIEDLTQSFEDAE ----- LKSDVVVEEGEKPDPLTQLVTTTF  
SEQ ID NO: 57 ACFRQTSLSLPRHRACNIFARTYYELWLEENI - GQEVMIEDLTQSFEDAE ----- LKSDVVVEEGEKPDPLTQLVTTTF  
SEQ ID NO: 58 SLITASHLYKTELHRGINFFLPAPSRWLWEEEDA - GQDQLIADICSGVVEEERPRIELIIEEGVPIVASEDTKEKETNPDPKQLIRCF  
SEQ ID NO: 59 ACFRMTPLHLPRHRAINFFLKAYKERWLSNEES - AQHLLIDDLTKCSSE ----- ELQEFEPENVKOPLYQLISTF  
SEQ ID NO: 60 ACFRMAPLYNLPRHRAVNLFQGYEKSWIETEEHYFEDKLIEDLAKPGAE ----- LPEEDEAMKRVDPLHQLILLF  
SEQ ID NO: 61 ACFRMAPLYNLPRHRAVNLFQGYEKSWIETEEHYFEDKLIEDLAKPGAE ----- PPEEDEVTKRVDPLHQLILLF  
SEQ ID NO: 62 ACFRMAPLYNLPRHRAVNLFQGYEKSWIETEEHYFEDKLIEDLAKPGAE ----- PPEDEGTKRVDPLHQLILLF  
  
SEQ ID NO: 2 CRGAMTERSGA -- LQEDPLMYSVAHIIAKSCGEEEEEGGEEEEEGGEEAEAEDEGRAS IHEQEMEKQKLLFHQARPADRGVAEMVLLHIS  
SEQ ID NO: 128 CRGAMTERSGA -- LQEDPLMYSVAHIIAKSCGEEEEEGGEEEEEGGEEAEAEDEGRAS IHEQEMEKQKLLFHQARLADRGVAEMVLLHIS  
SEQ ID NO: 130 CRGAMTERSGA -- LQEDPLMYSVAHIIAKSCGEEEEEGGEEEEEGGEEAEAEDEGRAS IHEQEMEKQKLLFHQARLADRGVAEMVLLHIS  
SEQ ID NO: 144 CRGAMTERSGA -- LQEDPLMYSVAHIIAKSCGEEEEEGGEEEEEGGEEAEAEDEGRAS IHEQEMEKQKLLFHQARLADRGVAEMVLLHIS  
SEQ ID NO: 146 CRGAMTERSGA -- LQEDPLMYSVAHIIAKSCGEEEEEGGEEEEEGGEEAEAEDEGRAS IHEQEMEKQKLLFHQARLADRGVAEMVLLHIS  
SEQ ID NO: 4 CRGAMTERSGA -- LQEDPLMYSVAHIIAKSCGEEEEEGGEEEEEGGEEAEAEDEGRAS IHEQEMEKQKLLFHQARLADRGVAEMVLLHIS  
SEQ ID NO: 6 CRGAMTERSGA -- LQEDPLMYSVAHIIAKSCGEEEEEGGEEEEEGGEEAEAEDEGRAS IHEQEMEKQKLLFHQARLADRGVAEMVLLHIS  
SEQ ID NO: 8 CRGAMTERSGA -- LQEDPLMYSVAHIIAKSCGEEEEEGGEEEEEGGEEAEAEDEGRAS IHEQEMEKQKLLFHQARLADRGVAEMVLLHIS  
SEQ ID NO: 10 CRGAMTERSGA -- LQEDPLMYSVAHIIAKSCGEEEEEGGEEEEEGGEEAEAEDEGRAS IHEQEMEKQKLLFHQARLADRGVAEMVLLHIS  
SEQ ID NO: 56 CRGAMTERSGA -- LQEDPLMYSVAHIIAKSCGEEEEEGGEEEEEGGEEAEAEDEGRAS IHEQEMEKQKLLFHQARLADRGVAEMVLLHIS  
SEQ ID NO: 57 CRGAMTERSGA -- LQEDPLMYSVAHIIAKSCGEEEEEGGEEEEEGGEEAEAEDEGRAS IHEQEMEKQKLLFHQARLADRGVAEMVLLHIS  
SEQ ID NO: 58 QRAATSEETAASAIEDSLYIRFADVMAKSIHIEEEDGED ----- GEEGETDQAACEEQSALRGEQAVLASRGAAIMCLMYLS  
SEQ ID NO: 59 SRAFGLOQ - DM -- LEEDPLYLSVAAIMSTSCSGEDDDDDDD -- G ----- GDENGTGFQEQEMEKQKLLSEQARLAERGAEMVLLIS  
SEQ ID NO: 60 SRTALTEK - CK -- LEEDFLYMAVADIMAKSCHDEEDDD ----- GEEVKSFEEMEKQKLLYQOARLHDRGAAEMVLOTIS  
SEQ ID NO: 61 SRTALTEK - CK -- LEEDFLYMAVADIMAKSCHDEEDDD ----- GEEVKSFEEMEKQKLLYQOARLHDRGAAEMVLOTIS  
SEQ ID NO: 62 SRTALTEK - CK -- LEEDFLYMAVADIMAKSCHDEEDDD ----- GEEVKSFEEMEKQKLLYQOARLHDRGAAEMVLOTIS

JC05 Rec'd T/PTO 21 MAR 2005

**THIS PAGE BLANK (USPTO)**



FIGURE 1Y

SEQ ID NO: 2	ASKGLPSEMVMTLQLGISILRGGNIDIQMGLNHLKDKDVGFFTSIAGLMNSCSVLDLAFERNTKAEGLVGLEGAA-----GEKD
SEQ ID NO: 128	ASKGLPSEMVMTLQLGISILRGGNIDIQMGLNHLKDKDVGFFTSIAGLMNSCSVLDLAFERNTKAEGLVGLEGAA-----GEKD
SEQ ID NO: 130	ASKGLPSEMVMTLQLGISILRGGNIDIQMGLNHLKDKDVGFFTSIAGLMNSCSVLDLAFERNTKAEGLVGLEGAA-----GEKD
SEQ ID NO: 144	ASKGLPSEMVMTLQLGISILRGGNIDIQMGLNHLKDKDVGFFTSIAGLMNSCSVLDLAFERNTKAEGLVGLEGAA-----GEKD
SEQ ID NO: 146	ASKGLPSEMVMTLQLGISILRGGNIDIQMGLNHLKDKDVGFFTSIAGLMNSCSVLDLAFERNTKAEGLVGLEGAA-----GEKD
SEQ ID NO: 4	ACKGIPSEMVMTLQLGIAVLRGGNLEIQMGLNHLKEKKDVGFFTSVAGLMNSCSVLDLAFERNTKAEGLVGSEGAA-----GEKD
SEQ ID NO: 6	ACKGIPSEMVMTLQLGIAVLRGGNLEIQMGLNHLKEKKDVGFFTSVAGLMNSCSVLDLAFERNTKAEGLVGSEGAA-----GEKD
SEQ ID NO: 8	ACNGVPSEMVMTLQLGISILRGGNIDIQMGLNHLKEKKDVGFFTSIAGLMNSCSVLDLAFERNTKAEGLVGSDGAA-----GEKD
SEQ ID NO: 10	ASKGIPSEMVMTLNLGIAILRGGNIDIQMGLNHLKEKKDVGFFTSIAGLMNSCSVLDLAFERNTKAEGLVGSEGAA-----GEKD
SEQ ID NO: 56	ASKGIPSEMVMTLNLGIAILRGGNIDIQMGLNHLKEKKDVGFFTSIAGLMNSCSVLDLAFERNTKAEGLVGSEGAA-----GEKD
SEQ ID NO: 57	ASKGVPSEMVMTLELGIATVLRGGNIDIQMGLNHLKEKKDVGFFTSIAGLMNSCSVLDLAFERNTKAEGLVGSDGAA-----GEKD
SEQ ID NO: 58	ASGGEPMEMVAQTLQGIHLLSGGNVEIQKMLIEYLQKDVGFFTSMAGLMNKC SVLNLMFERQIKAEGLMGMAELASG-----DNQE
SEQ ID NO: 59	ASKGEPSEMVMTLQGIHLLSGGNVEIQKMLIEYLQKDVGFFTSMAGLMNKC SVLNLMFERQIKAEGLMGMAELASG-----DNQE
SEQ ID NO: 60	ASKGETGPMVAATLKGIAILNGGNSTVQQKMLDYLKEKKDVGFQSLAGLMQSCSVLDLAFERQNKAEGLGMVTEEGS-----GEKN
SEQ ID NO: 61	ASKGETGPMVAATLKGIAILNGGNSTVQQKMLDYLKEKKDVGFQSLAGLMQSCSVLDLAFERQNKAEGLGMVTEEGS-----GEKN
SEQ ID NO: 62	ASKGETGPMVAATLKGIAILNGGNSTVQQKMLDYLKEKKDVGFQSLAGLMQSCSVLDLAFERQNKAEGLGMVTEEGS-----GEKN
SEQ ID NO: 2	NMHDAEFTCALFRFIQLTCEGHNLDWQNYLRTQAGNTTNNVVICITVDYLLRLQESIMDFYWHYSSKELIDPAGKANFFKKAIGVASQVFN
SEQ ID NO: 128	NMHDAEFTCALFRFIQLTCEGHNLDWQNYLRTQAGNTTNNVVICITVDYLLRLQESIMDFYWHYSSKELIDPAGKANFFKKAIGVASQVFN
SEQ ID NO: 130	NMHDAEFTCALFRFIQLTCEGHNLDWQNYLRTQAGNTTNNVVICITVDYLLRLQESIMDFYWHYSSKELIDPAGKANFFKKAIGVASQVFN
SEQ ID NO: 144	NMHDAEFTCALFRFIQLTCEGHNLDWQNYLRTQAGNTTNNVVICITVDYLLRLQESIMDFYWHYSSKELIDPAGKANFFKKAIGVASQVFN
SEQ ID NO: 146	NMHDAEFTCALFRFIQLTCEGHNLDWQNYLRTQAGNTTNNVVICITVDYLLRLQESIMDFYWHYSSKELIDPAGKANFFKKAIGVASQVFN
SEQ ID NO: 4	NMHDAEFTCTLFRFIQLTCEGHNLEWQNYLRTQAGNTTNNVVICITVDYLLRLQESIMDFYWHYSSKELIDPAGKANFFKKAIGVASQVFN
SEQ ID NO: 6	NMHDAEFTCTLFRFIQLTCEGHNLEWQNYLRTQAGNTTNNVVICITVDYLLRLQESIMDFYWHYSSKELIDPAGKANFFKKAIGVASQVFN
SEQ ID NO: 8	NMHDAEFTCTLFRFIQLTCEGHNLEWQNYLRTQAGNTTNNVVICITVDYLLRLQESIMDFYWHYSSKELIDPAGKANFFKKAIGVASQVFN
SEQ ID NO: 10	NMHDAEFTCTLFRFIQLTCEGHNLEWQNYLRTQAGNTTNNVVICITVDYLLRLQESIMDFYWHYSSKELIDPAGKANFFKKAIGVASQVFN
SEQ ID NO: 56	NMHDAEFTCTLFRFIQLTCEGHNLEWQNYLRTQAGNTTNNVVICITVDYLLRLQESIMDFYWHYSSKELIDPAGKANFFKKAIGVASQVFN
SEQ ID NO: 57	NMHDAEFTCTLFRFIQLTCEGHNLEWQNYLRTQAGNTTNNVVICITVDYLLRLQESIMDFYWHYSSKELIDPAGKANFFKKAIGVASQVFN
SEQ ID NO: 58	NLNDADFTCSLFRFLQTLCEGHNLEFQNYLRTQAGNTTNNVVICITVDYLLRLQESIMDFYWHYSSKELIDPAGKANFFKKAIGVASQVFN
SEQ ID NO: 59	AMHDAEFTCALFRFLQTLCEGHNLEFQNYLRTQAGNTTNNVVICITVDYLLRLQESIMDFYWHYSSKELIDPAGKANFFKKAIGVASQVFN
SEQ ID NO: 60	VLQDDEFTCDLFRFLQTLCEGHNLEFQNYLRTQAGNTTNNVVICITVDYLLRLQESIMDFYWHYSSKELIDPAGKANFFKKAIGVASQVFN
SEQ ID NO: 61	VLQDDEFTCDLFRFLQTLCEGHNLEFQNYLRTQAGNTTNNVVICITVDYLLRLQESIMDFYWHYSSKELIDPAGKANFFKKAIGVASQVFN
SEQ ID NO: 62	VLQDDEFTCDLFRFLQTLCEGHNLEFQNYLRTQAGNTTNNVVICITVDYLLRLQESIMDFYWHYSSKELIDPAGKANFFKKAIGVASQVFN

JC05 Rec'd [REDACTED] T/PTO 21 MAR 2005

**THIS PAGE BLANK (USPTO)**



**THIS PAGE BLANK (USPTO)**

**FIGURE 1AA**

SEQ ID NO: 2	AVLLTNLSEHMPNEPRLARFLETAGSVLDYFEPFLGRIEIMGGSKRIERVVFEIKESNIEQWEKPOIKESKRAFFYSIVTE -GGDREKLE
SEQ ID NO: 128	AVLLTNLSEHMPNEPRLARFLETAGSVLNYFEPFLGRIEIMGGSKRIERVVFEIKESNIEQWEKPOIKESKRAFFYSIVTE -GGDKEKLE
SEQ ID NO: 130	AVLLTNLSEHMPNEPRLARFLETAGSVLNYFEPFLGRIEIMGGSKRIERVVFEIKESNIEQWEKPOIKESKRAFFYSIVTE -GGDKEKLE
SEQ ID NO: 144	AVLLTNLSEHMPNEPRLARFLETAGSVLNYFEPFLGRIEIMGGSKRIERVVFEIKESNIEQWEKPOIKESKRAFFYSIVTE -GGDKEKLE
SEQ ID NO: 146	AVLLTNLSEHMPNEPRLARFLETAGSVLNYFEPFLGRIEIMGGSKRIERVVFEIKESNIEQWEKPOIKESKRAFFYSIVTE -GGDKEKLE
SEQ ID NO: 4	AVLLTNLSEHMPNEPRLTRFLETASSVLNYFQPFLLGRIEILGGSKRIERVVFEIKESNIEQWLKPOIKESKRAFFYSIVTE -GGDKEKLE
SEQ ID NO: 6	AVLLTNLSEHMPNEPRLTRFLETASSVLNYFQPFLLGRIEILGGSKRIERVVFEIKESNIEQWLKPOIKESKRAFFYSIVTE -GGDKEKLE
SEQ ID NO: 8	AVLLTNLSEHMPNEPRLARFLETAGSVLNYFEPFLGRIEIMGGSKRIERVVFEIKESNIEQWEKPOIKESKRAFFYSIVTE -GGDKEKLE
SEQ ID NO: 10	AVLLTNLSEHMPNEPRLARFLETAGSVLNYFEPFLGRIEILGGSKRIERVVFEIKESNIEQWEKPOIKESKRAFFYSIVTE -GGDKEKLE
SEQ ID NO: 56	AVLLTNLSEHMPNEPRLARFLETAGSVLNYFEPFLGRIEILGGSKRIERVVFEIKESNIEQWEKPOIKESKRAFFYSIVTE -GGDKEKLE
SEQ ID NO: 57	AVLLTNLSEHMPNEPRLARFLETAGSVLNYFEPFLGRIEILGGSKRIERVVFEIKESNIEQWEKPOIKESKRAFFYSIVTE -GGDKEKLE
SEQ ID NO: 58	AVLLVNLKEHITNDPRLEKIEKAQTLLEYFDPFLGRIEIMGGSKRIERVVFEIKESNIEQWEKPOIKESKRAFFYSIVTE -GGDKEKLE
SEQ ID NO: 59	AVLLTNLNDHMPGERRLERFLLQAESLLTYFEPYLGRIEIMGGSKRIERVVFEIKESNIEQWEKPOIKESKRAFFYSIVTE -GGDKEKLE
SEQ ID NO: 60	AVLLTNLSEHMPNDTRLQTFLELAESVLNYFQPFLLGRIEIMGGSKRIERVVFEIKESNIEQWEKPOIKESKRAFFYSIVTE -GGDKEKLE
SEQ ID NO: 61	AVLLTNLSEHMPNETRLQTFLELAESVLNYFQPFLLGRIEIMGGSKRIERVVFEIKESNIEQWEKPOIKESKRAFFYSIVTE -GGDKEKLE
SEQ ID NO: 62	AVLLTNLSEHMPNDTRLQTFLELAESVLNYFQPFLLGRIEIMGGSKRIERVVFEIKESNIEQWEKPOIKESKRAFFYSIVTE -GGDKEKLE
SEQ ID NO: 2	AFVNFCEDAIFEMTHASGLMAASEES -VGGTKNREASYM -YMGDDGDERAGKDPFRGLQSVKOGVATAFSSLSPSNIAKAKIADMQQMPP
SEQ ID NO: 128	AFVNFCEDAIFEMTHASGLMAASEES -VGGTKNREASYM -YMGDDDDDERAGKDPFRGLQSVKOGVATAFSSLSPSNIAKAKIADMQQMPP
SEQ ID NO: 130	AFVNFCEDAIFEMTHASGLMAASEES -VGGTKNREASYM -YMGDDDDDERAGKDPFRGLQSVKOGVATAFSSLSPSNIAKAKIADMQQMPP
SEQ ID NO: 144	AFVNFCEDAIFEMTHASGLMAASEES -VGGTKNREASYM -YMGDDDDDERAGKDPFRGLQSVKOGVATAFSSLSPSNIAKAKIADMQQMPP
SEQ ID NO: 146	AFVNFCEDAIFEMTHASGLMAASEES -VGGTKNREASYM -YMGDDDDDERAGKDPFRGLQSVKOGVATAFSSLSPSNIAKAKIADMQQMPP
SEQ ID NO: 4	AFVNFCEDAIFEMQHASGLMAVDGSGIGGKSRKTSVT -YLADDEENKTAADPERRGIQAIKYGFHLLFVLSPTNKNKINEIQQMSV
SEQ ID NO: 6	AFVNFCEDAIFEMQHASGLMAVDGSGIGGKSRKTSVT -YLADDEENKTAADPERRGIQAIKYGFHLLFVLSPTNKNKINEIQQMSV
SEQ ID NO: 8	AFVNFCEDAIFEMTHASGLMSVDDDSGGGGGK - --AAYT -YISEDEEKNAKDPRTTIQAFKDAIYFILTMLSPSNIKTKINEMQQMSV
SEQ ID NO: 10	AFVNFCEDAIFEMTHASGLMATDDG - --GGNVKROTAVSSYMSSEEEERAAADPRTTITAVKEGLKFGVHMLSPANIKHQIGVMQTKSI
SEQ ID NO: 56	AFVNFCEDAIFEMTHASGLMATDDG - --GGNVKROTAVSSYMSSEEEERAAADPRTTITAVKEGLKFGVHMLSPANIKHQIGVMQTKSI
SEQ ID NO: 57	AFVNFCEDAIFEMTHASGLMASDDD - --GGTVRRDQAF -YISEDEEKNAADPRTTITAVKEGLKFGVHMLSPANIKHQITVLQSKSF
SEQ ID NO: 58	AFVNFCEDAIFEMQHAASISSGSD - --TKMERAIKQDYFLQOTSADHISSETFKSGYNYGISAASALSPQNIYSTTMRNVSSSVRQMSW
SEQ ID NO: 59	DFVNFCEDTIFEMQHATSISDTGESL -PEVFMSSLLTFGASRDSNNLWLVVRGMRPSNICRLMGDDFFSSSQYNIQIRSLSLFRLFFGVI
SEQ ID NO: 60	LFVNFCEDTIFEMQLAAQISESDINE -RLANKEESEKERPEQAPRMGFFSLLTIQSALFALRYNVLTILVRMLSLKSLKKQMKMKMTV
SEQ ID NO: 61	LFVNFCEDTIFEMQLAAQISESDINE -RSANKEESEKERPEQPKMGFFSLLTIQSALFALRYNVLTILVRMLSLKSLKKQMKMKMTV
SEQ ID NO: 62	LFVNFCEDTIFEMQLAAQISESDINE -RSANKEESEKERPEQPRMAFFSLLTIQSALFALRYNVLTILVRMLSLKSLKKQMKMKMTV

RECEIVED 27143 2003

**THIS PAGE BLANK (USPTO)**

FIGURE 1BB

SEQ ID NO: 2	AELAVGFFKMFYFFYLYGVVVRVYIFGVLLGLMRGPQTDPEPPPEEKEKIG-----QLRHRLLATQSSR-----HLPALPPA
SEQ ID NO: 128	AELAVGFFKMFYFFYLYGVVVRVYIFGVLLGLMRGPQTDPEPPPEEKEKIG-----QLRHRLLATQSSR-----HLPALPPA
SEQ ID NO: 130	AELAVGFFKMFYFFYLYGVVVRVYIFGVLLGLMRGPQTDPEPPPEEKEKIG-----QLRHRLLATQSSR-----HLPALPPA
SEQ ID NO: 144	AELAVGFFKMFYFFYLYGVVVRVYIFGVLLGLMRGPQTDPEPPPEEKEKIG-----QLRHRLLATQSSR-----HLPALPPA
SEQ ID NO: 146	AELAVGFFKMFYFFYLYGVVVRVYIFGVLLGLMRGPQTDPEPPPEEKEKIG-----QLRHRLLATQSSR-----HLPALPPA
SEQ ID NO: 4	IELITSTFFKLFYLIFFYTGSGVYVLRVYISRIILQMLMSGTQSEETTVEVVEK-----SGSFR-----MLPALPSS
SEQ ID NO: 6	VELITSTFFKLFYLIFFYTGSGVYVLRVYISRIILQMLMSGTQSEETTVEVVEK-----AGSFR-----MLPALPSS
SEQ ID NO: 8	PELVVGFFKIFFYFYTGSAHFCVVRVYIFGRIILMLMRGPQTEEPVAEVKKEDEI-----MGPIR-----ALPPPPPD
SEQ ID NO: 10	PELIVGFFKIFFYFYTGSAHFCVVRVYIFGRIILMLMRGPQTEEPVAEVKKEDEI-----FGR-----ALPPLSLE
SEQ ID NO: 56	PELIVGFFKIFFYFYTGSAHFCVVRVYIFGRIILMLMRGPQTEEPVAEVKKEDEI-----FGR-----ALPPLPLE
SEQ ID NO: 57	PELIVGFFKIFFYFYTGSAHFCVVRVYIFGRIILMLMRGPQTEEPVAEVKKEDEI-----SLR-----ALPPLPLE
SEQ ID NO: 58	TQLLYAVIILFIRAGLAIGWAGYLLMTIFRFGYFLTTSEEEAARQEKQAKMN-----N-----EHPSFN-----PPIIQE
SEQ ID NO: 59	KLIFLGVPKLFKFAFVIVGKLIQ-LLVGTRILEDAREITGSIKSHLVPRVARQT-----SSIINVPGYMPARSARRNTSFQWYLTQYFT
SEQ ID NO: 60	KDMVLAFFSSYWSFVTLHFVAVSVCGRGFFRIVSSLLGGSLVEGAKKIKVAELLANMPDPTQDEVGRDDEEGEK-----PLESALPSEDLT
SEQ ID NO: 61	KDMVTAFFSSYWSIFMTLLHFVAVSVCGRGFFRIVCSLLGGSLVEGAKKIKVAELLANMPDPTQDEVGRDDEEGEK-----PMTETLPSEDLT
SEQ ID NO: 62	KDMVTAFFSSYWSIFMTLLHFVAVSVCGRGFFRIVCSLLGGSLVEGAKKIKVAELLANMPDPTQDEVGRDDEEGEK-----PLEAALPSEDLT
SEQ ID NO: 2	DDTGQMQVSAFGLDITKEDNGQ-----IQVKPHESPSTSTPSSGGE-AEVSPDESADHTEE-----QRPPSLIDLGGGEQAKK
SEQ ID NO: 128	DDTGQMQVSAFGLDITKEDNGQ-----IQVKPHESPSTSTPSSGGE-AEVSPDESADHTEE-----QRPPSLIDLGGGEQAKK
SEQ ID NO: 130	DDTGQMQVSAFGLDITKEDNGQ-----IQVKPHESPSTSTPSSGGE-AEVSPDESADHTEE-----QRPPSLIDLGGGEQAKK
SEQ ID NO: 144	DDTGQMQVSAFGLDITKEDNGQ-----IQVKPHESPSTSTPSSGGE-AEVSPDESADHTEE-----QRPPSLIDLGGGEQAKK
SEQ ID NO: 146	DDTGQMQVSAFGLDITKEDNGQ-----IQVKPHESPSTSTPSSGGE-AEVSPDESADHTEE-----QRPPSLIDLGGGEQAKK
SEQ ID NO: 4	GIDETPSTLTDSNNMRKNSGSL-----DSKHLKSTTGD--DKDETSAENHEKEDGVDG-----SELOASFDVLLVGESARK
SEQ ID NO: 6	GVDEPPSTLIDSSNNMRKNSGAP-----DSKHVKSSTVGD--DKDETSTENHEKEDGVKSE-----DNSELOASFDVLLVGESARK
SEQ ID NO: 8	NKEASSSSAKODSGQAKPADG-----GATLALTASGE--EHKEGGATEEGAEDGAKPEG--AETTEGTTMTLADLLGGGEAARK
SEQ ID NO: 10	EPPG--TVQAFGLDINKENGM-----YKVVVHESPAN--SSMEEGESSPEDGAAAAGELVEGEPHQGPISIVDILLGGGEAARK
SEQ ID NO: 56	EPPG--TVQAFGLDINKENGM-----YKVVVHESPAN--SSMEEGESSPEDGAAAAGELVEGEPHQGPISIVDILLGGGEAARK
SEQ ID NO: 57	EPPG--TVQAFGLDISKEENGQ-----YMAPHESPALSPSSSIETGESSPEDGAAELTG--EGVPPGEQMTLVLLGGGEAARK
SEQ ID NO: 58	FHSHVGVTAFGVGMNADHLN-----VNSLPDFVPPPERPETPEVLEEKPLN-----QETSPTPT
SEQ ID NO: 59	NVNSMDTVSAFGIDFLKKGCGGGGGAGGTDQYKLRMRKRRLPTPSSSFDDEMSMDNMPHTPTPSEASD--SSFDSGAMAKNDFSMPD
SEQ ID NO: 60	DLKELTEESDLSIDIFGLDLKREGG-----QYKLIHPNPAGLSDLMTNPNVPVPEVQEKFOEQKAKEE-----KEEKEETKSEPEKAE
SEQ ID NO: 61	DLKELTEESDLSIDIFGLDLKREGG-----QYKLIHPNPAGLSDLMTNPNVPVPEVQEKFOEQKAKEE-----KEEKEETKSEPEKAE
SEQ ID NO: 62	DLKELTEESDLSIDIFGLDLKREGG-----QYKLIHPNPAGLSDLMTNPNVPVPEVQEKFOEQKAKEE-----KEEKEETKSEPEKAE

JC05 Rec'd PCT/PTO 21 MAR 2005

**THIS PAGE BLANK** (USPTO)



**FIGURE 1CC**

SEQ ID NO:2 QAQERMEAQAQAAMSAIEAESKKAQVG-PAPSALSQVDLSQYTRRAVSFLARNFYNLKYVALVLAFCLNFVLLFYKVSITLDDGEGGE--  
SEQ ID NO:128 QAQERMEAQAQAAMSAIEAESKKAQVG-PAPSALSQVDLSQYTRRAVSFLARNFYNLKYVALVLAFCLNFVLLFYKVSITLDDGEGGE--  
SEQ ID NO:130 QAQERMEAQAQAAMSAIEAESKKAQVG-PAPSALSQVDLSQYTRRAVSFLARNFYNLKYVALVLAFCLNFVLLFYKVSITLDDGEGGE--  
SEQ ID NO:144 QAQERMEAQAQAAMSAIEAESKKAQVG-PAPSALSQVDLSQYTRRAVSFLARNFYNLKYVALVLAFCLNFVLLFYKVSITLDDGEGGE--  
SEQ ID NO:146 QAQERMEAQAQAAMSAIEAESKKAQVG-PAPSALSQVDLSQYTRRAVSFLARNFYNLKYVALVLAFCLNFVLLFYKVSITLDDGEGGE--  
SEQ ID NO:4 DSIAGPEVLAQQAQAVMAAVEAEIKQKNSV-ENPSAFSTIDINAYTHRALSFARNFYNLKYVALVLAFCLNFVLLFYKVSITLDDGEGGE--  
SEQ ID NO:6 DSIAGPEVLAQQAQAVMAAVEAEIKQKNSV-ENPSAFSTIDINAYTHRALSFARNFYNLKYVALVLAFCLNFVLLFYKVSITLDDGEGGE--  
SEQ ID NO:8 EAVARAEEVAAEQQAQAVMAAVEAEIKQKNSV-E-PSAFSQIDFNRYTHRAVSFLARNFYNLKYVALVLAFCLNFVLLFYKVSITLDDGEGGE--  
SEQ ID NO:10 AAQERQEAQAQAAMSAIEAEAKKSSAPQETPAVHQIDFSQYTHRAVSFLARNFYNLKYVALVLAFCLNFVLLFYKVSITLDDGEGGE--  
SEQ ID NO:56 AAQERQEAQAQAAMSAIEAEAKKSSAPQETPAVHQIDFSQYTHRAVSFLARNFYNLKYVALVLAFCLNFVLLFYKVSITLDDGEGGE--  
SEQ ID NO:57 AAQERTEAQAQAAMSLASIEAEKKAETKEPAVHQIDFSQYTHRAVSFLARNFYNLKYVALVLAFCLNFVLLFYKVSITLDDGEGGE--  
SEQ ID NO:58 SPASKAPSIYESIGAPQMVQLQSEADFOQOQYEPKIAESNSTKSRGSIILMLARNFKTIEKITLYLAFFINVILLFHRVD-----  
SEQ ID NO:59 MSAGRDSVFP-SLFLATEMPSTQVKEEEEEEPVYEPQMNRVKQTVVSLFARNFYNLKYVALVLAFCLNFVLLFYKVSITLDDGEGGE--  
SEQ ID NO:60 GEDGEKEEKAKDEKSKQLRQLHTRHYGEPEVPESAFWKI IAYQQKLLNYFARNFYNMRMLALFVAFAINFILLFYKVS--TSSVVE--  
SEQ ID NO:61 GEDGEKEEKAKDEKSKQLRQLHTRHYGEPEVPESAFWKI IAYQQKLLNYFARNFYNMRMLALFVAFAINFILLFYKVS--TSSVVE--  
SEQ ID NO:62 GEDGEKEEKAKDEKSKQLRQLHTRHYGEPEVPESAFWKI IAYQQKLLNYFARNFYNMRMLALFVAFAINFILLFYKVS--TSSVVE--

SEQ ID NO:2 -----GSGGLGDI IAGGGGSGSAGS-----GSGDGSGETGE-----DDDALEVVVHIDEFFYMEHV I KMAAVLHSIVSLAILIGYYHLKV  
SEQ ID NO:128 -----GSGGLGDI IAGGGGSGSAGS-----GSGDGSGETGE-----DDDALEVVVHIDEFFYMEHV I KMAAVLHSIVSLAILIGYYHLKV  
SEQ ID NO:130 -----GSGGLGDI IAGGGGSGSAGS-----GSGDGSGETGE-----DDDALEVVVHIDEFFYMEHV I KMAAVLHSIVSLAILIGYYHLKV  
SEQ ID NO:144 -----GSGGLGDI IAGGGGSGSAGS-----GSGDGSGETGE-----DDDALEVVVHIDEFFYMEHV I KMAAVLHSIVSLAILIGYYHLKV  
SEQ ID NO:146 -----GSGGLGDI IAGGGGSGSAGS-----GSGDGSGETGE-----DDDALEVVVHIDEFFYMEHV I KMAAVLHSIVSLAILIGYYHLKV  
SEQ ID NO:4 -----DVKEFALGSAGISNDDID-----DSNSTEMAD-----DDGALELVHVNEDFFYMAHVMRLAALLHSLASLAML IAYYHLKV  
SEQ ID NO:6 -----DSKDFALGSAGISNDDID-----DSNSTE IAD-----DDGALELVHVNEDFFYMAHVMRLAALLHSLASLAML IAYYHLKV  
SEQ ID NO:8 SGELGGGLAEDLLLEELGGSGGEGGLSG-GISGGESGEGSGE-----EEDPIELVHVNEDFFYMAHVMKIAAMHSLVSLAML IAYYHLKV  
SEQ ID NO:10 -----SABEELILGSGPGGADITGSGFGGSGDGGSGDGE-MEDEIPELVHVDDEFFYMEHVLRIACCHLSVSLAML IAYYHLKV  
SEQ ID NO:56 -----SABEELILGSGSGGADITGSGFGGSGDGGSGDGE-MEDEIPELVHVDDEFFYMEHVLRIACCHLSVSLAML IAYYHLKV  
SEQ ID NO:57 -----GSGESLMGLSGGLSGILGILETSGG-GEGGSGDGEGEEDPPEKVVHVDDEFFYMEHVLRIACCHLSVSLAML IAYYHLKV  
SEQ ID NO:58 -----I SHAENAEAAASEG-----DDEDALIESIFITGMQFPYVEITGMWLAQILYVWISVLHLSFALLVSFYQLKI  
SEQ ID NO:59 -----VDPYPHPVEILENATSPNG-----ADMAGDEDR-----VDDQIEQLINQOQMYLPVQLVLSILHSLVSI SML IAYCALKV  
SEQ ID NO:60 -----GKELPRTSSDTAKVTNS-----LDSSPHR-----I IAVHYVLESSSGYMEPTLRILAILHTTISFFCIIGYYCLKV  
SEQ ID NO:61 -----GKELPSRSTSENKVTTS-----LDSSSHR-----I IAVHYVLESSSGYMEPTLRILAILHTVVISFFCIIGYYCLKV  
SEQ ID NO:62 -----GKELPTRSSSENKVTTS-----LDSSSHR-----I IAVHYVLESSSGYMEPTLRILAILHTVVISFFCIIGYYCLKV

JC05 Rec'd CT/PTO 21 MAR 2005

**THIS PAGE BLANK (USPTO)**

**FIGURE 1DD**

SEQ ID NO: 2	PLAIFKREKEIARKLEFDGLYIAEQPED-----DDLKSHWDKLVISAKSPVNYWDKFVKKKVRAKYSETYDFDSISNMLGMEKTSFSAQ
SEQ ID NO: 128	PLAIFKREKEIARKLEFDGLYIAEQPED-----DDLKSHWDKLVISAKSPVNYWDKFVKKKVRAKYSETYDFDSISNMLGMEKTSFSAQ
SEQ ID NO: 130	PLAIFKREKEIARKLEFDGLYIAEQPED-----DDLKSHWDKLVISAKSPVNYWDKFVKKKVRAKYSETYDFDSISNMLGMEKTSFSAQ
SEQ ID NO: 144	PLAIFKREKEIARKLEFDGLYIAEQPED-----DDLKSHWDKLVISAKSPVNYWDKFVKKKVRAKYSETYDFDSISNMLGMEKTSFSAQ
SEQ ID NO: 146	PLAIFKREKEIARKLEFDGLYIAEQPED-----DDLKSHWDKLVISAKSPVNYWDKFVKKKVRAKYSETYDFDSISNMLGMEKTSFSAQ
SEQ ID NO: 4	PLAIFKREKEIARRLEFDGLYIIEQPED-----DDIKSHWDKLVISAKSPVNYWDKFVKKKVRQKQYSETYDFDSISNMLGMEKTSFSTQ
SEQ ID NO: 6	PLAIFKREKEIARRLEFDGLYIIEQPED-----DDIKSHWDKLVISAKSPVNYWDKFVKKKVRQKQYSETYDFDSISNMLGMEKTSFSTQ
SEQ ID NO: 8	PLAIFKREKEIARRLEFDGLYIAEQPED-----DDFKSHWDKLVISAKSPVNYWDKFVKKKVRQKQYSETYDFDSISNMLGMEKTSFSSQ
SEQ ID NO: 10	PLAIFKREKEIARRLEFDGLYIAEQPED-----DDFKSHWDKLVISAKSPVNYWDKFVKKKVRQKQYSETYDFDSISNMLGMEKTSFAAQ
SEQ ID NO: 56	PLAIFKREKEIARRLEFDGLYIAEQPED-----DDFKSHWDKLVISAKSPVNYWDKFVKKKVRQKQYSETYDFDSISNMLGMEKTSFAAQ
SEQ ID NO: 57	PLAIFKREKEIARRLEFDGLYIAEQPED-----DDIKSHWDKLVISAKTPVNYWDKFVKKKVRQKQYSETYDFDSISNMLGMEKTSFAAQ
SEQ ID NO: 58	PLITFKREKEIARKLMFDGCGWITEEDSEELGIVDTFMWYLDRIWVSAKSPMMYWDKFVRRKTRSKFDQVDEETLTSILGEEKMS---T
SEQ ID NO: 59	PLCLFKREKEIARKLEFDGQWITEQPTR-----DDIKGQWDSLAISTVSPVYWDKFVKKVLLKKYEDAVGEDKLCAMLGMEIGENPMA
SEQ ID NO: 60	PLVIFKREKEVARKLEFDGLYITEQPSB-----DDIKGQWDRLVINTQSFPPNYWDKFVKKVMDKYGEFYGRDRISELLGMDKAALDFS
SEQ ID NO: 61	PLVIFKREKEVARKLEFDGLYITEQPSB-----DDIKGQWDRLVINTQSFPPNYWDKFVKKVMDKYGEFYGRDRISELLGMDKAALDFS
SEQ ID NO: 62	PLVIFKREKEVARKLEFDGLYITEQPSB-----DDIKGQWDRLVINTQSFPPNYWDKFVKKVMDKYGEFYGRDRISELLGMDKAALDFS
SEQ ID NO: 2	EEEGSKG-----LIHYIINIDWRYQVWK-AGVTITDNSFLYSLWYFVSFVGMGNFNN-FFFAAHLDDVAVGFKTLRLLQSVTHNGKQLV
SEQ ID NO: 128	EEEGSKG-----LIHYIINIDWRYQVWK-AGVTITDNSFLYSLWYFVSFVGMGNFNN-FFFAAHLDDVAVGFKTLRLLQSVTHNGKQLV
SEQ ID NO: 130	EEEGSKG-----LIHYIINIDWRYQVWK-AGVTITDNSFLYSLWYFVSFVGMGNFNN-FFFAAHLDDVAVGFKTLRLLQSVTHNGKQLV
SEQ ID NO: 144	EEEGSKG-----LIHYIINIDWRYQVWK-AGVTITDNSFLYSLWYFVSFVGMGNFNN-FFFAAHLDDVAVGFKTLRLLQSVTHNGKQLV
SEQ ID NO: 146	EEEGSKG-----LIHYIINIDWRYQVWK-AGVTITDNSFLYSLWYFVSFVGMGNFNN-FFFAAHLDDVAVGFKTLRLLQSVTHNGKQLV
SEQ ID NO: 4	ENEERTG-----LINFVINIDWRYQVWK-AGVTITDNFLYSLWYFTFSLGNFNN-FFFAAHLDDVAVGFKTLRLLQSVTHNGKQLV
SEQ ID NO: 6	ENEERTG-----LINFVINIDWRYQVWK-AGVTITDNFLYSLWYFTFSLGNFNN-FFFAAHLDDVAVGFKTLRLLQSVTHNGKQLV
SEQ ID NO: 8	ETEERTG-----IINFILNIDWRYQVWK-AGVTITDNFLYSLWYFTFSLGNFNN-FFFAAHLDDVAVGFKTLRLLQSVTHNGKQLV
SEQ ID NO: 10	ESEETG-----IFKYIMNIDWRYQVWK-AGVTITDNFLYSLWYFTFSLGNFNN-FFFAAHLDDVAVGFKTLRLLQSVTHNGKQLV
SEQ ID NO: 56	ESEETG-----IFKYIMNIDWRYQVWK-AGVTITDNFLYSLWYFTFSLGNFNN-FFFAAHLDDVAVGFKTLRLLQSVTHNGKQLV
SEQ ID NO: 57	EANEGGG-----FFHFTINIDWRYQVWK-AGVTITDNFLYSLWYFTFSLGNFNN-FFFAAHLDDVAVGFKTLRLLQSVTHNGKQLV
SEQ ID NO: 58	DS-----S-YDYRYSCLWILGVTNGQFLYRVGYLLCSACGVFLSPFFYAFHLIDVVLSPMLKAILQSVTHNLQQLI
SEQ ID NO: 59	GNPTENP--NQGLESSLTSLDWKYHIWK-CQVIGTNSFLYIAWYLLFSLIGHINP-FFFAAHLDDVAVGFKTLRLLQSVTHNGKQLV
SEQ ID NO: 60	DAREKKPKKDDSLSAVLNSIDVKYQMWK-LGVVFTDNSFLYLAWYMTMSVLGHYNN-FFFAAHLDDVAVGFKTLRLLQSVTHNGKQLV
SEQ ID NO: 61	DAREKKPKKDDSLSAVLNSIDVKYQMWK-LGVVFTDNSFLYLAWYMTMSVLGHYNN-FFFAAHLDDVAVGFKTLRLLQSVTHNGKQLV
SEQ ID NO: 62	DAREKKPKKDDSLSAVLNSIDVKYQMWK-LGVVFTDNSFLYLAWYMTMSVLGHYNN-FFFAAHLDDVAVGFKTLRLLQSVTHNGKQLV

JCCF Rec'd T/PTO 21 MAR 2005

THIS PAGE BLANK (USPTO)

**FIGURE 1EE**

SEQ ID NO: 2	LTVMLLTIIVYIYTVIAFNFRKFYVQGED--DEVNRNCHDMLTCTFVNLYKGVRAAGGIGDELEPPDGGDDSEVYRIIFDISFFFFIIVI
SEQ ID NO: 128	LTVMLLTIIVYIYTVIAFNFRKFYVQEEED--DEVNRNCHDMLTCTFVNLYKGVRAAGGIGDELEPPDGGDDSEVYRIIFDISFFFFIIVI
SEQ ID NO: 130	LTVMLLTIIVYIYTVIAFNFRKFYVQEEED--DEVNRNCHDMLTCTFVNLYKGVRAAGGIGDELEPPDGGDDSEVYRIIFDISFFFFIIVI
SEQ ID NO: 144	LTVMLLTIIVYIYTVIAFNFRKFYVQEEED--DEVNRNCHDMLTCTFVNLYKGVRAAGGIGDELEPPDGGDDSEVYRIIFDISFFFFIIVI
SEQ ID NO: 146	LTVMLLTIIVYIYTVIAFNFRKFYVQEEED--DEVNRNCHDMLTCTFVNLYKGVRAAGGIGDELEPPDGGDDSEVYRIIFDISFFFFIIVI
SEQ ID NO: 4	LTVMLLTIIVYIYTVIAFNFRKFYVQEEED--DEVNRNCHDMLTCTFVNLYKGVRAAGGIGDELEPPDGGDDSEVYRIIFDISFFFFIIVI
SEQ ID NO: 6	LTVMLLTIIVYIYTVIAFNFRKFYVQEEED--DEVNRNCHDMLTCTFVNLYKGVRAAGGIGDELEPPDGGDDSEVYRIIFDISFFFFIIVI
SEQ ID NO: 8	LTVMLLTIIVYIYTVIAFNFRKFYVQEEED--DEVNRNCHDMLTCTFVNLYKGVRAAGGIGDELEPPDGGDDSEVYRIIFDISFFFFIIVI
SEQ ID NO: 10	LTVMLLTIIVYIYTVIAFNFRKFYVQEEED--DEVNRNCHDMLTCTFVNLYKGVRAAGGIGDELEPPDGGDDSEVYRIIFDISFFFFIIVI
SEQ ID NO: 56	LTVMLLTIIVYIYTVIAFNFRKFYVQEEED--DEVNRNCHDMLTCTFVNLYKGVRAAGGIGDELEPPDGGDDSEVYRIIFDISFFFFIIVI
SEQ ID NO: 57	LTVMLLTIIVYIYTVIAFNFRKFYVQEEED--DEVNRNCHDMLTCTFVNLYKGVRAAGGIGDELEPPDGGDDSEVYRIIFDISFFFFIIVI
SEQ ID NO: 58	LTVMLLTIIVYIYTVIAFNFRKFYVQEEED--DEVNRNCHDMLTCTFVNLYKGVRAAGGIGDELEPPDGGDDSEVYRIIFDISFFFFIIVI
SEQ ID NO: 59	LTVMLLTIIVYIYTVIAFNFRKFYVQEEED--DEVNRNCHDMLTCTFVNLYKGVRAAGGIGDELEPPDGGDDSEVYRIIFDISFFFFIIVI
SEQ ID NO: 60	LTVMLLTIIVYIYTVIAFNFRKFYVQEEED--DEVNRNCHDMLTCTFVNLYKGVRAAGGIGDELEPPDGGDDSEVYRIIFDISFFFFIIVI
SEQ ID NO: 61	LTVMLLTIIVYIYTVIAFNFRKFYVQEEED--DEVNRNCHDMLTCTFVNLYKGVRAAGGIGDELEPPDGGDDSEVYRIIFDISFFFFIIVI
SEQ ID NO: 62	LTVMLLTIIVYIYTVIAFNFRKFYVQEEED--DEVNRNCHDMLTCTFVNLYKGVRAAGGIGDELEPPDGGDDSEVYRIIFDISFFFFIIVI

SEQ ID NO: 2	LLAILQGLIIDAFAFGLRDQLESVKEDMESNCFICGINKDYFDKVPHGFDTHVQREHNLANYMFFLMHLINKPDTYTGQETYVWNMYTQR
SEQ ID NO: 128	LLAILQGLIIDAFAFGLRDQLESVKEDMESNCFICGINKDYFDKVPHGFDTHVQREHNLANYMFFLMHLINKPDTYTGQETYVWNMYTQR
SEQ ID NO: 130	LLAILQGLIIDAFAFGLRDQLESVKEDMESNCFICGINKDYFDKVPHGFDTHVQREHNLANYMFFLMHLINKPDTYTGQETYVWNMYTQR
SEQ ID NO: 144	LLAILQGLIIDAFAFGLRDQLESVKEDMESNCFICGINKDYFDKVPHGFDTHVQREHNLANYMFFLMHLINKPDTYTGQETYVWNMYTQR
SEQ ID NO: 146	LLAILQGLIIDAFAFGLRDQLESVKEDMESNCFICGINKDYFDKVPHGFDTHVQREHNLANYMFFLMHLINKPDTYTGQETYVWNMYTQR
SEQ ID NO: 4	LLAILQGLIIDAFAFGLRDQLESVKEDMESNCFICGINKDYFDKVPHGFDTHVQREHNLANYMFFLMHLINKPDTYTGQETYVWNMYTQR
SEQ ID NO: 6	LLAILQGLIIDAFAFGLRDQLESVKEDMESNCFICGINKDYFDKVPHGFDTHVQREHNLANYMFFLMHLINKPDTYTGQETYVWNMYTQR
SEQ ID NO: 8	LLAILQGLIIDAFAFGLRDQLESVKEDMESNCFICGINKDYFDKVPHGFDTHVQREHNLANYMFFLMHLINKPDTYTGQETYVWNMYTQR
SEQ ID NO: 10	LLAILQGLIIDAFAFGLRDQLESVKEDMESNCFICGINKDYFDKVPHGFDTHVQREHNLANYMFFLMHLINKPDTYTGQETYVWNMYTQR
SEQ ID NO: 56	LLAILQGLIIDAFAFGLRDQLESVKEDMESNCFICGINKDYFDKVPHGFDTHVQREHNLANYMFFLMHLINKPDTYTGQETYVWNMYTQR
SEQ ID NO: 57	LLAILQGLIIDAFAFGLRDQLESVKEDMESNCFICGINKDYFDKVPHGFDTHVQREHNLANYMFFLMHLINKPDTYTGQETYVWNMYTQR
SEQ ID NO: 58	LLAILQGLIIDAFAFGLRDQLESVKEDMESNCFICGINKDYFDKVPHGFDTHVQREHNLANYMFFLMHLINKPDTYTGQETYVWNMYTQR
SEQ ID NO: 59	LLAILQGLIIDAFAFGLRDQLESVKEDMESNCFICGINKDYFDKVPHGFDTHVQREHNLANYMFFLMHLINKPDTYTGQETYVWNMYTQR
SEQ ID NO: 60	LLAILQGLIIDAFAFGLRDQLESVKEDMESNCFICGINKDYFDKVPHGFDTHVQREHNLANYMFFLMHLINKPDTYTGQETYVWNMYTQR
SEQ ID NO: 61	LLAILQGLIIDAFAFGLRDQLESVKEDMESNCFICGINKDYFDKVPHGFDTHVQREHNLANYMFFLMHLINKPDTYTGQETYVWNMYTQR
SEQ ID NO: 62	LLAILQGLIIDAFAFGLRDQLESVKEDMESNCFICGINKDYFDKVPHGFDTHVQREHNLANYMFFLMHLINKPDTYTGQETYVWNMYTQR

JCC5 Rec'd PTO 21 MAR 2005

THIS PAGE BLANK (USPTO)



10/528611

**FIGURE 1FF**

SEQ ID NO:2	CWDFFPVGD	CFRKQYEDLMGE	-----
SEQ ID NO:128	CWDFFPVGD	CFRKQYEDLMGE	-----
SEQ ID NO:130	CWDFFPVGD	CFRKQYEDLMGE	-----
SEQ ID NO:144	CWDFFPVGD	CFRKQYEDLMGE	-----
SEQ ID NO:146	CWDFFPVGD	CFRKQYEDLMGE	-----
SEQ ID NO:4	CWDFFPVGD	CFRKQYEEELGGGGV-	
SEQ ID NO:6	CWDFFPVGD	CFRKQYEEELGGGGV-	
SEQ ID NO:8	CWDFFPVGD	CFRKQYEDLGGGG--	
SEQ ID NO:10	SWDFFPVGD	CFRKQYEDLSGGGGG	
SEQ ID NO:56	SWDFFPVGD	CFRKQYEDLSGGGGG	
SEQ ID NO:57	CWDFFPVGD	CFRKQYEDLGGGGS--	
SEQ ID NO:58	DWDFFPVGE	CFVKQYEDQLLQS----	
SEQ ID NO:59	CWDFFPVGD	CFRKQYDDEQA-----	
SEQ ID NO:60	CWEFFPAGD	CFRKQYEDQLN-----	
SEQ ID NO:61	CWEFFPAGD	CFRKQYEDQLN-----	
SEQ ID NO:62	CWEFFPAGD	CFRKQYEDQLN-----	
SEQ ID NO:2	=	tobacco budworm	(5142 amino acids)
SEQ ID NO:128	=	tobacco budworm HV7	(5128 amino acids)
SEQ ID NO:130	=	tobacco budworm HV2	(5135 amino acids)
SEQ ID NO:144	=	tobacco budworm HV3	(5142 amino acids)
SEQ ID NO:146	=	tobacco budworm HV6	(5100 amino acids)
SEQ ID NO:4	=	green peach aphid	(5101 amino acids)
SEQ ID NO:6	=	cotton melon aphid	(5104 amino acids)
SEQ ID NO:8	=	corn plant hopper	(5127 amino acids)
SEQ ID NO:10	=	fruitfly (DuPont)	(5109 amino acids)
SEQ ID NO:56	=	fruitfly gi17352471	(5113 amino acids)
SEQ ID NO:57	=	mosquito gi21301556	(4868 amino acids)
SEQ ID NO:58	=	nematode gi1871447	(5071 amino acids)
SEQ ID NO:59	=	sea urchin gi18656155	(5317 amino acids)
SEQ ID NO:60	=	mouse gi13569850	(4967 amino acids)
SEQ ID NO:61	=	rabbit gi1245376	(4968 amino acids)
SEQ ID NO:62	=	human gi4506757	(4967 amino acids)

THIS PAGE BLANK (USPTO)




**FIGURE 2****Group 1****Group 2****Group 3**

JCO5 Rec'd CT/PTO 21 MAR 2005

**THIS PAGE BLANK (USPTO)**

10/528611


Figure 3



THIS PAGE RI ANK (USPTO)


10/528611

Figure 4



**THIS PAGE BLANK (USPTO)**

Figure 5




JCC5 Rec'd PC TO 21 MAR 2005

**THIS PAGE BLANK (USPTO)**




Figure 6



JC05 Rec'd PPTO 21 MAR 2005

THIS PAGE BLANK (USPTO)

Figure 7



JC05 Rec'd [REDACTED] PTO 21 MAR 2005

THIS PAGE BLANK (USPTO)

DEST (Invitrogen Life Technologies™, Carlsbad, CA) vector cut with XbaI and HindIII to produce pIBDEST/LOX. pIBDEST/LOX and pDEST39/LOX are functionally similar, both having a stop fragment that can be removed by Cre. One difference is the promoter which controls the transcription of the Ryr gene in insect cells is the actin promoter in pDEST39/LOX but the OplE2 promoter in pIBDEST/LOX. Also, pIBDEST/LOX contains a blasticidin gene to allow stably transfected cells to be selected.

The *Heliothis* ryanodine receptor cDNA was transferred from pENTR2B/PvuI/HV7 to pDEST39/LOX using Invitrogen's Clonase LR reaction according to the manufacturer's recommendation to produce pHE7. In vitro reaction of pHE7 with Cre (Invitrogen) according to the manufacturer's recommendation correctly excised the stop fragment and left behind the predicted Lox footprint.

Excision of the stop fragment from pHE7, in the target insect cells was accomplished by cotransfecting them with pMLS104 (Siegal and Hartl (1996) *Genetics* 144:715-726), as a source of Cre, into SF9 cells. As an alternate approach, the Cre-mediated excision of the stop fragment was done by incubating pHE7 with Cre enzyme in vitro. In these cases, the pMLS104 plasmid was not cotransfected with the pHE7 plasmid. The conditions for the Cre reaction were taken from the Creator DNA cloning kit (BD Biosciences™, San Diego, CA, Clontech Protocol PT3460-1). For each 250 ng of pHE7 plasmid, 100 ng of Cre recombinase (Clontech Laboratories Inc.™, Palo Alto, CA, catalog no.8480-1) was used in a 15 minute, room temperature reaction. The reaction was performed in a reaction solution that included 1X Cre reaction buffer and 1X BSA supplied with the Cre recombinase as purchased from Clontech™. Following the 15 minute reaction, the enzyme was heat-killed at 70 degrees C for 5 minutes. With minor variations to account for non-unique restriction sites, four other Hv clones were constructed (pHI2, pHI3, pHI6, pHI7) with the organization of Cre recognition elements described for pHE7, but fused to the OplE2 promoter in pIBDEST/LOX.

In a second approach, the toxicity of expression of *Heliothis virescens* Ryr in *E. coli*, was overcome using a modified insect expression vector such as pIB/V5-His (Invitrogen). An intron fragment was amplified with primers (forward primer: SEQ ID NO:147, 5'-cagtaaagcttgagtcattgaaatttagac-3'; reverse primer: SEQ ID NO:148, 5'-tctggatcctggttggaataatgggga-3') from *Heliothis virescens* genomic DNA. The purified PCR product was inserted into a pIB vector into the HindIII and BamHI sites. The DNA sequence of the modified vector was confirmed by DNA sequencing and the Ryr gene from pXLHV7 excised and inserted behind the intron (SEQ ID NO:149), to produce vector pIBiHv7.

... two cloning strategies that completely eliminate any expression of the Ryr gene in *E. coli* would circumvent the growth problems.

In the first strategy, the Ryr gene is cloned into a modified pXINSECT-DEST39 vector (Invitrogen), placing the Ryr gene under the control of an insect actin promoter. In order to completely eliminate leaky expression of the Ryr gene during growth in *E. coli*, a "stop" fragment was placed just downstream of the His tag in the vector, but upstream of the Ryr gene. This stop fragment contains the strong transcriptional terminator T1T2 from the *E. coli* *rrnB* gene (Orosz et al (1991) *Eur J Biochem* 201:653-659). Also present within this stop fragment is a stop codon in frame with the initiator ATG of the vector. Flanking the stop fragment are Lox sites in direct orientation, such that in the presence of the Cre enzyme, the entire stop fragment will be excised from the vector (Odell and Russell (1994) *Homologous Recomb Gene Silencing Plants*; ed, J. Paszkowski; pp 219-270), leaving behind a "footprint" of a single Lox site. The stop vector was designed such that following Cre-mediated excision of the stop fragment, the Ryr gene is in frame with the initiator ATG and there are no stop codons present between the ATG and the Ryr gene. The combination of the ATG, His tag, and *attB1* from the vector and the residual Lox footprint and associated linker sequences, adds 53 foreign amino acids to the mature Ryr gene product. Construction of the pHE7 vector is outlined in Figure 7.

The Invitrogen Gateway Entry™ vector pEntr2B (Invitrogen Life Technologies™, Carlsbad, CA) was modified to add a PvuI site in the polylinker. pEntr2B was digested with EcoRI and KpnI. Two oligonucleotides, SEQ ID NO:131 (5'-gatccgcgccgcgcatcggtacc-3') and SEQ ID: 132 (5'-cgatcgcgccgcg -3') were annealed and ligated into the digested vector to produce pEntr2B/PvuI. The HV Ryr gene from pXLHv7 was digested with PaeI and PmeI. pENTR2B/PvuI was partially digested with PvuI (there is a second site in pEntr2B/PvuI) and completely digested with EcoRV and the correct fragment was gel-purified. The PaeI sticky end of the Ryr fragment is compatible with the PvuI sticky end and the PmeI and EcoRV ends are both blunt. The 15.4 kb Ryr gene fragment from pXLHv7 was then ligated into the pENTR2B/PvuI to create pENTR2B/PvuI/HV7.

The stop fragment was created by annealing 6 oligonucleotides, SEQ ID NO: 133 - SEQ ID NO:138 and then PCR amplified using primers SEQ ID NO:139 (5'-ccttttttcagcgcta-3') and SEQ ID NO:140 (5'-gagagagagttaaataa-3'). The resulting product was digested with AfeI and DraI to produce blunt ends, and ligated into the unique AfeI site of pXINSECT-DEST39 to produce pDEST39/LOX.

As an alternative to using pDEST39/LOX, the stop fragment from pDEST39/LOX was excised with XbaI and HindIII and cloned into the pIB/V5-His-

... sequences that when fused in-frame with the insert provide a polypeptide extension that can aid purification like a His tag, MBP or GST extension at either the N- or C-termini of the recombinant protein.

The cDNA inserts can also be expressed in yeast cells. The ryanodine receptor polypeptides can be evaluated by expression of the encoded polypeptides in a yeast (*Saccharomyces cerevisiae*) strain YPH (Stratagene) and assaying the membrane components for ryanodine-sensitive calcium transport. Plasmid DNA (200 ng) from any of the cDNA clones can be used as a template for PCR using primers set forth in the present invention. Amplification is performed using the GC melt kit (Clontech) with a 1 M final concentration of GC melt reagent. Amplification took place in a Perkin Elmer 9700 thermocycler for 30 cycles as follows: 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 2 minutes. The amplified insert is then incubated with a modified pRS315 plasmid (NCBI General Identifier No. 984798; Sikorski, R. S. and Hieter, P. (1989) *Genetics* 122:19-27) that had been digested with appropriate restriction enzymes. Plasmid pRS315 had been previously modified by the insertion of a bidirectional gal1/10 promoter between the Xho I and Hind III sites. The plasmid is then transformed into the YPH yeast strain using standard procedures where the insert recombines through gap repair to form the desired transformed yeast strain (Hua, S. B. et al. (1997) *Plasmid* 38:91-96.).

Yeast cells are prepared according to a modification of the methods of Pompon et al. (Pompon, D. et al. (1996) *Meth. Enz.* 272:51-64). Briefly, a yeast colony is grown overnight (to saturation) in SG (-Leucine) medium at 30°C with good aeration. A 1:50 dilution of this culture is made into 500 mL of YPGE medium with adenine supplementation and allowed to grow at 30°C with good aeration to an  $D_{600}$  of 1.6 (24-30 h). Fifty mL of 20% galactose is added, and the culture is allowed to grow overnight at 30°C. The cells are recovered by centrifugation at 500 rpm for five minutes in a Sorvall GS-3 rotor. The cell pellet is resuspended in 1 mL of 0.1 M potassium phosphate buffer (pH 7.0) and then allowed to grow at 30°C for another 24 hours.

The cells are recovered by centrifugation as described above and the presence of ryanodine receptor activity is determined using any of the assays described in Examples 9, 10, or 11.

#### EXAMPLE 7

##### Expression of *Heliothis virescens* Ryr cDNA in Insect Cells

The *Heliothis virescens*, and other, Ryr cDNAs appears to be quite toxic to *Escherichia coli* when placed into a vector under the control of an insect expression (e.g. pIB/V5-His, Invitrogen Life Technologies™, Carlsbad CA). Under these conditions, the cells grow very slowly and frameshift mutations are spontaneously

for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region, 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

- 5 Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the entire protein or a suitable subfragment or subdomain. This cDNA fragment may then be purified on a 1% NuSieve GTG™ low melting agarose gel (FMC, Philadelphia, PA). Buffer and agarose contain 10 µg/mL ethidium bromide for visualization of the DNA fragment. The fragment can then be
- 10 purified from the agarose gel by digestion with GELase™ (Epicentre Technologies) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 µL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase (New England Biolabs, Beverly, MA). The fragment containing the ligated adapters can be purified from the excess
- 15 adapters using low melting agarose as described above. The vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5 electrocompetent cells (Invitrogen Life Technologies™, Carlsbad, CA).
- 20 Transformants can be selected on agar plates containing LB media and 100 µg/mL ampicillin. Transformants containing the gene encoding the instant polypeptides are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.

For high level expression, a plasmid clone with the cDNA insert in the correct orientation relative to the T7 promoter can be transformed into *E. coli* strain BL21(DE3) (Studier et al. (1986) *J. Mol. Biol.* 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25°C. At an optical density at 600 nm of approximately 1, IPTG (isopropylthio-β-galactoside, the inducer) can be added to a final concentration of 0.4 mM and incubation can be continued for 3 h at 25°C. Cells are then harvested by centrifugation and re-suspended in 50 µL of 50 mM Tris-HCl at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe sonicator. The mixture is centrifuged and the protein concentration of the supernatant determined. One µg of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight. Clearly those skilled in the art might choose other bacterial expression vectors, particularly



infecting eukaryotic cells. In particular, baculovirus based systems for insect cell infection would be useful, as would any system allowing for the complete expression and modification of receptor proteins in its active form.

The *Spodoptera frugiperda* cell line Sf9 used for transfection studies, was maintained in Sf-900 II SFM medium (Invitrogen Life Technologies™, Carlsbad, CA) in T-75 flasks incubated at 27°C. It is understood that those skilled in the art might choose alternative cell types such as the *Spodoptera frugiperda* cell line Sf21 or the *Drosophila* cell line S2. For the purpose of general handling and propagation, cells were suspended through scraping or agitation and a volume of cell suspension was added to each well of a poly-L-lysine coated 96-well, glass-bottom plate so as to provide 70–80% confluence. Cells were maintained in an incubator at 27 °C until testing.

Sf-9 cells were grown at 27 degrees C in a Corning 125 ml polycarbonate Erlenmeyer flask to a density of 3.1 million cells per ml in SF900-II serum free media (Gibco cat. # 10902-088, Invitrogen Life Technologies™, Carlsbad, CA). One million cells were transferred to one well of a Corning 6-well, flat bottom cell culture dish (Corning 3516). SF900-II media was used to bring the final volume in the dish to 2 ml and the cells were incubated at 27 degrees C for 21 h. Following the incubation the media was aspirated from the dish and replaced with 1 ml of SF900-II media pre-warmed to 27 degrees C.

The transient transfection was carried out following an InsectSelect BSD System manual (Invitrogen Life Technologies™, Carlsbad, CA). Cellfectin reagent (Invitrogen Life Technologies™, Carlsbad, CA, catalog no. 10362-010) and SF900-II serum free media (Gibco cat. # 10902-088, Invitrogen Life Technologies™, Carlsbad, CA) were used in all transfection. The transfection was accomplished by adding the transfection solution drop-wise to the dish and incubating 4 h at room temperature with gentle rocking. After the 4 h incubation the media was replaced with 2 ml of SF900-II media pre-warmed to 27 degrees C and the cells were incubated 2-3 days at 27 degrees C before testing.

#### EXAMPLE 6

##### Expression of Chimeric Constructs in Microbial Cells

The cDNAs encoding the instant polypeptides can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites

Prior to the characterization of the sequences presented herein insect specific sequences could not be identified since the fruitfly sequence was the only insect sequence available and this had very low (less than 50%) homology to the other known animal ryanodine receptor sequences.

5 Table 5 shows the percent identity for the pairwise comparison of the ryanodine receptor sequences shown in Figure 1. The SEQ ID NOs for the sequences and their respective percent identities are shown.

10 Table 5  
Percent Identity For Pairwise Comparison Of Ryanodine Receptor Sequences  
Shown In Figure 1

SEQ ID NOs:	<u>128</u>	<u>130</u>	<u>144</u>	<u>146</u>	<u>4</u>	<u>6</u>	<u>8</u>	<u>10</u>	<u>56</u>	<u>57</u>	<u>58</u>	<u>59</u>	<u>60</u>	<u>61</u>	<u>62</u>
<u>2</u>	99.0	98.9	98.8	98.9	76.8	77.5	79.6	78.2	78.5	79.0	45.7	46.1	47.1	47.2	47.2
<u>128</u>	***	99.8	99.6	99.6	77.6	78.0	80.3	78.8	79.2	79.6	46.1	46.5	47.7	47.6	47.6
<u>130</u>		***	99.6	99.6	77.7	78.1	80.3	78.9	79.3	79.8	46.4	46.5	47.5	47.7	47.6
<u>144</u>			***	99.6	77.4	78.1	80.1	78.7	79.0	79.6	45.9	46.4	47.5	47.6	47.5
<u>146</u>				***	77.9	78.3	80.8	79.0	79.3	79.8	46.0	47.0	47.5	47.6	47.6
<u>4</u>					***	97.9	81.9	75.4	75.7	76.5	45.6	47.3	47.0	46.9	46.9
<u>6</u>						***	82.2	75.8	75.9	76.8	45.8	47.6	47.1	47.3	47.4
<u>8</u>							***	78.4	78.8	80.2	45.9	46.8	47.2	47.3	47.2
<u>10</u>								***	99.3	82.3	45.3	45.8	46.6	46.8	46.7
<u>56</u>									***	82.5	45.7	45.8	46.8	46.9	46.9
<u>57</u>										***	45.8	46.8	46.7	46.7	46.7
<u>58</u>											***	41.5	41.0	41.1	41.2
<u>59</u>												***	48.2	48.3	48.2
<u>60</u>													***	97.1	97.2
<u>61</u>														***	98.6

#### EXAMPLE 5

#### 15 Transient Expression of Ryanodine Recombinant Constructs in Insect Cell Lines

The cDNAs encoding ryanodine receptors from different insects were cloned into pIBV5His or pFASTBac as described in Example 2, respectively. However, one skilled in the art would realize that there are numerous other vectors and means of

SEQ ID NO.	Percent Identity to
146	17352471
4	79.3%
6	75.7%
8	75.9%
10	78.8%
	99.3%

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) CABIOS. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. For large protein sequences the Clustal W program (Thompson et al. (1994) Nuc Acids Res 22:4673-4680) was used. Default parameters were used (GAP PENALTY=10, GAP LENGTH PENALTY=0.2, DELAY DIVERGENT SEQ (%)=30, DNA TRANSITION WEIGHT=0.50, PROTEIN WEIGHT MATRIX: Gonnet Series, DNA WEIGHT MATRIX:IUB). Pairwise alignment also used default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=0.10, PROTEIN WEIGHT MATRIX: Gonnet 250, DNA WEIGHT MATRIX:IUB). Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of a ryanodine receptor protein.

Figure 1 shows an alignment using Clustal W of the tobacco budworm, green peach aphid, cotton melon aphid, and corn plant hopper (SEQ ID NOS:2, 128, 130, 144, 146, 4, 6, and 8) to a fruitfly (*Drosophila melanogaster*) sequence generated by the methods disclosed herein (SEQ ID NO:10), the *Drosophila* art sequence ((NCBI General Identifier No. gi 17352471, SEQ ID NO:56), an unannotated sequence from the mosquito (*Anopheles gambiae*) genome sequencing project encoding a partial ryanodine receptor (gi 21301556, SEQ ID NO:57), the ryanodine receptor from nematodes (*Caenorhabditis elegans*, gi 1871447, SEQ ID NO:58), sea urchin *Hemicentrotus pulcherrimus*, gi 18656155, SEQ ID NO:59), mouse (*Mus musculus*, gi 13569850, SEQ ID NO:60), rabbit (*Oryctolagus cuniculus*, gi 1245376, SEQ ID NO:61), and human (*Homo sapiens*, gi 4506757, SEQ ID NO:62). Insect specific sequences can be identified by finding homologous subsequences that are conserved between all of the insect sequences but not among the non-insect sequences. A number of these sequences can be found in SEQ ID NOS:63-119.

sequence were completed by gene walking.

#### EXAMPLE 4

##### Characterization of cDNA Clones Encoding Ryanodine Receptors

The BLASTX search using the EST sequences from clones listed in Table 3 revealed similarity of the polypeptides encoded by the cDNAs to the ryanodine receptor protein from *Drosophila* [*Drosophila melanogaster*] (NCBI General Identifier No. gi 17352471, [SEQ ID NO:56. Shown in Table 3 are the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), the sequences of contigs assembled from two or more ESTs ("Contig"), sequences of contigs assembled from an FIS and one or more ESTs ("Contig\*\*"), or sequences encoding an entire protein derived from an FIS, a contig, or an FIS and PCR ("CGS"):

TABLE 3

BLAST Results for Sequences Encoding Ryanodine Receptors

Clone	Status	BLAST pLog Score
		17352471
tobacco budworm	CGS	180.0
tobacco budworm	CGS	180.0
tobacco budworm	CGS	180.0
tobacco budworm	CGS	180.0
tobacco budworm	CGS	180.0
green peach aphid	CGS	180.0
cotton melon	CGS	180.0
aphid		
corn plant hopper	CGS	180.0
fruit fly	CGS	180.0

The data in Table 4 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOs:2, 4, 6, 8, 10, 128, 130, 144, and 146, and the ryanodine receptor protein from *Drosophila* [*Drosophila melanogaster*] (NCBI General Identifier No. gi 17352471, SEQ ID NO:56).

TABLE 4

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Ryanodine Receptors

SEQ ID NO.	Percent Identity to
	17352471
2	78.5%
128	79.2%
130	79.3%
144	79.0%

For corn plant hopper the 5' RACE primers were

CPH-DR1: CCGAAGCACATCGCCACCAAACAC (SEQ ID NO:46)

CPH-DR2: CCTGTGCCATAAGGCTGAACGGACC (SEQ ID NO:47)

5 CPH-DR3: CGTCACCAACTCGCACCTTCTCACCTCC (SEQ ID NO: 48)

and 3' RACE primers

CPH-EF1: GGAAGACATGGAGTCCAACTGTTTCATTTGTGGC (SEQ ID NO:49)

CPH-EF2: GTGCCGCATGGTTTCGATACTCATGTGCAGC (SEQ ID NO:50)

10 CPH-EF3: GCATAATCTCGCTAATTACATGTTCTTCCTCATGC (SEQ ID NO:51)

The sequences of the primers designed to incorporate the *PacI* and *Pme* sites at the ends of the ryanodine receptor coding regions for the cotton melon aphid are as follows:

15 pRCMAN-*PacI*: GCCAAGTTAATTAACGATGGCCGACAGCGAGGGAAGTTCTG (SEQ ID NO:52)

pRCMAC-*PmeI*: GAACTCGTTTAAACGAGACGCCTCCTCCGCCGCCAAGC (SEQ ID NO:53)

20 and those designed to incorporate the *PacI* and *Pme* sites at the ends of the ryanodine receptor coding regions for the corn plant hopper are as follows:

pRCPHN-*PacI*: GCCAAGTTAATTAACAATGGCGGATAGTGAGGGTGGATCTG (SEQ ID NO:54)

25 pRCPHC-*PmeI*: GAAGTCGTTTAAACGAGCCACCACCGCCTCCTAACTCATC (SEQ ID NO:55)

30 Both full-length ryanodine receptor coding regions were again cloned into the pCR-XL-TOPO<sup>®</sup> vector (Invitrogen<sup>™</sup>) and subsequently sub-cloned into the modified pIBV5His or pFASTBac as described in Example 2.

35 To complete the sequences of the ryanodine receptor coding regions, the inserts in the pCR-XL-TOPO<sup>®</sup> vector were digested with a mixture of *EcoRI* and *BamHI* restriction enzymes. The fragments were then subcloned into three pBluscript KS vectors, digested either with *EcoRI*, *BamHI* or both combined. The vectors were religated in the presence of the mixtures of the ryanodine receptor coding region sub-fragments. About forty individual clones for each of the CMA and CPH ryanodine receptor coding regions were isolated from individual bacterial colonies and the inserts sequenced using vector primers. The gaps remaining in the

codon of the full-length coding region of the ryanodine receptor.

The primers used were:

pRgN-PacI: GCCAAGTTAATTAACGATGGCCGACAGCGAGGGCAGTTCG (SEQ ID NO:37)

5 pRgC-PmeI: GGACTCGTTTAAACGAGACGCCTCCTCCGCCGCCGAGC (SEQ ID NO:38)

the full-length cDNA for the gene was thus isolated with PacI and PmeI sites at the 5' and 3' ends respectively.

10 The 16 kb PCR product was cloned into a pCR-XL-TOPO® vector (Invitrogen Life Technologies™, Carlsbad, CA) and the full-length ryanodine receptor coding region subsequently sub-cloned into pIBV5His or pFASTBac vectors modified between the BamHI and XbaI sites of the MCS of the vector with PacI and PmeI sites (SEQ ID NO:39).

15 Full-insert sequencing was achieved using a combination transposon and primer walking procedure. The transposon system used was the EZ::TN transposon insertion kit from Epicentre™ using the TET 1 version of the transposon (Goryshin and Reznikoff (1998) *J Biol Chem* 273:7367-7374). 200 clones were isolated to provide 380 sequences using forward and reverse primers supplied in the kit. Primers were then designed from these regions to fill in the gaps by gene walking.  
20 The sequence of the green peach aphid gene is shown in SEQ ID NO:3.

### EXAMPLE 3

#### Reconstruction of the Ryanodine Receptor Isolated Nucleic Acid Fragment From Cotton Melon Aphid and Corn Plant Hopper

25 cDNA for the ryanodine receptor coding regions from cotton melon aphid and corn plant hopper were obtained essentially as described in Example 2. The same D primer set used in Example 1 and E primer set used in Example 2 produced nearly the full-length sequence for the two homopteran species. The following primers were used for a RACE series of experiments to produce the sequences of the 5' and 3' ends of the ryanodine receptor coding regions. For cotton melon aphid  
30 the 5'RACE primers used were

CMA-DR1: GCTGGATGCACAGTCCACCAACAAGCTTC (SEQ ID NO:40)

CMA-DR2: CAATGTTCGGTGTCCAGATCCAGTTCC (SEQ ID NO:41)

CMA-DR3: GACGGGTACACACTGAGACAAGTCGGGTGG (SEQ ID NO:42)

35 and 3' RACE primers

CMA-EF1: CTGCGGCATCGGCAAAGATTATTTTCG (SEQ ID NO:43)

CMA-EF2: CCGCACGGTTTTGACACGCACGTTTC (SEQ ID NO:44)

CMA-EF3: CCGGCCAAGAAACGTACGTCTGGAAC (SEQ ID NO:45)

EXAMPLE 2Reconstruction of the Ryanodine Receptor Isolated Nucleic Acid Fragment From  
Green Peach Aphid

5 Total RNA was extracted from 0.5g of green peach aphid (*Myzus persicae*) or  
any Homopteran species flash frozen in liquid N<sub>2</sub> and ground to a powder in a  
chilled mortar. The powder was extracted with 20 ml of TriZOL<sup>®</sup> by vigorous  
shaking for 15 s and then incubation of the sample at 30C for 3 min. Two ml of  
chloroform was added and the shaking and incubation treatment repeated. The  
10 sample was spun at 12,000 g for 10 min at 8 C and the aqueous phase transferred  
to a fresh tube. 5 ml of isopropyl alcohol and 5 ml of 0.8 M sodium citrate  
containing 1.2 M NaCl was mixed with the aqueous fraction and after 10 min at  
room temperature the sample was centrifuged a second time. The pellet was  
washed with 10 ml of 70% EtOH, the suspension recentrifuged at 7500g for 5 min  
and the resulting pellet allowed to dry before dissolving in 2 ml water.

15 The same combination of the 'D' set of forward and reverse primers that  
successfully produced the 5'- sequences of the tobacco budworm gene were used  
as described before. A second set of primers to acquire most of the 3' region were  
also designed from regions of high homology for all the known ryanodine receptor  
sequences.

20 E-F1 GGAGGTGGNATHGGNGAYGA (SEQ ID NO:27)  
E-F2 ATCATCGAYGCNTTYGGNGA (SEQ ID NO:28)  
E-R1 AARCARTCNCCNACNGGRAA (SEQ ID NO:29)  
E-R2 ACNGGRAARAARTCCCARCA (SEQ ID NO:30)

25 The bands generated using the D-F and D-R combinations as well as the E-F  
and E-R combinations produced sequence consistent with their expected origin as  
segments of the receptor isolated nucleic acid fragment. The remaining sequences  
for the extreme 5' and 3'-ends were obtained using RACE procedures as described  
in Example 1 employing the following 5' RACE primers

30 F-R1: CCCTCTTGAGAACTTGCAGCTGTCAC (SEQ ID NO:31)  
F-R2: CGTCCGGTGTCCAGATCCAGTTCCGCC (SEQ ID NO:32)  
F-R3: GATGAACAGTCCACCAACAAGCTTCAC (SEQ ID NO:33)  
and 3' RACE primers  
G-F1: GCTGGAAAGCGTCAAGGAAGACATGG (SEQ ID NO:34)  
35 G-F2: GCGGTATCGGCAAAGATTATTTTCGAC (SEQ ID NO:35)  
G-F3: GTGCCGCATGGTTTCGACACTCAG (SEQ ID NO:36)

The sequences of the RACE products were used to design primers to  
incorporate the PmeI and PaeI unique restriction sites outside the starting and stop

segment missing was the starting 24 bases of the 5'-region. To obtain this section and complete the gene, a 5' RACE procedure was used as described by Clontech™ in their Marathon® Amplification kit.

WL3: CACACACTGCGACAGATCAGGCGG (SEQ ID NO:23)

5 WL4: GCAATATTCTCCAGGAAGCAGTGCCG (SEQ ID NO:24)

Based on this full-length sequence, new primers were designed:

pHVN3-PacI: GCCAAGTTAATTAACCATGGCGGAAGCAGAGGGGGGAG (SEQ ID NO:25)

pRhC1-PmeI: GGACTCGTTTAAACGATTCTCCCATGAGGTCTTCGTATTGC (SEQ ID NO:26)

10 These primers were used for long PCR reactions following the protocol in the Expand Long Template PCR System® kit supplied by Roche™. A two stage PCR protocol was used that first used the following reaction conditions 94°C for 5 minutes and then 10 cycles of 10 sec at 92°C followed by 68°C for 14 min. The next stage was 15 cycles of 10 sec at 92°C, followed by 68°C for 14 min with each cycle  
15 incremented by 20 sec producing the full-length isolated nucleic acid fragment with PacI and PmeI unique restriction sites at the 5' and 3' ends respectively.

A 15.6 Kb DNA fragment was cloned into a pCR-XL-TOPO® vector of Invitrogen™. The complete sequence for *H. virescens* Ryr transcript was obtained by standard sequencing method using plasmid and PCR products.

20 Sequences for cDNAs encoding ryanodine receptor proteins can also be identified by conducting BLAST searches. (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410) searches for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven  
25 Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm provided by the National Center for Biotechnology Information (NCBI). The DNA sequences were  
30 translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish and States (1993) *Nat. Genet.* 3:266-272) provided by the NCBI. For convenience, the P-value (probability) of observing a match of a cDNA sequence to a sequence contained in the searched databases merely by chance as calculated  
35 by BLAST are reported herein as "pLog" values, which represent the negative of the logarithm of the reported P-value. Accordingly, the greater the pLog value, the greater the likelihood that the cDNA sequence and the BLAST "hit" represent homologous proteins.



*Caenorhabditis elegans*, as well as comparison with other mammalian species, the following degenerate primers were designed and synthesized for this purpose:

A-F1: CCTGARGCNYTNAAYATGAT (SEQ ID NO:11)

A-F2: GATCCTAARGTNYTNGAYGT (SEQ ID NO:12)

5 A-F3: AAGTGGTAYTTYGARTTYGA (SEQ ID NO:13)

A-R1: TCGAAYTCRAARTACCAYTTNCC (SEQ ID NO:14)

A-R2: AATGGYTCTANCCYTCYTG (SEQ ID NO:15)

The 'A' designated primers cover a region of the sequence approximately 1722 nucleotides to 3702 nucleotides from the 5'-end (SEQ ID NO:1). All combinations of forward and reverse primers were used to amplify this putative region of the gene. PCR was carried out using 4  $\mu$ M of each of the primers, dNTPs (200  $\mu$ M), with 1  $\mu$ l cDNAs and subjected to 35 cycles of PCR. The PCR conditions were 94°C for 15 sec, 45°C for 30 sec and 72°C for 1 min. The primer combinations that produced a fragment of the expected size were A-F2/A-R2 and A-F3/A-R2. The amplified bands were purified from a 1.5% agarose gel and subcloned into a pDrive® TA cloning vector (Qiagen™) following standard protocols supplied with the kit. Subsequent sequencing of the PCR product confirmed that this region of the gene between nucleotides 1722 to 3702 (SEQ ID NO:1) had been successfully located when compared to the *Drosophila* sequence.

20 A similar approach was used to identify a region of the gene close to the extreme 5'-end between nucleotides 27 and 1443.

D-F1: GAGCAGGAYGAYGTNWSNTT (SEQ ID NO:16)

D-F2: GCTGCTGARGGNTTYGGNAA (SEQ ID NO:17)

D-F3: GGTGARGCNTGYTGGTGGAC (SEQ ID NO:18)

25 D-R1: GTCCACCARCANGCYTCNCC (SEQ ID NO:19)

D-R2: ACTCKTACYTTYTCNCCYTC (SEQ ID NO:20)

D-R3: GGTATTGTTARRCAYTCRTC (SEQ ID NO:21)

D-R4: TTTAGTACNCCYTCYTCYTGRAA (SEQ ID NO:22)

Nearly all combinations of forward and reverse primers were involved in the initial round of amplification and putative PCR products were immediately subjected to a second, or 'nested' round of amplification. In this case 1/100<sup>th</sup> volume of the product of the first round was used as a template along with the same cycling conditions. Using this approach it was found that D-F1/D-R3, nested with D-F1/D-R2; D-F2/D-R3 followed by D-F3/D-R3 and D-F2/D-R4 followed by D-F3/D-R3 produced bands of the expected size on an agarose gel. The bands were isolated and their sequence compared to the *Drosophila* sequence.

These regions of sequence indicate that more than 99% of the isolated nucleic acid fragment could be recovered from the cDNA preparation and the only

channel wherein said isolated nucleic acid fragment also comprises an intron which interferes with expression of the toxic insect ion channel.

### EXAMPLES

The present invention is further defined in the following Examples, in which parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

The disclosure of each reference set forth herein is incorporated herein by reference in its entirety.

#### EXAMPLE 1

##### Isolation of Ryanodine Receptor Nucleic Acid Fragment From Tobacco Budworm

Total RNA was extracted from 2g of 4<sup>th</sup> and 5<sup>th</sup> instar tobacco budworm larvae that had been flash frozen in liquid N<sub>2</sub> and ground to a powder in a chilled mortar. The powder was extracted with 20 ml of TriZOL™ by vigorous shaking for 15 s and then incubation of the sample at 30°C for 3 min. Two ml of chloroform was added and the shaking and incubation treatment repeated. The sample was spun at 12,000 g for 10 min at 8°C and the aqueous phase transferred to a fresh tube. 5 ml of isopropyl alcohol and 5 ml of 0.8 M sodium citrate containing 1.2 M NaCl was mixed with the aqueous fraction and after 10 min at room temperature the sample was centrifuged a second time. The pellet was washed with 10 ml of 70% EtOH, the suspension recentrifuged at 7500g for 5 min and the resulting pellet allowed to dry before dissolving in 2 ml water. OligoT primed cDNA synthesis used this total RNA as template and following the protocols that accompanied the cDNA synthesis kit purchased from Invitrogen™.

The isolated nucleic acid fragment encoding the tobacco budworm ryanodine receptor was cloned using a PCR based protocol (SEQ ID NO:1). Only the last 4056 bases of the 3'-end of the coding region is available from public databases.

To acquire the complete transcript meant designing oligonucleotide primers for regions of the transcript as close to the 5'-end as feasible. From an analysis of DNA sequence similarities of the receptor from *Drosophila melanogaster* and

Yet a further embodiment of the present invention would be a method for expressing an isolated nucleic acid fragment encoding a toxic insect ion channel comprising:

5 a) transforming a host with a recombinant construct comprising in the 5' to 3' direction a promoter operably linked to the toxic insect ion channel nucleic acid, wherein the promoter comprises a transcription termination nucleic acid fragment, and/or an in-frame translation stop codon, situated between said promoter and the isolated nucleic acid fragment encoding the toxic insect ion channel, and further wherein the transcription termination nucleic acid fragment, and/or an in-frame translation stop codon, is flanked on each end by at least one nucleic acid sequence consisting essentially of excisable sequences; and

10 b) growing the transformed host under conditions that are suitable for the expression of the recombinant construct. The excisable sequences may be any sequences recognized by recombinase enzymes, such as but not limited to, lox sites.

A related embodiment of the present would encompass the recombinant constructs themselves comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding a toxic insect ion channel, wherein the promoter comprises a transcription termination nucleic acid fragment, and/or at least one in-frame translational termination codon, situated between said promoter and the isolated nucleic acid fragment encoding the toxic insect ion channel, and further wherein the transcription termination nucleic acid fragment, and/or at least one in-frame translational termination codon, is flanked on each end by at least one nucleic acid sequence consisting essentially of excisable sequences. The excisable sequences may be any sequences recognized by recombinase enzymes, such as but not limited to, lox sites.

Another embodiment of the present invention would be a method for expressing an isolated nucleic acid fragment encoding a toxic insect ion channel comprising:

30 a) transforming a host with a recombinant expression construct comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding the toxic insect ion channel, wherein said fragment also comprises an intron which interferes with expression of said fragment, and

35 b) growing the transformed host under conditions that are suitable for the expression of the recombinant construct.

In still another embodiment, the present invention would encompass a recombinant expression construct comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding a toxic insect ion

In a further embodiment, this invention concerns a method for evaluating at least one compound which modulates ryanodine receptor activity, the method comprising the steps of:

5 (a) contacting at least one compound with a polypeptide encoded by any one of the aforementioned isolated nucleic acid fragments; and

(b) evaluating the ryanodine receptor activity of the polypeptide of (a) after said polypeptide has been contacted with the compound or compounds.

10 This method wherein the method can be, but is not limited to, a ligand binding assay. Furthermore, this method can be useful wherein the polypeptide is contacted with more than one compound.

Insect specific sequences can be identified by finding homologous subsequences that are conserved between all of the insect sequences but not among the non-insect sequences. A number of these sequences can be found in SEQ ID NOs:63-119. Prior to the characterization of the sequences presented  
15 herein insect specific sequences could not be identified since the fruitfly sequence was the only insect sequence available and this had very low (less than 50%) homology to the animal ryanodine receptor sequences.

A further embodiment of the present invention would be an isolated nucleic acid fragment encoding an insect ion channel comprising at least two polypeptide  
20 sequences set forth in any of SEQ ID NOs:63-119 provided that said polypeptide sequences do not comprise any of SEQ ID NOs:56, 120-126.

Yet another embodiment would be a method for identifying a nucleic acid sequence encoding an insect ion channel comprising:

25 a) obtaining an isolated nucleic acid sequence encoding a first polypeptide having at least 100 amino acids;

b) comparing the first polypeptide sequence with a comparative polypeptide sequence selected from the group consisting of SEQ ID NOs:63-119 to identify a region between the first polypeptide and the comparative polypeptide having 100% sequence identity wherein said region is as long as the comparative  
30 polypeptide; and

c) repeating step (b) with a different comparative polypeptide sequence, wherein said different comparative polypeptide sequence is selected from the group consisting of SEQ ID NOs:63-119 until a second region having 100% sequence identity is found, wherein said second region is as long as the different comparative  
35 polypeptide. The method could be further characterized by the length of the first polypeptide having a length of from 100 to 6,000 amino acids.

Genome Analysis: Detecting Genes, 1, Cold Spring Harbor, New York (1998); Birren et al., Genome Analysis: Analyzing DNA, 2, Cold Spring Harbor, New York (1998); Plant Molecular Biology: A Laboratory Manual, eds. Clark, Springer, New York (1997)).

5 In a still further aspect this invention concerns a method to isolate nucleic acid fragments encoding ryanodine receptors and related polypeptides, comprising:

(a) comparing SEQ ID NO:2, 4, 6, 8, 10, 128, 130, 144, and 146 and other ion channel and receptor polypeptide sequences;

(b) identifying the conserved sequences of 4 or more amino acids

10 obtained in step a;

(c) designing degenerate oligomers based on the conserved sequences identified in step b; and

(d) using the degenerate oligomers of step c to isolate sequences encoding polypeptides having ryanodine receptor activity by sequence dependent protocols.

15 In another aspect, this invention concerns an isolated polypeptide having ryanodine receptor activity, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10, 128, 130, 144, and 146 have at least 75%, 80%, 85%, 90%, 95%, or 100% identity. One skilled in the art would

20 realize that any integer percent identity from 75% to 100% would be useful in identifying ryanodine receptor-like polypeptide sequences.

In another embodiment, this invention concerns a method for evaluating at least one compound for its ability to modulate calcium homeostasis, the method comprising the steps of:

25 (a) transforming a host cell with any one of the aforementioned recombinant constructs, or any recombinant construct containing any one of SEQ ID NOs:56-62;

(b) growing the transformed host cell under conditions that are suitable for expression of the recombinant construct wherein expression of the recombinant

30 construct results in altered calcium homeostasis;

(c) treating the transformed host cell of step (a) with a compound to be tested; and

(d) determining changes in intracellular calcium homeostasis by the test compound in order to select compounds with potential for altering calcium release.

35 This method wherein the method can be, but is not limited to, a ligand binding assay. Furthermore, this method can be based on assessing functional activity by detecting the effect of a compound on the functional activity of the transformed host cell or ion channels obtained from such cells.

constitutively or in response to defined conditions. Selection of those cells expressing the recombinant receptor would be identified by their perturbation of ryanodine receptor function detected through changes in calcium dependent fluorescence (see Example 9 for details), or ion channel conductance, and these  
5 used for screening purposes or for further investigation of the components that are involved in calcium homeostasis and signalling. The cells would also be a source of the functional receptor for further biochemical work. Results from such work would include, but not be limited to, fractionation and purification of the protein, subfragment analysis for binding domain characterization, swapping of domains  
10 encoding regions from different ryanodine receptors to form chimeric receptor proteins, mutagenesis of the receptor to isolate isoforms that have altered ion channel activity, and mutagenesis of the receptor to isolate isoforms that have altered ryanodine or GN binding.

In another aspect, this invention concerns an isolated nucleotide fragment  
15 selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 127, 129, 143, and 145. Also, of interest is the complement of this isolated nucleotide fragment.

In still another aspect, this invention concerns recombinant DNA constructs comprising any of the above-identified isolated nucleic acid fragments or complements thereof or parts of such fragments or complements operably linked to  
20 at least one regulatory sequence. These recombinant DNA constructs are useful for the purpose of over-expression, antisense inhibition, or co-suppression of ryanodine receptor activity in a transformed host cell.

Also, of interest are eukaryotic or prokaryotic host cells comprising such chimeric constructs in their genome. Useful host cells include, but are not limited to,  
25 E.coli, yeast, Sf9, Sf21, S2, Xenopus oocytes, HEK293, and CHO.

The cDNAs encoding the instant polypeptides may be introduced into the baculovirus genome itself, using standard methods of cloning and transformation (see Example 5 for details). The *Spodoptera frugiperda* cell lines Sf9, Sf21, or the *Drosophila* S2 cell lines can be used for transfection studies. The supernatant fluid  
30 from co-transfection experiments may be used to isolate recombinant virus and/or expressed protein (see Example 5).

In addition to the above discussed procedures, those skilled in the art are familiar with the standard resource materials which describe specific conditions and procedures for the construction, manipulation and isolation of macromolecules (e.g.,  
35 DNA molecules, plasmids, etc.), generation of recombinant organisms and the screening and isolating of clones, (see for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989); Maliga et al., Methods in Plant Molecular Biology, Cold Spring Harbor Press (1995); Birren et al.,

post-translational modification or for altering the interactions of the receptor and ion channel with its membrane, secondary messengers, or attendant proteins also involved, directly or indirectly in calcium homeostasis. Fusion of the nucleic acid fragment with other ORFs that encode reporter proteins e.g. GFP, luciferase have application for assisting in localization of the gene product in the cell, or for assessing production of the receptor. In another example, domains of beta-galactosidase can be fused to different proteins suspected of interacting with the receptor. The interaction between the receptor and the fusion protein can then be investigated using the beta-galactosidase activity as an assayable reporter.

RNA transcribed from the native gene or any variant, chimeras, precursors either in vivo or in vitro would be useful in a number of applications e.g. in vitro translation to produce the mature protein, a precursor or sub-fragments to study further the function in calcium homeostasis and cell signaling. Sub-fragments of the protein generated in vitro could have utility for producing antibodies (Chen et al (1993) *J Biol Chem* 268:13414-21) or biochemical analysis to identify ligand or attendant protein binding sites (Callaway et al (1994) *J Biol Chem* 269:15876-84).

The sequence of the protein is valuable for designing antibodies that are either specific for a particular variant of the receptor or alternatively using those areas of homology, generally cross react with many forms of the receptor. An additional use of the protein sequence is to identify regions that are susceptible to digestion by specific proteases. Digestion of the protein into subfragments with or without bound molecules would allow the sites where these molecules bind to be mapped. Understanding the nature of the receptor binding sites of small organic molecules could be used to apply a number of different computational modeling approaches to design other small molecules that target the same site and may have other desired biological and ecotoxicological activities and attributes.

Receptor isolated from any source may be post-translationally modified, processed, proteolytically cleaved to form sub-fragments that are separate or still associated with the body of the protein and still be functional. Because the genomic DNA is likely to be composed of multiple exons and introns there is a possibility of one gene producing different receptor-ion channel types due to alternate spliced versions of the messenger RNA. These different subtypes may have different functional properties in calcium homeostasis.

The isolated nucleic acid fragment or its variants may be cloned into any suitable vector, such as, but not limited to, plasmids, virus or binary vectors for infection purposes. The isolated nucleic acid fragment could be coupled to a multiplicity of promoter sequences that allow transcription and translation in the relevant bacterial, yeast, plant, oocyte, insect, or mammalian cell hosts either

There are many ways that a nucleic acid fragment encoding a ryanodine receptor might be used once it has been first isolated and then cloned into a suitable vector. Methods for isolating such nucleic acid fragments include, but are not limited to, isolating the RNA from cells that are known to express the native Ryr protein. In this case the tissue source was from lepidopteran and homopteran pests. Other pests might include, but are not limited to, all those from the invertebrate kingdom and parasitic pathogens, e.g. those causing animal health problems or considered household pests. Examples of such pests include but are not restricted to, fleas, ticks, roaches, mosquitos, nematodes, Plasmodium falciparum, sheep blowfly.

RNA could then be used, if enough DNA sequence were available to design and synthesize oligonucleotide primers and then those skilled in the art use these primers to generate DNA by RT PCR. The sequence of the DNA is therefore valuable for allowing primers to be designed that will allow the receptor gene to be isolated from a wide range of other invertebrates. The gene might be generated in toto if the primers are designed from the extreme 5'- and 3'- regions of the gene. Alternatively, the gene might be built from a number of sub-fragments isolated after RT PCR of internal regions of the gene. In this case acquiring regions at the extreme ends of the gene may be challenging and then procedures like 5'-RACE or inverse PCR may need to be employed. The RNA could be total or fractionated material to enrich some specific type such as mRNA. The RNA might be generally expressed and amplified in a number of ways to generate e.g. a cDNA library, or variant of library production that would capture all versions of the gene, if more than one exists.

Alternatively the isolated nucleic acid fragment of the invention could be extracted from complete cells, cell lysates sub-cellular components and purified from other cellular material. In the case of nuclear material, the nucleic acid fragment will be genomic and thus likely to contain many introns which may offer the ability to provide alternative sequence arrangements and thus different variants of the functional protein. This nucleic acid fragment might be used to generate a BAC, cosmid, fosmid or other variation of a genomic library to ensure all variants of the exons and introns of the gene are available.

The nucleic acid fragment coding for the native gene, chimeric or mutagenic variants or subfragments thereof might also be synthesized chemically using the known sequence as offered by a number of commercial enterprises.

Sequences of other utility outside the ORF (open reading frame) or internal to the ORF might also be considered, such as specific promoters for transcription control, precursor sequences for targeting to particular cellular compartments, or for



may be Fab-type fragments which are defined as fragments devoid of the Fc portion, e.g., Fab, Fab' and F(ab')<sub>2</sub> fragments, or may be so-called "half-molecule" fragments obtained by reductive cleavage of the disulfide bonds connecting the heavy chain components of the intact antibody. If the antigen member of the specific binding pair is not immunogenic, e.g., a hapten, it can be covalently coupled to a carrier protein to render it immunogenic.

Non-immune binding pairs include systems wherein the two components share a natural affinity for each other but are not antibodies. Exemplary non-immune binding pairs are biotin-avidin or biotin-streptavidin, folic acid-folate binding protein, complementary nucleic acid probes, etc. Also included are non-immune binding pairs which form a covalent bond with each other. Exemplary covalent binding pairs include sulfhydryl reactive groups such as maleimides and haloacetyl derivatives and amine reactive groups such as isothiocyanates, succinimidyl esters, sulfonyl halides and coupler dyes such as 3-methyl-2-benzothiazolinone hydrazone (MBTH) and 3-(dimethyl-amino)benzoic acid (DMAB), etc.

Suitable supports used in assays include, but are not limited to, synthetic polymer supports such as polystyrene, polypropylene, substituted polystyrene. E.g., aminated or carboxylated polystyrene; polyacrylamides; polyamides; polyvinylchloride, etc.; glass beads; agarose; nitrocellulose; nylon; polyvinylidenedifluoride; surface-modified nylon, etc.

One further example of an affinity tag is a photoaffinity label that is an analog of a tight binding modulator or effector and might be used to covalently label residues of the receptor that compose the binding site of the effector. The small analog not only has been altered to covalently modify the protein using light irradiation to activate the affinity moiety but also carries a radioactive label for further convenient identification of the region of the receptor that has been modified. Further analysis of the labeled receptor or peptide fragments that carry the modified residues can lead to identifying the region of the protein that comprises the analog binding site.

Functional assays for the identification of low molecular weight compounds and natural products that modulate calcium homeostasis through their action on the receptor directly, or through their effect on attendant proteins involved in the process of calcium signaling have been developed (Mackrill et al. (1999) *Biochem J* 337:345-361). Additional methods include, but are not limited to, planar lipid bilayer recording, and imaging and fluorometric monitoring of in situ calcium concentration changes (Brillantes et al. (1994) *Cell* 77:513-523; Mack et al. (1994) *J Biol Chem* 269:23236-23249; Chen et al. (1999) *J Biol Chem* 274:32603-32612; Rodney et al. (2001) *Biochemistry* 40:12430-12435)

useful alternatives. Alternatively, preparations can be assessed based on the quantity of functional receptor per unit weight of tissue determined from the amount of radiolabelled ligand that is bound.

Unfortunately tissue samples are not available from all pests of interest in quantities necessary for effective screening or analysis. Therefore, a significant advantage of working with recombinant material is the ability to express a single variant of any gene in many cellular types and backgrounds and thus produce homogeneous experimental preparations in relatively controlled amounts depending on the choice of promoter. A further advantage is that species specific receptors often have unique binding sites, thus a recombinant system offers flexibility in terms of which source of the gene is chosen for expression. This provides a means of comparative analysis of the response of the system in various pre-selected conditions.

Pest receptors in enough quantities from any of these sources, would form the basis of assays that have utility for identifying other synthetic compounds or natural ligands that have the same mode of action. In the case of an assay based on monitoring of intracellular calcium concentration, modulators that cause activation of the ion channel or its blockage can be identified. A binding assay can be used to identify those modulators that interact with the receptor or ion channel at the specific site where the labeled analog binds or at allosteric sites which alter the binding of the analog.

In binding assays one partner molecule is immobilized and the other is labeled in some fashion (e.g. using a nonradioactive label such as an enzyme or fluorescent tag or by using a radioactive label) and added free in solution. After incubation to allow molecular interaction, and a wash step, the amount of ligand bound is measured using an appropriate detection system. Ligands showing significant binding may then be studied further by ensuring that the protein is in excess, and carrying out experiments with a dilution series of the ligand at a set of known concentrations, typically from  $10^{-2}$  to  $10^{-10}$ M.

Proteins may be immobilized using an epitope or other affinity tag on a support material to which an appropriate antibody or binding agent for the tag is attached. For example, members of specific binding pairs can be of the immune or non-immune type. Immune specific binding pairs are exemplified by antigen/antibody systems or hapten/antihapten systems. The antibody member, whether polyclonal or monoclonal or an immunoreactive fragment thereof, of the binding pair can be produced by customary methods familiar to those skilled in the art. The terms immunoreactive antibody fragment or immunoreactive fragment mean fragments which contain the binding region of the antibody. Such fragments

ryanodine by opening calcium release channels. This channel activation leads to depletion of calcium stores whereas ryanodine acts by locking channels in a sub-conductance state. The binding site of these "GN" molecules has also been found to be different than that of ryanodine. Nonetheless, the ability of these molecules to release calcium stores in recombinant cell lines expressing insect ryanodine receptors, as shown in Figures 3 and 4, but not in control cell lines lacking these ryanodine receptors, lends further support that the ryanodine receptor protein itself is the binding site of "GN" chemistry.

Based on the effects of this structural class of compounds it is clear that the ryanodine receptor is a valuable biochemical target for the discovery of new pesticides. Like other insect ion channels and receptors, there are potentially multiple binding sites on the protein that could influence the functional properties of the channel-receptor and thus cellular calcium balance. In addition to small molecule binding sites, numerous proteins interact with the receptor on both sides and within the reticulum membrane ( see Mackrill, (1999) *Biochem. J.* 337: 345-361 for a review). Compounds found to interfere with these interactions could also be useful as pesticides.

The Ryr gene from invertebrates is expressed widely in all muscle types and in neurones and so accessibility to active compounds would be expected.

Symptomology of the mode of action of the anthranilamides is consistent with a direct effect of these compounds on all the muscle cells of the insect, skeletal, smooth and cardiac. Fluorescence imaging analysis of roach neuronal cells or binding studies using roach leg muscle indicates that there is a close correlation between calcium influx in neurons, or binding to leg muscle preparations, and the activity of these compounds in insect pest screens.

Tissue preparations from muscle and neuronal cells are thus sources of the insect receptor for isolation and binding studies. Selection of the most appropriate cells can be achieved using, e.g. the binding affinity of a radiolabeled analog of the chemistry being investigated or radiolabeled ryanodine, which is commercially available. Binding studies using radioactive ryanodine and GN analogs are presented in Example 9. This might be determined in a number of ways, which could include but not be limited to the fate of a radiolabeled analog during receptor preparation, or monitoring a specific spectroscopic characteristic of the analog or its derivative. Quality of preparations might be assessed based on the intensities of fluorescence from calcium flux induced by specific receptor modulators, such as caffeine, as detected using calcium specific fluorescence indicators. Examples of indicators useful for monitoring changes in intracellular calcium include FURA-2, Fluo-3, and Fluo-4 but other compounds exist that are well known and would be

"Modulation" as used herein refers to the alteration of the function of activity of the protein, in this case, alteration of calcium homeostasis or as mentioned below, alteration of ryanodine receptor activity.

In still a further embodiment, this invention concerns a method for evaluating at least one compound which modulates ryanodine receptor activity, the method comprising the steps of:

(a) contacting at least one compound with a polypeptide encoded by an isolated nucleic acid fragment of the invention; and

(b) evaluating the ryanodine receptor activity of the polypeptide of (a) after said polypeptide has been contacted with the compound or compounds.

The ryanodine receptor from a variety of species is functional as a homotetramer of subunits each one being about 0.5MDa in size. The C-terminal 20% of the protein forms the membrane spanning region that constitutes the channel through which calcium ions flow into the cytosolic milieu from internal calcium stores (Bhat et al. (1997), *Biophys J* 73:1329-36). The remaining 80% of the protein on the cytosolic side of the membrane interacts with a number of other proteins and cellular low molecular weight components. The effects of these components is to modulate calcium flow by favoring the 'open' or 'closed' state of the channel thus the release of calcium and the balance of the ion in the cytosol relative to internal stores.

The effect of interfering with the calcium balance particularly in muscle tissue is to disrupt the normal processes involved in contraction and relaxation, i.e. excitation-contraction coupling (ECC). For example, mutations in the human cardiac ryanodine type 2 receptor have been implicated in sudden cardiac arrest syndrome (Marks et al (2000) *Cell* 101:365-76) and malignant hypothermia (Tong et al (1997) *J Biol Chem* 272:26322-26326).

While ryanodine has been used as a natural insect control agent, the structural complexity of the compound has prevented significant commercialization. It would be desirable to identify easily synthesized small compounds, possessing insecticidal activity, that stimulate the release of internal calcium stores via interaction with the ryanodine receptor complex.

Other small molecules that have been found to interact with the ryanodine receptor are those based on an anthranilamide structure. Examples of these molecules termed "GN analog" compounds are shown in Figure 2 and their use is outlined in Examples 9 and 11. It is envisioned that many types of chemistry and derivatives may be useful in altering the function of the ryanodine receptor complex. While the overall effect on the organism is comparable to that of ryanodine, namely lethargy and paralysis, these other molecules differ in their mode of action from

The isolated nucleic acid fragment encoding a ryanodine receptor which is modulated by ryanodine alkaloids and anthranilamide insecticides has been isolated from the lepidopteran, tobacco budworm (*Heliothis virescens*, five isoforms) and three homopteran insects, cotton melon aphid (*Aphis gossypii*) corn plant hopper (*Peregrinus maidis*) green peach aphid (*Myzus persicae*), and fruit fly (*Drosophila melanogaster*). Heretofore, the full-length nucleic acid sequence or amino acid sequence of the ryanodine receptor from tobacco budworm, a lepidopteran pest species, was not known, nor that there are at least two variants of these nucleic acid sequences. Examples of homopteran sequences from cotton melon aphid, corn plant hopper, and green peach aphid were also unknown previous to the disclosure in the present invention. The fruit fly sequence is a new variant that differs from all previously disclosed nucleic acid sequences encoding a *Drosophila* ryanodine receptor.

Nucleic acid fragments were isolated from these pest species using PCR and their DNA and amino acid sequence as described below in the Examples. The use of these genes for the development of assays to screen for other insecticides with similar modes of action is described. Use of the isolated nucleic acid fragments, subfragments thereof or the polypeptide encoded by these fragments for insecticidal applications is also disclosed.

The isolated nucleic acid fragments can be expressed in cells to provide a functioning ryanodine receptor that responds to the presence or absence of modulators of calcium homeostasis. This would provide a basis to screen for compounds that activate the release of internal calcium stores, block their release or like ryanodine, hold the ion channel in an open configuration at particular concentrations, yet block the channel at elevated concentrations.

Thus, in another embodiment the present invention concerns a method for evaluating at least one compound for its ability to modulate calcium homeostasis, the method comprising the steps of:

(a) transforming a host cell with a recombinant construct as described herein;

(b) growing the transformed host cell under conditions that are suitable for expression of the recombinant construct wherein expression of the recombinant construct results in altered calcium homeostasis;

(c) treating the transformed host cell of step (a) with a compound to be tested; and

(d) determining changes in intracellular calcium homeostasis by the test compound in order to select compounds with potential for altering calcium release.

218:78-86), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

5       The term "ryanodine receptor" as used herein refers to an internal calcium (Ca or Ca<sup>++</sup>) release channel-receptor associated with the endoplasmic/sarcoplasmic reticulum. While these channels are known to exhibit selectivity for calcium ions, other cations such as, but not limited to, potassium can permeate through these channels. The terms "ryanodine receptor", "ion channel  
10 receptor", "ion channel", and "ryanodine-like receptor" are meant to encompass the family of ion-channel membrane proteins of the present invention. The terms are used interchangeably herein. The ryanodine receptor does not necessarily require ryanodine binding activity to serve as an ion channel. Functional ion channels with the characteristics described in the present invention are claimed even when the  
15 binding of ryanodine or other compounds may be altered due to amino acid changes in the protein sequence. The binding of other non-ryanodine compounds by the ryanodine receptor may occur at the same, or different, regions of the ryanodine receptor.

20       The term "toxic nucleic acid fragment", "toxic ryanodine receptor nucleic acid fragment", or "toxic insect ion channel" refers to an isolated nucleic acid fragment or subfragment thereof which when present in an organism causes the growth and/or survival of the organism to be compromised. Toxicity may be due to the isolated nucleic acid fragment itself, an RNA that is transcribed from the isolated nucleic acid fragment or a protein which is translated from an RNA derived from the isolated  
25 nucleic acid fragment. The growth defect caused by the gene may be alleviated by a mutation within the isolated nucleic acid fragment or subfragment thereof that modifies that part of the gene that causes the toxicity. In this case, growth impairment may be entirely relieved, but the original gene is still considered toxic because growth impairment was only relieved by the modification of the isolated  
30 nucleic acid fragment.

35       The present invention relates to an isolated nucleotide fragment comprising: a nucleic acid sequence encoding a ryanodine receptor having an amino acid sequence identity of at least 75% when compared to a polypeptide selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, 128, 130, 144, and 146; or the complement thereof.

      In a preferred embodiment, the amino acid sequence identity can be at least 80%, 85%, 90%, 95% or 100% or any integer percentage from 80% to 100%.

"PCR" or "Polymerase Chain Reaction" is a technique for the synthesis of large quantities of specific DNA segments, consists of a series of repetitive cycles (Perkin Elmer Cetus Instruments, Norwalk, CT). Typically, the double stranded DNA is heat denatured, the two primers complementary to the 3' boundaries of the target segment are annealed at low temperature and then extended at an intermediate temperature. One set of these three consecutive steps is referred to as a cycle.

Polymerase chain reaction ("PCR") is a powerful technique used to amplify DNA millions of fold, by repeated replication of a template, in a short period of time. (Mullis et al, *Cold Spring Harbor Symp. Quant. Biol.* 51:263-273 (1986); Erlich et al, European Patent Application 50,424; European Patent Application 84,796; European Patent Application 258,017, European Patent Application 237,362; Mullis, European Patent Application 201,184, Mullis et al U.S. Patent No. 4,683,202; Erlich, U.S. Patent No. 4,582,788; and Saiki et al, U.S. Patent No. 4,683,194). The process utilizes sets of specific in vitro synthesized oligonucleotides to prime DNA synthesis.

The design of the primers is dependent upon the sequences of DNA that are desired to be analyzed. The technique is carried out through many cycles (usually 20-50) of melting the template at high temperature, allowing the primers to anneal to complementary sequences within the template and then replicating the template with DNA polymerase.

The products of PCR reactions are analyzed by separation in agarose gels followed by ethidium bromide staining and visualization with UV transillumination. Alternatively, radioactive dNTPs can be added to the PCR in order to incorporate label into the products. In this case the products of PCR are visualized by exposure of the gel to x-ray film. The added advantage of radiolabeling PCR products is that the levels of individual amplification products can be quantitated.

The terms "recombinant construct", "expression construct" and "recombinant expression construct" are used interchangeably herein. These terms refer to a functional unit of genetic material that can be inserted into the genome of a cell using standard methodology well known to one skilled in the art. Such construct may be itself or may be used in conjunction with a vector. If a vector is used then the choice of vector is dependent upon the method that will be used to transform host plants as is well known to those skilled in the art. For example, a plasmid vector can be used. The skilled artisan is well aware of the genetic elements that must be present on the vector in order to successfully transform, select and propagate host cells comprising any of the isolated nucleic acid fragments of the invention. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al., (1985) *EMBO J.* 4:2411-2418; De Almeida et al., (1989) *Mol. Gen. Genetics*

of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

"Motifs" , "subsequences" or "segment" refer to short regions of conserved sequences of nucleic acids or amino acids that comprise part of a longer sequence. For example, it is expected that such conserved subsequences would be important for function, and could be used to identify new homologues of ryanodine receptors. It is expected that some or all of the elements may be found in a putative ryanodine receptor. Also, it is expected that one or two of the conserved amino acids in any given motif may differ in a true ryanodine receptor.

The term "homologous subsequence" used herein is meant to indicated two sequences that have 100% identity and co-linearity without gaps when aligned.

"Stable transformation" refers to the transfer of a nucleic acid fragment into a genome of a host organism, including both nuclear and organellar genomes, resulting in genetically stable inheritance. In contrast, "transient transformation" refers to the transfer of a nucleic acid fragment into the nucleus, or DNA-containing organelle, of a host organism resulting in gene expression without integration or stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" organisms. The preferred method of cell transformation of rice, corn and other monocots is the use of particle-accelerated or "gene gun" transformation technology (Klein et al., (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050), or an *Agrobacterium*-mediated method using an appropriate Ti plasmid containing the transgene (Ishida Y. et al., 1996, *Nature Biotech.* 14:745-750). The term "transformation" as used herein refers to both stable transformation and transient transformation.

The term "host cell" refers to any cell or organism into which an isolated nucleic acid fragment has been stably or transiently introduced. The host cell may be part of a larger organism, an individual in tissue culture, or a free-living organism. Examples of host cells include, but are not limited to, bacteria, fungi, insect, plant, and animal.

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook, J., Fritsch, E.F. and Maniatis, T. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter "Sambrook").

The term "recombinant" refers to an artificial combination of two otherwise separated segments of sequence, e.g., by chemical synthesis or by the manipulation of isolated segments of nucleic acids by genetic engineering techniques.



The term "expression", as used herein, refers to the production of a functional end-product. Expression of a gene involves transcription of the gene and translation of the mRNA into a precursor or mature protein. "Antisense inhibition" refers to the production of antisense RNA transcripts capable of suppressing the expression of the target protein. "Co-suppression" refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Patent No. 5,231,020).

The term "excisable sequence", "excision site", or "excision sequence" are used interchangeably, and refer to any sequence, such as the Lox sequence, that is recognized by a recombinase enzyme, such as Cre. The activity of the Cre removes two Lox sequences, and any other nucleic acid between the Lox sequences, from a longer DNA fragment by recombination. As one skilled in the art would appreciate, several excision systems can be used that would be comparable to Cre/Lox described in Example 7. Examples of excision systems would include, but are not limited to, Cre/Lox (Odell et al. (1990) *Mol Gen Genet* 223:369-378); Flp/Frt (Lyznik et al. (1993) *Nuc Acids Res* 21:969-975); Clonase™/Att (Invitrogen Life Technologies™); Gin/Gix (Maeser and Kahmann (1991) *Mol Gen Genet* 230:170-176); and R/RS (Onouchi et al. (1991) *Nuc Acids Res* 19: 6373-6378).

As one skilled in the art would appreciate, several fragments flanked by excision sites can be used to eliminate or down-regulate expression in host cells equivalent to that described herein. Examples of such fragments include, but are not limited to, transcriptional terminators, stop codons that are in frame with the Ryr coding sequence, operators that are recognized by transcriptional repressors, translational attenuators, and sequences which interact with antisense or co-suppression constructs.

As one skilled in the art would appreciate, a stop fragment can be inserted at many different locations in the Ryr cDNA equivalent to that described herein. Examples of suitable locations would include, but are not limited to, in the promoter upstream of the gene, in the 5' untranslated leader, within the coding sequence, and in the 3' untranslated region.

As one skilled in the art would realize, placement of an intron within the coding region of a ryanodine receptor gene would impair the expression of active ryanodine receptor in host cells that are incapable of processing the intron removal from the RNA transcript.

"Mature" protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. "Precursor" protein refers to the primary product of translation

or it may be a RNA sequence derived from post-transcriptional processing of the primary transcript and is referred to as the mature RNA. "Messenger RNA (mRNA)" refers to the RNA that is without introns and that can be translated into protein by the cell. "cDNA" refers to a DNA that is complementary to and synthesized from a mRNA template using the enzyme reverse transcriptase. The cDNA can be single-stranded or converted into the double-stranded form using the Klenow fragment of DNA polymerase I. "Sense" RNA refers to RNA transcript that includes the mRNA and can be translated into protein within a cell or *in vitro*. "Antisense RNA" refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (U.S. Patent No. 5,107,065). The complementarity of an antisense RNA may be with any part of the specific gene transcript, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. "Functional RNA" refers to antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes. The terms "complement" and "reverse complement" are used interchangeably herein with respect to mRNA transcripts, and are meant to define the antisense RNA of the message.

The term "endogenous RNA" refers to any RNA which is encoded by any nucleic acid sequence present in the genome of the host prior to transformation with the recombinant construct of the present invention, whether naturally-occurring or non-naturally occurring, i.e., introduced by recombinant means, mutagenesis, etc.

The term "non-naturally occurring" means artificial, not consistent with what is normally found in nature.

The term "operably linked" refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is regulated by the other. For example, a promoter is operably linked with a coding sequence when it is capable of regulating the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in a sense or antisense orientation. In another example, the complementary RNA regions of the invention can be operably linked, either directly or indirectly, 5' to the target mRNA, or 3' to the target mRNA, or within the target mRNA, or a first complementary region is 5' and its complement is 3' to the target mRNA.

The term "transcriptional termination nucleic acid fragment" refers to a nucleic acid fragment containing sequences recognized by nucleic acid binding proteins, or causing secondary structure(s), that cause RNA polymerase to stop transcription.

entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a gene to be expressed in most cell types at most times are commonly referred to as "constitutive promoters". New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and Goldberg, (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of some variation may have identical promoter activity. The term "inducible promoter" refers to a promoter that is normally quiescent that can be activated by trans-acting factors. Examples of such factors include, but are not limited to, proteins, chemicals, and factors that alter the local structure of the DNA.

An "intron" is an intervening sequence in a gene that does not encode a portion of the protein sequence. Thus, such sequences are transcribed into RNA but are then excised and are not translated. The term is also used for the excised RNA sequences. An "exon" is a portion of the sequence of a gene that is transcribed and is found in the mature messenger RNA derived from the gene, but is not necessarily a part of the sequence that encodes the final gene product.

The "translation leader sequence" refers to a DNA sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner, R. and Foster, G. D. (1995) *Molecular Biotechnology* 3:225).

The "3' non-coding sequences" refer to DNA sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al., (1989) *Plant Cell* 1:671-680.

"RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript

and DIAGONALS SAVED=4. For large protein sequences the Clustal W program (Thompson et al. (1994) Nuc Acids Res 22:4673-4680) was used. Default parameters were used (GAP PENALTY=10, GAP LENGTH PENALTY=0.2, DELAY DIVERGENT SEQ (%)=30, DNA TRANSITION WEIGHT=0.50, PROTEIN WEIGHT MATRIX: Gonnet 250, DNA WEIGHT MATRIX:IUB). Pairwise alignment also used default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=0.10, PROTEIN WEIGHT MATRIX: Gonnet Series, DNA WEIGHT MATRIX:IUB).

"Gene" refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. "Native gene" refers to a gene as found in nature with its own regulatory sequences. "Chimeric construct", "recombinant construct", or recombinant expression construct" refers to a combination of nucleic acid fragments that are not normally found together in nature. Accordingly, a recombinant construct may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that normally found in nature. A "foreign" gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric constructs. A "transgene" is a gene that has been introduced into the genome by a transformation procedure.

"Coding sequence" refers to a DNA sequence that codes for a specific amino acid sequence. "Regulatory sequences" refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include, but are not limited to, promoters, translation leader sequences, introns, and polyadenylation recognition sequences. The term "in-frame translational termination codon" refers to a UAA, UAG, or UGA stop codon present within the preferred reading frame of an RNA transcript.

"Promoter" refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an "enhancer" is a DNA sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoter sequences can also be located within the transcribed portions of genes, and/or downstream of the transcribed sequences. Promoters may be derived in their

Moreover, the skilled artisan recognizes that substantially similar nucleic acid sequences encompassed by this invention are also defined by their ability to hybridize, under moderately stringent conditions (for example, 1 X SSC, 0.1% SDS, 60°C) with the sequences exemplified herein, or to any portion of the nucleotide sequences reported herein and which are functionally equivalent to the gene or the promoter of the invention. Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar fragments, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes determine stringency conditions. One set of preferred conditions involves a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 45°C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions involves the use of higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60°C. Another preferred set of highly stringent conditions involves the use of two final washes in 0.1X SSC, 0.1% SDS at 65°C.

With respect to the degree of substantial similarity between the target (endogenous) mRNA and the RNA region in the construct having homology to the target mRNA, such sequences should be at least 25 nucleotides in length, preferably at least 50 nucleotides in length, more preferably at least 100 nucleotides in length, again more preferably at least 200 nucleotides in length, and most preferably at least 300 nucleotides in length; and should be at least 80% identical, preferably at least 85% identical, more preferably at least 90% identical, and most preferably at least 95% identical.

It is well understood by one skilled in the art that many levels of sequence identity are useful in identifying related polypeptide sequences. Useful examples of percent identities are 75%, 80%, 85%, 90%, or 95%, or any integer percentage from 75% to 100%. Sequence alignments and percent similarity calculations may be determined using a variety of comparison methods designed to detect homologous sequences including, but not limited to, the Megalign program of the LASARGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences are performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments and calculation of percent identity of protein sequences using the Clustal method are KTUPLE=1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. For nucleic acids these parameters are KTUPLE=2, GAP PENALTY=5, WINDOW=4

The Sequence Listing contains the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUBMB standards described in *Nucleic Acids Res.* 13:3021-3030 (1985) and in the *Biochemical J.* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

#### DETAILED DESCRIPTION OF THE INVENTION

As used herein, an "isolated nucleic acid fragment" is a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. An isolated nucleic acid fragment in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA. Nucleotides (usually found in their 5'-monophosphate form) are referred to by their single letter designation as follows: "A" for adenylate or deoxyadenylate (for RNA or DNA, respectively), "C" for cytidylate or deoxycytidylate, "G" for guanylate or deoxyguanylate, "U" for uridylate, "T" for deoxythymidylate, "R" for purines (A or G), "Y" for pyrimidines (C or T), "K" for G or T, "H" for A or C or T, "I" for inosine, "W" for A or T, "S" for C or G, and "N" for any nucleotide.

The terms "subfragment that is functionally equivalent" and "functionally equivalent subfragment" are used interchangeably herein. These terms refer to a portion or subsequence of an isolated nucleic acid fragment in which the ability to alter gene expression or produce a certain phenotype is retained whether or not the fragment or subfragment encodes an active enzyme. For example, the fragment or subfragment can be used in the design of chimeric constructs to produce the desired phenotype in a transformed plant. Chimeric constructs can be designed for use in co-suppression or antisense by linking a nucleic acid fragment or subfragment thereof, whether or not it encodes an active enzyme, in the appropriate orientation relative to a plant promoter sequence.

The terms "homology", "homologous", "substantially similar", "consisting essentially of", and "corresponding substantially" are used interchangeably herein. They refer to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid fragment to mediate gene expression or produce a certain phenotype. These terms also refer to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially alter the functional properties of the resulting nucleic acid fragment relative to the initial, unmodified fragment. It is therefore understood, as those skilled in the art will appreciate, that the invention encompasses more than the specific exemplary sequences.

**TABLE 1**  
**Nucleic Acid Fragments Encoding Ryanodine Receptors**

Ryanodine Receptor	Clone Designation	SEQ ID NO:	
		(Nucleotide)	(Amino Acid)
tobacco budworm ( <i>Heliothis virescens</i> )	pXL-Hv3-5	1	2
tobacco budworm ( <i>Heliothis virescens</i> )	pXLHv7	127	128
tobacco budworm ( <i>Heliothis virescens</i> )	pXLHv2	129	130
tobacco budworm ( <i>Heliothis virescens</i> )	pXLHv3	143	144
tobacco budworm ( <i>Heliothis virescens</i> )	pXLHv6	145	146
green peach aphid ( <i>Myzus persicae</i> )	pIB-GPA7-1	3	4
cotton melon aphid ( <i>Aphis gossypii</i> )	pIB-CMA4-3	5	6
corn plant hopper ( <i>Peregrinus maidis</i> )	pXL-CPH9	7	8
fruit fly ( <i>Drosophila melanogaster</i> )	pIB43D	9	10

5 The odd-numbered SEQ ID NOs:1, 3, 5, 7, 9, 127, 129, 143, and 145  
 represent the polynucleotide sequences for the sequences encoding a ryanodine  
 receptor from the species indicated. The even-numbered SEQ ID NOs:2, 4, 6, 8, 10,  
 128, 130, 144, and 146 represent the translated amino acid sequence derived from  
 the corresponding odd-numbered polynucleotide sequence. SEQ ID NOs:11-55 are  
 10 nucleotide primers used in PCR amplification, and sequencing, experiments during  
 the isolation and characterization of the ryanodine receptors from various insect  
 sources. An unannotated mosquito genomic sequence (SEQ ID NO:57) is believed  
 to encode a partial ryanodine receptor (from analysis done by the authors of the  
 present invention). SEQ ID NOs:56, 58-62 and 120-126 are ryanodine receptor  
 sequences existing in the Genbank database. SEQ ID NOs:63-119 are amino acid  
 5 sequence motifs believed to be conserved in insect ryanodine receptors. SEQ ID  
 NOs:131-142 represent PCR primer sequences and oligonucleotides used in the  
 amplification of ryanodine receptor coding regions for cloning into expression  
 vectors (see Example 7).

calcium probe Fura-2 AM and assayed using a calcium imaging system to monitor calcium mobilization.

Figure 6 shows the caffeine dose response curve for wild type *Spodoptera frugiperda* (Sf9-WT), and recombinant Sf9 cells stably expressing *Drosophila melanogaster* ryanodine receptors (Sf9-DryR). Sf9 cells were loaded with the calcium probe Fura-2 then plated into a 96-well microtiter plate and assayed using a Molecular Devices' FlexStation™ plate reader with integrated fluidics to measure calcium mobilization.

Figure 7 shows a schematic overview of construction of pHE7. For clarity, DNA fragments are not drawn to scale, circular plasmids are depicted in a linear fashion, and only the relevant portions of the plasmids are shown.

Table 1 lists the polypeptides that are described herein, the designation of the genomic or cDNA clones that comprise the nucleic acid fragments encoding polypeptides representing all or a substantial portion of these polypeptides, and the corresponding identifier (SEQ ID NO:) as used in the attached Sequence Listing. The sequence descriptions and Sequence Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825.



Figure 1 shows an alignment of the deduced amino acid sequences for five ryanodine receptors from a lepidopteran species, tobacco budworm (*Heliothis virescens*, SEQ ID NOs:2, 128, 130, 144 and 146), green peach aphid (*Myzus persicae*, SEQ ID NO:4), cotton melon aphid (*Aphis gossypii*, SEQ ID NO:6), and corn plant hopper (*Peregrinus maidis*, SEQ ID NO:8), compared to a fruitfly (*Drosophila melanogaster*) sequence generated by the methods disclosed herein (SEQ ID NO:10), the *Drosophila* art sequence (NCBI General Identifier No. gi 17352471, SEQ ID NO:56), an unannotated sequence from the mosquito (*Anopheles gambiae*) genome sequencing project (gi 21301556, SEQ ID NO:57), the ryanodine receptor from nematodes (*Caenorhabditis elegans*, gi 1871447, SEQ ID NO:58), sea urchin (*Hemicentrotus pulcherrimus*, gi 18656155, SEQ ID NO:59), mouse (*Mus musculus*, gi 13569850, SEQ ID NO:60), rabbit (*Oryctolagus cuniculus*, gi 1245376, SEQ ID NO:61), and human (*Homo sapiens*, gi 4506757, SEQ ID NO:62). Insect specific sequences can be identified by finding homologous subsequences that are conserved between all of the insect sequences but not among the non-insect sequences. A number of these sequences can be found in SEQ ID NOs:63-119.

Figure 2 shows chemical structures of three classes of anthranilamides that were used in the calcium release assays presented in Example 9, or in the radio-labeled binding studies presented in Example 11.

Figure 3 shows an example of calcium responses elicited by either caffeine or Compound 16 (Table 7), from a recombinant *Spodoptera frugiperda* cell line (Sf9) transiently expressing a *Drosophila melanogaster* ryanodine receptor. Cells were challenged 96 hr post-transfection with the ryanodine receptor agonist, caffeine (10 mM) and Compound 16 (10 and 100 nM). No significant calcium responses were observed with caffeine (10 mM) or Compound 16 (10 and 100 nM) in control cells without DNA.

Figure 4 shows an example of calcium responses elicited by either caffeine or Compound 5 (Table 7), from a recombinant *Spodoptera frugiperda* cell line (Sf9) transiently expressing a recombinant *Heliothis virescens* ryanodine receptor. Cells were challenged 72 hr post-transfection with the ryanodine receptor agonist, caffeine (10 mM) and Compound 5 (3  $\mu$ M). No significant calcium responses were observed with caffeine (10 mM) or Compound 5 (3  $\mu$ M) in control cells without DNA.

Figure 5 shows an example of calcium responses elicited by either caffeine or Compound 14 (Table 7), from a recombinant *Spodoptera frugiperda* cell line (Sf9) stably expressing a recombinant *Heliothis virescens* ryanodine receptor. Cells were challenged with the ryanodine receptor agonist, caffeine (10 mM) and Compound 14 (1  $\mu$ M). Sf9 cells were allowed to attach to a glass coverslip then loaded with the

and the isolated nucleic acid fragment encoding the toxic insect ion channel, and further wherein the transcription termination nucleic acid fragment, and/or an in-frame translation stop codon, is flanked on each end by at least one nucleic acid sequence consisting essentially of excisable sequences; and

- 5           b) growing the transformed host under conditions that are suitable for the expression of the recombinant construct. The excisable sequences may be any sequences recognized by recombinase enzymes, such as but not limited to, lox sites.

10           A related embodiment of the present would encompass the recombinant constructs themselves comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding a toxic insect ion channel, wherein the promoter comprises a transcription termination nucleic acid fragment, and/or at least one in-frame translational termination codon, situated between said promoter and  
15           wherein the transcription termination nucleic acid fragment, and/or at least one in-frame translational termination codon, is flanked on each end by at least one nucleic acid sequence consisting essentially of excisable sequences. The excisable sequences may be any sequences recognized by recombinase enzymes, such as but not limited to, lox sites.

20           Another embodiment of the present invention would be a method for expressing an isolated nucleic acid fragment encoding a toxic insect ion channel comprising:

- 25           a) transforming a host with a recombinant expression construct comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding the toxic insect ion channel, wherein said fragment also comprises an intron which interferes with expression of said fragment, and  
            b) growing the transformed host under conditions that are suitable for the expression of the recombinant construct.

30           In still another embodiment, the present invention would encompass a recombinant expression construct comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding a toxic insect ion channel wherein said isolated nucleic acid fragment also comprises an intron which interferes with expression of the toxic insect ion channel.

#### BRIEF DESCRIPTION OF THE FIGURES AND SEQUENCE LISTINGS

35           The invention can be more fully understood from the following detailed description and the accompanying drawings and Sequence Listing which form a part of this application.

activity by detecting the effect of a compound on the functional activity of the transformed host cell or ion channels obtained from such cells.

In an eighth embodiment, this invention concerns a method for evaluating at least one compound which modulates ryanodine receptor activity, the method comprising the steps of:

- (a) contacting at least one compound with a polypeptide encoded by any one of the aforementioned isolated nucleic acid fragments; and
- (b) evaluating the ryanodine receptor activity of the polypeptide of (a) after said polypeptide has been contacted with the compound or compounds.

This method wherein the method can be, but is not limited to, a ligand binding assay. Furthermore, this method can be useful wherein the polypeptide is contacted with more than one compound.

A further embodiment of the present invention would be an isolated nucleic acid fragment encoding an insect ion channel comprising at least two polypeptide sequences set forth in any of SEQ ID NOs:63-119 provided that said polypeptide sequences do not comprise any of SEQ ID NOs:56, 120-126.

Yet another embodiment would be a method for identifying a nucleic acid sequence encoding an insect ion channel comprising:

- a) obtaining an isolated nucleic acid sequence encoding a first polypeptide having at least 100 amino acids;
- b) comparing the first polypeptide sequence with a comparative polypeptide sequence selected from the group consisting of SEQ ID NOs:63-119 to identify a region between the first polypeptide and the comparative polypeptide having 100% sequence identity wherein said region is as long as the comparative polypeptide; and
- c) repeating step (b) with a different comparative polypeptide sequence, wherein said different comparative polypeptide sequence is selected from the group consisting of SEQ ID NOs:63-119 until a second region having 100% sequence identity is found, wherein said second region is as long as the different comparative polypeptide. The method could be further characterized by the length of the first polypeptide having a length of from 100 to 6,000 amino acids.

Yet a further embodiment of the present invention would be a method for expressing an isolated nucleic acid fragment encoding a toxic insect ion channel comprising:

- a) transforming a host with a recombinant construct comprising in the 5' to 3' direction a promoter operably linked to the toxic insect ion channel nucleic acid, wherein the promoter comprises a transcription termination nucleic acid fragment, and/or an in-frame translation stop codon, situated between said promoter

In a fourth embodiment, this invention concerns recombinant DNA constructs comprising any of the foregoing nucleic acid fragment or complement thereof or part of either operably linked to at least one regulatory sequence. Also, of interest are eukaryotic or prokaryotic host cells comprising such recombinant DNA constructs in their genome. Useful host cells include, but are not limited to, E.coli, yeast, Sf9, S2, Xenopus oocytes, HEK-293 and CHO cells.

In a fifth embodiment, this invention concerns a method to isolate nucleic acid fragments encoding ryanodine receptors and related polypeptides, comprising:

- (a) comparing SEQ ID NO:2, 4, 6, 8, 10, 128, 130, 144, and 146 and other ion channel and receptor polypeptide sequences;
- (b) identifying the conserved sequences of 4 or more amino acids obtained in step a;
- (c) designing degenerate oligomers based on the conserved sequences identified in step b; and
- (d) using the degenerate oligomers of step c to isolate sequences encoding polypeptides having ryanodine receptor activity by sequence dependent protocols.

In a sixth embodiment, this invention concerns an isolated polypeptide having ryanodine receptor activity, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10, 128, 130, 144, or 146 have at least 75%, 80%, 85%, 90%, 95%, or 100% identity. One skilled in the art would realize that any integer percent identity from 75% to 100% would be useful in isolating ryanodine receptor-like polypeptide sequences.

In a seventh embodiment, this invention concerns a method for evaluating at least one compound for its ability to modulate calcium homeostasis, the method comprising the steps of:

- (a) transforming a host cell with any one of the aforementioned recombinant constructs;
- (b) growing the transformed host cell under conditions that are suitable for expression of the recombinant construct wherein expression of the recombinant construct results in altered calcium homeostasis;
- (c) treating the transformed host cell of step (a) with a compound to be tested; and
- (d) determining changes in intracellular homeostasis by the test compound in order to select compounds with potential for altering calcium release.

This method wherein the method can be, but is not limited to, a ligand binding assay. Furthermore, this method can be based on assessing functional

currently recognized isoforms (types 1, 2, and 3) which are subject to differential regulation and have different tissue distributions.

Full-length genomic DNA sequence (Takeshima et al. (1994) *FEBS Lett.*, 337: 81-87) and cDNA sequence (Xu et al. (2000) *Biophys J.* 78: 1270-1281) of the *Drosophila* gene encoding a ryanodine receptor is known and available from public databases (NCBI Accession No. D17389), from other invertebrates, e.g. *Caenorhabditis elegans* (NCBI Accession No. D45899) and a small segment of the C-terminus of the ryanodine receptor from the tobacco budworm, a lepidopteran pest (*Heliothis virescens*; Puente et al., (2000) *Insect Biochem. Mol Biol.* 30: 335-347). The sequence from *Drosophila* has been cloned and expressed in Chinese Hamster Ovary (CHO) cells and the receptor-ion channel shown to be functional using electro-conductance techniques (Xu et al. (2000) *Biophys J.* 78: 1270-1281).

Crop destruction by pests such as insects results in a considerable economic loss and serious reduction in productivity. For example, lepidopteran pest species cause \$500MM of damage to various crop species annually. Homopteran pests account for a further \$2000MM. Recently, two areas of chemistry have shown good control of lepidopteran pests. From an analysis of intracellular calcium changes and the physiological response of the pest to the compounds the mode of action is by disruption of normal muscle function through the release and eventual depletion of internal calcium stores in the muscle and central nervous system. Thus, based on the response of cells expressing the ryanodine receptor either in natural or recombinant systems to various types of low molecular weight chemical structures, it is clear the receptor and potentially other attendant components that interact with it are important targets for pest control.

#### SUMMARY OF THE INVENTION

This invention concerns an isolated nucleotide fragment comprising a nucleic acid sequence consisting of a nucleic acid sequence encoding a ryanodine receptor having an amino acid sequence identity of at least 75%, 80%, 85%, 90%, 95%, or 100% when compared to a polypeptide selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, 128, 130, 144, or 146. Also of interest is the complement of such isolated nucleic acid fragments.

In a second embodiment, this invention concerns an isolated nucleic acid fragment wherein the nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO:1, 3, 5, 7, 9, 127, 129, 143, or 145.

In a third embodiment, this invention concerns such previously mentioned nucleic acid fragments, and complements thereof, wherein the fragment or parts thereof are useful in a recombinant construct for the purpose of over-expression, antisense inhibition, or co-suppression of ryanodine receptor activity in a host cell.

## TITLE

### ISOLATION AND USE OF RYANODINE RECEPTORS

This application claims the benefit of U.S. Provisional Application No. 60/412,795, filed September 23, 2002, and of U.S. Provisional Application  
5 No. 60/427,324, filed November 18, 2002, the disclosures of which are hereby incorporated by reference in their entirety.

### FIELD OF THE INVENTION

The present invention is in the field of ryanodine receptors and, in particular, relates to recombinant constructs useful for modulating ryanodine receptor activity  
10 and to methods for evaluating compounds that modulate such activity.

### BACKGROUND OF THE INVENTION

Calcium homeostasis in the cytosol of vertebrate and invertebrate muscle cells is essential for normal cellular activity. It is a complex process involving balancing calcium from extracellular sources that moves through calcium selective  
15 channels on the plasma membrane of the cell, and calcium in internal stores controlled by a calcium activated calcium release channel located in the membrane of the sarcoplasmic reticulum. Release of calcium from the sarcoplasmic reticulum plays a crucial role in excitation-contraction coupling in muscle tissue (Pessah et al., (1986) *J Biol Chem* 261:8643-8648) and the initiation and propagation of calcium  
20 signaling events.

The calcium activated calcium release channel internal to the cell is called the ryanodine receptor (Ryr) because of the interaction of the receptor with a natural insecticide ryanodine, an alkaloid from the *Ryania speciosa*. Ryanodine binding sites have been studied in an effort to understand the properties of the Ca<sup>2+</sup> release  
25 channel in insects as a possible target for insecticide action (Lehmberg et al., (1994) *Pesticide Biochem and Physiol* 48: 145-152). However, no synthetic insecticides acting on the ryanodine receptor as a primary mode of action have been discovered until recently. Chemistry based on derivatives of anthranilamides with very potent activity on pest species activate this receptor in a manner leading to calcium  
30 release, thereby disrupting the calcium balance of the insect cell. The response of the organism as a result of this disruption is unrelieved muscle contraction, including cardiac, skeletal and pharyngeal muscles, leading to lethargy and cessation of feeding.

It is reported in insects that there is only one form of the receptor-ion channel.  
35 Studies in insect tissues indicate that the receptor has similar properties and size to its mammalian homologue (Denser et al., (1998) *Pestic. Sci.* 54:345-352). The ryanodine receptor has been most studied in mammals where there are three

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number  
WO 2004/027042 A2

- (51) International Patent Classification<sup>7</sup>: C12N
- (21) International Application Number:  
PCT/US2003/029834
- (22) International Filing Date:  
23 September 2003 (23.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/412,795 23 September 2002 (23.09.2002) US  
60/427,324 18 November 2002 (18.11.2002) US
- (71) Applicant (for all designated States except US): E. I. DU  
PONT DE NEMOURS AND COMPANY [US/US]; 1007  
Market Street, Wilmington, DE 19898 (US).

Steven [US/US]; 4 Austin Road, Wilmington, DE 19810  
(US). RAUH, James, J. [US/US]; 55 Martha's Drive,  
Conowingo, MD 21918 (US). SMITH, Rejane, M.  
[US/US]; 176 Middlecroft Road, Elkton, MD 21921 (US).  
WU, Lihong [CN/US]; 301 Winterview Way, Newark, DE  
19711 (US). TAO, Yong [CN/US]; 9 Hummingbird Lane,  
Newark, DE 19711 (US).

(74) Agents: CHRISTENBURY, Lynne, M. et al.; E. I. Du  
Pont De Nemours and Company, Legal Patent Records  
Center, 4417 Lancaster Pike, Wilmington, DE 19805 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]

(54) Title: ISOLATION AND USE OF RYANODINE RECEPTORS

SEQ ID NO: 2 MAAEAGGAS EDDVSTFLPTEDVNCVLCSTATO-----ERVCLAAEDGQRHCFLENIAD-KNIPDLSCQVFIQALSVRALQELV  
SEQ ID NO: 128 MAAEAGGAS EDDVSTFLPTEDVNCVLCSTATO-----ERVCLAAEDGQRHCFLENIAD-KNIPDLSCQVFIQALSVRALQELV  
SEQ ID NO: 144 MAAEAGGAS EDDVSTFLPTEDVNCVLCSTATO-----ERVCLAAEDGQRHCFLENIAD-KNIPDLSCQVFIQALSVRALQELV  
SEQ ID NO: 146 MAAEAGGAS EDDVSTFLPTEDVNCVLCSTATO-----ERVCLAAEDGQRHCFLENIAD-KNIPDLSCQVFIQALSVRALQELV  
SEQ ID NO: 4 MAAEAGGAS EDDVSTFLPTEDVNCVLCSTATO-----ERVCLAAEDGQRHCFLENIAD-KNIPDLSCQVFIQALSVRALQELV  
SEQ ID NO: 8 MAAEAGGAS EDDVSTFLPTEDVNCVLCSTATO-----ERVCLAAEDGQRHCFLENIAD-KNIPDLSCQVFIQALSVRALQELV  
SEQ ID NO: 16 MAAEAGGAS EDDVSTFLPTEDVNCVLCSTATO-----ERVCLAAEDGQRHCFLENIAD-KNIPDLSCQVFIQALSVRALQELV  
SEQ ID NO: 54 MAAEAGGAS EDDVSTFLPTEDVNCVLCSTATO-----ERVCLAAEDGQRHCFLENIAD-KNIPDLSCQVFIQALSVRALQELV  
SEQ ID NO: 57 MAAEAGGAS EDDVSTFLPTEDVNCVLCSTATO-----ERVCLAAEDGQRHCFLENIAD-KNIPDLSCQVFIQALSVRALQELV  
SEQ ID NO: 58 MAAEAGGAS EDDVSTFLPTEDVNCVLCSTATO-----ERVCLAAEDGQRHCFLENIAD-KNIPDLSCQVFIQALSVRALQELV  
SEQ ID NO: 59 MAAEAGGAS EDDVSTFLPTEDVNCVLCSTATO-----ERVCLAAEDGQRHCFLENIAD-KNIPDLSCQVFIQALSVRALQELV  
SEQ ID NO: 60 MAAEAGGAS EDDVSTFLPTEDVNCVLCSTATO-----ERVCLAAEDGQRHCFLENIAD-KNIPDLSCQVFIQALSVRALQELV  
SEQ ID NO: 61 MAAEAGGAS EDDVSTFLPTEDVNCVLCSTATO-----ERVCLAAEDGQRHCFLENIAD-KNIPDLSCQVFIQALSVRALQELV  
SEQ ID NO: 62 MAAEAGGAS EDDVSTFLPTEDVNCVLCSTATO-----ERVCLAAEDGQRHCFLENIAD-KNIPDLSCQVFIQALSVRALQELV

SEQ ID NO: 2 TAAGSETG-----KCTGSGHRTLLYGNATLLRHNSDNYLACLS-SEDKLAPDVGLQNSGQACWTLHPASKQSEG  
SEQ ID NO: 128 TAAGSETG-----KCTGSGHRTLLYGNATLLRHNSDNYLACLS-SEDKLAPDVGLQNSGQACWTLHPASKQSEG  
SEQ ID NO: 144 TAAGSETG-----KCTGSGHRTLLYGNATLLRHNSDNYLACLS-SEDKLAPDVGLQNSGQACWTLHPASKQSEG  
SEQ ID NO: 146 TAAGSETG-----KCTGSGHRTLLYGNATLLRHNSDNYLACLS-SEDKLAPDVGLQNSGQACWTLHPASKQSEG  
SEQ ID NO: 4 TAAGSETG-----KCTGSGHRTLLYGNATLLRHNSDNYLACLS-SEDKLAPDVGLQNSGQACWTLHPASKQSEG  
SEQ ID NO: 8 TAAGSETG-----KCTGSGHRTLLYGNATLLRHNSDNYLACLS-SEDKLAPDVGLQNSGQACWTLHPASKQSEG  
SEQ ID NO: 16 TAAGSETG-----KCTGSGHRTLLYGNATLLRHNSDNYLACLS-SEDKLAPDVGLQNSGQACWTLHPASKQSEG  
SEQ ID NO: 54 TAAGSETG-----KCTGSGHRTLLYGNATLLRHNSDNYLACLS-SEDKLAPDVGLQNSGQACWTLHPASKQSEG  
SEQ ID NO: 57 TAAGSETG-----KCTGSGHRTLLYGNATLLRHNSDNYLACLS-SEDKLAPDVGLQNSGQACWTLHPASKQSEG  
SEQ ID NO: 58 TAAGSETG-----KCTGSGHRTLLYGNATLLRHNSDNYLACLS-SEDKLAPDVGLQNSGQACWTLHPASKQSEG  
SEQ ID NO: 59 TAAGSETG-----KCTGSGHRTLLYGNATLLRHNSDNYLACLS-SEDKLAPDVGLQNSGQACWTLHPASKQSEG  
SEQ ID NO: 60 TAAGSETG-----KCTGSGHRTLLYGNATLLRHNSDNYLACLS-SEDKLAPDVGLQNSGQACWTLHPASKQSEG  
SEQ ID NO: 61 TAAGSETG-----KCTGSGHRTLLYGNATLLRHNSDNYLACLS-SEDKLAPDVGLQNSGQACWTLHPASKQSEG  
SEQ ID NO: 62 TAAGSETG-----KCTGSGHRTLLYGNATLLRHNSDNYLACLS-SEDKLAPDVGLQNSGQACWTLHPASKQSEG

(57) Abstract: The genes encoding ryanodine receptor homologs have been characterized from multiple insect families including lepidopteran tobacco budworm (*Heliothis virescens*), homopteran green peach aphid (*Myzus persicae*), corn plant hopper (*Peregrinus maidis*), cotton melon aphid (*Aphis gossypii*) and fruitfly (*Drosophila melanogaster*). The full-length genes have been isolated, cloned and amplified in bacterial cells. Expression in insect cells shows that the recombinant protein folds into a functional calcium release channel. The genes and their corresponding polypeptides have a number of uses including, but not limited to, the isolation of other pest ryanodine receptors, the development of screens to identify insecticidally active compounds, use of fragments of genes as pesticides, fragments of protein for antibody production, fragments of protein for determination of the structure of insecticide binding sites, and identification of insecticides that disrupt the calcium balance in cells through other messengers that interact with the receptor calcium release mechanism. Methods are outlined for overcoming toxic effects of expressing recombinant proteins in host cells.

WO 2004/027042 A2



ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *without international search report and to be republished upon receipt of that report*



sequences could not be identified since the fruitfly sequence was the only insect sequence available and this had very low (less than 50%) homology to the other known animal ryanodine receptor sequences.

Table 5 shows the percent identity for the pairwise comparison of the ryanodine receptor sequences shown in Figure 1. The SEQ ID NOs for the sequences and their respective percent identities are shown.

**Table 5**  
**Percent Identity For Pairwise Comparison Of Ryanodine Receptor Sequences**  
**Shown In Figure 1**

SEQ ID NOs:	<u>128</u>	<u>130</u>	<u>144</u>	<u>146</u>	<u>4</u>	<u>6</u>	<u>8</u>	<u>10</u>	<u>56</u>	<u>57</u>	<u>58</u>	<u>59</u>	<u>60</u>	<u>61</u>	<u>62</u>
<u>2</u>	99.0	98.9	98.8	98.9	76.8	77.5	79.6	78.2	78.5	79.0	45.7	46.1	47.1	47.2	47.2
<u>128</u>	***	99.8	99.6	99.6	77.6	78.0	80.3	78.8	79.2	79.6	46.1	46.5	47.7	47.6	47.6
<u>130</u>		***	99.6	99.6	77.7	78.1	80.3	78.9	79.3	79.8	46.4	46.5	47.5	47.7	47.6
<u>144</u>			***	99.6	77.4	78.1	80.1	78.7	79.0	79.6	45.9	46.4	47.5	47.6	47.5
<u>146</u>				***	77.9	78.3	80.8	79.0	79.3	79.8	46.0	47.0	47.5	47.6	47.6
<u>4</u>					***	97.9	81.9	75.4	75.7	76.5	45.6	47.3	47.0	46.9	46.9
<u>6</u>						***	82.2	75.8	75.9	76.8	45.8	47.6	47.1	47.3	47.4
<u>8</u>							***	78.4	78.8	80.2	45.9	46.8	47.2	47.3	47.2
<u>10</u>								***	99.3	82.3	45.3	45.8	46.6	46.8	46.7
<u>56</u>									***	82.5	45.7	45.8	46.8	46.9	46.9
<u>57</u>										***	45.8	46.8	46.7	46.7	46.7
<u>58</u>											***	41.5	41.0	41.1	41.2
<u>59</u>												***	48.2	48.3	48.2
<u>60</u>													***	97.1	97.2
<u>61</u>														***	98.6

### EXAMPLE 5

#### Transient Expression of Ryanodine Recombinant Constructs in Insect Cell Lines

The cDNAs encoding ryanodine receptors from different insects were cloned into pIBV5His or pFASTBac as described in Example 2, respectively. However, one skilled in the art would realize that there are numerous other vectors and means of

infecting eukaryotic cells. In particular, baculovirus based systems for insect cell infection would be useful, as would any system allowing for the complete expression and modification of receptor proteins in its active form.

The *Spodoptera frugiperda* cell line Sf9 used for transfection studies, was maintained in Sf-900 II SFM medium (Invitrogen Life Technologies™, Carlsbad, CA) in T-75 flasks incubated at 27°C. It is understood that those skilled in the art might choose alternative cell types such as the *Spodoptera frugiperda* cell line Sf21 or the *Drosophila* cell line S2. For the purpose of general handling and propagation, cells were suspended through scraping or agitation and a volume of cell suspension was added to each well of a poly-L-lysine coated 96-well, glass-bottom plate so as to provide 70–80% confluence. Cells were maintained in an incubator at 27 °C until testing.

Sf-9 cells were grown at 27 degrees C in a Corning 125 ml polycarbonate Erlenmeyer flask to a density of 3.1 million cells per ml in SF900-II serum free media (Gibco cat. # 10902-088, Invitrogen Life Technologies™, Carlsbad, CA). One million cells were transferred to one well of a Corning 6-well, flat bottom cell culture dish (Corning 3516). SF900-II media was used to bring the final volume in the dish to 2 ml and the cells were incubated at 27 degrees C for 21 h. Following the incubation the media was aspirated from the dish and replaced with 1 ml of SF900-II media pre-warmed to 27 degrees C.

The transient transfection was carried out following an InsectSelect BSD System manual (Invitrogen Life Technologies™, Carlsbad, CA). Cellfectin reagent (Invitrogen Life Technologies™, Carlsbad, CA, catalog no. 10362-010) and SF900-II serum free media (Gibco cat. # 10902-088, Invitrogen Life Technologies™, Carlsbad, CA) were used in all transfection. The transfection was accomplished by adding the transfection solution drop-wise to the dish and incubating 4 h at room temperature with gentle rocking. After the 4 h incubation the media was replaced with 2 ml of SF900-II media pre-warmed to 27 degrees C and the cells were incubated 2-3 days at 27 degrees C before testing.

#### EXAMPLE 6

##### Expression of Chimeric Constructs in Microbial Cells

The cDNAs encoding the instant polypeptides can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites

sequence were completed by gene walking.

#### EXAMPLE 4

##### Characterization of cDNA Clones Encoding Ryanodine Receptors

The BLASTX search using the EST sequences from clones listed in Table 3 revealed similarity of the polypeptides encoded by the cDNAs to the ryanodine receptor protein from *Drosophila* [*Drosophila melanogaster*] (NCBI General Identifier No. gi 17352471, [SEQ ID NO:56]. Shown in Table 3 are the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), the sequences of contigs assembled from two or more ESTs ("Contig"), sequences of contigs assembled from an FIS and one or more ESTs ("Contig\*"), or sequences encoding an entire protein derived from an FIS, a contig, or an FIS and PCR ("CGS"):

TABLE 3

BLAST Results for Sequences Encoding Ryanodine Receptors

Clone	Status	BLAST pLog Score
		17352471
tobacco budworm	CGS	180.0
tobacco budworm	CGS	180.0
tobacco budworm	CGS	180.0
tobacco budworm	CGS	180.0
tobacco budworm	CGS	180.0
green peach aphid	CGS	180.0
cotton melon	CGS	180.0
aphid		
corn plant hopper	CGS	180.0
fruit fly	CGS	180.0

The data in Table 4 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOs:2, 4, 6, 8, 10, 128, 130, 144, and 146, and the ryanodine receptor protein from *Drosophila* [*Drosophila melanogaster*] (NCBI General Identifier No. gi 17352471, SEQ ID NO:56).

TABLE 4

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Ryanodine Receptors

SEQ ID NO.	Percent Identity to
	17352471
2	78.5%
128	79.2%
130	79.3%
144	79.0%

For corn plant hopper the 5' RACE primers were

CPH-DR1: CCGAAGCACATCGCCACCAAACAC (SEQ ID NO:46)

CPH-DR2: CCTGTGCCATAAGGCTGAACGGACC (SEQ ID NO:47)

5 CPH-DR3: CGTCACCAACTCGCACCTTCTCACCCCTCC (SEQ ID NO: 48)

and 3' RACE primers

CPH-EF1: GGAAGACATGGAGTCCAACCTGTTTCATTTGTGGC (SEQ ID NO:49)

CPH-EF2: GTGCCGCATGGTTTCGATACTCATGTGCAGC (SEQ ID NO:50)

10 CPH-EF3: GCATAATCTCGCTAATTACATGTTCTTCCTCATGC (SEQ ID NO:51)

The sequences of the primers designed to incorporate the *PacI* and *PmeI* sites at the ends of the ryanodine receptor coding regions for the cotton melon aphid are as follows:

15 pRCMAN-*PacI*: GCCAAGTTAATTAACGATGGCCGACAGCGAGGGAAGTTCG (SEQ ID NO:52)

pRCMAC-*PmeI*: GAACTCGTTTAAACGAGACGCCTCCTCCGCCGCAAGC (SEQ ID NO:53)

20 and those designed to incorporate the *PacI* and *PmeI* sites at the ends of the ryanodine receptor coding regions for the corn plant hopper are as follows:

pRCPHN-*PacI*: GCCAAGTTAATTAACAATGGCGGATAGTGAGGGTGGATCTG (SEQ ID NO:54)

25 pRCPHC-*PmeI*: GAAGTCGTTTAAACGAGCCACCACCGCCTCCTAACTCATC (SEQ ID NO:55)

Both full-length ryanodine receptor coding regions were again cloned into the pCR-XL-TOPO® vector (Invitrogen™) and subsequently sub-cloned into the modified pBV5His or pFASTBac as described in Example 2.

30 To complete the sequences of the ryanodine receptor coding regions, the inserts in the pCR-XL-TOPO® vector were digested with a mixture of *EcoRI* and *BamHI* restriction enzymes. The fragments were then subcloned into three pBluscript KS vectors, digested either with *EcoRI*, *BamHI* or both combined. The  
35 vectors were religated in the presence of the mixtures of the ryanodine receptor coding region sub-fragments. About forty individual clones for each of the CMA and CPH ryanodine receptor coding regions were isolated from individual bacterial colonies and the inserts sequenced using vector primers. The gaps remaining in the

codon of the full-length coding region of the ryanodine receptor.

The primers used were:

pRgN-PacI: GCCAAGTTAATTAACGATGGCCGACAGCGAGGGCAGTTTCG (SEQ ID NO:37)

5 pRgC-PmeI: GGACTCGTTTAAACGAGACGCCTCCTCCGCCGCCGAGC (SEQ ID NO:38)

the full-length cDNA for the gene was thus isolated with PacI and PmeI sites at the 5' and 3' ends respectively.

10 The 16 kb PCR product was cloned into a pCR-XL-TOPO® vector (Invitrogen Life Technologies™, Carlsbad, CA) and the full-length ryanodine receptor coding region subsequently sub-cloned into pIBV5His or pFASTBac vectors modified between the BamHI and XbaI sites of the MCS of the vector with PacI and PmeI sites (SEQ ID NO:39).

15 Full-insert sequencing was achieved using a combination transposon and primer walking procedure. The transposon system used was the EZ::TN transposon insertion kit from Epicentre™ using the TET 1 version of the transposon (Goryshin and Reznikoff (1998) *J Biol Chem* 273:7367-7374). 200 clones were isolated to provide 380 sequences using forward and reverse primers supplied in the kit. Primers were then designed from these regions to fill in the gaps by gene walking.  
20 The sequence of the green peach aphid gene is shown in SEQ ID NO:3.

### EXAMPLE 3

#### Reconstruction of the Ryanodine Receptor Isolated Nucleic Acid Fragment From Cotton Melon Aphid and Corn Plant Hopper

25 cDNA for the ryanodine receptor coding regions from cotton melon aphid and corn plant hopper were obtained essentially as described in Example 2. The same D primer set used in Example 1 and E primer set used in Example 2 produced nearly the full-length sequence for the two homopteran species. The following primers were used for a RACE series of experiments to produce the sequences of the 5' and 3' ends of the ryanodine receptor coding regions. For cotton melon aphid  
30 the 5'RACE primers used were

CMA-DR1: GCTGGATGCACAGTCCACCAACAAGCTTC (SEQ ID NO:40)

CMA-DR2: CAATGTTTCGGTGTCCAGATCCAGTTCC (SEQ ID NO:41)

CMA-DR3: GACGGGTACACACTGAGACAAGTCGGGTGG (SEQ ID NO:42)

35 and 3' RACE primers

CMA-EF1: CTGCGGCATCGGCAAAGATTATTTTCG (SEQ ID NO:43)

CMA-EF2: CCGCACGGTTTTTGACACGCACGTTC (SEQ ID NO:44)

CMA-EF3: CCGGCCAAGAAACGTACGTCTGGAAC (SEQ ID NO:45)

EXAMPLE 2Reconstruction of the Ryanodine Receptor Isolated Nucleic Acid Fragment From  
Green Peach Aphid

Total RNA was extracted from 0.5g of green peach aphid (*Myzus persicae*) or any Homopteran species flash frozen in liquid N<sub>2</sub> and ground to a powder in a chilled mortar. The powder was extracted with 20 ml of TriZOL<sup>®</sup> by vigorous shaking for 15 s and then incubation of the sample at 30C for 3 min. Two ml of chloroform was added and the shaking and incubation treatment repeated. The sample was spun at 12,000 g for 10 min at 8 C and the aqueous phase transferred to a fresh tube. 5 ml of isopropyl alcohol and 5 ml of 0.8 M sodium citrate containing 1.2 M NaCl was mixed with the aqueous fraction and after 10 min at room temperature the sample was centrifuged a second time. The pellet was washed with 10 ml of 70% EtOH, the suspension recentrifuged at 7500g for 5 min and the resulting pellet allowed to dry before dissolving in 2 ml water.

The same combination of the 'D' set of forward and reverse primers that successfully produced the 5'- sequences of the tobacco budworm gene were used as described before. A second set of primers to acquire most of the 3' region were also designed from regions of high homology for all the known ryanodine receptor sequences.

E-F1 GGAGGTGGNATHGGNGAYGA (SEQ ID NO:27)  
E-F2 ATCATCGAYGCNTTYGGNGA (SEQ ID NO:28)  
E-R1 AARCARTCNCCNACNGGRAA (SEQ ID NO:29)  
E-R2 ACNGGRAARAARTCCCARCA (SEQ ID NO:30)

The bands generated using the D-F and D-R combinations as well as the E-F and E-R combinations produced sequence consistent with their expected origin as segments of the receptor isolated nucleic acid fragment. The remaining sequences for the extreme 5' and 3'-ends were obtained using RACE procedures as described in Example 1 employing the following 5' RACE primers

F-R1: CCCTCTTGAGAACTTGCAGCTGTCAC (SEQ ID NO:31)  
F-R2: CGTCCGGTGTCCAGATCCAGTTCCGCC (SEQ ID NO:32)  
F-R3: GATGAACAGTCCACCAACAAGCTTCAC (SEQ ID NO:33)

and 3' RACE primers

G-F1: GCTGGAAAGCGTCAAGGAAGACATGG (SEQ ID NO:34)  
G-F2: GCGGTATCGGCAAAGATTATTTTCGAC (SEQ ID NO:35)  
G-F3: GTGCCGCATGGTTTCGACACTCACG (SEQ ID NO:36)

The sequences of the RACE products were used to design primers to incorporate the PmeI and PaeI unique restriction sites outside the starting and stop

segment missing was the starting 24 bases of the 5'-region. To obtain this section and complete the gene, a 5' RACE procedure was used as described by Clontech™ in their Marathon® Amplification kit.

WL3: CACACACTGCGACAGATCAGGCGG (SEQ ID NO:23)

5 WL4: GCAATATTCTCCAGGAAGCAGTGCCG (SEQ ID NO:24)

Based on this full-length sequence, new primers were designed:

pHVN3-PacI: GCCAAGTTAATTAACCATGGCGGAAGCAGAGGGGGGAG (SEQ ID NO:25)

pRhC1-PmeI: GGACTCGTTTAAACGATTCTCCCATGAGGTCTTCGTATTGC (SEQ ID NO:26)

10 These primers were used for long PCR reactions following the protocol in the Expand Long Template PCR System® kit supplied by Roche™. A two stage PCR protocol was used that first used the following reaction conditions 94°C for 5 minutes and then 10 cycles of 10 sec at 92°C followed by 68°C for 14 min. The next stage was 15 cycles of 10 sec at 92°C, followed by 68°C for 14 min with each cycle  
15 incremented by 20 sec producing the full-length isolated nucleic acid fragment with PacI and PmeI unique restriction sites at the 5' and 3' ends respectively.

A 15.6 Kb DNA fragment was cloned into a pCR-XL-TOPO® vector of Invitrogen™. The complete sequence for *H. virescens* Ryr transcript was obtained by standard sequencing method using plasmid and PCR products.

20 Sequences for cDNAs encoding ryanodine receptor proteins can also be identified by conducting BLAST searches. (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410) searches for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven  
25 Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm provided by the National Center for Biotechnology Information (NCBI). The DNA sequences were  
30 translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish and States (1993) *Nat. Genet.* 3:266-272) provided by the NCBI. For convenience, the P-value (probability) of observing a match of a cDNA sequence to a sequence contained in the searched databases merely by chance as calculated  
35 by BLAST are reported herein as "pLog" values, which represent the negative of the logarithm of the reported P-value. Accordingly, the greater the pLog value, the greater the likelihood that the cDNA sequence and the BLAST "hit" represent homologous proteins.

*Caenorhabditis elegans*, as well as comparison with other mammalian species, the following degenerate primers were designed and synthesized for this purpose:

A-F1: CCTGARGCNYTNAAYATGAT (SEQ ID NO:11)

A-F2: GATCCTAARGTNYTNGAYGT (SEQ ID NO:12)

5 A-F3: AAGTGGTAYTTYGARTTYGA (SEQ ID NO:13)

A-R1: TCGAAYTCRAARTACCAYTTNCC (SEQ ID NO:14)

A-R2: AATGGYTCRTANCCYTCYTG (SEQ ID NO:15)

The 'A' designated primers cover a region of the sequence approximately 1722 nucleotides to 3702 nucleotides from the 5'-end (SEQ ID NO:1). All

10 combinations of forward and reverse primers were used to amplify this putative region of the gene. PCR was carried out using 4  $\mu$ M of each of the primers, dNTPs (200  $\mu$ M), with 1  $\mu$ l cDNAs and subjected to 35 cycles of PCR. The PCR conditions were 94°C for 15 sec, 45°C for 30 sec and 72°C for 1 min. The primer combinations that produced a fragment of the expected size were A-F2/A-R2 and A-F3/A-R2. The  
15 amplified bands were purified from a 1.5% agarose gel and subcloned into a pDrive® TA cloning vector (Qiagen™) following standard protocols supplied with the kit. Subsequent sequencing of the PCR product confirmed that this region of the gene between nucleotides 1722 to 3702 (SEQ ID NO:1) had been successfully located when compared to the *Drosophila* sequence.

20 A similar approach was used to identify a region of the gene close to the extreme 5'-end between nucleotides 27 and 1443.

D-F1: GAGCAGGAYGAYGTNWSNTT (SEQ ID NO:16)

D-F2: GCTGCTGARGGNTTYGGNAA (SEQ ID NO:17)

D-F3: GGTGARGCNTGYTGGTGGAC (SEQ ID NO:18)

25 D-R1: GTCCACCARCANGCYTCNCC (SEQ ID NO:19)

D-R2: ACTCKTACYTTYTCNCCYTC (SEQ ID NO:20)

D-R3: GGTATTGTTARRCAYTCRTC (SEQ ID NO:21)

D-R4: TTTAGTACNCCYTCYTCYTGRAA (SEQ ID NO:22)

Nearly all combinations of forward and reverse primers were involved in the  
30 initial round of amplification and putative PCR products were immediately subjected to a second, or 'nested' round of amplification. In this case 1/100<sup>th</sup> volume of the product of the first round was used as a template along with the same cycling conditions. Using this approach it was found that D-F1/D-R3, nested with D-F1/D-R2; DF2/D-R3 followed by D-F3/D-R3 and D-F2/D-R4 followed by D-F3/D-R3  
35 produced bands of the expected size on an agarose gel. The bands were isolated and their sequence compared to the *Drosophila* sequence.

These regions of sequence indicate that more than 99% of the isolated nucleic acid fragment could be recovered from the cDNA preparation and the only



channel wherein said isolated nucleic acid fragment also comprises an intron which interferes with expression of the toxic insect ion channel.

### EXAMPLES

The present invention is further defined in the following Examples, in which parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

The disclosure of each reference set forth herein is incorporated herein by reference in its entirety.

### EXAMPLE 1

#### Isolation of Ryanodine Receptor Nucleic Acid Fragment From Tobacco Budworm

Total RNA was extracted from 2g of 4<sup>th</sup> and 5<sup>th</sup> instar tobacco budworm larvae that had been flash frozen in liquid N<sub>2</sub> and ground to a powder in a chilled mortar. The powder was extracted with 20 ml of TriZOL™ by vigorous shaking for 15 s and then incubation of the sample at 30°C for 3 min. Two ml of chloroform was added and the shaking and incubation treatment repeated. The sample was spun at 12,000 g for 10 min at 8°C and the aqueous phase transferred to a fresh tube. 5 ml of isopropyl alcohol and 5 ml of 0.8 M sodium citrate containing 1.2 M NaCl was mixed with the aqueous fraction and after 10 min at room temperature the sample was centrifuged a second time. The pellet was washed with 10 ml of 70% EtOH, the suspension recentrifuged at 7500g for 5 min and the resulting pellet allowed to dry before dissolving in 2 ml water. OligoT primed cDNA synthesis used this total RNA as template and following the protocols that accompanied the cDNA synthesis kit purchased from Invitrogen™.

The isolated nucleic acid fragment encoding the tobacco budworm ryanodine receptor was cloned using a PCR based protocol (SEQ ID NO:1). Only the last 4056 bases of the 3'-end of the coding region is available from public databases.

To acquire the complete transcript meant designing oligonucleotide primers for regions of the transcript as close to the 5'-end as feasible. From an analysis of DNA sequence similarities of the receptor from *Drosophila melanogaster* and

Yet a further embodiment of the present invention would be a method for expressing an isolated nucleic acid fragment encoding a toxic insect ion channel comprising:

5 a) transforming a host with a recombinant construct comprising in the 5' to 3' direction a promoter operably linked to the toxic insect ion channel nucleic acid, wherein the promoter comprises a transcription termination nucleic acid fragment, and/or an in-frame translation stop codon, situated between said promoter and the isolated nucleic acid fragment encoding the toxic insect ion channel, and further  
10 wherein the transcription termination nucleic acid fragment, and/or an in-frame translation stop codon, is flanked on each end by at least one nucleic acid sequence consisting essentially of excisable sequences; and

b) growing the transformed host under conditions that are suitable for the expression of the recombinant construct. The excisable sequences may be any sequences recognized by recombinase enzymes, such as but not limited to, lox  
15 sites.

A related embodiment of the present would encompass the recombinant constructs themselves comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding a toxic insect ion channel, wherein the promoter comprises a transcription termination nucleic acid fragment, and/or at least  
20 one in-frame translational termination codon, situated between said promoter and the isolated nucleic acid fragment encoding the toxic insect ion channel, and further wherein the transcription termination nucleic acid fragment, and/or at least one in-frame translational termination codon, is flanked on each end by at least one nucleic acid sequence consisting essentially of excisable sequences. The excisable  
25 sequences may be any sequences recognized by recombinase enzymes, such as but not limited to, lox sites.

Another embodiment of the present invention would be a method for expressing an isolated nucleic acid fragment encoding a toxic insect ion channel comprising:

30 a) transforming a host with a recombinant expression construct comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding the toxic insect ion channel, wherein said fragment also comprises an intron which interferes with expression of said fragment, and

b) growing the transformed host under conditions that are suitable for the  
35 expression of the recombinant construct.

In still another embodiment, the present invention would encompass a recombinant expression construct comprising in the 5' to 3' direction a promoter operably linked to an isolated nucleic acid fragment encoding a toxic insect ion

In a further embodiment, this invention concerns a method for evaluating at least one compound which modulates ryanodine receptor activity, the method comprising the steps of:

(a) contacting at least one compound with a polypeptide encoded by any one of the aforementioned isolated nucleic acid fragments; and

(b) evaluating the ryanodine receptor activity of the polypeptide of (a) after said polypeptide has been contacted with the compound or compounds.

This method wherein the method can be, but is not limited to, a ligand binding assay. Furthermore, this method can be useful wherein the polypeptide is contacted with more than one compound.

Insect specific sequences can be identified by finding homologous subsequences that are conserved between all of the insect sequences but not among the non-insect sequences. A number of these sequences can be found in SEQ ID NOs:63-119. Prior to the characterization of the sequences presented herein insect specific sequences could not be identified since the fruitfly sequence was the only insect sequence available and this had very low (less than 50%) homology to the animal ryanodine receptor sequences.

A further embodiment of the present invention would be an isolated nucleic acid fragment encoding an insect ion channel comprising at least two polypeptide sequences set forth in any of SEQ ID NOs:63-119 provided that said polypeptide sequences do not comprise any of SEQ ID NOs:56, 120-126.

Yet another embodiment would be a method for identifying a nucleic acid sequence encoding an insect ion channel comprising:

a) obtaining an isolated nucleic acid sequence encoding a first polypeptide having at least 100 amino acids;

b) comparing the first polypeptide sequence with a comparative polypeptide sequence selected from the group consisting of SEQ ID NOs:63-119 to identify a region between the first polypeptide and the comparative polypeptide having 100% sequence identity wherein said region is as long as the comparative polypeptide; and

c) repeating step (b) with a different comparative polypeptide sequence, wherein said different comparative polypeptide sequence is selected from the group consisting of SEQ ID NOs:63-119 until a second region having 100% sequence identity is found, wherein said second region is as long as the different comparative polypeptide. The method could be further characterized by the length of the first polypeptide having a length of from 100 to 6,000 amino acids.

Genome Analysis: Detecting Genes, 1, Cold Spring Harbor, New York (1998); Birren et al., Genome Analysis: Analyzing DNA, 2, Cold Spring Harbor, New York (1998); Plant Molecular Biology: A Laboratory Manual, eds. Clark, Springer, New York (1997)).

5 In a still further aspect this invention concerns a method to isolate nucleic acid fragments encoding ryanodine receptors and related polypeptides, comprising:

(a) comparing SEQ ID NO:2, 4, 6, 8, 10, 128, 130, 144, and 146 and other ion channel and receptor polypeptide sequences;

(b) identifying the conserved sequences of 4 or more amino acids  
10 obtained in step a;

(c) designing degenerate oligomers based on the conserved sequences identified in step b; and

(d) using the degenerate oligomers of step c to isolate sequences encoding polypeptides having ryanodine receptor activity by sequence dependent  
15 protocols.

In another aspect, this invention concerns an isolated polypeptide having ryanodine receptor activity, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10, 128, 130, 144, and 146 have at least 75%, 80%, 85%, 90%, 95%, or 100% identity. One skilled in the art would  
20 realize that any integer percent identity from 75% to 100% would be useful in identifying ryanodine receptor-like polypeptide sequences.

In another embodiment, this invention concerns a method for evaluating at least one compound for its ability to modulate calcium homeostasis, the method comprising the steps of:

25 (a) transforming a host cell with any one of the aforementioned recombinant constructs, or any recombinant construct containing any one of SEQ ID NOs:56-62;

(b) growing the transformed host cell under conditions that are suitable for expression of the recombinant construct wherein expression of the recombinant  
30 construct results in altered calcium homeostasis;

(c) treating the transformed host cell of step (a) with a compound to be tested; and

(d) determining changes in intracellular calcium homeostasis by the test compound in order to select compounds with potential for altering calcium release.

35 This method wherein the method can be, but is not limited to, a ligand binding assay. Furthermore, this method can be based on assessing functional activity by detecting the effect of a compound on the functional activity of the transformed host cell or ion channels obtained from such cells.

constitutively or in response to defined conditions. Selection of those cells expressing the recombinant receptor would be identified by their perturbation of ryanodine receptor function detected through changes in calcium dependent fluorescence (see Example 9 for details), or ion channel conductance, and these  
5 used for screening purposes or for further investigation of the components that are involved in calcium homeostasis and signalling. The cells would also be a source of the functional receptor for further biochemical work. Results from such work would include, but not be limited to, fractionation and purification of the protein, subfragment analysis for binding domain characterization, swapping of domains  
10 encoding regions from different ryanodine receptors to form chimeric receptor proteins, mutagenesis of the receptor to isolate isoforms that have altered ion channel activity, and mutagenesis of the receptor to isolate isoforms that have altered ryanodine or GN binding.

In another aspect, this invention concerns an isolated nucleotide fragment  
15 selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 127, 129, 143, and 145. Also, of interest is the complement of this isolated nucleotide fragment.

In still another aspect, this invention concerns recombinant DNA constructs comprising any of the above-identified isolated nucleic acid fragments or  
complements thereof or parts of such fragments or complements operably linked to  
20 at least one regulatory sequence. These recombinant DNA constructs are useful for the purpose of over-expression, antisense inhibition, or co-suppression of ryanodine receptor activity in a transformed host cell.

Also, of interest are eukaryotic or prokaryotic host cells comprising such chimeric constructs in their genome. Useful host cells include, but are not limited to,  
25 *E.coli*, yeast, Sf9, Sf21, S2, *Xenopus* oocytes, HEK293, and CHO.

The cDNAs encoding the instant polypeptides may be introduced into the baculovirus genome itself, using standard methods of cloning and transformation (see Example 5 for details). The *Spodoptera frugiperda* cell lines Sf9, Sf21, or the *Drosophila* S2 cell lines can be used for transfection studies. The supernatant fluid  
30 from co-transfection experiments may be used to isolate recombinant virus and/or expressed protein (see Example 5).

In addition to the above discussed procedures, those skilled in the art are familiar with the standard resource materials which describe specific conditions and procedures for the construction, manipulation and isolation of macromolecules (e.g.,  
35 DNA molecules, plasmids, etc.), generation of recombinant organisms and the screening and isolating of clones, (see for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press (1989); Maliga et al., *Methods in Plant Molecular Biology*, Cold Spring Harbor Press (1995); Birren et al.,

post-translational modification or for altering the interactions of the receptor and ion channel with its membrane, secondary messengers, or attendant proteins also involved, directly or indirectly in calcium homeostasis. Fusion of the nucleic acid fragment with other ORFs that encode reporter proteins e.g. GFP, luciferase have application for assisting in localization of the gene product in the cell, or for assessing production of the receptor. In another example, domains of beta-galactosidase can be fused to different proteins suspected of interacting with the receptor. The interaction between the receptor and the fusion protein can then be investigated using the beta-galactosidase activity as an assayable reporter.

RNA transcribed from the native gene or any variant, chimeras, precursors either in vivo or in vitro would be useful in a number of applications e.g. in vitro translation to produce the mature protein, a precursor or sub-fragments to study further the function in calcium homeostasis and cell signaling. Sub-fragments of the protein generated in vitro could have utility for producing antibodies (Chen et al (1993) *J Biol Chem* 268:13414-21) or biochemical analysis to identify ligand or attendant protein binding sites (Callaway et al (1994) *J Biol Chem* 269:15876-84).

The sequence of the protein is valuable for designing antibodies that are either specific for a particular variant of the receptor or alternatively using those areas of homology, generally cross react with many forms of the receptor. An additional use of the protein sequence is to identify regions that are susceptible to digestion by specific proteases. Digestion of the protein into subfragments with or without bound molecules would allow the sites where these molecules bind to be mapped. Understanding the nature of the receptor binding sites of small organic molecules could be used to apply a number of different computational modeling approaches to design other small molecules that target the same site and may have other desired biological and ecotoxicological activities and attributes.

Receptor isolated from any source may be post-translationally modified, processed, proteolytically cleaved to form sub-fragments that are separate or still associated with the body of the protein and still be functional. Because the genomic DNA is likely to be composed of multiple exons and introns there is a possibility of one gene producing different receptor-ion channel types due to alternate spliced versions of the messenger RNA. These different subtypes may have different functional properties in calcium homeostasis.

The isolated nucleic acid fragment or its variants may be cloned into any suitable vector, such as, but not limited to, plasmids, virus or binary vectors for infection purposes. The isolated nucleic acid fragment could be coupled to a multiplicity of promoter sequences that allow transcription and translation in the relevant bacterial, yeast, plant, oocyte, insect, or mammalian cell hosts either

There are many ways that a nucleic acid fragment encoding a ryanodine receptor might be used once it has been first isolated and then cloned into a suitable vector. Methods for isolating such nucleic acid fragments include, but are not limited to, isolating the RNA from cells that are known to express the native Ryr protein. In this case the tissue source was from lepidopteran and homopteran pests. Other pests might include, but are not limited to, all those from the invertebrate kingdom and parasitic pathogens, e.g. those causing animal health problems or considered household pests. Examples of such pests include but are not restricted to, fleas, ticks, roaches, mosquitos, nematodes, Plasmodium falciparum, sheep blowfly.

RNA could then be used, if enough DNA sequence were available to design and synthesize oligonucleotide primers and then those skilled in the art use these primers to generate DNA by RT PCR. The sequence of the DNA is therefore valuable for allowing primers to be designed that will allow the receptor gene to be isolated from a wide range of other invertebrates. The gene might be generated in toto if the primers are designed from the extreme 5'- and 3'- regions of the gene. Alternatively, the gene might be built from a number of sub-fragments isolated after RT PCR of internal regions of the gene. In this case acquiring regions at the extreme ends of the gene may be challenging and then procedures like 5'-RACE or inverse PCR may need to be employed. The RNA could be total or fractionated material to enrich some specific type such as mRNA. The RNA might be generally expressed and amplified in a number of ways to generate e.g. a cDNA library, or variant of library production that would capture all versions of the gene, if more than one exists.

Alternatively the isolated nucleic acid fragment of the invention could be extracted from complete cells, cell lysates sub-cellular components and purified from other cellular material. In the case of nuclear material, the nucleic acid fragment will be genomic and thus likely to contain many introns which may offer the ability to provide alternative sequence arrangements and thus different variants of the functional protein. This nucleic acid fragment might be used to generate a BAC, cosmid, fosmid or other variation of a genomic library to ensure all variants of the exons and introns of the gene are available.

The nucleic acid fragment coding for the native gene, chimeric or mutagenic variants or subfragments thereof might also be synthesized chemically using the known sequence as offered by a number of commercial enterprises.

Sequences of other utility outside the ORF (open reading frame) or internal to the ORF might also be considered, such as specific promoters for transcription control, precursor sequences for targeting to particular cellular compartments, or for

may be Fab-type fragments which are defined as fragments devoid of the Fc portion, e.g., Fab, Fab' and F(ab')<sub>2</sub> fragments, or may be so-called "half-molecule" fragments obtained by reductive cleavage of the disulfide bonds connecting the heavy chain components of the intact antibody. If the antigen member of the specific binding pair is not immunogenic, e.g., a hapten, it can be covalently coupled to a carrier protein to render it immunogenic.

Non-immune binding pairs include systems wherein the two components share a natural affinity for each other but are not antibodies. Exemplary non-immune binding pairs are biotin-avidin or biotin-streptavidin, folic acid-folate binding protein, complementary nucleic acid probes, etc. Also included are non-immune binding pairs which form a covalent bond with each other. Exemplary covalent binding pairs include sulfhydryl reactive groups such as maleimides and haloacetyl derivatives and amine reactive groups such as isothiocyanates, succinimidyl esters, sulfonyl halides and coupler dyes such as 3-methyl-2-benzothiazolinone hydrazone (MBTH) and 3-(dimethyl-amino)benzoic acid (DMAB), etc.

Suitable supports used in assays include, but are not limited to, synthetic polymer supports such as polystyrene, polypropylene, substituted polystyrene. E.g., aminated or carboxylated polystyrene; polyacrylamides; polyamides; polyvinylchloride, etc.; glass beads; agarose; nitrocellulose; nylon; polyvinylidenedifluoride; surface-modified nylon, etc.

One further example of an affinity tag is a photoaffinity label that is an analog of a tight binding modulator or effector and might be used to covalently label residues of the receptor that compose the binding site of the effector. The small analog not only has been altered to covalently modify the protein using light irradiation to activate the affinity moiety but also carries a radioactive label for further convenient identification of the region of the receptor that has been modified. Further analysis of the labeled receptor or peptide fragments that carry the modified residues can lead to identifying the region of the protein that comprises the analog binding site.

Functional assays for the identification of low molecular weight compounds and natural products that modulate calcium homeostasis through their action on the receptor directly, or through their affect on attendant proteins involved in the process of calcium signaling have been developed (Mackrill et al. (1999) *Biochem J* 337:345-361). Additional methods include, but are not limited to, planar lipid bilayer recording, and imaging and fluorometric monitoring of in situ calcium concentration changes (Brillantes et al. (1994) *Cell* 77:513-523; Mack et al. (1994) *J Biol Chem* 269:23236-23249; Chen et al. (1999) *J Biol Chem* 274:32603-32612; Rodney et al. (2001) *Biochemistry* 40:12430-12435)



useful alternatives. Alternatively, preparations can be assessed based on the quantity of functional receptor per unit weight of tissue determined from the amount of radiolabelled ligand that is bound.

Unfortunately tissue samples are not available from all pests of interest in quantities necessary for effective screening or analysis. Therefore, a significant advantage of working with recombinant material is the ability to express a single variant of any gene in many cellular types and backgrounds and thus produce homogeneous experimental preparations in relatively controlled amounts depending on the choice of promoter. A further advantage is that species specific receptors often have unique binding sites, thus a recombinant system offers flexibility in terms of which source of the gene is chosen for expression. This provides a means of comparative analysis of the response of the system in various pre-selected conditions.

Pest receptors in enough quantities from any of these sources, would form the basis of assays that have utility for identifying other synthetic compounds or natural ligands that have the same mode of action. In the case of an assay based on monitoring of intracellular calcium concentration, modulators that cause activation of the ion channel or its blockage can be identified. A binding assay can be used to identify those modulators that interact with the receptor or ion channel at the specific site where the labeled analog binds or at allosteric sites which alter the binding of the analog.

In binding assays one partner molecule is immobilized and the other is labeled in some fashion (e.g. using a nonradioactive label such as an enzyme or fluorescent tag or by using a radioactive label) and added free in solution. After incubation to allow molecular interaction, and a wash step, the amount of ligand bound is measured using an appropriate detection system. Ligands showing significant binding may then be studied further by ensuring that the protein is in excess, and carrying out experiments with a dilution series of the ligand at a set of known concentrations, typically from  $10^{-2}$  to  $10^{-10}$ M.

Proteins may be immobilized using an epitope or other affinity tag on a support material to which an appropriate antibody or binding agent for the tag is attached. For example, members of specific binding pairs can be of the immune or non-immune type. Immune specific binding pairs are exemplified by antigen/antibody systems or hapten/antihapten systems. The antibody member, whether polyclonal or monoclonal or an immunoreactive fragment thereof, of the binding pair can be produced by customary methods familiar to those skilled in the art. The terms immunoreactive antibody fragment or immunoreactive fragment mean fragments which contain the binding region of the antibody. Such fragments

ryanodine by opening calcium release channels. This channel activation leads to depletion of calcium stores whereas ryanodine acts by locking channels in a sub-conductance state. The binding site of these "GN" molecules has also been found to be different than that of ryanodine. Nonetheless, the ability of these molecules to release calcium stores in recombinant cell lines expressing insect ryanodine receptors, as shown in Figures 3 and 4, but not in control cell lines lacking these ryanodine receptors, lends further support that the ryanodine receptor protein itself is the binding site of "GN" chemistry.

Based on the effects of this structural class of compounds it is clear that the ryanodine receptor is a valuable biochemical target for the discovery of new pesticides. Like other insect ion channels and receptors, there are potentially multiple binding sites on the protein that could influence the functional properties of the channel-receptor and thus cellular calcium balance. In addition to small molecule binding sites, numerous proteins interact with the receptor on both sides and within the reticulum membrane ( see Mackrill, (1999) *Biochem. J.* 337: 345-361 for a review). Compounds found to interfere with these interactions could also be useful as pesticides.

The Ryr gene from invertebrates is expressed widely in all muscle types and in neurones and so accessibility to active compounds would be expected.

Symptomology of the mode of action of the anthranilamides is consistent with a direct effect of these compounds on all the muscle cells of the insect, skeletal, smooth and cardiac. Fluorescence imaging analysis of roach neuronal cells or binding studies using roach leg muscle indicates that there is a close correlation between calcium influx in neurons, or binding to leg muscle preparations, and the activity of these compounds in insect pest screens.

Tissue preparations from muscle and neuronal cells are thus sources of the insect receptor for isolation and binding studies. Selection of the most appropriate cells can be achieved using, e.g. the binding affinity of a radiolabeled analog of the chemistry being investigated or radiolabeled ryanodine, which is commercially available. Binding studies using radioactive ryanodine and GN analogs are presented in Example 9. This might be determined in a number of ways, which could include but not be limited to the fate of a radiolabeled analog during receptor preparation, or monitoring a specific spectroscopic characteristic of the analog or its derivative. Quality of preparations might be assessed based on the intensities of fluorescence from calcium flux induced by specific receptor modulators, such as caffeine, as detected using calcium specific fluorescence indicators. Examples of indicators useful for monitoring changes in intracellular calcium include FURA-2, Fluo-3, and Fluo-4 but other compounds exist that are well known and would be